akao-10q_20170331.htm

0001564590-17-009402.txt : 20170508 0001564590-17-009402.hdr.sgml : 20170508 20170508161853 ACCESSION NUMBER: 0001564590-17-009402 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 78 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170508 DATE AS OF CHANGE: 20170508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Achaogen Inc CENTRAL INDEX KEY: 0001301501 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680533693 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36323 FILM NUMBER: 17822463 BUSINESS ADDRESS: STREET 1: 7000 SHORELINE COURT STREET 2: SUITE 371 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-800-3636 MAIL ADDRESS: STREET 1: 7000 SHORELINE COURT STREET 2: SUITE 371 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 10-Q 1 akao-10q_20170331.htm 10-Q akao-10q_20170331.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-36323

ACHAOGEN, INC.

(Exact name of registrant as specified in its charter)

Delaware

68-0533693

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

1 Tower Place, Suite 300

South San Francisco, CA

(Address of principal executive offices)

94080

(Zip Code)

7000 Shoreline Court, Suite 371

South San Francisco, CA 94080

(Former name or former address, if changed since last report)

(650) 800-3636

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

Large accelerated filer	☐		Accelerated filer	☒
Non-accelerated filer	☐	(Do not check if a smaller reporting company)	Smaller reporting company	☐
			Emerging growth company	☒

If an emerging growth company, indicate by check mark if registrant has elected not to use the extended transition period for complying with any new or reviewed accounting standards provided pursuant to Section 13(a) of the Exchange Act ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 3, 2017, there were 35,853,669 shares of the registrant’s common stock, par value $0.001 per share, outstanding.

ACHAOGEN, INC.

TABLE OF CONTENTS

		Page

PART I—FINANCIAL INFORMATION		3

Item 1. Condensed Consolidated Financial Statements (unaudited)		3

Condensed Consolidated Balance Sheets		3

Condensed Consolidated Statements of Operations		4

Condensed Consolidated Statements of Comprehensive Loss		5

Condensed Consolidated Statements of Cash Flows		6

Notes to Condensed Consolidated Financial Statements		7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		23

Item 3. Quantitative and Qualitative Disclosures About Market Risk		30

Item 4. Controls and Procedures		30

PART II—OTHER INFORMATION		31

Item 1. Legal Proceedings		31

Item 1A. Risk Factors		31

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		65

Item 3. Defaults Upon Senior Securities		65

Item 4. Mine Safety Disclosures		65

Item 5. Other Information		65

Item 6. Exhibits		65

SIGNATURES		66

EXHIBIT INDEX		67

Page 2 of 68

PART I—FINANCIAL INFORMATION

Item 1.

Financial Statements.

Achaogen, Inc.

Condensed Consolidated Balance Sheets

(In thousands except share and per share data)

	March 31, 2017			December 31, 2016
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	37,639		$	118,964
Short-term investments		94,405			26,912
Contracts receivable		5,866			12,151
Prepaids and other current assets		9,037			2,189
Restricted cash		127			127
Total current assets		147,074			160,343
Property and equipment, net		8,449			3,261
Restricted cash		250			250
Deposit and other assets		33			71
Total assets	$	155,806		$	163,925
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	11,585		$	5,739
Accrued liabilities		6,490			9,698
Loan payable, current portion		7,292			4,167
Other current liabilities		45			104
Total current liabilities		25,412			19,708
Loan payable, long-term		18,192			21,110
Warrant liability		27,289			13,874
Derivative liability		622			602
Deferred Rent		5,654			1,896
Total liabilities		77,169			57,190
Commitments and contingencies
Common stock, $0.001 par value, 290,000,000 shares authorized at March 31, 2017 and December 31, 2016; 35,846,301 and 35,638,052 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively		36			35
Preferred stock, $0.001 par value, 10,000,000 shares authorized and zero shares issued and outstanding at March 31, 2017 and December 31, 2016		—			—
Additional paid-in-capital		359,139			353,927
Accumulated deficit		(280,479	)		(247,220	)
Accumulated other comprehensive loss		(59	)		(7	)
Total stockholders’ equity		78,637			106,735
Total liabilities and stockholders’ equity	$	155,806		$	163,925

See accompanying notes to condensed consolidated financial statements.

Page 3 of 68

Achaogen, Inc.

Condensed Consolidated Statements of Operations

(In thousands except share and per share data)

(unaudited)

	Three Months Ended
	March 31,
	2017			2016
Contract revenue	$	7,463		$	5,849
Operating expenses
Research and development		18,597			13,893
General and administrative		6,751			3,777
Total operating expenses		25,348			17,670
Loss from operations		(17,885	)		(11,821	)
Interest expense		(706	)		(438	)
Change in warrant and derivative liabilities		(14,956	)		(12	)
Other income, net		288			74
Net Loss	$	(33,259	)	$	(12,197	)
Basic and diluted net loss per common share	$	(0.93	)	$	(0.66	)
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share		35,725,876			18,398,288

See accompanying notes to condensed consolidated financial statements.

Page 4 of 68

Achaogen, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(In thousands)

(unaudited)

	Three Months Ended
	March 31,
	2017			2016
Net Loss	$	(33,259	)	$	(12,197	)
Other comprehensive (loss) income:
Net unrealized gain (loss) on available-for-sale securities		(52	)		55
Total comprehensive loss	$	(33,311	)	$	(12,142	)

See accompanying notes to condensed consolidated financial statements.

Page 5 of 68

Achaogen, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(unaudited)

	Three Months Ended March 31,
	2017			2016
Cash flows from operating activities:
Net loss	$	(33,259	)	$	(12,197	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		113			121
Amortization of premium (discount) on short-term investments		(42	)		160
Stock-based compensation expense		2,911			827
Change in warrant and derivative liabilities		14,956			12
Non-cash interest expense relating to notes payable		207			135
Change in operating assets and liabilities:
Contracts receivable		6,285			(27	)
Prepaids and other assets		(6,810	)		(1,390	)
Accounts payable and accrued liabilities		2,316			3,544
Other liabilities		(95	)		(51	)
Net cash used in operating activities		(13,418	)		(8,866	)
Cash flows from investing activities:
Purchase of property and equipment		(1,185	)		(269	)
Purchase of short-term investments		(86,759	)		—
Maturities of short-term investments		19,256			8,280
Net cash used in investing activities		(68,688	)		8,011
Cash flows from financing activities:
Payments of issuance costs, related to underwritten public offering		(42	)		—
Proceeds from the issuance of common stock in connection with equity incentive plans		535			—
Proceeds from exercise of stock warrants		288			—
Net cash provided by financing activities		781			—
Net increase (decrease) in cash, cash equivalents, and restricted cash		(81,325	)		(855	)
Cash, cash equivalents, and restricted cash at beginning of period		119,341			20,414
Cash, cash equivalents, and restricted cash at end of period	$	38,016		$	19,559
Supplemental disclosures of cash flow information
Interest paid	$	499		$	303
Supplemental disclosures of noncash investing and financing information
Reclassification of warrant liability to additional paid-in capital	$	1,521		$	—
Purchases of property plant and equipment included in deferred rent	$	3,794		$	—

See accompanying notes to condensed consolidated financial statements.

Page 6 of 68

Achaogen, Inc.

March 31, 2017

Notes to Condensed Consolidated Financial Statements

(unaudited)

1. Organization and Basis of Presentation and Consolidation

Achaogen, Inc. (together with its consolidated subsidiary, the “Company”) is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterial treatments against multi-drug resistant gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of bacterial infections due to multi-drug resistant Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (“CRE”). The Company’s Phase 3 study of plazomicin in the treatment of patients with complicated urinary tract infections (“cUTI”) and acute pyelonephritis (“AP”), entitled EPIC (Evaluating Plazomicin In cUTI), is expected to serve as a single pivotal study supporting a new drug application (“NDA”) for plazomicin in the United States. In addition, the Company’s Phase 3 study of plazomicin, the CARE (Combating Antibiotic Resistant Enterobacteriaceae) trial, which is a resistant pathogen-specific trial designed to evaluate the efficacy and safety of plazomicin in patients with infections due to CRE.

The Company was incorporated in Delaware in 2002 and commenced operations in 2004. Since commencing operations in 2004, the Company has devoted substantially all its resources to identifying and developing its product candidates, including conducting preclinical studies and clinical trials and providing general and administrative support for these operations.

Reclassifications

The change in derivative liability for the three-month period ended March 31, 2016 has been reclassified to be included in the change in warrant and derivative liabilities to conform to the current year’s presentation. Such reclassifications did not impact the Company’s net loss or financial position.

Basis of Presentation and Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and following the requirements of the Securities and Exchange Commission (the “SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company’s financial information. The results of operations for the three-month period ended March 31, 2017 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December 31, 2016 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. Intercompany accounts and transactions have been eliminated upon consolidation.

The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K.

In May 2017, the Company entered into an agreement with the Bill & Melinda Gates Foundation (the “Gates Foundation”) to discover drug candidates against gram-negative pathogens intended to prevent neonatal sepsis (the “Grant Agreement”). Pursuant to the Grant Agreement, the Gates Foundation awarded the Company up to approximately $10.5 million in grant funding over a three-year research term, of which approximately $3.2 million will be advanced to the Company within 15 days after signing (the “Advance Funds”). Concurrently with the Grant Agreement, the Company entered into a Common Stock Purchase Agreement with the Gates Foundation, pursuant to which the Company agreed to sell 407,331 shares of its redeemable common stock to the Gates Foundation in a private placement at a purchase price per share equal to $24.55, for gross proceeds to the Company of $10.0 million (“Gates Investment”).

Page 7 of 68

Access will continue for any products or services developed with funding provided by the Gates Foundation which continue to be developed or available in certain developing countries.

On December 19, 2016, the Company completed an underwritten public offering of common stock made under a prospectus supplement and related prospectus pursuant to a Registration Statement on Form S-3 (File No. 333-203282) filed on April 7, 2015 (the “Shelf Registration Statement”). This offering resulted in the sale of 7,475,000 shares, at a price to the public of $13.50 per share, including the full exercise of the underwriters’ option to purchase an additional 975,000 shares of common stock. The Company received net proceeds from the offering of $94.6 million, after deducting the underwriting discounts and commissions and estimated offering expenses.

On June 3, 2016, the Company sold 7,999,996 shares of its common stock and warrants to purchase 1,999,999 shares of its common stock pursuant to Securities Purchase Agreement (the "Purchase Agreement") for aggregate gross proceeds of $25.4 million and aggregate net proceeds of $25.1 million, after deducting the issuance costs, in connection with a private placement financing transaction (the "Private Placement"). The warrants have an exercise price of $3.66 per share and are exercisable up to five years from the date of issuance.

On April 7, 2015, the Company filed the Shelf Registration Statement, declared effective by the SEC on April 21, 2015, covering the offering of up to $150.0 million of common stock, preferred stock, debt securities, warrants, purchase contracts and/or units. The Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $30.0 million of shares of our common stock from time to time in an "at-the-market" ("ATM") equity offering pursuant to a sales agreement with Cowen and Company, LLC. As of March 31, 2017, the Company had sold 1,105,549 shares pursuant to its ATM equity offering program at a weighted-average price of $4.82 per share for aggregate offering proceeds of $5.3 million and aggregate net proceeds of $5.1 million, after deducting the sales commissions and offering expenses.

The Company has incurred losses and negative cash flows from operations every year since its inception. As of March 31, 2017, the Company had unrestricted cash, cash equivalents and short-term investments of approximately $132.0 million and an accumulated deficit of approximately $280.5 million. Management expects that, based on its current operating plans, the Company’s existing cash, cash equivalents and short-term investments as of March 31, 2017 will be sufficient to fund its current planned operations for at least the next twelve months from the issuance of these financial statements. Management plans to raise additional funds through equity or debt financing arrangements, government contracts, and/or third party collaboration funding in the future to fund its operations, including the commercial launch of plazomicin. However, there can be no assurance that such funding sources will be available at terms acceptable to the Company or at all. If the Company is unable to raise additional funding to meet its working capital needs, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.

2. Summary of Significant Accounting Policies

Use of Estimates

The accompanying financial statements have been prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, assumptions and estimates that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures of contingent liabilities. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of liabilities, common stock and stock-based awards and income taxes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.

Fair Value of Financial Instruments

The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, contracts receivable, prepaid and other current assets, accounts payable, accrued liabilities, and other current liabilities approximate fair value due to their short-term maturities. Short-term investments consist of available-for-sale securities and are carried at fair value. Based upon the borrowing rates (which is a Level 2 input) currently available to the Company for loans with similar terms, the Company believes the carrying amount of the loan payable approximates its fair value. The warrant and derivative liabilities are recorded at estimated fair value with changes in estimated fair value recorded in the Company's statements of operations.

Page 8 of 68

Cash and Cash Equivalents

Cash equivalents include only securities having a maturity of three months or less at the time of purchase. As of March 31, 2017 and December 31, 2016, cash and cash equivalents consisted of bank deposits, cash, commercial paper, cash repurchase agreement investments and investments in money market funds.

Short-term Investments

Short-term investments consist of debt securities with maturities greater than three months, but less than one year from the date of acquisition, and are classified as available for sale. Short-term investments are carried at fair value. Unrealized gains and losses on available-for-sale securities are excluded from earnings and reported as a component of net unrealized gain (loss) on available-for-sale securities in the Company's consolidated statements of comprehensive loss. The amortized cost of debt securities reflects amortization of purchase premiums and accretion of purchase discounts to date, which are included in interest income.

The Company reviews all of its marketable securities on a regular basis to evaluate whether any security has experienced an other-than-temporary decline in fair value.

Restricted Cash

At March 31, 2017 and December 31, 2016, the Company had restricted cash of $377,000. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):

	March 31, 2017		December 31, 2016
Cash and cash equivalents	$	37,639	$	118,964
Restricted cash, current		127		127
Restricted cash, non-current		250		250
Total cash, cash equivalents, and restricted cash	$	38,016	$	119,341

The restricted cash, which consists of money market accounts with one of the Company’s financial institutions, serves as collateral for the letters of credit provided as security deposits under the Company’s facility leases. As of March 31, 2017 and December 31, 2016, $127,000 of restricted cash is classified as current assets and relates to the current facility lease that expires on April 14, 2017.

Warrant Liability

On June 3, 2016, the Company issued warrants to purchase 1,999,999 shares of its common stock in connection with the Private Placement. Each warrant has an exercise price of $3.66 per share and is exercisable for five years from the date of issuance. The Company accounts for these warrants as a liability instrument measured at estimated fair value. The initial fair value of the warrants was determined using a calibration model that involved using the Black-Scholes Pricing Model ("Black-Scholes"), which requires inputs such as the risk-free interest rate, expected share price volatility, underlying price per share of the Company's common stock and remaining term of the warrants. The warrants are subject to remeasurement at each balance sheet date, using Black-Scholes, with any changes in the fair value of the outstanding warrants recognized in the condensed consolidated statements of operations.

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The Company has one operating segment.

Customer Concentration

For the three-month periods ended March 31, 2017 and 2016, the Company’s revenue was generated solely from funding pursuant to U.S. government contracts, and accordingly all contracts receivable relate to funding from U.S. government contracts.

Concentration of Credit Risk

Page 9 of 68

investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of default by the institutions holding its cash and cash equivalents or issuing the debt securities. As of March 31, 2017 and December 31, 2016, the Company had not experienced any credit losses in such accounts or investments.

Revenue Recognition

The Company recognizes revenue when: (i) evidence of an arrangement exists, (ii) fees are fixed or determinable, (iii) services have been delivered, and (iv) collectability is reasonably assured. The Company currently generates revenue entirely from government contracts. Government contracts are agreements that provide the Company with payments for certain types of expenditures in return for research and development activities over a contractually-defined period. Revenue from government contracts is recognized in the period during which the related costs are incurred and the related services are rendered, provided that the applicable conditions under the government contracts have been met. Costs of contract revenue are recorded as a component of operating expenses in the Company's consolidated statement of operations.

Funds received from third parties under contract arrangements are recorded as revenue if the Company is deemed to be the principal participant in the contract arrangements because the activities under the contracts are part of the Company’s development programs. If the Company is not the principal participant, the funds from contracts are recorded as a reduction to research and development expense. Contract funds received are not refundable and are recognized when the related qualified research and development costs are incurred and when there is reasonable assurance that the funds will be received. Funds billed and received in advance are recorded as deferred revenue.

Research and Development Costs

Research and development costs are expensed as incurred. Research and development expenses include certain payroll and personnel expenses; laboratory supplies; consulting costs; external contract research and development expenses; and allocated overhead, including rent, equipment depreciation and utilities, and relate to both Company-sponsored programs as well as costs incurred pursuant to collaboration agreements and government contracts.

The Company estimates preclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.

Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and other current assets and recognized as an expense as the goods are delivered or the related services are performed.

Recent Accounting Pronouncements

In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740) - Balance Sheet Classification of Deferred Taxes. This guidance simplifies the presentation of deferred income taxes in a classified balance sheet to require that deferred tax liabilities and assets be classified as noncurrent and is effective for annual reporting periods, including interim reporting periods, beginning after December 15, 2016. The Company adopted this ASU effective January 1, 2017. The adoption had no impact on the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, which, for operating leases, requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. This ASU will be effective for the Company in fiscal year 2019. Early adoption is permitted. The Company is currently assessing the potential effects of this ASU on its consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815) - Contingent Put and Call Options in Debt Instruments. This ASU clarifies the requirements for assessing whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. An entity performing the assessment under the amendments in this Update is required to assess the embedded call (put) options solely in accordance with the four-step decision sequence. This guidance should be applied on a modified retrospective basis to existing debt instruments as of the beginning of the fiscal year in which the amendments are effective. This ASU is effective beginning January 1, 2017 and the Company assessed that the effects of this ASU had no impact on its consolidated financial statements.

Page 10 of 68

In March 2016, the FASB issued ASU No 2016-09, Compensation - Stock Compensation (Topic 718) - Improvements to Employee Share-Based Payment Accounting. This ASU simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. This ASU will be effective for fiscal years beginning after December 15, 2016, including interim periods. The Company adopted this ASU effective January 1, 2017 and elected to account for forfeitures on an estimated basis. The adoption had no impact on the Company’s consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The Company has not yet finalized its preliminary assessment and conclusions on how the adoption of this ASU will affect its current policies related to revenue recognition. The Company expects to adopt the new revenue standard on January 1, 2018, and through the remainder of 2017, will continue to assess the potential impact of adopting this new standard on any current, new or significantly modified customer contracts. In subsequent quarters, the Company will finalize its selection of transition methods and complete its evaluation of additional disclosures that may be required upon adoption of the new standard.

Net Loss Per Share

Basic net loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common share equivalents outstanding during the period. For purposes of this calculation, preferred stock, stock options, restricted stock units and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

For the three-month periods ended March 31, 2017 and 2016, all potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported. Below are listed the potentially dilutive securities outstanding as of March 31, 2017 and 2016:

	March 31,
	2017		2016
Options to purchase common stock		4,470,187		2,793,404
Restricted stock units		800,658		495,274
Warrants to purchase common stock		1,231,659		30,024

Warrants outstanding as of March 31, 2017 have a weighted-average exercise price of $3.78.

3. Fair Value Measurements

Financial assets and liabilities are recorded at fair value. The carrying amount of certain financial instruments, including cash and cash equivalents, contracts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Page 11 of 68

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

Where quoted prices are available in an active market, securities are classified as Level 1 of the valuation hierarchy. The Company’s Level 2 valuations of marketable securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets.

In certain cases, where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy. Level 3 liabilities that are measured at estimated fair value on a recurring basis consist of a derivative liability in connection with loan payable and a warrant liability in connection with the Private Placement.

As of March 31, 2017 and December 31, 2016, financial assets and liabilities measured and recognized at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above were as follows (in thousands):

	March 31, 2017
	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Assets
Cash	$	4,779	$	—	$	—		$	4,779
Level 1:
Restricted cash		377		—		—			377
Money market funds		14,860		—		—			14,860
Subtotal		15,237		—		—			15,237
Level 2:
Corporate debt securities		31,031		—		(24	)		31,007
U.S. Treasury bills		35,033		—		(35	)		34,998
Commercial paper		46,400		—		—			46,400
Subtotal		112,464		—		(59	)		112,405
Total	$	132,480	$	—	$	(59	)	$	132,421
Reported as:
Cash and cash equivalents								$	37,639
Short-term investments								$	94,405
Restricted cash								$	377

Liabilities, Level 3
Warrant Liability								$	27,289
Derivative Liability								$	622
Total								$	27,911

Page 12 of 68

	December 31, 2016
	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Assets
Cash	$	3,728	$	—	$	—		$	3,728
Level 1:
Restricted cash		377		—		—			377
Money market funds		115,236		—		—			115,236
Subtotal		115,613		—		—			115,613
Level 2:
Corporate debt securities		12,969		—		(7	)		12,962
Commercial paper		13,950		—		—			13,950
Subtotal		26,919		—		(7	)		26,912
Total	$	146,260	$	—	$	(7	)	$	146,253
Reported as:
Cash and cash equivalents								$	118,964
Short-term investments								$	26,912
Restricted cash								$	377

Liabilities, Level 3
Warrant liability								$	13,874
Derivative liability								$	602
Total								$	14,476

All available-for-sale securities held as of March 31, 2017 had maturities less than one year from the date of acquisition. There were no sales of available-for-sale securities in any of the periods presented. The carrying value of debt securities that were in unrealized loss positions totaled $63.9 million as of March 31, 2017. The Company has determined that (i) it does not have the intent to sell any of these investments, and (ii) it is not more likely than not that it will be required to sell any of these investments before recovery of the entire amortized cost basis. The Company anticipates that it will recover the entire amortized cost basis of such debt securities and has determined that no other-than-temporary impairments associated with credit losses were required to be recognized during the three-month period ended March 31, 2017.

Pursuant to the loan and security agreement with Solar Capital Ltd. (see Note 7), the Company entered into a Success Fee Agreement under which the Company agreed to pay $1.0 million in cash (the "Success Fee") if the Company obtains approval to market plazomicin from the Food and Drug Administration (the "FDA"). If such approval is obtained, the Success Fee shall be due the later of (i) August 5, 2019 or (ii) the date such FDA approval is obtained. The fair value of the Success Fee, approximately $602,000 at December 31, 2016, is recorded as a derivative liability and included in other long-term liabilities on the accompanying condensed consolidated balance sheet. The estimated fair value of the derivative liability as of March 31, 2017 increased by $20,000 to $622,000 from December 31, 2016, as a result of the time value of money, which is presented as change in warrant and derivative liabilities in the Company's condensed consolidated statements of operations for the three-month period ended March 31, 2017.

The fair value of the derivative liability was determined using a discounted cash flow analysis, and is classified as a Level 3 measurement within the fair value hierarchy since the Company’s valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the derivative instrument include: i) the Company’s estimates of both the probability and timing of a potential $1.0 million payment to Solar Capital Ltd. upon FDA approval to market plazomicin, and ii) a discount rate of 13% which was derived from the Company's estimated cost of debt. The estimated fair value of the derivative liability is most sensitive to the probability of FDA approval. Should the probability of FDA approval change by 5%, the fair value of the derivative liability as of March 31, 2017 would change by approximately $37,000. For the three-month period ended March 31, 2017, there was no change to the key assumptions used in the calculation of the estimated fair value. Any changes in the estimated fair values are presented as changes in warrant and derivative liabilities in the Company's condensed consolidated statements of operations.

Page 13 of 68

Pursuant to the Private Placement (see Note 2), the Company issued warrants to purchase 1,999,999 shares of common stock at an exercise price of $3.66. The Company classified these warrants as a liability measured at fair value using Black-Scholes. Under certain entity conditions, the holder of a warrant may require the Company to settle the warrant in cash at its estimated fair value using Black-Scholes. On the closing date of the Private Placement, June 3, 2016, the $2.6 million initial estimated fair value of the warrants was recorded as a warrant liability on the accompanying condensed consolidated balance sheet. At March 31, 2017 and December 31, 2016, the estimated fair values of the warrants were approximately $27.3 million and $13.9 million, respectively. The change in the estimated fair value is primarily due to the increase in the Company's stock price and is included in changes in warrant and derivative liabilities in the Company's condensed consolidated statements of operations.

In February 2017, certain holders of these warrants exercised warrants to purchase 78,585 shares of common stock. The Company received $0.3 million in proceeds from these warrant exercises. The Company is required to record the exercised warrants at its estimated fair value at the time of exercise, with any change included in changes in warrant and derivative liabilities in the Company’s condensed consolidated statements of operations. The Company estimated the fair value of these exercised warrants at their respective exercise dates to be $1.5 million, an increase of $1.4 million from its initial valuation, at June 3, 2016, of $0.1 million, primarily due to an increase in the Company’s stock price.

The fair value of the warrant liability is classified as a Level 3 measurement within the fair value hierarchy since the Company’s valuation utilized significant unobservable inputs, including the risk-free interest rate, expected share price volatility, underlying price per share of the Company's common stock and remaining term of the warrants. At March 31, 2017 and December 31, 2016, the estimated fair values of the warrants were determined using Black-Scholes with the following assumptions:

	March 31, 2017		December 31, 2016
Expected volatility		80%		80%
Expected term	4.2 years		4.2 years
Risk-free interest rate		1.8%		1.8%
Dividend yield		—%		—%

The expected volatility is based on the Company's expected volatility. The expected term is based on the remaining life of the warrants. The risk-free interest rate is obtained from the yields on actively traded U.S. Treasury securities for a period equal to the expected term of the warrants. The dividend yield is zero because the Company has never paid cash dividends and has no present intention to pay cash dividends. Should the share price change by 5%, the fair value of the warrant liability as of March 31, 2017 would change by approximately $1.5 million.

Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as changes in warrant and derivative liabilities in the Company's condensed consolidated statements of operations and were as follows for the three-month period ended March 31, 2017 (in thousands):

	Estimated Fair Value of Warrant Liability			Estimated Fair Value of Derivative Liability
Balance of Level 3 Liabilities at December 31, 2016	$	13,874		$	602
Change in estimated fair value of warrant liability		14,936		—
Reclassification of warrant liability to additional paid in capital upon exercise of warrants		(1,521	)	—
Change in estimated fair value of derivative liability	—				20
Balance of Level 3 Liabilities at March 31, 2017	$	27,289		$	622

4. Balance Sheet Components

Prepaids and other current assets

Prepaids and other current assets consisted of the following (in thousands):

	March 31, 2017		December 31, 2016
Deferred research and development costs	$	6,042	$	660
Prepaid expenses		2,660		1,390
Other current assets		335		139
	$	9,037	$	2,189

Page 14 of 68

Property and Equipment, net

Property and equipment, net consisted of the following (in thousands):

	March 31, 2017			December 31, 2016
Office equipment	$	1,071		$	644
Laboratory equipment		3,989			4,038
Leasehold improvements		1,072			1,072
Construction-in-progress		6,751			1,896
		12,883			7,650
Less: accumulated depreciation and amortization		(4,434	)		(4,389	)
Property and equipment, net	$	8,449		$	3,261

Depreciation and amortization expense for the three-month periods ended March 31, 2017 and 2016 was $113,000 and $121,000, respectively.

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	March 31, 2017		December 31, 2016
Accrued clinical and development expenses	$	2,394	$	3,681
Payroll and related bonus expenses		2,788		4,941
Other		1,308		1,076
	$	6,490	$	9,698

5. License and Collaboration Agreements

Thermo Fisher Scientific, Inc.

In April 2016, the Company entered into an agreement with its collaboration partner, Microgenics Corporation (“Thermo Fisher”), a wholly owned subsidiary of Thermo Fisher Scientific, Inc., to develop and commercialize an assay to support plazomicin. If approved, the Company and Thermo Fisher plan to have a commercial assay for plazomicin available at launch to enable health care professionals to make decisions on safe and efficacious doses of plazomicin. In accordance with the terms of the agreement, the Company is required to make milestone payments with respect to research, development, regulatory and commercialization milestones (if any). All such milestone payments may total, in aggregate, up to but no more than $6,453,000. In further consideration of this agreement, in the event of a successful commercialization of the assay, the Company is required to pay a minimum threshold annual revenue to Thermo Fisher.

As of March 31, 2017, the Company has incurred $1,433,000 in milestone payments and the cost was fully recorded as research and development expense. The Company recorded $915,000 and zero of research and development expense during the three-month periods ending March 31, 2017 and 2016, respectively, under this agreement. In February 2017, the Company announced the achievement of a strategic milestone in its ongoing collaboration to develop an assay enabling therapeutic drug management of plazomicin.

Crystal Biosciences, Inc.

In May 2016, the Company entered into a collaboration and license agreement with Crystal Biosciences, Inc. (“Crystal”). Pursuant to the terms of this agreement, the Company and Crystal agreed to collaborate on the discovery of monoclonal antibodies against multiple targets. Crystal agreed to conduct the initial discovery work with its antibody platform and the Company has the right to develop and commercialize the antibodies discovered through this collaboration. The Company is required to provide signing and milestone payments with respect to research, development, regulatory and commercialization milestones (if any). All such milestone payments may total, in aggregate, up to but no more than $20,550,000. The upfront signing fee, technology access fees and research funding were recorded as research and development expense. This collaboration and license agreement also provides that the Company shall pay royalties equal to a low single-digit percentage of annual worldwide net sales of the commercialized product.

Ionis Pharmaceuticals

In January 2006, the Company entered into a license agreement with Ionis Pharmaceuticals, Inc. (“Ionis”). Ionis granted the Company an exclusive, worldwide license with the right to grant and authorize sublicenses related to the research and development of

Page 15 of 68

aminoglycoside products. As an up-front fee, the Company issued 97,402 shares of Series A convertible preferred stock at a fair value of $15.40 per share. This license fee of $1,500,000 was recorded as research and development expense in 2006. In further consideration of this license, and in accordance with the terms of the agreement, the Company is required to make milestone payments with respect to development, regulatory and commercialization milestones, and to pay a percentage of revenue received from sublicensees (if any). All such milestone and sublicense revenue payments may total, in the aggregate, up to but no more than $19,500,000 for the first product and $9,750,000 following the second product commercialized under the agreement with Ionis. The Company is also required to pay additional milestone payments of up to $20,000,000 in the aggregate upon the first achievement of specified threshold levels of annual net sales of all aminoglycoside products in a calendar year. The license agreement also provides that the Company shall pay royalties equal to a low single-digit percentage of annual worldwide net sales of all licensed products, including, if applicable, plazomicin.

Through March 31, 2017, the Company had compensated Ionis $7,000,000 in connection with the first three milestones under the license for the first aminoglycoside product candidate. As of March 31, 2017, the Company had no outstanding payments due under the agreement.

6. Government Contracts

Certain of the Company’s drug discovery and development activities are performed under contracts with U.S. government agencies. Management has determined that the Company is the principal participant in the following contract arrangements, and, accordingly, the Company records amounts earned under the arrangements as revenue. Costs incurred under revenue contracts are recorded as operating expenses in the Company's consolidated statements of operations.

Biomedical Advanced Research and Development Authority

In August 2010, the Company was awarded a contract with the Biomedical Advanced Research and Development Authority (“BARDA”) for the development, manufacturing, nonclinical and clinical evaluation of, and regulatory filings for, plazomicin as a countermeasure for disease caused by antibiotic-resistant pathogens and biothreats. The original contract included committed funding of $27,600,000 for the first two years of the contract and subsequent options exercisable by BARDA to provide additional funding. In September 2012, BARDA exercised an additional $15,798,000 contract option ("Option 1"), which increased the total contract committed funding to $43,398,000 through March 2014. In April 2013, the Company was awarded an additional $60,410,000 under the contract to support its Phase 3 clinical trial of plazomicin ("Option 2") to increase the total committed funding under this contract to $103,808,000. On May 26, 2016, the Company was awarded an additional $20 million ("Option 3") under the contract to support its Phase 3 EPIC trial of plazomicin. This brings the total committed funding under the contract to $123,808,000. The Company recorded contract revenue of $7,114,000 and $5,270,000 under this agreement during the three-month periods ended March 31, 2017 and 2016, respectively.

National Institute of Allergy and Infectious Diseases

In July 2015, the Company was awarded a contract by the National Institute of Allergy and Infectious Diseases ("NIAID") for $1.5 million committed through June 30, 2016, with total funding of up to $4.5 million available if all options are exercised under the contract. In January 2016, an additional committed funding of $0.5 million was added to the awarded funding and the total potential funding was increased to $5.0 million. In April 2016, NIAID modified the contract to exercise an option which increased the total contract committed funding to $4.4 million through February 2018, with total potential funding remaining at $5.0 million if the remaining option is exercised.

In July 2014, the Company was awarded a one-year, $407,000 grant by NIAID to conduct discovery research on novel antibiotics targeting gram-negative bacteria. In July 2015, NIAID extended the grant term through July 31, 2016. The Company recorded contract revenue of $349,000 and $579,000 under these agreements during the three-month periods ended March 31, 2017 and 2016, respectively.

7. Borrowings

Solar Capital Ltd. Loan Agreement

Page 16 of 68

all of the Company’s assets except intellectual property (which is subject to a negative pledge) and contains customary affirmative and negative covenants, and also includes standard events of default, including payment defaults. Upon the occurrence of an event of default, a default interest rate of an additional 4% may be applied to the outstanding loan balances, and the Lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. There were no financial covenants attached to the loan. The Loan Agreement included a closing fee of $250,000 which was paid at closing, and the Company is obligated to pay a fee equal to 8% of the term loans funded upon the earliest to occur of the maturity date, the acceleration of the term loans or the voluntary prepayment of the term loans. The cost of these fees is being amortized as interest expense over the term of the loan using the effective-interest method. The Company may voluntarily prepay all, but not less than all, of the outstanding term loans. The Loan Agreement contains customary representations, warranties and covenants. In addition, the Loan Agreement contains customary events of default that entitle the Lender to cause the Company’s indebtedness under the Loan Agreement to become immediately due and payable.

On August 5, 2015, pursuant to the Loan Agreement, the Company entered into a Success Fee Agreement with the Lender under which the Company agreed to pay the Lender $1.0 million if the Company obtains FDA approval to market plazomicin. If such approval is obtained, the Success Fee shall be due the later of (i) August 5, 2019 or (ii) the date such FDA approval is obtained. The fair value of the Success Fee at the date of issuance of approximately $356,000 was recorded as a debt discount and is being amortized as interest expense over the term of the loan using the effective-interest method.

Future principal debt payments on the currently outstanding term loan are payable as follows (in thousands):

	March 31, 2017
2017	$	4,167
2018		12,500
2019		8,333
Total principal payments		25,000
Final fee due at maturity in 2019		2,000
Total principal and final fee payments		27,000
Unamortized discount and debt issuance costs		(1,516	)
Less current portion		(7,292	)
Loan payable, long-term	$	18,192

The obligation includes a final fee of $2,000,000, representing 8% of the term loan currently funded, which accretes over the life of the loan as interest expense. The Company recorded interest expense related to the loan of $0.7 million and $0.4 million for the three-month periods ended March 31, 2017 and 2016, respectively.

8. Stockholders' Equity

On April 7, 2015, the Company entered into a Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”), pursuant to which the Company may issue and sell shares of its common stock having aggregate sales proceeds of up to $30.0 million from time to time through an ATM equity program under which Cowen acts as sales agent.

As of March 31, 2017, the Company had sold 1,105,549 shares of common stock under the Sales Agreement, at a weighted-average price of approximately $4.82 per share for aggregate gross proceeds of $5.3 million and net proceeds of $5.1 million after deducting the sales commissions and offering expenses. As of March 31, 2017, $24.7 million of common stock remained available to be sold under the Sales Agreement, subject to certain conditions specified therein.

On June 3, 2016, the Company sold 7,999,996 shares of its common stock and warrants to purchase 1,999,999 shares of its common stock pursuant to the Purchase Agreement for aggregate gross proceeds of $25.4 million in the Private Placement. The warrants have an exercise price of $3.66 and are exercisable up to five years from the date of issuance. The Company's Chief Operating Officer, a related party, participated in the Private Placement by purchasing 141,453 shares of common stock and a warrant to purchase 35,363 shares of common stock for an aggregate purchase price of $0.5 million. Issuance costs of $0.3 million were offset against equity as a reduction from gross proceeds.

At the close of the Private Placement, the estimated fair values of the common stock and warrants issued were $22.9 million and $2.6 million, respectively. At March 31, 2017, using Black-Scholes, the Company estimated the fair value of the remaining warrants outstanding to be $27.3 million and recorded a charge of $11.3 million and $13.4 million, for the increase in the liability, in the condensed consolidated statements of operations, for the year ended December 31, 2016 and three-month period ended March 31, 2017, respectively.

Page 17 of 68

Equity Incentive Plans

2014 Equity Incentive Award Plan

In February 2014, the Company’s stockholders approved the 2014 Equity Incentive Award Plan (the "2014 Plan"), which became effective as of March 11, 2014. Under the 2014 Plan, the Company may grant incentive stock options ("ISOs"), nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units ("RSUs") and other stock-based awards for the purchase of that number of shares of common stock. Effective, January 1, 2017, the compensation committee of the board of directors approved an evergreen increase of 1,425,522 shares that may be granted in accordance with the terms of the 2014 Plan. As of March 31, 2017, 909,040 shares were available for future issuance under the 2014 Plan.

Under the 2014 Plan, the terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2014 Plan. Options granted by the Company typically vest over a four year period and the exercise price may not be less than fair market value on the date of grant. Certain of the options are subject to acceleration of vesting in the event of certain change of control transactions. Options granted under the 2014 Plan expire no later than 10 years from the date of grant.

2014 Employment Commencement Incentive Plan

In December 2014, the Company adopted a 2014 Employment Commencement Incentive Plan (the "Inducement Plan"). The Inducement Plan is designed to comply with the inducement exemption contained in Nasdaq’s Rule 5635(c)(4), which provides for the grant of non-qualified stock options, RSUs, restricted stock awards, performance awards, dividend equivalents, deferred stock awards, deferred stock units, stock payment and stock appreciation rights to a person not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to the individual’s entering into employment with the Company. As of March 31, 2017, a total of 1,600,000 shares of common stock have been authorized under the Inducement Plan, including the additional 450,000 shares that became available resulting from an amendment adopted by the board of directors as of February 22, 2017. As of March 31, 2017, 356,588 shares were available for future issuance under the Inducement Plan.

2014 Employee Stock Purchase Plan

In February 2014, the Company’s stockholders approved the 2014 Employee Stock Purchase Plan (the “ESPP”), which became effective as of March 11, 2014. Effective, January 1, 2017, the compensation committee of the board of directors approved an evergreen increase of 178,190 shares that may be granted in accordance with the terms of the ESPP. As of March 31, 2017, 225,261 shares of common stock have been issued to employees participating in the ESPP, and 461,406 shares are available for issuance under the ESPP.

Amended and Restated 2003 Stock Plan

The Company’s Amended and Restated 2003 Stock Plan (the "2003 Plan"), provided for the granting of incentive and non-statutory stock options to employees, directors and consultants at the discretion of the board of directors. The Company granted options under its 2003 Plan until January 2014 and it was terminated as to future awards in March 2014, although it continues to govern the terms of options that remain outstanding under the 2003 Plan.

Options granted under the 2003 Plan expire no later than 10 years from the date of grant. Options granted under the 2003 Plan vest over periods determined by the board of directors, generally over four years.

The 2003 Plan allows for early exercise of certain options prior to vesting. Upon termination of employment, the unvested shares are subject to repurchase at the original exercise price. Stock options granted or modified after March 21, 2002, that are subsequently exercised for cash prior to vesting, are not deemed to be issued until those shares vest. As of March 31, 2017 and December 31, 2016 there were no shares subject to repurchase relating to the early exercise of options.

In connection with the board of directors’ and stockholders’ approval of the 2014 Plan, all remaining shares available for future awards under the 2003 Plan were transferred to the 2014 Plan, and the 2003 Plan was terminated as to future awards. As of March 31, 2017, a total of 862,720 shares of common stock are subject to options outstanding under the 2003 plan, which shares will become available under the 2014 Plan to the extent the options are forfeited or lapse unexercised.

Page 18 of 68

The following table summarizes stock option activity under the stock plans, excluding the ESPP, and related information:

	Shares Available for grant			Shares Subject to Options Outstanding			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (years)
Balance, December 31, 2016		639,374			3,540,293		$	6.31		7.98
Additional shares authorized		1,875,522			—
Options granted		(1,067,657	)		1,067,657		$	23.23
Options exercised		—			(54,585	)	$	9.79
Options cancelled		83,178			(83,178	)	$	6.61
RSUs granted		(288,064	)		—
RSUs cancelled		23,275			—
Balance, March 31, 2017		1,265,628			4,470,187		$	10.31		7.90

Stock-based compensation expense recognized for stock options granted to employees and non-employee directors in the Company’s condensed consolidated statements of operations was as follows (in thousands):

	Three Months Ended March 31,
	2017		2016
Research and development	$	1,602	$	454
General and administrative		1,090		373
Total	$	2,692	$	827

Stock based compensation expense for the three-month period ended March 31, 2017 includes $0.7 million of expense that relate to stock options and restricted stock units held by the former Chief Medical Officer, which were modified upon his resignation in March 2017, including $0.7 million related to such modifications.

As of March 31, 2017, approximately $20,534,000 of total unrecognized stock-based compensation expense related to unvested stock options is expected to be recognized over a weighted-average period of 3.37 years.

The estimated grant date fair value of employee stock options with time-based vesting terms was calculated using the Black-Scholes valuation model, based on the following assumptions:

	Three Months Ended March 31,
	2017		2016
Expected term	6.0 years		6.0 years
Expected volatility	80%–81%			73%
Risk-free interest rate	2.0%–2.1%			1.4%
Expected dividend yield		—%		—%

Stock Options Granted to Non-Employees

During the three-month periods ended March 31, 2017 and 2016, the Company did not grant any stock options to non-employees. The Company recorded non-employee stock-based compensation expense of approximately $219,000 and zero for the three-month periods ended March 31, 2017 and 2016, respectively. The Company measures the estimated fair value of the award for each period until the award is fully vested. The non-employee stock-based compensation expense, during the three-month period ended March 31, 2017, was estimated using Black-Scholes with the following assumptions:

	Three Months Ended March 31,
	2017
Expected term	0.51 years
Expected volatility		77%
Risk-free interest rate		0.9%
Expected dividend yield		—%

Page 19 of 68

Restricted Stock Units Granted to Employees

During the three-month period ended March 31, 2017, the Company granted RSUs to employees to receive 288,064 shares of common stock under the Company's stock plans with a weighted-average estimated grant-date fair value of $21.90 per share. RSUs generally vest annually over a 4-year service period and vesting is contingent on continued service. As of March 31, 2017, there were unrecognized compensation costs of $8,401,000 related to outstanding RSUs, which are expected to be recognized over a weighted-average period of 3.33 years.

A summary of RSU activity is as follows:

	RSU Awards Outstanding
	Number of Shares			Weighted-Average Grant Date Fair Market Value		Aggregate Intrinsic Value (in thousands)
Balance, December 31, 2016		605,052		$	5.60	$	7,878
RSUs granted		288,064		$	21.90
RSUs released		(69,183	)	$	5.11
RSUs cancelled		(23,275	)	$	6.32
Balance, March 31, 2017		800,658		$	11.49	$	20,201

Stock Options and Restricted Stock Units Granted to Employees that Contain Performance Conditions

During the three-month periods ended March 31, 2017 and 2016, the Company granted options to purchase an aggregate of 142,200 and 199,750 shares of common stock, respectively, and 25,800 and 47,425 RSUs, respectively, that vest upon the achievement of market-based common stock price targets.

The fair value was estimated at the grant date using a Monte-Carlo simulation model (“Monte-Carlo”), which requires the use of a range of assumptions. The expected life assumption is not used in Monte-Carlo, but the output of the model indicates an expected term. The associated stock-based compensation expense is being recognized on a straight-line basis over the implicit service period (expected time to vest) derived from Monte-Carlo. The fair value of awards granted to employees was estimated using Monte-Carlo with the following assumptions:

	Three Months Ended March 31,
	2017		2016
Expected term	0.5–2.0 years		3.0–6.0 years
Expected volatility	70%			70%
Risk-free interest rate		2.4%		1.8%
Expected dividend yield		—%		—%

9. Commitments

Commercial Manufacturing Agreement

In March 2017, the Company entered into a commercial validation and manufacturing agreement (the “Manufacturing Agreement”) with Hovione Limited (“Hovione”). Under the Manufacturing Agreement, Hovione has agreed to complete the validation program to validate and scale up the Company’s technology to manufacture the active pharmaceutical ingredient for plazomicin (the “Product”) and supply the Product to the Company. The Manufacturing Agreement has an initial term of seven years after the first delivery of the Product.

Subject to the successful completion of the validation program and the Company’s launch of plazomicin, the Company has agreed to purchase a minimum quantity of the Product from Hovione depending on the Company’s requirements and the period of time following approval by the FDA. For the first three years following approval of plazomicin by the FDA, the Company is required to purchase at least 80% of its required quantity from Hovione. Following the initial three years after FDA approval, the Company is required to purchase between 40% and 66% of its required quantity from Hovione, depending on the amounts required during any such fiscal year. Contingent upon FDA’s approval of plazomicin, the Company has minimum annual purchase commitments from Hovione, beginning in 2020 through 2024.

Page 20 of 68

resources, plus procurement of long lead raw materials, paid in full under a separate agreement executed in July 2015. Such advance payments are initially capitalized as prepaid and other current assets and will be recognized as research and development expenses as goods are delivered and/or services are performed. The Company assesses such prepaid and other current assets for impairment if events or changes in circumstances indicate that the carrying amount may not be recoverable or may not provide future economic benefits. Further, the Work Plans include certain terms that require the Company to compensate Hovione if it chooses to cancel the Work Plans (“Cancellation Clause”). As of March 31, 2017, $9.8 million is committed under the Cancellation Clause and the total aggregate amount of potential commitments, if all the services are rendered by Hovione, is approximately $28.1 million. As of March 31, 2017 and December 31, 2016, the Company has recorded approximately $4.8 million and $0.7 million, respectively as prepaid and other current assets and, during the three-month periods ended March 31, 2017 and 2016, has recognized $0.4 million and $0.1 million, respectively, as research and development expenses, related to the Work Plans.

In December 2016, the Company entered into an agreement with Hovione to procure certain long lead raw materials to be used in the commercial production of plazomicin (the “Raw Material Agreement”). The Raw Material Agreement includes $1.2 million in nonrefundable advance payments. As of March, 31 2017, the Company has recorded $1.2 million of these nonrefundable advance payments as prepaid and other current assets.

Facilities Lease Obligation

The Company leased its former principal executive offices in South San Francisco under a non-cancelable lease agreement that expired on April 14, 2017. In August 2016, the Company entered into a non-cancelable agreement (the "Lease") to lease approximately 47,000 square feet of office, laboratory and research and development space for the Company's new principal executive offices (“Premises”) in South San Francisco. The Lease commenced in March 2017, after the substantial completion of certain improvements ("Tenant Improvements") required under the Lease, set to expire in August 2027 ("Lease Term"), and the Company moved into the Premises in April 2017. The Lease contains expansion options and an option to extend the Lease Term for an additional 5 years. Base rent for the first year of the Lease Term is approximately $2.7 million, with an increase in annual base rent of approximately 3.5% in each subsequent year of the Lease Term. The Lease also provides for rent abatement of approximately $1.8 million for the first year of the Lease Term.

The Company is entitled to a one-time improvement allowance of $5.7 million for the Tenant Improvements (the "Allowance"). The Landlord disburses the Allowance for the Tenant Improvement on behalf of the Company. As of March 31, 2017, the Company has recorded approximately $5.9 million within construction-in-progress under property, plant and equipment, net and other current liabilities in the condensed consolidated balance sheet related to costs incurred under the Allowance. At its election, the Company is also entitled to an additional improvements allowance of $0.9 million ("Additional Allowance"). In the event the Company elects to use the Additional Allowance, the base rent will be increased as calculated in the Lease. Further, the Company had a deposit of $250,000 included in long-term restricted cash as of March 31, 2017, restricted from withdrawal and held in a money market account with one of the Company’s financial institutions in the form of collateral for a letter of credit held as security for the Lease.

Future minimum lease payments under the operating leases as of March 31, 2017 are as follows (in thousands):

Year Ending December 31,	Amounts
2017	$	663
2018		2,353
2019		2,890
2020		2,991
2021		3,098
Thereafter		20,036
Total minimum lease payments	$	32,031

The Company recognizes rent expense on a straight-line basis over the non-cancelable lease period. Rent expense was $211,000 and $146,000 for the three-month periods ended March 31, 2017 and 2016, respectively.

10. Subsequent Events

In May 2017, the Company entered into an agreement with the Bill & Melinda Gates Foundation (the “Gates Foundation”) to discover drug candidates against gram-negative pathogens intended to prevent neonatal sepsis (the “Grant Agreement”). Pursuant to the Grant Agreement, the Gates Foundation awarded the Company up to approximately $10.5 million in grant funding over a three-year research term, of which approximately $3.2 million will be advanced to the Company within 15 days after signing (the “Advance Funds”). The Advance Funds are replenished by the Gates Foundation each calendar year, or sooner, following the Company’s submission of a progress report, including expenses incurred for the research activities. Under certain conditions, as described in the

Page 21 of 68

Grant Agreement, the Gates Foundation may terminate the Grant Agreement and the Company is obligated to return to the Gates Foundation any unused portion of the Advance Funds.

Concurrently with the Grant Agreement, the Company entered into a Common Stock Purchase Agreement with the Gates Foundation, pursuant to which the Company agreed to sell 407,331 shares of its redeemable common stock (the “Shares”) to the Gates Foundation in a private placement at a purchase price per share equal to $24.55, for gross proceeds to the Company of $10.0 million (“Gates Investment”).

In connection with the Grant Agreement and the Gates Investment, the Company entered into a strategic relationship with the Gates Foundation (the “Letter Agreement”). Under the terms of the Letter Agreement, the Advanced Funds and the Gates Investment may only be used to conduct mutually agreed upon work, including the scale up of the Company’s platform technology to launch a product intended to prevent neonatal sepsis (the “NSP”). If the Company defaults in its obligation to conduct certain mutually-agreed upon work or use the proceeds from the Gates Investment as described in the Letter Agreement, or otherwise triggers certain other events of default as described in the Letter Agreement (“Charitable Default”), subject to a cure period, the Gates Foundation will have the right to request that (a) the Company redeem, or facilitate the purchase by a third party of, the Shares then held by the Gates Foundation at a price per share equal to the greater of (i) the fair market value of the common stock (if the Shares are freely tradable, the closing price of the Company’s common stock on the trading day prior to the redemption or purchase, as applicable), or (ii) an amount equal to $24.55 plus a compounded annual return of 5% from the date of issuance of the Shares, or (b) if the Shares then held by the Gates Foundation are not freely tradeable, the Company register the resale of the Shares held by the Gates Foundation on an effective registration statement, subject to certain conditions and qualifications.

Pursuant to the Letter Agreement, the Company agreed to make the NSP available and accessible in certain developing countries and to grant the Gates Foundation a non-exclusive license to commercialize selected drug candidates in specified developing countries, which may only be exercised in the event of a Charitable Default (the “Global Access”). The Global Access will continue in effect until the earlier of 25 years from the closing of the Gates Investment or 7 years following the termination of all funding provided by the Gates Foundation; provided, that the Global Access will continue for any products or services developed with funding provided by the Gates Foundation which continue to be developed or available in certain developing countries.

Page 22 of 68

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2016.

In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements are often identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “estimate,” or “continue,” and similar expressions or variations. These forward-looking statements are subject to risks and uncertainties, including those set forth in Part II – Other Information, Item 1A. Risk Factors below and elsewhere in this report, that could cause actual results to differ materially from historical results or anticipated results. The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.

Overview

We are a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterial treatments against multi-drug resistant (“MDR”) gram-negative infections. We are researching and developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (“cUTI”), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (“CRE”). In 2013, the Centers for Disease Control and Prevention identified CRE as a “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action” and in 2017 the World Health Organization identified CRE as a Global Priority 1 Pathogen: Critical Need for Research and Development of New Antibiotics.

On December 12, 2016, we announced positive data from our two Phase 3 clinical trials for plazomicin. The first study, a Phase 3 trial of plazomicin for the treatment of patients with cUTI and acute pyelonephritis (“AP”), entitled EPIC (Evaluating Plazomicin In cUTI), is expected to serve as a single pivotal study supporting a new drug application (“NDA”) for plazomicin in the United States. The Phase 3 EPIC trial is a randomized, double blind, active controlled study in patients with cUTI and AP and allowed broad enrollment of patients with gram-negative infections. We reached agreement with the U.S. Food and Drug Administration (“FDA”) that this trial, with a 15% non-inferiority margin, comparing plazomicin to meropenem is acceptable as the single study required for potential approval. The first patient was enrolled in the Phase 3 EPIC trial in January 2016 and enrollment was closed in August 2016 with 609 patients.

In the EPIC trial, plazomicin successfully met or exceeded the objective of non-inferiority compared to meropenem for the FDA-specified primary efficacy endpoints, and achieved superiority for the primary efficacy endpoints specified by the European Medicines Agency (“EMA”). Results for the FDA pre-specified composite endpoint of clinical cure and microbiological eradication in the microbiological modified intent-to-treat (“mMITT”) population at Day 5 achieved statistical non-inferiority, and Test-of-Cure (Day ~17) achieved statistical superiority. Results for EMA-specified endpoints of microbiological eradication at the test-of-cure visit achieved statistical superiority in both the mMITT and microbiologically evaluable (“ME”) populations. Plazomicin was generally well tolerated with no new safety concerns identified in the EPIC trial.

The second study, our Phase 3 CARE (Combating Antibiotic Resistant Enterobacteriaceae) trial was a resistant pathogen trial designed to evaluate the efficacy and safety of plazomicin in patients with serious bacterial infections due to CRE. We closed enrollment in the CARE study in August 2016 with 69 patients, comprised of 39 patients enrolled in Cohort 1, comparing plazomicin to colistin-based therapy in patients with bloodstream infections or pneumonia due to CRE, and 30 patients in Cohort 2, a single arm cohort of plazomicin treatment in patients with serious infections due to CRE. In Cohort 1 of the CARE trial, a lower rate of mortality or serious disease-related complications was observed for plazomicin compared with colistin therapy. The safety profile of plazomicin was favorable to that of colistin in critically ill patients in the CARE trial.

We plan to submit an NDA, which will include data from both the EPIC and CARE Phase 3 clinical trials, to the FDA in the second half of 2017, with a planned commercial launch of plazomicin in the United States in 2018, if our NDA is approved. We also plan to submit a Marketing Authorization Application to the EMA for plazomicin in 2018.

In May 2017, we entered into an agreement with the Bill & Melinda Gates Foundation (the “Gates Foundation”) to discover drug candidates against gram-negative pathogens intended to prevent neonatal sepsis (the “Grant Agreement”). Pursuant to the Grant Agreement, the Gates Foundation awarded us up to approximately $10.5 million in grant funding over a three-year research term, of which approximately $3.2 million will be advanced to us within 15 days after signing (the “Advance Funds”). Concurrently with the

Page 23 of 68

Grant Agreement, we entered into a Common Stock Purchase Agreement with the Gates Foundation, pursuant to which we agreed to sell 407,331 shares of our redeemable common stock to the Gates Foundation in a private placement at a purchase price per share equal to $24.55, for gross proceeds to us of $10.0 million (“Gates Investment”). In connection with the Grant Agreement and Gates Investment, we entered into a strategic relationship with the Gates Foundation (the “Letter Agreement”). Under the terms of the Letter Agreement, the Gates Investment and Advanced Funds may only be used to conduct mutually agreed upon work, including the scale up of our platform technology to launch a product intended to prevent neonatal sepsis (the “NSP”). Pursuant to the Letter Agreement, we agreed to make the NSP available and accessible in certain developing countries and to grant the Gates Foundation a non-exclusive license to commercialize selected drug candidates in specified developing countries, which may only be exercised in the event of certain defaults as described in the Letter Agreement (the “Global Access”). The Global Access will continue in effect until the earlier of 25 years from the closing of the Gates Investment or 7 years following the termination of all funding provided by the Gates Foundation; provided, that the Global Access will continue for any products or services developed with funding provided by the Gates Foundation which continue to be developed or available in certain developing countries.

In 2012, the FDA granted fast-track designation for the development and regulatory review of plazomicin to treat serious and life-threatening CRE infections. In 2014, plazomicin received Qualified Infectious Disease Product (“QIDP”) designation from the FDA. The QIDP designation was created by the Generating Antibiotic Incentives Now Act (the “GAIN Act”), which was part of the FDA Safety and Innovation Act and provides certain incentives for the development of new antibiotics, including eligibility for priority review and of the NDA extension by an additional five years of any existing market exclusivity the product may be granted upon approval. Our plazomicin program has been funded in part with a contract from the Biomedical Advanced Research and Development Authority (“BARDA”) for up to $123.8 million and as of March 31, 2017, $0.1 million remained available from the funding committed under the BARDA contract. We have global commercialization rights to plazomicin, which has patent protection in the United States extending through at least 2031.

Since commencing operations in 2004, we have devoted substantially all of our resources to identifying and developing our product candidates, including conducting preclinical studies and clinical trials and providing general and administrative support for these functions. In addition to plazomicin, our research team is focused on discovering medicines with novel mechanisms of action for serious infections caused by gram-negative bacteria, including MDR Escherichia coli, MDR Klebsiella pneumoniae, MDR Pseudomonas aeruginosa and MDR Acinetobacter baumannii.

We recently announced our orally-available antibacterial candidate, C-Scape, a combination of an approved β-lactam and an approved β-lactamase inhibitor. We believe that C-Scape has the potential to rapidly address a serious unmet need for an effective oral treatment for patients with cUTI, including AP, caused by ESBL-producing Enterobacteriaceae. We intend to begin a Phase 1 study outside the United States in the second quarter of 2017. We intend to initiate a single pivotal Phase 3 study in patients with cUTI, including AP, who are suitable for treatment with oral antibiotics, by the first half of 2018. We also have a program to discover and develop small molecule inhibitors of LpxC (an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria), which could be ready to file an investigational new drug application (“IND”) as early as 2018. Our therapeutic antibody program is utilizing a built-for-purpose discovery platform to identify and develop monoclonal antibodies for the treatment of MDR bacterial infections. We are also pursuing small molecule research and development programs targeting other essential gram-negative enzymes. We are taking a multifaceted approach to identify new antibacterial agents through our research. In May 2016, we entered into a collaboration and license agreement with Crystal Biosciences, Inc. to identify and generate therapeutic antibodies against multiple novel targets.

Since our inception, we have financed our operations with the proceeds from our initial public offering (“IPO”) of our common stock, proceeds from the underwritten public offering of our common stock, proceeds from sales of our common stock through the use of our at-the-market (“ATM”) equity offering program, funding under our contracts with government agencies, private placements of our equity securities and certain debt-related financing arrangements.

Our plazomicin program is funded in part with a contract from BARDA. Our other programs are currently funded primarily with company funds, although we also received a contract for $4.4 million in 2015 from the National Institute of Allergy and Infectious Diseases (“NIAID”), with additional funding of up to $0.6 million available if all options are exercised. Historically, our preclinical programs have received funding support from organizations in addition to the NIH, such as the U.S. Department of Defense and The Wellcome Trust, a global charitable foundation. We intend to continue to seek further collaborations with government agencies, non-profit foundations, and other research and development funding organizations to support our discovery efforts and advance the product candidates in our pipeline.

On March 17, 2014, we completed our IPO of common stock. We sold 6,900,000 shares of our common stock, which included 900,000 shares issued as a result of the underwriters exercising their over-allotment option in full. We received cash proceeds of approximately $73.9 million from the IPO, net of underwriting commissions and related expenses.

On April 7, 2015, we entered into the Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”), pursuant to which we may issue and sell shares of our common stock having aggregate sales proceeds of up to $30.0 million from time

Page 24 of 68

to time through an ATM equity offering program under which Cowen acts as sales agent. As of March 31, 2017, we had sold 1,105,549 shares under the Sales Agreement at an average price of $4.82 per share and we received aggregate cash proceeds of $5.1 million, after deducting the sales commissions and offering expenses.

On May 26, 2016, BARDA exercised an additional option ("Option 3") under its existing contract, and we were awarded an additional $20.0 million in contract funding. Option 3 also includes a no-cost extension of the period of performance for Option 1 to September 20, 2016, under the contract to support our Phase 3 EPIC trial of plazomicin. The funding from Option 3 is focused on the Phase 3 pivotal clinical trial of plazomicin, the EPIC study, in cUTI. This brings the total committed funding under the contract to $123.8 million.

On June 3, 2016, we sold 7,999,996 shares of common stock and warrants to purchase 1,999,999 shares of common stock pursuant to a Securities Purchase Agreement (“Purchase Agreement”) for aggregate gross proceeds of $25.4 million and aggregate net proceeds of $25.1 million, after deducting the issuance costs, in a private placement financing transaction (the "Private Placement"). The warrants have an exercise price of $3.66 and are exercisable up to five years from the date of issuance.

On December 19, 2016, we completed an underwritten public offering of common stock, which resulted in the sale of 7,475,000 shares, at a price of $13.50 per share to the public, including the full exercise of the underwriters’ option to purchase an additional 975,000 shares of common stock. We received net proceeds from the offering of $94.6 million, after deducting the underwriting discounts and commissions and estimated offering expenses.

We have never been profitable and have incurred net losses in each year since the commencement of our operations. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and associated general and administrative costs. We expect to incur substantial losses from operations in the foreseeable future as we advance plazomicin and other product candidates through preclinical and clinical development, seek regulatory approval, and prepare for, if approved, commercialization. Management expects that, based on its current operating plans, our existing cash, cash equivalents and short-term investments, will be sufficient to fund our current planned operations for at least the next twelve months from the issuance of these financial statements. We will be required to obtain further funding through public or private equity offerings, debt financings, collaboration and licensing arrangements or other sources to fund the commercial launch of plazomicin and continued progress with our research and development efforts. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy.

We have no manufacturing facilities and all of our manufacturing activities are contracted out to third parties. Additionally, we currently utilize third-party clinical research organizations (“CROs”) to carry out our clinical development and we do not yet have an established sales organization. We will need substantial additional funding to support our operating activities and adequate funding may not be available to us on acceptable terms, or at all.

Financial Overview

Contract Revenue

We have derived all of our revenue to date from funding provided under U.S. government contracts in connection with the development of our product candidates. Our product candidates are still in clinical and preclinical development and may never be successfully developed or commercialized. Other than this contract revenue from government funding, we do not expect to derive any revenue from any product candidates that we develop until we obtain regulatory approval and commercialize such products, which we do not expect will occur before 2018, if at all, or until such time that we potentially enter into collaboration agreements with third parties for the development and commercialization of such product candidates.

Biomedical Advanced Research and Development Authority (BARDA). We have received funding for our lead product candidate, plazomicin, under a contract with BARDA, an agency of the U.S. Department of Health and Human Services for the development, manufacturing, nonclinical and clinical evaluation of, and regulatory filings for, plazomicin as a countermeasure for disease caused by antibiotic-resistant pathogens and biothreats. Our BARDA contract provides for payments to us based on direct costs incurred and allowances for overhead, plus a fee, where applicable. The total committed funding under our BARDA contract is $123.8 million, including $20.0 million for Option 3, exercised by BARDA on May 26, 2016. The exercised option relates to the support of our Phase 3 EPIC study and the preparation and submission of an NDA to the FDA.

Page 25 of 68

For the three-month periods ended March 31, 2017 and 2016, total revenue recognized under the BARDA contract was $7.1 million and $5.3 million, respectively. Through March 31, 2017, a total of $123.7 million under the BARDA contract was recorded as revenue, with $0.1 million remaining available from the funding committed under the contract.

National Institute of Allergy and Infectious Diseases (NIAID). In July 2014, the Company was awarded a one-year, $0.4 million grant by NIAID to conduct discovery research on novel antibiotics targeting gram-negative bacteria. The contract was subsequently modified to extend through July 31, 2016.

In July 2015, the Company was awarded a contract by NIAID for $1.5 million committed through September 30, 2016, with total funding of up to $4.5 million available if all options are exercised under the contract. In January 2016, an additional committed funding of $0.5 million was added to the awarded funding and the total potential funding was increased to $5.0 million. In April 2016, NIAID modified the contract to exercise an option which increased the total contract committed funding to $4.4 million through February 2018, with total potential funding remaining at $5.0 million if the remaining option is exercised.

For the three-month periods ended March 31, 2017 and 2016, total revenue recognized under the NIAID contracts was $0.3 million and $0.6 million, respectively.

Research and Development Expenses

Research and development expenses consist primarily of costs associated with research, discovery and preclinical studies of potential new drug compounds, plus product development efforts related to clinical trials and materials manufacturing processes. Research and development costs are expensed as incurred and include the following:

•

expenses incurred under agreements with contract research organizations, investigative sites, and consultants that conduct our clinical trials and a substantial portion of our preclinical activities;

•

employee and consultant-related expenses, which include salaries, benefits, stock-based compensation and consulting fees;

•

third-party supplier expenses including the cost of acquiring and manufacturing clinical trial and other materials; and

•

facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, amortization or depreciation of leasehold improvements, equipment and laboratory supplies and other expenses.

Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as an expense as the goods are delivered or the related services are performed.

We expect to continue to incur substantial expenses for the foreseeable future related to our research and development activities as we continue research programs and the development of our product candidates. Further, we have incurred substantial research and development costs associated with our plazomicin program as our Phase 3 EPIC and CARE trials have completed patient enrollment. We expect to continue to incur substantial research and development expenses in the future as we continue to support plazomicin development, including preparations to submit an NDA for plazomicin to the FDA.

General and Administrative Expenses

General and administrative expenses consist principally of personnel-related costs, professional fees for legal, consulting, audit and tax services, rent and other general operating expenses not otherwise included in research and development. We anticipate general and administrative expenses will continue to increase in future periods, reflecting an expanding infrastructure in preparation for commercialization of plazomicin, if approved.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of financial condition and results of operations are based upon our unaudited condensed financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an on-going basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions. Our significant accounting policies are more fully described in Note 2 of the accompanying unaudited condensed consolidated financial statements and in Note 2 to our audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2016.

Page 26 of 68

During the three-month period ended March 31, 2017, there were no material changes to our critical accounting policies. Our critical accounting policies are described under Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2016.

Results of Operations

Comparison of the Three-Month Periods Ended March 31, 2017 and 2016

	Three Months Ended March 31,
	2017			2016			Change
Contract revenue	$	7,463		$	5,849		$	1,614
Operating expenses
Research and development		18,597			13,893			4,704
General and administrative		6,751			3,777			2,974
Total operating expenses		25,348			17,670			7,678
Loss from operations		(17,885	)		(11,821	)		(6,064	)
Interest expense		(706	)		(438	)		(268	)
Change in warrant and derivative liabilities		(14,956	)		(12	)		(14,944	)
Other income, net		288			74			214
Net loss	$	(33,259	)	$	(12,197	)	$	(21,062	)

Contract Revenue

Contract revenue in each period related solely to funding pursuant to our government contracts. Contract revenue increased $1.7 million to $7.5 million in the three-month period ended March 31, 2017 from $5.8 million in the comparable period in 2016. This increase was primarily due to an increase in research and development services performed under our BARDA contract.

Research and Development Expenses

Research and development expenses increased $4.7 million to $18.6 million in the three-month period ended March 31, 2017 from $13.9 million in the comparable period in 2016. This was primarily due to increases of $5.4 million in personnel and facility related costs as net headcount increased by 37 employees in our research and development organization since March 2016, including $1.1 million for stock compensation expense, of which $0.7 million of expense relate to equity awards held by our former Chief Medical Officer that were modified in connection with his resignation in March 2017, $1.2 million in external expenses related to C-Scape, mainly attributed to start-up costs for our Phase 1 study, partially offset by a decrease of $1.9 million in the external expenses related to our plazomicin program, mainly attributable to the completion of the Phase 3 studies.

We record research and development expenses by program where directly identifiable. In the table below, we have allocated indirect research and development costs based on time charged directly to programs by research and development employees. Indirect research and development costs include employee benefit expenses, employee time not charged directly to a program, laboratory supplies and expenses, and allocated facility expenses.

	Three Months Ended March 31,
	2017		2016		Change
	(in thousands)
Research and development expenses by program:
Plazomicin	$	12,244	$	11,263	$	981
C-Scape		2,650		—	$	2,650
Other research programs		3,703		2,630		1,073
Total research and development expenses	$	18,597	$	13,893	$	4,704

General and Administrative Expenses

General and administrative expenses increased $3.0 million to $6.8 million for the three-month period ended March 31, 2017 from $3.8 million for the comparable period in 2016. The increase in general and administrative expenses was primarily due to an increase of $2.0 million in personnel and facility related costs, including $0.7 million for stock compensation expense, as net headcount increased by 19 employees, an increase of $0.8 million in costs to prepare for registration and commercialization of plazomicin and $0.2 million in consulting and professional fees.

Interest Expense

Page 27 of 68

Interest expense increased $0.3 million to $0.7 million for the three-month period ended March 31, 2017 from $0.4 million for the comparable period in 2016. The increase was a result of an additional $10.0 million of borrowings under the Solar Capital loan agreement in June 2016.

Change in Warrant and Derivative Liabilities

Change in warrant and derivative liabilities increased to $15.0 million for the three-month period ended March 31, 2017 from nil for the comparable period in 2016. The increase is primarily due to the change in the estimated fair value of the warrant liability, which increased mainly due to the change in our stock price.

Liquidity and Capital Resources

	Three Months Ended March 31,
	2017			2016
	(in thousands)
Cash Flows from Continuing Operations:
Net cash used in operating activities	$	(13,418	)	$	(8,866	)
Net cash provided by (used in) investing activities		(68,688	)		8,011
Net cash provided by financing activities		781			—
Net increase in cash, cash equivalents and restricted cash	$	(81,325	)	$	(855	)

Cash Flows from Operating Activities

Net cash used in operating activities was $13.4 million for the three-month period ended March 31, 2017. The primary use of cash was to fund our operations related to the research and development of our product candidates. Our net loss from operations in the three-month period ended March 31, 2017 of $33.3 million was partially offset by non-cash charges of $15.0 million for the revaluation of the warrant and derivative liabilities, $0.1 million for depreciation and amortization, $0.2 million for non-cash interest expense, $2.9 million for stock-based compensation, and a change in net operating assets and liabilities of $1.7 million. The change in net operating assets and liabilities was primarily due to an increase in accounts payable, accrued liabilities and prepaid expenses and other assets, as a result of commitments and deferred research and development costs related to our commercial validation and manufacturing for plazomicin, partially offset by a decrease in contract receivables.

Net cash used in operating activities was $8.9 million for the three-month period ended March 31, 2016. The primary use of cash was to fund our operations related to the research and development of our product candidates. Our net loss from operations in the three-month period ended March 31, 2016 of $12.2 million was partially offset by non-cash charges of $0.1 million for depreciation and amortization, $0.2 million for amortization of premium on short-term investments and $0.8 million for stock-based compensation and a change in net operating assets and liabilities of $2.1 million. The change in net operating assets and liabilities was primarily due to an increase in accounts payable and accrued liabilities partially offset by a decrease prepaid expenses and other assets, as a result of costs related to preparing for our Phase 3 EPIC trial and the timing of our payments.

Cash Flows from Investing Activities

Net cash used in investing activities was $68.7 million for the three-month period ended March 31, 2017. The net cash used in investing activities during the three-month period ended March 31, 2017 is primarily a result of purchases in excess of maturities of short-term investments of $67.5 million and purchases of property, plant and equipment of $1.2 million related to our move into new corporate headquarters and to facilitate our research and development activities.

Net cash provided by investing activities was $8.0 million for the three-month period ended March 31, 2016. The net cash provided by investing activities during the three-month period ended March 31, 2016 is primarily a result of maturities in excess of purchases of short-term investments of $8.3 million. Other uses of cash in both periods resulted from purchases of property, plant and equipment to facilitate our increased research and development activities.

Cash Flows from Financing Activities

Net cash provided by financing activities was $0.8 million and zero for the three-month periods ended March 31, 2017 and 2016, respectively. The net cash provided by financing activities during the three-month period ended March 31, 2017 includes $0.3 million of proceeds from the exercise of certain warrants issued from the Private Placement and $0.5 million from issuance of common stock pursuant to our equity incentive plans.

Page 28 of 68

Plan of Operations and Future Funding Requirements

We expect to incur substantial expenditures in the foreseeable future for research, development and potential commercialization of our product candidates. Specifically, we have incurred and we expect to continue to incur substantial expenses in connection with our clinical development of plazomicin and C-Scape and the advancement our research and development programs. Management expects that, based on its current operating plans, our existing cash, cash equivalents and short-term investments as of March 31, 2017 will be sufficient to fund our current planned operations for at least the next twelve months from the issuance of these financial statements.

We anticipate that we will need to raise substantial additional financing in the future to fund our operations, including enabling us to commercially launch plazomicin. We may obtain additional financing through public or private equity offerings, debt financings, a credit facility, government contracts and/or strategic collaborations. Additional financing may not be available to us when we need it or it may not be available to us on acceptable terms, if at all. Our ability to obtain debt financing may be limited by covenants we have made under our loan and security agreement with Solar Capital Ltd. and our pledge to Solar Capital Ltd. of substantially all of our assets, other than our intellectual property, as collateral. The negative pledge in favor of Solar Capital Ltd. with respect to our intellectual property under the loan and security agreement could further limit our ability to obtain additional debt financing. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies.

The amount and timing of our future financing requirements will depend on many factors, including:

•

the size, timing and type of the nonclinical and clinical studies that we decide to pursue in the development of our product candidates, including plazomicin;

•

the type, number, costs and results of the product candidate development programs which we are pursuing or may choose to pursue in the future;

•

the rate of progress and cost of clinical trials we may commence, preclinical studies and other discovery and research and development activities;

•

the costs associated with developing a plazomicin IVD assay to support therapeutic drug monitoring;

•

the timing of, and costs involved in, seeking and obtaining FDA and other regulatory approvals, including the preparation of a NDA for plazomicin, and any supplemental applications thereto;

•

our ability to enter into additional collaboration, licensing or other arrangements and the terms and timing of such arrangements;

•

the costs of preparing, filing, prosecuting, maintaining and enforcing any patent claims and other intellectual property rights, including litigation costs and the results of such litigation;

•

the emergence of competing technologies and other adverse market developments;

•

the resources we devote to marketing, and, if approved, commercializing our product candidates;

•

the scope, progress, expansion, and costs of manufacturing our product candidates;

•

our ability to enter into additional government contracts, or other collaborative agreements, to support the development of our product candidates and development efforts; and

•

the costs associated with being a public company.

Contractual Obligations and Commitments

There have been no material changes to our contractual obligations and commitments as included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2017, except as noted below:

•

In March 2017, we executed certain work plans with Hovione Limited (“Hovione”) to carry out our validation and commercial manufacturing of plazomicin (the “Work Plans”). The Work Plans include certain terms that require us to compensate Hovione if we choose to cancel the Work Plans (“Cancellation Clause”). The total aggregate amount of potential commitments under the Work Plans is approximately $28.1 million, of which $9.8 million is committed under

Page 29 of 68

the Cancellation Clause, as of March 31, 2017. See Note 9 of the accompanying unaudited condensed consolidated financial statements for more information.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk.

There have not been any material changes to our exposure to market risk during the three-month period ended March 31, 2017. For additional information regarding market risk, refer to the Quantitative and Qualitative Disclosures About Market Risk section of our Annual Report on Form 10-K for the year ended December 31, 2016.

Item 4.

Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.

Our management, with the participation of our Chief Executive Officer and Principal Financial and Accounting Officer, has evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2017, the end of the period covered by this Quarterly Report on Form 10-Q. Based upon such evaluation, our Chief Executive Officer and Principal Financial and Accounting Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Page 30 of 68

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings.

We are not currently a party to any material litigation or other material legal proceedings.

Item 1A.

Risk Factors.

Risks Related to Our Business and Capital Requirements

We have a limited operating history, have incurred net losses in each year since our inception and anticipate that we will continue to incur significant losses for the foreseeable future, and if we are unable to achieve and sustain profitability, the market value of our common stock will likely decline.

We are a late-stage biopharmaceutical company with a limited operating history. We have not generated any revenue from the sale of products and have incurred losses in each year since we commenced operations in 2004. All of our product candidates are in development, and none has been approved for sale. In the years ended December 31, 2016 and 2015 and the three months ended March 31, 2017, we derived all of our revenue from government contracts for research and development. We will seek continued revenue from government contracts and additional sources of public health funding. Revenues from such government contracts and other sources can be uncertain because milestones or other contingent payments under them may not be achieved or received. In addition, we may not be able to enter into other contracts that will generate significant cash. Our net losses for the years ended December 31, 2016 and 2015 were $71.2 million and $27.1 million, respectively. Our net losses for the three months ended March 31, 2017 and 2016 were $33.3 million and $12.2 million, respectively. As of March 31, 2017, we had an accumulated deficit of $280.5 million.

We expect to continue incurring significant expenses and increasing operating losses for the foreseeable future as we seek marketing approvals from the U.S. Food and Drug Administration (“FDA”) and similar regulatory authorities outside the United States, build commercial supply and conduct pre-marketing activities for plazomicin, and continue the development of our other product candidates. Our expenses will also increase substantially if and as we:

•

conduct additional clinical trials for our product candidates;

•

continue to discover and develop additional product candidates;

•

establish a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval;

•

establish a manufacturing and supply chain sufficient for commercial quantities of any product candidates for which we may obtain marketing approval;

•

maintain, expand and protect our intellectual property portfolio;

•

hire additional clinical, scientific and commercial personnel;

•

add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, as well as operating as a public reporting company; and

•

acquire or in-license other product candidates and technologies.

If our product candidates fail to demonstrate safety and efficacy in clinical trials, do not gain regulatory approval, or do not achieve market acceptance following regulatory approval and commercialization, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ equity and working capital. If we are unable to achieve and sustain profitability, the market value of our common stock will likely decline. Because of the numerous risks and uncertainties associated with developing biopharmaceutical products, we are unable to predict the extent of any future losses or when, if ever, we will become profitable.

Page 31 of 68

We are substantially dependent on the approval and success of our lead product candidate, plazomicin. If we are unable to obtain marketing approval for and successfully commercialize plazomicin, or experience significant delays in doing so, our business could be materially harmed.

We currently have no products approved for sale, and since 2007, we have invested a significant portion of our efforts and financial resources in the development of plazomicin. Our future success is substantially dependent on our ability to successfully develop, obtain regulatory approval for and, ultimately, successfully commercialize plazomicin. Our ability to develop, obtain regulatory approval for, and successfully commercialize plazomicin effectively will depend on several factors, including the following:

•

receipt of marketing approvals from the FDA and similar regulatory authorities outside the United States;

•

receiving the product labeling that enables the successful promotion of plazomicin;

•

satisfying post-approval conditions or suggestions, if any, based on discussions with FDA;

•

establishing commercial manufacturing and supply arrangements;

•

establishing a commercial infrastructure;

•

identifying and successfully establishing one or more collaborations to commercialize plazomicin;

•

acceptance of the product by patients, the medical community and third-party payors;

•

establishing market share while competing with other therapies;

•

successfully executing our pricing and reimbursement strategy;

•

a continued acceptable safety and adverse event profile of the product following regulatory approval; and

•

qualifying for, identifying, registering, maintaining, enforcing and defending intellectual property rights and claims covering the product.

In addition, our product development and commercialization program includes the development of an in vitro diagnostic (“IVD”) assay or related diagnostic which must be developed and would need to successfully complete a clinical performance study in order to be approved or cleared for marketing by the FDA and certain other foreign regulatory agencies and then be commercialized concurrently with plazomicin in the associated markets for the appropriate populations. If we are unable to develop, receive marketing approval for plazomicin or an IVD assay in a timely manner or at all, we could experience significant delays to successfully commercialize plazomicin, which would materially and adversely affect our business, financial condition, and results of operations.

We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or terminate our product development, other operations or commercialization efforts and impact our status as a going concern.

Developing biopharmaceutical products, including conducting preclinical studies and clinical trials, is an expensive and highly uncertain process that takes years to complete. We expect our expenses to increase substantially as we seek marketing approval for our lead product candidate, plazomicin, and continue the development of our other product candidates. If we obtain marketing approval of plazomicin, we also expect to incur significant sales, marketing, manufacturing and supply expenses.

As of March 31, 2017, we had working capital of $121.7 million and unrestricted cash, cash equivalents and short-term investments of $132.0 million. Management expects that, based on its current operating plans, our existing cash, cash equivalents and short-term investments as of March 31, 2017, will enable us to fund our current planned operations for at least the next twelve months. In addition, other factors may arise causing us to need additional capital resources sooner than anticipated. We anticipate that we will need to raise substantial additional financing in the future to fund our operations.

We may obtain additional financing through public or private equity offerings, debt financings, a credit facility, government contracts and/or strategic collaborations. Additional financing may not be available to us when we need it or it may not be available to us on acceptable terms, if at all. Our ability to obtain debt financing may be limited by covenants we have made under our loan and security agreement with Solar Capital Ltd. and our pledge to Solar Capital Ltd. of substantially all of our assets, other than our intellectual property, as collateral. The negative pledge in favor of Solar Capital Ltd. with respect to our intellectual property under the loan and security agreement could further limit our ability to obtain additional debt financing. Our failure to raise capital as and when

Page 32 of 68

needed could have a negative impact on our financial condition and our ability to pursue our business strategies. The amount and timing of our future financing requirements will depend on many factors, including:

•

the size, timing and type of the nonclinical and clinical studies that we decide to pursue in the development of our product candidates, including plazomicin;

•

the type, number, costs and results of the product candidate development programs that we are pursuing or may choose to pursue in the future;

•

the rate of progress and cost of clinical trials we may commence, preclinical studies and other discovery and research and development activities;

•

the costs associated with developing a plazomicin IVD assay or related diagnostic to support therapeutic drug monitoring;

•

the timing of, and costs involved in, seeking and obtaining FDA and other regulatory approvals, including the preparation of a NDA for plazomicin, and any supplemental applications thereto;

•

our ability to enter into additional collaboration, licensing or other arrangements and the terms and timing of such arrangements;

•

the costs of preparing, filing, prosecuting, maintaining and enforcing any patent applications or claims and other intellectual property rights, including litigation costs and the results of such litigation;

•

the emergence of competing technologies and other adverse market developments;

•

the resources we devote to marketing, and, if approved, commercializing our product candidates;

•

the scope, progress, expansion, and costs of manufacturing our product candidates;

•

our ability to enter into additional government contracts, or other collaborative agreements, to support the development of our product candidates and development efforts; and

•

the costs associated with being a public company.

Future capital requirements will also depend on the extent to which we acquire or invest in additional complementary businesses, products and technologies. We currently have no understandings, commitments or agreements relating to any of these types of transactions.

If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials and we may not be able to continue as a going concern. We may also be required to sell or license to others technologies or clinical product candidates or programs that we would prefer to develop and commercialize ourselves.

Clinical drug development involves a lengthy and expensive process with uncertain outcomes that may lead to delayed timelines and increased cost, and may prevent us from being able to complete clinical trials.

Clinical testing is expensive, can take many years to complete, and its outcome and timeline is inherently uncertain. The results of preclinical and clinical studies of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies, and we cannot be certain that we will not face similar setbacks.

We expect to submit a New Drug Application (“NDA”) for plazomicin in the second half of 2017, with a planned commercial launch of plazomicin in the U.S. in 2018, if our NDA is approved. We also plan to submit a Marketing Authorization Application to the European Medicines Agency (“EMA”) for plazomicin in 2018.

We plan to submit the results to a peer-reviewed journal and for presentation at medical meetings in 2017. Based on physician market research, we believe the Phase 3 CARE study will provide important and meaningful data regarding the efficacy, safety, microbiology, and dosing, as well as important health economic data, to better inform use of plazomicin in the treatment of patients with CRE infections.

Page 33 of 68

We cannot be certain that our future clinical trials for plazomicin, or other product candidates, will progress as expected, not need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all, or support continued clinical development of the associated product candidate.

Clinical trials can be delayed, aborted or fail for a variety of reasons, including delay or failure:

•

to obtain regulatory approval to commence a trial in the countries where the trial is to be conducted;

•

to successfully initiate a clinical trial, enroll patients, and complete clinical trial activities in foreign countries;

•

to recruit and enroll suitable patients to participate in a trial;

•

to reach agreement on acceptable terms with prospective contract research organizations (“CROs”), clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

•

to obtain institutional review board (“IRB”) approval at each site;

•

to have patients complete a trial or return for post-treatment follow-up;

•

of clinical sites to adhere to trial protocols or continue to participate in a trial;

•

to address any patient safety concerns that arise during the course of a trial;

•

to address any conflicts with new or existing laws or regulations;

•

to add a sufficient number of clinical trial sites;

•

to manufacture sufficient quantities of product supply for use in clinical trials; or

•

to ensure clinical trial sites comply with Good Clinical Practice (“GCP”) guidelines.

Enrollment delays in our clinical trials may result in increased development costs for our product candidates, slow down or halt our product development and approval processes, and jeopardize our ability to commence product sales and generate revenue, which would cause the value of our company to decline and limit our ability to obtain additional financing if needed. Patient enrollment in clinical trials is a function of many factors, including: the nature of clinical trial protocols, existence of competing protocols or treatments (if any), the size and longevity of the target patient population, proximity of patients to clinical sites and eligibility criteria for the clinical trials. Although we will continue to look for opportunities for faster regulatory approval of plazomicin or our other product candidates, we cannot guarantee that additional opportunities will arise, that the FDA or other regulatory authorities will agree with any additional proposals we make or that such additional proposals, even if approved, will be successful.

We could also encounter delays if a clinical trial is suspended or terminated by us upon recommendation of the data monitoring committee for such trial, by the IRBs of the institutions in which such trials are being conducted, or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial.

If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate revenue from the sale of any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval processes, and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may significantly harm our business, financial condition and prospects.

The revisions to our Phase 3 CARE trial protocol did not allow it to be powered to demonstrate a superiority outcome and the FDA, the EMA and other regulatory authorities as well as physicians and other third parties may not consider the data from our Phase 3 CARE trial to be supportive of plazomicin’s potential to address serious bacterial infections caused by CRE.

Cohort 1 of our Phase 3 CARE trial was originally planned and the size estimated based on a superiority design. We decided to reduce the planned enrollment of our Phase 3 CARE trial. However, with this reduced sample size, the study was not powered to demonstrate superiority. Our ability to claim certain of the market and label benefits that a successful superiority trial would have provided, are reduced because we completed Cohort 1 of the trial with a reduced enrollment size in our Phase 3 CARE trial. Further,

Page 34 of 68

because of this, the FDA, the EMA and other regulatory authorities as well as physicians and other third parties may not consider the data from our Phase 3 CARE trial to be supportive of plazomicin’s potential to address serious bacterial infections caused by CRE.

Failure to successfully develop, validate and obtain regulatory clearance or approval of a plazomicin IVD assay or related diagnostic could harm our development and commercialization strategy for plazomicin for the treatment of serious bacterial infections caused by CRE.

An important element of our development and commercialization strategy for plazomicin for the treatment of serious bacterial infections caused by CRE is the development of an IVD assay or related diagnostic to support the Therapeutic Drug Management (“TDM”) of patients dosed with plazomicin; the plazomicin IVD assay is intended to measure levels of plazomicin in the blood so patients can receive safe and efficacious doses of plazomicin. In collaboration with ARK Diagnostics, Inc. (“ARK”), we previously co-developed such an assay for use in our Phase 3 CARE study and we are currently co-developing and intend to commercialize an assay capable of use with plazomicin, if approved.

We, and our partner, Microgenics Corporation (a part of Thermo Fisher Scientific, Inc.) (“Thermo Fisher”) are co-developing a diagnostic assay for plazomicin and intend to work together to generate the data required for submission of either a 510(k) submission or a Premarket Approval (PMA) application to the FDA. The ability to collect such data and to prepare such a submission can be impacted by a variety of financial, clinical, and regulatory factors that could impact our timing and the ultimate availability of such an assay.

IVD assays can be subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices and therefore require separate regulatory clearance or approval prior to commercialization. The development of a new IVD assay for novel therapeutic such as plazomicin can be complex from an operational and regulatory perspective because of the need for both the drug and the diagnostic to receive regulatory clearance or approval. Should the regulatory clearance or approval process for our IVD assay be delayed, it could impact our ability to successfully commercialize plazomicin for the treatment of certain patients.

It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of a plazomicin assay during the development and regulatory approval process. We also expect to develop an assay for use on additional analyzers beyond the current Roche Modular P. We, or our other current or future collaboration partners may encounter difficulties in developing, obtaining regulatory clearance or approval for, and manufacturing of, an assay with appropriate quality standards, similar to those we face with respect to our drug product candidates themselves. Failure to overcome these hurdles could have an adverse effect on our ability to obtain regulatory clearance or approval for or to obtain market acceptance for and to commercialize an IVD assay or plazomicin.

If the FDA does not conclude that our product candidate, C-Scape, satisfies the requirements for the 505(b)(2) regulatory approval pathway, or if the requirements for approval under Section 505(b)(2) are not as we expect, the approval pathway for C-Scape will likely take significantly longer, cost significantly more and encounter significantly greater complications and risks than anticipated, and in any case may not be successful.

We intend to pursue clinical trials and seek FDA approval through the 505(b)(2) regulatory pathway for our product candidate, C-Scape, which is a combination of two previously-approved drugs. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, added Section 505(b)(2) to the Federal Food, Drug and Cosmetic Act, or FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. If the FDA does not allow us to pursue the 505(b)(2) regulatory pathway for C-Scape as anticipated, we may need to conduct additional clinical trials beyond our current expectations, provide additional data and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for C-Scape would likely substantially increase. Moreover, the inability to pursue the 505(b)(2) regulatory pathway could result in new competitive products reaching the market faster than C-Scape, which could materially adversely impact our competitive position and prospects. Even if we are allowed to pursue the 505(b)(2) regulatory pathway for C-Scape, we cannot assure you that we will receive the requisite or timely approvals for commercialization of such product candidate. In addition, it is possible competitors or others will file citizens’ petitions with the FDA in an attempt to persuade the FDA that C-Scape, or the clinical studies that support their approval, contain deficiencies. Such actions by our competitors or others could delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2).

If we fail to demonstrate the safety and efficacy of plazomicin or any other product candidate that we develop to the satisfaction of the FDA or comparable foreign regulatory authorities we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of plazomicin or such other product candidate. This would adversely impact our ability to generate revenue, our business and our results of operations.

We are not permitted to commercialize, market, promote, or sell any product candidate in the United States without obtaining marketing approval from the FDA or in other countries without obtaining approvals from comparable foreign regulatory authorities,

Page 35 of 68

such as the EMA, and we may never receive such approvals. To gain approval to market a drug product, we must complete extensive preclinical development and clinical trials that demonstrate the safety and efficacy of the product for the intended indication to the satisfaction of the FDA or other regulatory authority.

We have not previously submitted an NDA to the FDA, or similar drug approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that plazomicin will receive regulatory approval. Further, plazomicin may not receive regulatory approval even though it was successful in certain clinical trials. If we do not receive regulatory approval for plazomicin, we may not be able to continue our operations. Even if we successfully obtain regulatory approval to market plazomicin, our revenue from this approval will be dependent, in part, upon our or a commercial partner’s ability to obtain regulatory approval of an IVD assay to be used with plazomicin for the treatment of serious bacterial infections caused by CRE, as well as upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights.

The FDA or any foreign regulatory agencies can delay, limit, or deny approval of plazomicin for many reasons, including:

•

our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory agency that plazomicin is safe and effective for the requested indication;

•

our inability to demonstrate that plazomicin fits an appropriate profile in interacting with other possible drugs or treatment regimens;

•

the FDA’s or the applicable foreign regulatory agency’s disagreement with the interpretation of data from preclinical studies or clinical trials;

•

our inability to demonstrate that the clinical and other benefits of plazomicin outweigh any safety or other perceived risks;

•

the FDA’s or the applicable foreign regulatory agency’s requirement for additional preclinical or clinical studies;

•

the FDA’s or the applicable foreign regulatory agency’s non-approval of the formulation, labeling or the specifications of plazomicin;

•

the FDA’s or the applicable foreign regulatory agency’s failure to approve the manufacturing processes or facilities of third-party manufacturers with which we contract;

•

the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval; or

•

failure to adequately demonstrate study conduct oversight, ensure data integrity, and that clinical study sites complied with the principles of Good Clinical Practice, such that we do not pass pre-approval inspections by the FDA or other foreign regulatory agencies.

Even if we complete clinical testing and receive approval of an NDA or foreign regulatory filing for plazomicin, the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials which may be required after approval. The FDA or the applicable foreign regulatory agency also may approve plazomicin for a more limited indication or a narrower patient population than we originally requested, and the FDA, or applicable foreign regulatory agency, may not approve the labeling that we believe is necessary or desirable for the successful commercialization of plazomicin. For example, we anticipate the NDA for plazomicin will initially be based on our Phase 3 EPIC trial and that, if approved, we anticipate the U.S. label will indicate that plazomicin is for use in patients with infections that have limited or no alternative antibiotic treatment options. In addition, we believe that the label will include in vitro data against antibiotic resistant pathogens in the microbiology section of the drug label. However, the FDA may approve a label that omits this in vitro data or that limits plazomicin to a more limited indication or narrower patient population, which may harm our ability to successfully commercialize plazomicin, if approved. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of plazomicin and would materially adversely impact our business and prospects. Any other product candidate we advanced to the marketing approval stage would also be subject to the risks delineated above.

Serious adverse events or other unexpected properties of plazomicin or any other product candidate may be identified during development or after approval that could delay, prevent or cause the withdrawal of regulatory approval, limit the commercial potential, or result in significant negative consequences following marketing approval.

Serious adverse events or undesirable side effects caused by, or other unexpected properties of, our product candidates could result in a more restrictive label, the imposition of distribution or use restrictions or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. If plazomicin or any of our other product candidates are associated with serious adverse events or undesirable side effects or have properties that are unexpected, we may need to abandon their development or limit

Page 36 of 68

development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in clinical or earlier stage testing have later been found to cause undesirable or unexpected side effects that prevented further development of the compound.

To date, plazomicin has generally been well tolerated in clinical trials conducted in healthy subjects, subjects with renal impairment, and in patients with cUTI, and in patients with serious infections due to CRE and there have been no reports of serious adverse events related to plazomicin in our completed clinical trials. Toxicity in the kidneys and inner ear are the most significant identified risks for plazomicin, which are well-known risks for the aminoglycoside class of antibiotics. Hypotension is also a potential risk for plazomicin.

Undesirable side effects or other unexpected adverse events or properties of plazomicin or any of our other product candidates could arise or become known either during clinical development or, if approved, after the approved product has been marketed. If such an event occurs during development, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of, or deny approval of, plazomicin or our other product candidates. If such an event occurs after plazomicin or such other product candidates are approved, a number of potentially significant negative consequences may result, including:

•

regulatory authorities may withdraw the approval of such product;

•

regulatory authorities may require additional warnings on the label or impose distribution or use restrictions;

•

regulatory authorities may require one or more post-market studies;

•

we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;

•

we could be sued and held liable for harm caused to patients;

•

healthcare providers may choose to treat patients with other drugs; and

•

our reputation may suffer.

Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate, if approved, or could substantially increase commercialization costs and expenses, which could delay or prevent us from generating revenue from the sale of our products and harm our business and results of operations.

We cannot predict to what extent bacteria may develop resistance to plazomicin or how resistance could spread, which could affect the revenue potential for plazomicin.

We are developing plazomicin to treat multi-drug resistant (“MDR”) infections. The bacteria responsible for these infections evolve quickly and readily transfer their resistance mechanisms within and between species. Furthermore, some resistance to plazomicin already exists and we cannot predict how the prevalence of bacterial resistance to plazomicin will change over time.

As with some other commercially available aminoglycosides, plazomicin is not active against organisms expressing a resistance mechanism known as ribosomal methyltransferase. Although occurrence of this resistance mechanism among CRE varies regionally and is currently rare in the United States, there have been isolated cases of infections by bacteria carrying ribosomal methyltransferase in the United States. We cannot predict whether ribosomal methyltransferase will become widespread in regions where we intend to market plazomicin if it is approved. The growth of MDR infections in community settings or in countries with poor public health infrastructures, or the potential use of plazomicin outside of controlled hospital settings, could contribute to the rise of plazomicin resistance. If resistance to plazomicin becomes prevalent, our ability to generate revenue from plazomicin could suffer.

We may become dependent on our partner Thermo Fisher to commercialize an IVD assay.

We have entered into a collaboration with Thermo Fisher for the development and commercialization of a plazomicin IVD assay, we may be dependent on Thermo Fisher with respect to such manufacturing and supply and with respect to commercialization in the United States and the EU. This reduces our control over these activities but would not relieve us of our responsibility to ensure compliance with all required legal, regulatory and scientific standards with respect to plazomicin.

We or Thermo Fisher may encounter difficulties in developing an assay for commercial application in one or more countries, including issues in relation to automation, selectivity/specificity, analytical validation, reproducibility, or clinical validation of such assay. If Thermo Fisher does not perform its contractual duties or obligations, experiences work stoppages, does not meet expected deadlines, terminates its agreements with us or needs to be replaced, or if they otherwise do not meet our expectations for development, manufacture or commercialization of the assay, we may need to enter into new arrangements with one or more

Page 37 of 68

alternative third parties for development, manufacture or commercialization of the assay or an alternative assay. We may not be able to do so on commercially reasonably terms, or within the terms of the commercialization agreement without amending such terms, or at all, which could adversely impact our business and results of operations related to plazomicin for the treatment of serious bacterial infections caused by CRE.

If we are not successful in discovering, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.

Although a substantial amount of our efforts is focused, and will continue to be focused, on the potential approval of our lead product candidate, plazomicin, a key element of our strategy is to discover, develop and commercialize a portfolio of therapeutics to treat MDR bacterial infections and potentially additional disease areas. We are seeking to do so through our internal research programs and are exploring, and intend to explore in the future, strategic partnerships for the development of new products. Other than plazomicin, all of our other potential product candidates remain in the discovery and preclinical stages.

Research programs to identify product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following:

•

the research methodology used may not be successful in identifying potential product candidates;

•

we may be unable to successfully modify candidate compounds to be active in gram-negative bacteria or defeat bacterial resistance mechanisms or identify viable product candidates in our screening campaigns;

•

competitors may develop alternatives that render our product candidates obsolete;

•

product candidates we develop may nevertheless be covered by third party patents or other exclusive rights;

•

a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;

•

a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;

•

a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors; and

•

the development of bacterial resistance to potential product candidates may render them ineffective against target infections.

We cannot guarantee that these efforts will be successful. If we identify viable product candidates, we would have to submit a new IND application for any compound we seek to advance to clinical trials.

If we are unsuccessful in identifying and developing additional product candidates, our potential for growth may be impaired.

Even if a product candidate does obtain regulatory approval it may never achieve market acceptance by physicians, patients, hospitals, third-party payors and others in the medical community necessary for commercial success and the market opportunity may be smaller than we estimate.

Even if we obtain FDA or other regulatory approvals, and are able to launch plazomicin or any other product candidate commercially, the product candidate may not achieve market acceptance among physicians, patients, hospitals (including pharmacy directors) and third-party payors and, ultimately, may not be commercially successful. Market acceptance and market opportunity of any product candidate for which we receive approval depends on a number of factors, including:

•

the efficacy and safety of the product candidate as demonstrated in clinical trials;

•

relative convenience and ease of administration;

•

the clinical indications for which the product candidate is approved;

•

the potential and perceived advantages and disadvantages of the product candidates, including cost and clinical benefit relative to alternative treatments;

•

the willingness of physicians to prescribe the product;

Page 38 of 68

•

the willingness of hospital pharmacy directors to purchase our products for their formularies;

•

acceptance by physicians, operators of hospitals and treatment facilities and parties responsible for reimbursement of the product;

•

the availability of adequate coverage and reimbursement by third-party payors and government authorities;

•

the effectiveness of our sales and marketing efforts;

•

the strength of our marketing and distribution support;

•

limitations or warnings, including distribution or use restrictions, contained in the product’s approved labeling or an approved risk evaluation and mitigation strategy;

•

whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular infections;

•

the approval of other new products for the same indications;

•

the timing of market introduction of the approved product as well as competitive products;

•

adverse publicity about the product or favorable publicity about competitive products;

•

the emergence of bacterial resistance to the product candidate; and

•

the rate at which resistance to other drugs in the target infections grow.

Any failure by plazomicin or any other product candidate that obtains regulatory approval to achieve market acceptance or commercial success would adversely affect our business prospects.

The availability of adequate third-party coverage and reimbursement for approved products is uncertain, and failure to obtain adequate coverage and reimbursement from government and other third-party payors could impede our ability to market any future products we may develop and could limit our ability to generate revenue.

There is significant uncertainty related to the third-party payor coverage and reimbursement of newly approved medical products. In addition, there is uncertainty for continued levels of reimbursement for any medical products in consideration of competition, issues concerning the global healthcare infrastructure and other issues that may be beyond our control. The commercial success of our future products in both domestic and international markets depends on whether third-party coverage and reimbursement is available and ongoing for our future products. Governmental payors, including Medicare and Medicaid, health maintenance organizations and other third-party payors are increasingly attempting to manage their healthcare expenditures by limiting both coverage and the level of reimbursement of new drugs and biologics and, as a result, they may not cover or provide adequate reimbursement for our future products or related diagnostics. These payors may not view our future products as cost-effective, and coverage and reimbursement may not be available to our customers or may not be sufficient to allow our future products to be marketed on a competitive basis.

Third-party payors are exerting increasing influence on decisions regarding the use of, and coverage and reimbursement levels for, particular treatments. Such third-party payors, including Medicare, are challenging the prices charged for medical products and services, and many third-party payors limit or delay coverage and reimbursement for newly approved healthcare products. In particular, third-party payors may limit the covered indications. Cost-control initiatives could cause us to decrease the price we might establish for products, which could result in lower than anticipated revenue from the sale of our product candidates. If we decrease the prices for our product candidates or are unable to occasionally increase prices because of competitive pressures or if governmental and other third-party payors do not provide adequate coverage or reimbursement, our prospects for revenue and profitability will suffer.

In addition, to the extent that our product candidates will be used in a hospital inpatient setting, hospitals often receive fixed reimbursement for all of a patient’s care, including the cost of our drug products and IVD assay, based on the patient’s diagnosis. For example, Medicare reimbursement for hospital inpatient stays is generally made under a prospective payment system that is determined by a classification system known as the Medicare severity diagnosis-related groups. Our patients’ access to adequate coverage and reimbursement by government and private insurance plans is central to the acceptance of our future products. We may be unable to sell our products on a profitable basis if third-party payors reduce their current levels of payment, or if our costs of production increase faster than increases in reimbursement levels.

Page 39 of 68

We are developing our lead product candidate plazomicin for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including CRE, which constitute a growing but relatively small patient population. Antibiotics have historically been marketed towards broad patient populations at relatively low prices. Based on the high unmet medical need in the treatment of these infections and the high costs of treating antibiotic resistant infections, we are targeting value-based pricing for plazomicin. If hospitals or governmental or other third-party payors do not view the benefits of plazomicin as worth the cost, we will be unable to achieve our pricing and reimbursement objectives and our prospects for revenue and profitability will suffer.

We rely on third parties to conduct some of our preclinical studies and all of our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize any of our product candidates.

We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct our preclinical studies and clinical trials on our product candidates in compliance with applicable regulatory requirements. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely on these third parties to conduct our preclinical studies and clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and the applicable legal, regulatory, and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. The FDA and regulatory authorities in other jurisdictions require us to comply with regulations and standards, commonly referred to as current good clinical practices (“cGCPs”), for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. If we or any of our third party contractors fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, we are required to report certain financial interests of our third party investigators if these relationships exceed certain financial thresholds and meet other criteria. The FDA or comparable foreign regulatory authorities may question the integrity of the data from those clinical trials conducted by principal investigators who previously served or currently serve as scientific advisors or consultants to us from time to time and receive cash compensation in connection with such services. Our clinical trials must also generally be conducted with products produced under current good manufacturing practice (“cGMP”) regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.

Many of the third parties with whom we contract may also have relationships with other commercial entities, some of which may compete with us. If the third parties conducting our preclinical studies or our clinical trials do not perform their contractual duties or obligations or comply with regulatory requirements we may need to enter into new arrangements with alternative third parties. This could be costly, and our preclinical studies or clinical trials may need to be extended, delayed, terminated or repeated, and we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, or to commercialize such product candidate being tested in such studies or trials. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third party contractors or to do so on commercially reasonable terms. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.

We rely on third-party contract manufacturing organizations to manufacture and supply plazomicin and other product candidates for us, as well as certain raw materials used in the production thereof. If one of our suppliers or manufacturers fails to perform adequately we may be required to incur significant delays and costs to find new suppliers or manufacturers.

We currently have limited experience in, and we do not own facilities for, manufacturing our product candidates, including plazomicin. We rely upon third-party manufacturing organizations to manufacture and supply our product candidates and certain raw materials used in the production thereof. Some of our key components for the production of plazomicin have a limited number of suppliers. In particular, sisomicin, the aminoglycoside precursor for plazomicin, is supplied by a single manufacturer in China for which we do not have a commercial supply agreement.

The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit our NDA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacture of our drug products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. If any of the manufacturers receive warning letters or other notices of violations from the FDA or others, they may be unable to timely address the issues raised in such warnings or notices. This could cause a delay or inability to supply materials or services on a timely basis. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve

Page 40 of 68

these facilities for the manufacture of our product candidates or if it delays or withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.

Our third party suppliers may not be able to meet our supply needs or timelines and this may negatively affect our business. A majority of the manufacturing process is operated internationally, and therefore may be subject to similar risks of the sort described by the risk factor entitled “A variety of risks associated with international operations could materially adversely affect our business.”

The failure of third-party manufacturers or suppliers to perform adequately or the termination of our arrangements with any of them may adversely affect our business.

A variety of risks associated with international operations could materially adversely affect our business.

Certain existing suppliers we use are located outside of the United States, including our sole source supplier for sisomicin, a key raw material for the production of plazomicin, which is located in China, and for which we do not have a commercial supply agreement. Additionally, if plazomicin is approved for commercialization outside the United States, we will likely seek to enter into agreements with third parties to market plazomicin outside the United States. We are, or we expect that we will be, subject to additional risks related to these international business relationships, including:

•

different regulatory requirements for drug approvals in foreign countries;

•

differing U.S. and foreign drug import and export rules;

•

reduced protection for intellectual property rights in certain foreign countries;

•

unexpected changes in tariffs, trade barriers and regulatory requirements;

•

different reimbursement systems;

•

economic weakness, including inflation, or political instability in particular foreign economies and markets;

•

compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;

•

foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;

•

potential liability resulting from development work conducted by these third parties; and

•

business interruptions resulting from geopolitical events, including war and terrorism, or natural disasters.

We may be subject to costly product liability claims related to our clinical trials and product candidates and, if we are unable to obtain adequate insurance or are required to pay for liabilities resulting from a claim excluded from, or beyond the limits of our insurance coverage, a material liability claim could adversely affect our financial condition.

Because we conduct clinical trials with human patients, we face the risk that the use of our product candidates may result in adverse side effects to patients in our clinical trials. We face even greater risks upon any commercialization of our product candidates. Although we have product liability insurance, which covers our clinical trials for up to $5 million, our insurance may be insufficient to reimburse us for any expenses or losses we may suffer, and we will be required to increase our product liability insurance coverage for our advanced clinical trials that we plan to initiate. We do not know whether we will be able to continue to obtain product liability coverage and obtain expanded coverage if we require it, on acceptable terms, if at all. We may not have sufficient resources to pay for any liabilities resulting from a claim excluded from, or beyond the limits of, our insurance coverage. Where we have provided indemnities in favor of third parties under our agreements with them, there is also a risk that these third parties could incur liability and bring a claim under such indemnities. An individual may bring a product liability claim against us alleging that one of our product candidates or products causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought against us, with or without merit, could result in:

•

withdrawal of clinical trial volunteers, investigators, patients or trial sites;

•

the inability to commercialize our product candidates;

•

decreased demand for our product candidates;

•

regulatory investigations that could require costly recalls or product modifications;

Page 41 of 68

•

loss of revenue;

•

substantial costs of litigation;

•

liabilities that substantially exceed our product liability insurance, which we would then be required to pay ourselves;

•

an increase in our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, if at all;

•

the diversion of management’s attention from our business; and

•

damage to our reputation and the reputation of our products.

Product liability claims may subject us to the foregoing and other risks, which could have a material adverse effect on our business, results of operations, financial condition and prospects.

If we fail to establish an effective distribution process, which includes utilizing cold-chain logistics for plazomicin and the associated IVD assay, our business may be adversely affected.

We do not currently have the infrastructure necessary for distributing pharmaceutical products to patients. We intend to contract with a third-party logistics company to warehouse these products and distribute them, and we will require plazomicin and the associated IVD assay to be maintained at a controlled temperature for some of the distribution chain. Failure to secure contracts with a logistics company could negatively impact the distribution of plazomicin or the IVD assay. If we are unable to effectively establish and manage the distribution process, the commercial launch and sales of plazomicin and the associated IVD assay will be delayed or severely compromised and our results of operations may be harmed.

In addition, the use of third party distributors, including with respect to cold-chain logistics for plazomicin and the associated IVD assay, involves certain risks, including, but not limited to, risks that distributors or pharmacies will:

•

not provide us with accurate or timely information regarding their inventories, the number of patients who are using plazomicin or the IVD assay, or complaints regarding them;

•

not effectively sell or support plazomicin or the associated IVD assay with sufficient cold storage;

•

reduce their efforts or discontinue to sell or support plazomicin or the IVD assay;

•

not devote the resources necessary to sell plazomicin or the IVD assay in the volumes and within the time frames that we expect;

•

be unable to satisfy financial obligations to us or others; or

•

cease operations.

Plazomicin is still undergoing evaluation for, and we expect our IVD assay will have, a room temperature shelf life. Currently cold-chain logistics is required and if we do not effectively maintain our cold-chain supply logistics, then we may experience an unusual number of product returns or out of date product. Any such failure may result in decreased product sales and lower product revenue, which would harm our business.

We currently have limited sales and marketing and distribution staff. If we are unable to develop an adequate sales and marketing and distribution capability on our own or through third parties, we will not be successful in commercializing our future products.

We currently have limited sales, marketing and distribution staff and no history in this capacity. To achieve commercial success for any approved product candidate, we must either develop an adequate sales, marketing and distribution organization or outsource these functions to third parties. If we rely on third parties for selling, marketing and distributing our approved products, any revenue we receive will depend upon the efforts of third parties, which may not be successful and are only partially within our control, and our product revenue may be lower than if we directly sold or marketed our products. If we are unable to enter into arrangements with third parties to sell, market and distribute product candidates for which we have received regulatory approval on acceptable terms or at all, we will need to market these products ourselves. This is likely to be expensive and logistically difficult, as it would require us to build our own sales, marketing and distribution capacity. We have no historical operations in this area, and if such efforts were necessary, we may not be able to successfully commercialize our future products. If we are not successful in commercializing our future products, either on our own or through third parties, any future product revenue will be materially and adversely affected, which would harm our business.

Page 42 of 68

We face substantial competition and our competitors may discover, develop or commercialize products faster or more successfully than us.

The development and commercialization of new drug products is highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide with respect to plazomicin and other product candidates that we may seek to develop or commercialize in the future. There are a number of pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of MDR infections. Potential competitors also include academic institutions, government agencies and other public and private research organizations. Our competitors may succeed in developing, acquiring or licensing technologies and drug products that are more effective, safer or less costly than plazomicin or any other product candidates that we are currently developing or that we may develop, which could render our product candidates obsolete and noncompetitive.

There are a variety of available therapies marketed for the treatment of MDR infections that we would expect would compete with plazomicin, including Avycaz^TM (ceftazadime/avibactam), which is marketed by Allergan plc in the United States and marketed by Pfizer outside the United States, tigecycline, which is marketed by Pfizer as Tygacil®, other aminoglycosides that are generically available (such as gentamicin, amikacin, tobramycin), and polymixins that are generically available (colistin and polymixin B). Many of the available therapies are well-established and widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic products. If plazomicin is approved, it may be priced at a premium over other competitive products. This may limit plazomicin’s adoption for MDR gram-negative infections.

There are also a number of products in late-stage clinical development by third parties to treat MDR gram-negative infections. Tetraphase Pharmaceuticals, Inc. is developing eravacycline for complicated urinary and intra-abdominal infections, as well as pneumonia. The Medicines Company is developing Carbavance™ for cUTI and various infection types due to CRE. Merck & Co., Inc. is developing imipenem/relebactam for certain life-threatening infections caused by MDR strains, including infections due to metallo-β-lactamase producing gram-negative pathogens. Zavante Therapeutics, Inc. is developing ZTI-01 for cUTI. Shionogi is developing cefiderocol for carbapenem-resistant gram-negative pathogens. We may also eventually face competition from products in earlier development stage. If our competitors obtain marketing approval from the FDA or comparable foreign regulatory authorities for their product candidates more rapidly than us, it could result in our competitors establishing a strong market position before we are able to enter the market.

In July 2012, the Food and Drug Administration Safety and Innovation Act was passed, which included the Generating Antibiotics Incentives Now Act (the “GAIN Act”). The GAIN Act provides incentives for the development of new, qualified infectious disease products, including adding five years to the otherwise applicable regulatory exclusivity period. We requested and the FDA granted qualified infectious disease product designation for plazomicin for the treatment of hospital acquired bacterial pneumonia, ventilator-associated pneumonia, complicated intra-abdominal infections, cUTIs, and catheter-related bloodstream infections on December 14, 2014. The incentives provided under the GAIN Act, along with government contract funding and other incentives for antibiotic research, may result in more competition in the market for new antibiotics.

In addition to the GAIN Act, the 21st Century Cures Act was signed into law in December 2016. This act establishes a new approval process (Limited Population Antibacterial Drug or “LPAD”) for antimicrobials intended for the treatment of serious infections in limited patient populations with an unmet medical need. It also provides a mechanism to establish, update, and communicate susceptibility test interpretive criteria for antimicrobial drugs. Although the 21st Century Cures Act and other contemplated acts in this space can help or support Achaogen, they also increase competition in the market for antimicrobials and provide incentives for the potentials of new competitors in this disease area.

Many of our competitors have materially greater name recognition and financial, manufacturing, marketing, research and drug development resources than we do. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Large pharmaceutical companies in particular have extensive expertise in preclinical and clinical testing and in obtaining regulatory approvals for drugs. In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies. These organizations may also establish exclusive collaborative or licensing relationships with our competitors.

Finally, the success of any product that is successfully commercialized will depend in large part on our ability to prevent competitors from launching a generic version that would compete with such product. If such competitors are able to establish that our patents are invalid or not infringed by the generic version of our product, they may be able to launch a generic product prior to the expected expiration of our relevant patents, and any generic competition could have a material adverse effect on our business, results of operations, financial condition and prospects.

Page 43 of 68

We may attempt to form collaborations in the future with respect to our technology and product candidates, but we may not be able to do so, which may cause us to alter our development and commercialization plans.

We may form strategic alliances, create joint ventures or collaborations or enter into licensing arrangements with third parties with respect to our programs that we believe will complement or augment our existing business. For example, we currently intend to identify one or more strategic partners for the commercialization of plazomicin, and we may also attempt to find one or more strategic partners for the development or commercialization of one or more of our other product candidates. We face significant competition in seeking appropriate strategic partners, and the negotiation process to secure appropriate terms is time-consuming and complex. We may not be successful in our efforts to establish strategic partnerships for our product candidates and programs on terms that are acceptable to us, or at all.

Any delays in identifying suitable collaborators and entering into agreements to develop or commercialize our product candidates could negatively impact the development or commercialization of our product candidates in geographic regions where we do not have development and commercialization infrastructure. Absent a collaboration partner, we would need to undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we are unable to do so, we may not be able to develop our product candidates or bring them to market and our business may be materially and adversely affected.

We may be unable to realize the potential benefits of any collaboration.

Even if we are successful in entering into a collaboration with respect to the development or commercialization of one or more product candidates, there is no guarantee that the collaboration will be successful. Collaborations may pose a number of risks, including:

•

collaborators often have significant discretion in determining the efforts and resources that they will apply to the collaboration, and may not commit sufficient resources to the development, marketing or commercialization of the product or products that are subject to the collaboration;

•

collaborators may not perform their obligations as expected;

•

collaborators may cease to devote resources to the development or commercialization of our product candidates if the collaborators view our product candidates as competitive with their own products or product candidates;

•

disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the course of development, might cause delays or termination of the development or commercialization of product candidates, and might result in legal proceedings, which would be time-consuming, distracting and expensive;

•

collaborators may be impacted by changes in their strategic focus or available funding, or business combinations involving them, which could cause them to divert resources away from the collaboration;

•

collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;

•

the collaborations may not result in us achieving revenue to justify such transactions; and

•

collaborations may be terminated and, if terminated, may result in a need for us to raise additional capital to pursue further development or commercialization of the applicable product candidate.

As a result, a collaboration may not result in the successful development or commercialization of our product candidates.

Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan agreement and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.

On August 5, 2015, we entered into a loan and security agreement with Solar Capital Ltd., pursuant to which Solar Capital Ltd. agreed to make available to us term loans with an aggregate principal amount of up to $25 million, $15 million of which was provided to us on August 5, 2015 and $10 million of which was provided to us on June 20, 2016. Until we have repaid such indebtedness, the loan and security agreement subjects us to various customary covenants, including requirements as to financial reporting and insurance, and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or

Page 44 of 68

other distributions on capital stock other than dividends payable solely in capital stock, to redeem capital stock, to enter into licensing agreements, to engage in transactions with affiliates, or to encumber our intellectual property. Our business may be adversely affected by these restrictions on our ability to operate our business.

Additionally, we may be required to repay the outstanding indebtedness under the loan facility if an event of default occurs under the loan and security agreement. Under the loan and security agreement, an event of default will occur if, among other things, we fail to make payments under the loan and security agreement; we breach any of our covenants under the loan and security agreement, subject to specified cure periods with respect to certain breaches; the Lender determines that a material adverse change has occurred; we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings; we are unable to pay our debts as they become due; or we default on contracts with third parties which would permit the holder of indebtedness to accelerate the maturity of such indebtedness or that could have a material adverse change on us. We may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time any such event of default occurs. In this case, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant to others rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Solar Capital Ltd. could also exercise its rights as collateral agent to take possession of and to dispose of the collateral securing the term loans, which collateral includes substantially all of our property (excluding intellectual property, which is subject to a negative pledge). Our business, financial condition and results of operations could be materially adversely affected as a result of any of these events.

We may need to grow our organization, and we may experience difficulties in managing growth.

As of March 31, 2017, we had 121 employees. We will need to expand our managerial, operational, financial and other resources in order to manage our operations and clinical trials, continue our development activities and commercialize plazomicin or other product candidates. Our management and personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our business strategy requires that we:

•

manage all our planned clinical trials;

•

manage our internal discovery and development efforts effectively while carrying out our contractual obligations to licensors, contractors, government agencies, any future collaborators and other third parties;

•

conduct pre-commercial activities for plazomicin;

•

continue to improve our operational, financial and management controls, reporting systems and procedures; and

•

identify, recruit, maintain, motivate and integrate additional employees.

If we are unable to expand our managerial, operational, financial and other resources to the extent required to manage our development and commercialization activities, our business will be materially adversely affected.

We are highly dependent on the services of our executive team and our ability to attract and retain qualified personnel.

We may not be able to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses, particularly in the San Francisco Bay Area. We are highly dependent on the principal members of our management and scientific staff, particularly our executive team. If we are not able to retain our executive team or are not able to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow. Although we have executed employment agreements with each member of our current executive management team, we may not be able to retain their services as expected. In addition to the competition for personnel, the San Francisco Bay Area in particular is characterized by a high cost of living. Although we historically have not had any material difficulty attracting qualified experienced personnel to our company, we could in the future have such difficulties and may be required to expend significant financial resources in our employee recruitment and retention efforts.

In addition, we have scientific and clinical advisors who assist us in formulating our product development and clinical strategies. These advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us, or may have arrangements with other companies to assist in the development of products that may compete with ours.

If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.

Page 45 of 68

Recent changes in our executive leadership and any similar changes in the future may serve as a significant distraction for our management and employees.

Since the beginning of 2016, there have been a number of changes to our executive leadership team. In February 2017, we hired our Chief Commercial Officer, Janet Dorling, in November 2016, we hired our General Counsel, Gary Loeb, and in July 2016, we hired our Chief Financial Officer, Tobin Schilke. In March 2017, our former Chief Medical Officer, Ian Friedland, resigned and transitioned to a consulting position. Such changes, or any other future changes in our executive leadership, may disrupt our operations as we adjust to the reallocation of responsibilities and assimilate new leadership and, potentially, differing perspectives on our strategic direction. If the transition in executive leadership is not smooth, the resulting disruption could negatively affect our operations and impede our ability to execute our strategic plan.

Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which may be expensive and restrict how we do business.

Our third-party manufacturers’ activities and our own activities involve the controlled storage, use and disposal of hazardous materials, including the components of our pharmaceutical product candidates, test samples and reagents, biological materials and other hazardous compounds. We and our manufacturers are subject to federal, state, local and foreign laws and regulations governing the use, generation, manufacture, storage, handling and disposal of these hazardous materials. We currently carry no insurance specifically covering environmental claims relating to the use of hazardous materials. Although we believe that our safety procedures for handling and disposing of these materials and waste products comply with the standards prescribed by these laws and regulations, we cannot eliminate the risk of accidental injury or contamination from the use, storage, handling or disposal of hazardous materials. In the event of an accident, state or federal or other applicable authorities may curtail our use of these materials and/or interrupt our business operations. In addition, if an accident or environmental discharge occurs, or if we discover contamination caused by prior operations, including by prior owners and operators of properties we acquire, we could be liable for cleanup obligations, damages and fines. If such unexpected costs are substantial, this could significantly harm our financial condition and results of operations.

Risks associated with a company-wide implementation of an enterprise resource planning, or ERP, system may adversely affect our business and results of operations or the effectiveness of our control environment.

We are implementing a company-wide ERP system to handle the business and financial processes within our operations and corporate functions. ERP implementations are complex and time-consuming projects that involve substantial expenditures on system software and implementation activities. ERP implementations also require transformation of business and financial processes in order to reap the benefits of the ERP system. Our business and results of operations may be adversely affected if we experience operating problems or cost overruns during the ERP implementation process, or if the ERP system and the associated process changes do not give rise to the benefits that we expect. If we do not effectively implement the ERP system as planned or if the system does not operate as intended, it may adversely affect our ability to manage and run our business operations, file reports with the SEC in a timely manner, and/or otherwise affect our controls environment. Any of these consequences could have an adverse effect on our results of operations and financial condition.

Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our business operations.

Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage or disruption from computer viruses, software bugs, unauthorized access, natural disasters, terrorism, war, and telecommunication, equipment and electrical failures. While we have not, to our knowledge, experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical trial data from completed or ongoing clinical trials for any of our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure or theft of confidential or proprietary information, we could incur liability, or adversely affect our business operations and/or financial condition.

Our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (1) FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA; (2) manufacturing standards; (3) federal and state healthcare fraud and abuse laws and regulations; or (4) laws that require the true, complete and accurate reporting of financial information or data. Specifically,

Page 46 of 68

sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

We incur significant costs as a result of operating as a public company, and our management devotes substantial time to new compliance initiatives.

Prior to our initial public offering (“IPO”) in March 2014, we had not been subject to the reporting requirements of the Exchange Act of 1934, as amended (the “Exchange Act”), or the other rules and regulations of the Securities and Exchange Commission (the “SEC”) or any securities exchange relating to public companies. We continue to identify those areas in which changes should be made to our financial and management control systems to manage our growth and our obligations as a public company. These areas include corporate governance, corporate control, disclosure controls and procedures and financial reporting and accounting systems. We have made, and will continue to make, changes in these and other areas. However, the expenses associated with being a public company could be material, particularly after we cease to be an “emerging growth company.” Compliance with the various reporting and other requirements applicable to public companies require considerable time and attention of management. In addition, the changes we make may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis.

In addition, certain types of insurance, including directors’ and officers’ liability insurance are more expensive as a public company. Being a public company could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.

If we are not able to implement the requirements of Section 404 of the Sarbanes-Oxley Act of 2002 in a timely manner or with adequate compliance, we may be subject to sanctions by regulatory authorities.

Section 404 of the Sarbanes-Oxley Act of 2002 requires that we evaluate and determine the effectiveness of our internal controls over financial reporting and provide a management report on the internal control over financial reporting. If we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We will be evaluating our internal controls systems to allow management to report on, and eventually our independent auditors will attest to, the effectiveness of the operation of our internal controls. We will be performing the system and process evaluation and testing (and any necessary remediation) required to comply with the management certification and eventual auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002. The aforementioned auditor attestation requirements will not apply to us until we are no longer considered an “emerging growth company.”

We cannot be certain as to the timing of completion of our evaluation, testing and remediation action or the impact of the same on our operations. If we are not able to comply with the requirements of Section 404 in a timely manner, or if we or our independent registered public accounting firm identifies deficiencies in our internal controls that are deemed to be material weaknesses, we could be subject to sanctions or investigations by The NASDAQ Stock Market LLC, the SEC or other regulatory authorities, which would entail expenditure of additional financial and management resources and could materially adversely affect our stock price. Deficient internal controls could also cause us to fail to meet our reporting obligations or cause investors to lose confidence in our reported financial information, which could have a negative effect on our stock price.

Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

We have designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the acts of some individuals, by collusion of two

Page 47 of 68

or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.

We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Our corporate headquarters is located in the San Francisco Bay Area, which in the past has experienced severe earthquakes. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.

If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our information technology systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.

Furthermore, integral parties in our supply chain are geographically concentrated and operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.

Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.

Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change” (generally defined as a greater than 50 percentage points change (by value) in the ownership of its equity by certain significant stockholders over a rolling three year period), the corporation’s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income and taxes may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future and/or subsequent shifts in our stock ownership, some of which would be outside our control. If our ability to use our net operating losses and other tax attributes is limited by ownership changes, we may be unable to utilize a material portion of our net operating losses and other tax attributes.

Risks Related to Our U.S. Government Contracts and to Certain Grant Agreements

Our use of government funding for certain of our programs adds uncertainty to our research and commercialization efforts with respect to those programs and may impose requirements that increase the costs of commercialization and production of product candidates developed under those government-funded programs.

Our development of plazomicin as a countermeasure for diseases caused by antibiotic-resistant pathogens and biothreats is currently being funded in significant part through a contract with BARDA. We are also receiving funding from the National Institute of Allergy and Infectious Diseases (“NIAID”) for one of our pre-clinical programs and we in the past received funding for other programs from the Defense Threat Reduction Agency (“DTRA”) and from NIAID. Contracts funded by the U.S. government and its agencies, including our contract with BARDA, include provisions that reflect the government’s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to:

•

terminate agreements, in whole or in part, for any reason or no reason;

•

reduce or modify the government’s obligations under such agreements without the consent of the other party;

•

claim rights, including intellectual property rights, in products and data developed under such agreements;

•

audit contract-related costs and fees, including allocated indirect costs;

•

suspend the contractor from receiving new contracts pending resolution of alleged violations of procurement laws or regulations;

•

impose U.S. manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements;

•

suspend or debar the contractor from doing future business with the government;

•

control and potentially prohibit the export of products; and

Page 48 of 68

•

pursue criminal or civil remedies under the False Claims Act (“FCA”), the False Statements Act and similar remedy provisions specific to government agreements.

We may not have the right to prohibit the U.S. government from using or allowing others to use certain technologies developed by us, and we may not be able to prohibit third-party companies, including our competitors, from using those technologies in providing products and services to the U.S. government. The U.S. government generally obtains the right to royalty-free use of technologies that are developed under U.S. government contracts.

In addition, government contracts normally contain additional requirements that may increase our costs of doing business, reduce our profits, and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:

•

specialized accounting systems unique to government contracts;

•

mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent;

•

public disclosures of certain contract information, which may enable competitors to gain insights into our research program; and

•

mandatory socioeconomic compliance requirements, including labor standards, anti-human-trafficking, non-discrimination, and affirmative action programs and environmental compliance requirements.

If we fail to maintain compliance with these requirements, we may be subject to potential contract or FCA liability and to termination of our contracts.

U.S. government agencies have special contracting requirements that give them the ability to unilaterally control our contracts.

U.S. government contracts typically contain unfavorable termination provisions and are subject to audit and modification by the government at its sole discretion, which will subject us to additional risks. These risks include the ability of the U.S. government to unilaterally:

•

audit and object to our BARDA contract-related costs and fees, and require us to reimburse all such costs and fees;

•

suspend or prevent us for a set period of time from receiving new contracts or extending our existing contracts based on violations or suspected violations of laws or regulations;

•

cancel, terminate or suspend our contracts based on violations or suspected violations of laws or regulations;

•

terminate our contracts if in the government’s interest, including if funds become unavailable to the applicable governmental agency;

•

reduce the scope and value of our contract; and

•

change certain terms and conditions in our contract.

The U.S. government will be able to terminate any of its contracts with us, either for convenience or if we default by failing to perform in accordance with or to achieve the milestones set forth in the contract schedules and terms. Termination-for-convenience provisions generally enable us to recover only our costs incurred or committed and settlement expenses on the work completed prior to termination. Except for the amount of services received by the government, termination-for-default provisions do not permit these recoveries and would make us liable for excess costs incurred by the U.S. government in procuring undelivered items from another source.

The U.S. government’s determination to award a future contract or contract option may be challenged by an interested party, such as another bidder, at the U.S. Government Accountability Office (the “GAO”), or in federal court. If such a challenge is successful, our BARDA contract or any future contract we may be awarded may be terminated.

The laws and regulations governing the procurement of goods and services by the U.S. government provide procedures by which other bidders and interested parties may challenge the award of a government contract. If we are awarded a government contract, such challenges or protests could be filed even if there are not any valid legal grounds on which to base the protest. If any such protests are filed, the government agency may decide to suspend our performance under the contract while such protests are being considered by the GAO or the applicable federal court, thus potentially delaying delivery of payment. In addition, we could be

Page 49 of 68

forced to expend considerable funds to defend any potential award. If a protest is successful, the government may be ordered to terminate any one or more of our contracts and reselect bids. The government agencies with which we have contracts could even be directed to award a potential contract to one of the other bidders.

Our business is subject to audit by the U.S. government and other potential sources for grant funding, including under our contracts with BARDA, NIAID and the Gates Foundation, and a negative outcome in an audit could adversely affect our business.

U.S. government agencies such as the Department of Health and Human Services (“DHHS”) and the Defense Contract Audit Agency (the “DCAA”) routinely audit and investigate government contractors. These agencies review a contractor’s performance under its contracts, cost structure and compliance with applicable laws, regulations and standards.

The DHHS and the DCAA also review the adequacy of, and a contractor’s compliance with, its internal control systems and policies, including the contractor’s purchasing, property, estimating, compensation and management information systems. Any costs found to be improperly allocated to a specific contract will not be paid, while such costs already paid must be refunded. If an audit uncovers improper or illegal activities, we may be subject to civil and criminal penalties and administrative sanctions, including:

•

termination of contracts;

•

forfeiture of profits;

•

suspension of payments;

•

fines; and

•

suspension or prohibition from conducting business with the U.S. government.

In addition, we could suffer serious reputational harm if allegations of impropriety were made against us, which could cause our stock price to decrease. We have also agreed to allow the Gates Foundation to audit our compliance with using specified proceeds from

Laws and regulations affecting government contracts make it more expensive and difficult for us to successfully conduct our business.

We must comply with numerous laws and regulations relating to the formation, administration and performance of government contracts, which can make it more difficult for us to retain our rights under our BARDA contract. These laws and regulations affect how we conduct business with government agencies. Among the most significant government contracting regulations that affect our business are:

•

the Federal Acquisition Regulations (“FAR”) and agency-specific regulations supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts;

•

business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and include other requirements such as the Anti-Kickback Statute and Foreign Corrupt Practices Act;

•

export and import control laws and regulations; and

•

laws, regulations and executive orders restricting the use and dissemination of information classified for national security purposes and the exportation of certain products and technical data.

Any changes in applicable laws and regulations could restrict our ability to maintain our existing BARDA contract and obtain new contracts, which could limit our ability to conduct our business and materially adversely affect our results of operations.

Risks Related to Intellectual Property

If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates may be adversely affected.

We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our technologies. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. In particular, our success depends in large part on our ability to obtain and maintain patent protection in the United States and other

Page 50 of 68

countries with respect to our product candidates. However, we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection.

Further, the patentability of inventions, and the validity, enforceability and scope of patents in the biotechnology and pharmaceutical field involve complex legal and scientific questions and can be uncertain. As a result, patent applications that we own or license may fail to result in issued patents in the United States or in other foreign countries for many reasons. For example, there is no assurance that we were the first to invent or the first to file patent applications in respect of the inventions claimed in our patent applications. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. We may also be unaware of certain prior art relating to our patent applications and patents, which could prevent a patent from issuing from a pending patent application, or result in an issued patent being invalidated. Even if patents have issued, or do successfully issue, from patent applications, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents and patent applications we hold, license or pursue with respect to our product candidates is threatened, it could threaten our ability to commercialize our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market any of our product candidates under patent protection, if approved, would be reduced. Changes to the patent laws in the United States and other jurisdictions could also diminish the value of our patents and patent applications or narrow the scope of our patent protection.

Further, one of our proposed development candidates, C-Scape, involves an innovative treatment combination of two previously-identified and approved products. In addition to all of the risks and uncertainties with pharmaceutical candidates in general, these prior products have extensive patent and intellectual property portfolios that once protected them and may continue to protect certain aspects of these products. Such portfolios create additional risks and uncertainties for our own ability to obtain material patent or intellectual property protection on our combination development candidate, including the possibility that existing patents or applications relate to and cover combinations of these same products or product classes and the possibility that prior patent positions on these compounds will make it more difficult for us to obtain our own affirmative patents in this area. Antibacterial products are commonly used in combination with one another in research, development and treatment. We may not be aware of all the ways these prior products have been used in combination and of the various intellectual property that may relate to such combination or combinations or the prior uses of these compounds that may prevent us from obtaining our own intellectual property.

If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed.

In addition to the protection afforded by patents, we rely on confidential proprietary information, including trade secrets, and know-how to develop and maintain our competitive position. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. We seek to protect our confidential proprietary information, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and collaborators. These agreements are designed to protect our proprietary information. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Further, the laws of some foreign countries, including China, where we currently source raw materials for plazomicin, do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the intellectual property related to our technologies to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.

Page 51 of 68

If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.

There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our technology or product candidates, including proceedings such as post-grant review and inter partes review before the U.S. Patent and Trademark Office (“USPTO”). Third parties may assert infringement claims against us based on existing or future intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving that a patent is invalid is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on us. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.

If we are found to infringe a third party’s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys’ fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. We may also elect to enter into license agreements in order to settle patent infringement claims or to resolve disputes prior to litigation, and any such license agreements may require us to pay royalties and other fees that could be significant. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.

We may be involved in lawsuits to protect or enforce our intellectual property rights, which could be expensive, time consuming and unsuccessful.

Competitors may infringe or otherwise violate our patents, the patents of our licensors, or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims that we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property rights. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, in whole or in part, or may refuse to stop the other party in such infringement proceeding from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly, and could put any of our patent applications at risk of not yielding an issued patent.

Interference or derivation proceedings provoked by third parties or brought by the USPTO or any foreign patent authority may be necessary to determine the priority of inventions or other matters of inventorship with respect to our patents or patent applications. We may also become involved in other proceedings, such as re-examination or opposition proceedings, before the USPTO or its foreign counterparts relating to our intellectual property or the intellectual property rights of others. An unfavorable outcome in any such proceedings could require us to cease using the related technology or to attempt to license rights to it from the prevailing party, or could cause us to lose valuable intellectual property rights. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. Litigation or other proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may also become involved in disputes with others regarding the ownership of intellectual property rights. For example, we jointly develop intellectual property with certain parties, and disagreements may therefore arise as to the ownership of the intellectual property developed pursuant to these relationships. If we are unable to resolve these disputes, we could lose valuable intellectual property rights.

We may not be able to prevent misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.

Page 52 of 68

Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and/or management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions, including China, where we currently source raw materials for plazomicin. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.

If we breach any of the agreements under which we license the use, development and commercialization rights to our product candidates from third parties, we could lose license rights that are important to our business.

While the primary patent family covering plazomicin is Achaogen-owned, our development and commercialization of plazomicin is subject to our license agreement with Ionis Pharmaceuticals, Inc. (formerly known as Isis Pharmaceuticals, Inc.), and a portion of the patent portfolio for our LpxC inhibitor program is in-licensed from UW. Under our existing license agreements, we are subject to various obligations, including diligence obligations with respect to development and commercialization activities, payment obligations for achievement of certain milestones and royalties on product sales, as well as other material obligations. If we fail to comply with any of these obligations or otherwise breach our license agreements, our licensing collaborators may have the right to terminate the applicable license in whole or in part. The loss of our license agreement with Ionis Pharmaceuticals, Inc. could materially adversely affect our ability to proceed with the development or potential commercialization of plazomicin as currently planned, while the loss of our license agreement with UW could materially adversely affect our ability to proceed with any development or potential commercialization of our LpxC inhibitor program.

The risks described elsewhere pertaining to our patents and other intellectual property rights also apply to the intellectual property rights that we license, and any failure by us or our licensors to obtain, maintain and enforce these rights could have a material adverse effect on our business. In some cases, we do not have control over the prosecution, maintenance or enforcement of the patents that we license, and may not have sufficient ability to consult and input into the patent prosecution and maintenance process with respect to such patents, and our licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain and enforce the licensed patents.

Intellectual property rights do not necessarily address all potential threats to our competitive advantage.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative:

•

others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of the patents that we own or license;

•

we or our licensors or collaborators might not have been the first to make the inventions covered by an issued patent or pending patent application that we own or license;

•

we or our licensors or collaborators might not have been the first to file patent applications covering an invention;

•

others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;

Page 53 of 68

•

pending patent applications that we own or license may not lead to issued patents;

•

issued patents that we own or license may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;

•

our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;

•

we may not develop or in-license additional proprietary technologies that are patentable; and

•

the patents of others may have an adverse effect on our business.

Should any of these events occur, they could significantly harm our business, results of operations and prospects.

Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to use our technologies and this circumstance would have a material adverse effect on our business.

We do not have exclusive rights to intellectual property we developed under U.S. federally-funded research grants and contracts in connection with certain neglected diseases initiatives, including our collaboration with the Gates Foundation, and, in the case of those funded research activities, we could ultimately share or lose the rights we do have under certain circumstances. Provisions in our U.S. government contracts, including our contract with BARDA, may affect our intellectual property rights.

Certain of our activities have been funded, and may in the future be funded, by the U.S. government, including our contract with BARDA. When new technologies are developed with U.S. government funding, the government obtains certain rights in any resulting patents, including the right to a nonexclusive license authorizing the government to use the invention under these rights may permit the government to disclose our confidential information to third parties and to exercise “march-in” rights to use or allow third parties to use our patented technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the U.S. government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, U.S. government-funded inventions must be reported to the government, U.S. government funding must be disclosed in any resulting patent applications, and our rights in such inventions may be subject to certain requirements to manufacture products in the United States.

Under our Gates Foundation collaboration, our research with respect to certain antibody platform and treatment development in identified developing countries are subject to certain intellectual property rights held by the Gates Foundation. While we have rights to develop and commercialize these technologies, we are required to implement a global access program for such technologies and we may not be able to further develop or exploit in certain territories, primarily those considered as developing countries.

Recent patent reform legislation and potential new legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.

On September 16, 2011, the Leahy-Smith America Invents Act (the “AIA”) was signed into law. The AIA includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The passage of the AIA in 2011 added a new procedure to U.S. patent law. This procedure, inter partes review (“IPR”), allows any member of the public to file a petition with the USPTO seeking the review of any issued U.S. patent. IPRs are conducted before Administrative Patent Judges in the USPTO using a lower standard of proof than used in Federal District Court. In addition, the challenged patents are not accorded the presumption of validity as they are in Federal District Court. There are now instances where generic drug companies and some investment funds are attempting to invalidate patents by filing IPR challenges in the USPTO. The USPTO has promulgated regulations and developed procedures to govern administration of the AIA, and many of the substantive changes to patent law associated with the AIA, and in particular, the first to file provisions, did not come into effect until March 16, 2013. Accordingly, it is not yet clear what, if any, impact the AIA will have on the operation of our business.

Page 54 of 68

However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. Patent reform continues to be a topic that could arise in a number of legislative and regulatory proposals, in particular related to patents and their impacts on ability to compete in healthcare. We cannot predict the way such future legislation, regulations or administrative procedures could impact our patent rights.

We may be subject to claims that our employees or consultants have wrongfully used or disclosed alleged trade secrets of former or other employers.

Many of our employees and consultants, including our senior management, have been employed or retained by other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees or consultants have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee’s or consultant’s former or other employer. We are not aware of any material threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.

If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for our product candidates, our business may be materially harmed.

Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, if any, one or more of our U.S. patents, if any, covering our approved product(s) or the use thereof may be eligible for up to five years of patent term restoration under the Hatch-Waxman Act. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product. Patent term extension also may be available in certain foreign countries upon regulatory approval of our product candidates. Nevertheless, we may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request.

If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially.

Risks Related to Government Regulation

The regulatory approval process is expensive, time consuming and uncertain and may prevent us from obtaining, or cause delays in obtaining, approvals for the commercialization of some or all of our product candidates, which will materially impair our ability to generate revenue.

The design, development, research, testing, manufacturing, labeling, storage, recordkeeping, approval, selling, import, export, advertising, promotion, and distribution of drug products are subject to extensive and evolving regulation by federal, state and local governmental authorities in the United States, principally by the FDA, and foreign regulatory authorities, with regulations differing from country to country. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. Neither we nor any future collaboration partner is permitted to market plazomicin or any other product candidate in the United States until we receive regulatory approval of an NDA from the FDA.

We have not submitted an application or obtained marketing approval for plazomicin or any other product candidate anywhere in the world. An NDA must include extensive preclinical and clinical data and supporting information to establish to the FDA’s satisfaction the product candidate’s safety and efficacy for each desired indication. The NDA must also include significant information regarding the chemistry, manufacturing and controls for the product candidate. Obtaining regulatory approval of an NDA can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and other applicable U.S. and foreign regulatory requirements may subject us to administrative or judicially imposed sanctions, including:

•

warning letters;

•

civil and criminal penalties;

•

injunctions;

Page 55 of 68

•

withdrawal of approved products;

•

product seizure or detention;

•

product recalls;

•

total or partial suspension of production; and

•

refusal to approve pending NDAs or supplements to approved NDAs.

Prior to receiving approval to commercialize any of our product candidates in the United States or abroad, we and any applicable collaboration partners must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA and other regulatory authorities abroad, that such product candidates are safe and effective for their intended uses. Preclinical testing and clinical trials are long, expensive and uncertain processes. We may spend several years completing our testing for any particular product candidate, and failure can occur at any stage. Negative or inconclusive results or adverse medical events during a clinical trial could also cause the FDA or us to terminate a clinical trial or require that we repeat it or conduct additional clinical trials. Additionally, data obtained from preclinical studies and clinical trials can be interpreted in different ways and the FDA or other regulatory authorities may interpret the results of our studies and trials less favorably than we do. Even if we believe the preclinical or clinical data for a product candidate is promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Administering any product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials of such product candidates and result in the FDA or other regulatory authorities denying approval of such product candidates for any or all targeted indications. The FDA or other regulatory authorities may determine that plazomicin or any other product candidate that we develop is not effective, or is only moderately effective, or has undesirable or unintended side effects, toxicities, safety profile or other characteristics that preclude marketing approval or prevent or limit commercial use. In addition, any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.

The regulatory approval process is expensive and may take several years to complete. The FDA and foreign regulatory entities have substantial discretion in the approval process. Despite the time and expense exerted, failure can occur at any stage, and we could encounter problems that cause us to abandon or repeat clinical trials, or perform additional preclinical studies and clinical trials. The number of preclinical studies and clinical trials that will be required for FDA approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular product candidate. The FDA can delay, limit or deny approval of a product candidate for many reasons, including, but not limited to, the following:

•

product candidate may not be deemed safe or effective;

•

FDA officials may not find the data from preclinical studies and clinical trials sufficient;

•

the FDA may request additional analyses, reports, data and studies;

•

the FDA may ask questions regarding, or adopt different interpretations of, data and results;

•

the FDA might not approve our or our third-party manufacturer’s processes or facilities; or

•

the FDA may change its approval policies or adopt new regulations.

Although we have received FDA fast-track designation for our development of plazomicin to treat serious CRE infections, we cannot guarantee that we will experience a faster review or approval process compared to conventional FDA procedures. The FDA may withdraw fast-track designation if it believes that the designation is no longer supported by data from our clinical development program.

If any of our product candidates fails to demonstrate safety and efficacy in clinical trials or does not gain regulatory approval, or if we experience delays in obtaining regulatory approval, our business and results of operations will be materially and adversely harmed.

Page 56 of 68

Even if we receive regulatory approval for a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to restrictions, withdrawal from the market, or penalties if we fail to comply with applicable regulatory requirements or if we experience unanticipated problems with our product candidates, when and if approved.

Once regulatory approval has been granted, the approved product and its manufacturer are subject to continual review by the FDA and/or non-U.S. regulatory authorities. Any regulatory approval that we receive for our product candidates may be subject to limitations on the indicated uses for which the product may be marketed or contain requirements for potentially costly post-marketing follow-up studies or surveillance to monitor the safety and efficacy of the product. In addition, if the FDA and/or non-U.S. regulatory authorities approve any of our product candidates, we will be subject to extensive and ongoing regulatory requirements by the FDA and other regulatory authorities with regard to labeling, packaging, adverse event reporting, storage, distribution, advertising, promotion, recordkeeping and submission of safety and other post-market information. Manufacturers of our products and manufacturers’ facilities are required to comply with cGMP regulations, which include requirements related to quality control and quality assurance as well as the corresponding maintenance of records and documentation. Further, regulatory authorities must approve these manufacturing facilities before they can be used to manufacture our products, and these facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. We will also be required to report certain adverse reactions and production problems, if any, to the FDA and to comply with requirements concerning advertising and promotion for our products. If we, any future collaboration partner or a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory authority may impose restrictions on that product, the collaboration partner, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing.

The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling and regulatory requirements. The FDA also imposes stringent restrictions on manufacturers’ communications regarding off-label use and if we do not restrict the marketing of our products only to their approved indications, we may be subject to enforcement action for off-label marketing. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with regulatory requirements of the FDA and/or other non-U.S. regulatory authorities, we could be subject to administrative or judicially imposed sanctions, including:

•

warning letters or untitled letters;

•

mandated modifications to promotional materials or the required provision of corrective information to healthcare practitioners;

•

restrictions imposed on the product or its manufacturers or manufacturing processes;

•

restrictions imposed on the labeling or marketing of the product;

•

restrictions imposed on product distribution or use;

•

requirements for post-marketing clinical trials;

•

suspension of any ongoing clinical trials;

•

suspension of or withdrawal of regulatory approval;

•

voluntary or mandatory product recalls and publicity requirements;

•

refusal to approve pending applications for marketing approval of new products or supplements to approved applications filed by us;

•

restrictions on operations, including costly new manufacturing requirements;

•

seizure or detention of our products;

•

refusal to permit the import or export of our products;

•

required entry into a consent decree, which can include imposition of various fines (including restitution or disgorgement of profits or revenue), reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;

Page 57 of 68

•

civil or criminal penalties; or

•

injunctions.

Widely publicized events concerning the safety risk of certain drug products have resulted in the withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and the imposition by the FDA of risk evaluation and mitigation strategies (“REMS”) to ensure that the benefits of the drug outweigh its risks. In addition, because of the serious public health risks of high profile adverse safety events with certain products, the FDA may require, as a condition of approval, costly REMS programs.

The regulatory requirements and policies may change and additional government regulations may be enacted for which we may also be required to comply. For example, in December 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and spur innovation, but its ultimate implementation is unclear. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or any future collaboration partner are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.

We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or in other countries. For example, certain policies of the current administration may impact our business and industry. The current administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, FDA’s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. Notably, on January 23, 2017, a hiring freeze was ordered for all executive departments and agencies, including the FDA, which prohibits the FDA from filling employee vacancies or creating new positions. Under the terms of the order, the freeze will remain in effect until implementation of a plan to be recommended by the Director for the Office of Management and Budget, or OMB, in consultation with the Director of the Office of Personnel Management, to reduce the size of the federal workforce through attrition. An under-staffed FDA could result in delays in FDA’s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all. Moreover, on January 30, 2017, an Executive Order was issued, applicable to all executive agencies, including the FDA, that requires that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017, the agency shall identify at least two existing regulations to be repealed, unless prohibited by law. These requirements are referred to as the “two-for-one” provisions. This Executive Order includes a budget neutrality provision that requires the total incremental cost of all new regulations in the 2017 fiscal year, including repealed regulations, to be no greater than zero, except in limited circumstances. For fiscal years 2018 and beyond, the Executive Order requires agencies to identify regulations to offset any incremental cost of a new regulation and approximate the total costs or savings associated with each new regulation or repealed regulation. In interim guidance issued by the Office of Information and Regulatory Affairs within OMB on February 2, 2017, the administration indicates that the “two-for-one” provisions may apply not only to agency regulations, but also to significant agency guidance documents. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA’s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA’s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.

Failure to obtain regulatory approvals in foreign jurisdictions will prevent us from marketing our product candidates internationally.

We may seek a distribution and marketing collaborator for plazomicin or other product candidates commercialized outside of the United States. In order to market our product candidates in the European Economic Area (the “EEA”), which is comprised of the 28 Member States of the EU, plus Norway, Iceland and Liechtenstein), and many other foreign jurisdictions, we or our collaboration partners must obtain separate regulatory approvals. More concretely, in the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization (“MA”). There are two types of marketing authorizations:

•

the Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use of the EMA, and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as for drugs produced through certain specified biotechnological processes (such as recombinant DNA technology, controlled expression of genes coding for biologically active proteins in prokaryotes and eukaryotes including transformed mammalian cells, and hybridoma and monoclonal antibody methods), advanced therapy medicinal products, orphan medicinal products, and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.

Page 58 of 68

•

national MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.

Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.

We have had limited interactions with foreign regulatory authorities, and approval procedures vary among countries and can involve additional clinical testing. In addition, the time required to obtain approval from foreign regulatory authorities may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on our ability to obtain approval in other countries. The foreign regulatory approval process generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may or may not obtain foreign regulatory approvals on a timely basis, if at all. We may not be able to file for regulatory approvals and even if we file, we may not receive necessary approvals to commercialize our product candidates in any market.

Healthcare reform measures could hinder or prevent our product candidates’ commercial success.

In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could affect our future revenue and profitability and the future revenue and profitability of our potential customers. Federal and state lawmakers regularly propose and, at times, enact legislation that results in significant changes to the healthcare system, some of which is intended to contain or reduce the costs of medical products and services. For example, in March 2010, the President signed one of the most significant healthcare reform measures in decades, the Affordable Care Act (“ACA”). It contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which will impact existing government healthcare programs and will result in the development of new programs. The ACA, among other things:

•

imposes a non-deductible annual fee on pharmaceutical manufacturers or importers who sell “branded prescription drugs” to specified federal government programs;

•

increases the minimum level of Medicaid rebates payable by manufacturers of brand-name drugs from 15.1% to 23.1%;

•

imposes a 2.3% medical device excise tax that manufacturers and importers will be required to pay on their sales of certain medical devices, which, under the Consolidated Appropriations Act, 2016, is suspended from January 1, 2016 to December 31, 2017, and, absent further legislative action, will be reinstated starting January 1, 2018;

•

requires collection of rebates for drugs paid by Medicaid managed care organizations;

•

addresses new methodologies by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and for drugs that are line extension products;

•

requires manufacturers to participate in a coverage gap discount program, under which they must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D; and

•

expands eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer’s Medicaid rebate liability.

We expect that the new presidential administration and U.S. Congress will seek to modify, repeal, or otherwise invalidate all or certain provisions of, the ACA. In January 2017, the House and Senate passed a budget resolution that authorizes congressional committees to draft legislation to repeal all or portions of the ACA and permits such legislation to pass with a majority vote in the Senate. There is still uncertainty with respect to the impact the current administration and the U.S. Congress may have, if any, and any

Page 59 of 68

changes will likely take time to unfold, and could have an impact on coverage and reimbursement for healthcare items and services covered by plans that were authorized by the ACA.

Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregated reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect on April 1, 2013, and, due to subsequent legislative amendments, will remain in effect through 2025 unless additional Congressional action is taken. On January 2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Recently, there has also been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures.

We are subject to healthcare laws, regulation and enforcement and our failure to comply with those laws could adversely affect our business, operations and financial condition.

Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients’ rights are and will be applicable to our business. We could be subject to healthcare fraud and abuse and patient privacy regulation by both the federal government and the states in which we conduct our business. The regulations that may affect our ability to operate include, without limitation:

•

the federal Anti-Kickback Statute, which prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;

•

the federal False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, false claims, or knowingly using false statements, to obtain payment from the federal government, and which may apply to entities that provide coding and billing advice to customers;

•

federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;

•

the federal physician sunshine requirements under the ACA, which requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to the Centers for Medicare & Medicaid Services information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members;

•

the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and

•

state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent healthcare reform legislation has strengthened these laws. For example, the recently enacted ACA, among other things, amends the intent requirement of the Federal Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items

Page 60 of 68

or services resulting from a violation of the Federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.

Achieving and sustaining compliance with these laws may prove costly. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal and other related expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the exclusion from participation in federal and state healthcare programs, imprisonment, or the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results.

Risks Related to Our Common Stock

The price of our common stock may be volatile and our stockholders may not be able to resell shares of our common stock at or above the price they paid.

There was no public market for our common stock prior to our IPO in March 2014, the trading volume of our common stock on The NASDAQ Global Market has been limited since then, and there can be no assurance that an active and liquid trading market for our common stock will be sustained. We cannot predict the extent to which investor interest in our company will lead to the development of or sustain an active trading market on The NASDAQ Global Market or otherwise or how liquid that market might become. If an active public market is not sustained, it may be difficult for stockholders to sell their shares of common stock at prices that are attractive to them, or at all. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products, product candidates or technologies by using our shares of common stock as consideration. The trading price of our common stock is highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. Factors that could cause volatility in the market price of our common stock include, but are not limited to:

•

announcements relating to our current development and commercialization program for product candidates, including but not limited to plazomicin;

•

results from, or any delays in, clinical trial programs relating to our product candidates;

•

delays in commercializing or obtaining regulatory approval for our product candidates;

•

any need to suspend or discontinue clinical trials due to side effects or other safety risks, or any need to conduct studies on the long-term effects associated with the use of our product candidates;

•

capital fundraising or other financing activities that contain onerous or unfavorable terms;

•

manufacturing issues related to our product candidates for clinical trials or future products for commercialization;

•

commercial success and market acceptance of our product candidates following regulatory approval;

•

undesirable side effects caused by product candidates after they have entered the market;

•

spread of bacterial resistance to our product candidates;

•

ability to discover, develop and commercialize additional product candidates;

•

announcements relating to collaborations that we may enter into with respect to the development or commercialization of our product candidates, or the timing of payments we may make or receive under these arrangements;

•

announcements relating to the receipt, modification or termination of government contracts or grants, or the timing of payments we may receive under these arrangements;

•

success of our competitors in discovering, developing or commercializing products;

•

delay or failure to successfully develop, validate and obtain regulatory clearance or approval of plazomicin in vitro diagnostic assay;

•

strategic transactions undertaken by us;

•

additions or departures of key personnel;

Page 61 of 68

•

product liability claims related to our clinical trials or product candidates;

•

prevailing economic conditions;

•

business disruptions caused by earthquakes or other natural disasters;

•

disputes concerning our intellectual property or other proprietary rights;

•

litigation or the threat of litigation;

•

FDA or other U.S. or foreign regulatory actions affecting us or our industry;

•

healthcare reform measures in the United States or other countries;

•

sales of our common stock by our officers, directors or significant stockholders;

•

future sales or issuances of equity or debt securities by us;

•

fluctuations in our quarterly operating results; and

•

the issuance of new or changed securities analysts’ reports or recommendations regarding us.

In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our management would be diverted from the operation of our business, which could seriously harm our financial position. Any adverse determination in litigation could also subject us to significant liabilities.

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

As of March 31, 2017 our executive officers, directors, and their respective affiliates beneficially owned approximately 8% of our outstanding voting stock. Accordingly, these stockholders may continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets or any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The concentration of stock ownership may adversely affect the trading price of our common stock due to investors’ perception that conflicts of interest may exist or arise.

We are an “emerging growth company” and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.

We are an “emerging growth company,” as defined in the JOBS Act, and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including not being required to comply with the auditor attestation requirements of section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

In addition, Section 102 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. An “emerging growth company” can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we have chosen to “opt out” of such extended transition period, and as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Section 107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.

Page 62 of 68

Raising additional funds by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights.

To the extent that we raise additional capital by issuing equity securities, the share ownership of existing stockholders will be diluted. For example, on April 7, 2015, we filed the Shelf Registration Statement, covering the offering of up to $150 million of common stock, preferred stock, debt securities, warrants, purchase contracts and units. The Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $30.0 million of shares of our common stock from time to time in “at the market” (“ATM”) offerings pursuant to a Common Stock Sales Agreement entered into with Cowen and Company, LLC (the “Sales Agreement”) on April 7, 2015. Through March 31, 2017, we have sold 1,105,549 shares of common stock under the Sales Agreement, at a weighted-average price of approximately $4.82 per share for aggregate gross proceeds of $5.3 million.

As of March 31, 2017, approximately $43.8 million in securities remained unissued under the Shelf Registration Statement, including up to $24.7 million of common stock available to be sold under the Sales Agreement, subject to certain conditions specified therein.

In June 2016, we issued 7,999,996 shares of its common stock and warrants to purchase 1,999,999 shares of its common stock for aggregate gross proceeds of $25.4 million in connection with the Private Placement. Any future debt financing may involve covenants that restrict our operations, including, among other restrictions, limitations on our ability to incur liens or additional debt, pay dividends, redeem our stock, make certain investments, and engage in certain merger, consolidation, or asset sale transactions. In addition, if we raise additional funds through licensing arrangements, it may be necessary to grant potentially valuable rights to our product candidates or grant licenses on terms that are not favorable to us. Further, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, including under our ATM, the issuance of these securities could result in further dilution to our stockholders or result in downward pressure on the price of our common stock.

Future sales by our existing holders of our common stock or securities convertible or exchangeable for our common stock may depress our stock price.

If our existing stockholders or holders of our options or warrants sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline. The perception in the market that these sales may occur could also cause the trading price of our common stock to decline. As of March 31, 2017, we have outstanding a total of 35,846,301 shares of common stock. Other than any shares held by our directors, officers and certain existing investors, all of these are currently freely tradable.

In addition, based on the number of shares subject to outstanding awards under our Amended and Restated 2003 Stock Plan (the “2003 Plan”) or subject to outstanding awards or available for issuance under our 2014 Equity Incentive Award Plan (our “2014 Plan”), our 2014 Employment Commencement Incentive Plan (our “Inducement Plan”) and our 2014 Employee Stock Purchase Plan (our “ESPP”), in each case, as of March 31, 2017, 6,997,879 shares of common stock that are either subject to outstanding awards, outstanding but subject to vesting, or reserved for future issuance under our 2003 Plan, 2014 Plan, Inducement Plan or ESPP will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules. We have filed registration statements permitting shares of common stock issued in the future pursuant to the 2003 Plan, 2014 Plan, Inducement Plan or ESPP to be freely resold by plan participants in the public market and, for shares held by directors, executive officers and other affiliates, subject to compliance with Rule 144. The 2014 Plan and ESPP also contain a provision for the annual increase of the number of shares reserved for issuance under such plan, which shares we also intend to register in the future as such annual increases occurs. If the shares we may issue from time to time under the 2003 Plan, 2014 Plan, the Inducement Plan or ESPP are sold, or if it is perceived that they will be sold, by the award recipient in the public market, the trading price of our common stock could decline.

As of May 3, 2017, certain holders of 1,746,461 shares of our common stock and warrants exercisable for 17,514 shares of our common stock are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares purchased by affiliates. Sales of such shares could also cause the trading price of our common stock to decline.

Page 63 of 68

Provisions of our charter documents or Delaware law could delay or prevent an acquisition of our company, even if the acquisition would be beneficial to our stockholders, and could make it more difficult for you to change management.

Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. In addition, these provisions may frustrate or prevent any attempt by our stockholders to replace or remove our current management by making it more difficult to replace or remove our board of directors. These provisions include:

•

a classified board of directors so that not all directors are elected at one time;

•

a prohibition on stockholder action through written consent;

•

no cumulative voting in the election of directors;

•

the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director;

•

a requirement that special meetings of stockholders be called only by the board of directors, the chairman of the board of directors, the chief executive officer or, in the absence of a chief executive officer, the president;

•

an advance notice requirement for stockholder proposals and nominations;

•

directors may not be removed without cause and may only be removed with cause by the affirmative vote of 66 2/3% of all outstanding shares of our capital stock with the power to vote in the election of directors;

•

the authority of our board of directors to issue preferred stock with such terms as our board of directors may determine; and

•

a requirement of approval of not less than 66 2/3% of all outstanding shares of our capital stock with the power to vote to amend any bylaws by stockholder action, or to amend specific provisions of our certificate of incorporation.

In addition, Delaware law prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person who, together with its affiliates, owns or within the last three years has owned 15% or more of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Accordingly, Delaware law may discourage, delay or prevent a change in control of our company. Furthermore, our amended and restated certificate of incorporation will specify that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders. We believe this provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in such action.

Provisions in our charter and other provisions of Delaware law could limit the price that investors are willing to pay in the future for shares of our common stock.

If we commit certain material breaches under the research agreement with the Gates Foundation, and fail to cure them, we may be required to redeem shares of our common stock held by the Gates Foundation and its affiliates.

In the event of termination of the research agreement by the Gates Foundation for certain specified uncured material breaches by us, we will be obligated, among other remedies, to either redeem our common stock purchased by the Gates Foundation in connection with the research agreement, facilitate the purchase of such common stock by a third party or elect to register the resale of such common stock into the public markets unless certain specified conditions are satisfied. If we are required to redeem such shares of common stock, our financial condition could be materially and adversely affected.

We do not anticipate paying any cash dividends on our capital stock in the foreseeable future; as a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

We have never declared or paid cash dividends on our capital stock. We do not anticipate paying any cash dividends on our capital stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the

Page 64 of 68

development and growth of our business. In addition, the terms of any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline.

The trading market for our common stock will depend, in part, on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. In addition, if our operating results fail to meet the forecast of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

(a) Recent Sales of Unregistered Equity Securities

From January 1, 2017 through March 31, 2017, other than as indicated in the paragraph below, we have not issued any securities in a transaction not registered under the Securities Act that have not been previously disclosed in an Annual report on Form 10-K or Current Report on Form 8-K.

In February 2016, we issued 78,585 shares of common stock pursuant to the exercise of warrants to purchase 78,585 shares of common stock to 2 accredited investors at an exercise price per share of $3.66. The aggregate cash consideration received for these issuances was approximately $0.3 million.

No underwriters were involved in the foregoing sales of securities. The issuances described above were undertaken in reliance upon the exemption from registration requirements of Section 4(a)(2) of the Securities Act of 1933, as amended, including Rule 506 of the Securities Act. The recipients of these shares of common stock represented their intentions to acquire the shares for investment only and not with a view to or for sale in connection with any distribution, and appropriate restrictions were set out in the applicable agreements issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us.

(b) Use of Proceeds

None.

Not applicable.

Item 3.

Defaults Upon Senior Securities.

None.

Item 4.

Mine Safety Disclosures.

Not applicable.

Item 5.

Other Information.

None.

Item 6.

Exhibits.

See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this Quarterly Report on Form 10-Q, which Exhibit Index is incorporated herein by reference.

Page 65 of 68

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 8, 2017	ACHAOGEN, INC.

	By:	/s/ Kenneth J. Hillan
		Kenneth J. Hillan, M.B., Ch. B.
		Chief Executive Officer (principal executive officer)

Date: May 8, 2017	By:	/s/ Tobin C. Schilke
		Tobin C. Schilke
		Chief Financial Officer (principal financial and accounting officer)

Page 66 of 68

EXHIBIT INDEX

Exhibit

Number

Description of Document

Incorporated by Reference from

Provided

Herewith

Registrant’s

Form

File No.

Date Filed

with the

SEC

Exhibit

Number

3.1

Amended and Restated Certificate of Incorporation of Achaogen, Inc.

8-K

001-36323

3/17/2014

3.1

3.2

Amended and Restated Bylaws of Achaogen, Inc.

8-K

001-36323

3/17/2014

3.2

4.1

Reference is made to Exhibits 3.1 through 3.2.

4.2

Form of Common Stock Certificate.

S-1/A

333-193559

3/10/2014

4.1

4.3

Warrant issued to Oxford Finance LLC on November 1, 2011.

S-1

333-193559

1/24/2014

4.4

4.5

Warrant issued to Oxford Finance LLC on April 30, 2012 (Term A Loan (2)).

S-1

333-193559

1/24/2014

4.6

Warrant issued to Oxford Finance LLC on April 30, 2012 (Term B Loan).

S-1

333-193559

1/24/2014

4.7

Form of Warrant, issued pursuant to the Securities Purchase Agreement, dated June 1, 2016, by and among Achaogen, Inc. and the purchasers named therein.

S-3

333-212253

6/24/2016

4.3

10.1#

Transition and Separation Agreement, dated March 15, 2017, by and between the Company and Dr. Ian Friedland.

10.2#

Consulting Agreement, dated March 15, 2013, as amended, by and between the Company and Planet Pharma, LLC.

10.3†

Validation and Manufacturing Agreement, dated March 5, 2017, by and between the Company and Hovione Limited.

10.4

Modification 0026, dated March 30, 2017, to Contract Award issued by the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services, dated August 30, 2010.

10.5†

Collaborative Development and Commercialization Agreement, dated April 26, 2016, by and between the Company and Microgenics Corporation.

10.6

Form of Change in Control Severance Agreement

10-K

001-36323

3/14/2017

10.20

31.1

Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.

31.2

Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.

32.1*

Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350.

101.INS

XBRL Instance Document.

101.SCH

XBRL Taxonomy Extension Schema Document.

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB

XBRL Taxonomy Extension Label Linkbase Document.

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document.

Page 67 of 68

#	Indicates management contract or compensatory plan.

†	Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment and this exhibit has been filed separately with the SEC.

The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Achaogen, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.

Page 68 of 68

EX-10.1 2 akao-ex101_799.htm EX-10.1 akao-ex101_799.htm

Exhibit 10.1

TRANSITION AND SEPARATION AGREEMENT

This Transition and Separation Agreement (the “Agreement”) by and between Dr. Ian Friedland (“Executive”) and Achaogen, Inc., a Delaware corporation (the “Company”), is made effective as March 15, 2017 (the “Effective Date”) with reference to the following facts:

A.Executive’s employment with the Company and status as an officer and employee of the Company and each of its affiliates will end effective as of March 15, 2017.

B.Executive and the Company want to establish the obligations of the parties including, without limitation, all amounts due and owing to Executive.

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, the parties agree as follows:

1.Employment Termination and Transition Services.

(a)Effective Date. Executive acknowledges and agrees that his status as an officer and employee of the Company will end effective as of the Effective Date. Executive hereby agrees to execute such further document(s) as shall be determined by the Company as necessary or desirable to give effect to the termination of Executive’s status as an officer of the Company and each of its subsidiaries.

(b)Transition Consulting Services. Until July 31, 2017, Executive shall be available to provide transition services to the Company, on a non-exclusive basis, as a consultant and shall provide such transition services in accordance with a Consulting Agreement to be entered into between Executive and the Company substantially in the form attached hereto as Exhibit A (the “Consulting Agreement”). The end of services by Executive under the Consulting Agreement, July 31, 2017, shall be the “Completion Date” for purposes of this Agreement unless the Consulting Agreement is terminated earlier. If additional services are required after the Completion Date, the parties shall mutually agree on another consulting arrangement.

2.Final Paycheck: Payment of Accrued Wages and Expenses.

(a)Final Paycheck. As soon as administratively practicable on or after the Effective Date, the Company will pay Executive all accrued but unpaid base salary and all accrued and unused vacation earned through the Effective Date, subject to standard payroll deductions and withholdings. Executive is entitled to these payments regardless of whether Executive executes the Acceptance of Release.

(b)Business Expenses. The Company shall reimburse Executive for all outstanding expenses incurred prior to the Effective Date which are consistent with the Company’s policies in effect from time to time with respect to travel, entertainment and other business expenses, subject to the Company’s requirements with respect to reporting and documenting such expenses. Executive is entitled to these reimbursement regardless of whether Executive executes the Acceptance of Release.

(c)SEC Reporting. Executive acknowledges that to the extent required by the Securities Exchange Act of 1934, as amended (the “Exchange Act”), he will have continuing obligations under Section 16(a) and 16(b) of the Exchange Act to report matching transactions, if any, in Company common stock for six (6) months following the Effective Date. Executive further acknowledges that any transactions by Executive involving Company securities will remain subject to securities laws in all respects, including, without limitation, laws regarding trading on the basis of material nonpublic information.

3.Employment Termination Payments and Benefits. Without admission of any liability, fact or claim, the Company hereby agrees, subject to this Agreement becoming effective and irrevocable (the date of such effectiveness and irrevocability, the “Release Effective Date”) and Executive’s performance of his continuing obligations pursuant to this Agreement, the Consulting Agreement and that certain At Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement (the “Confidentiality Agreement”), to provide Executive the severance benefits set forth below.

Specifically, upon Executive’s signing of this Agreement and the separate Acceptance of Release in this Agreement and the passing of any applicable revocation period, the Company and Executive agree as follows:

(a)Severance. Executive shall be entitled to receive an amount equal to nine (9) months of base salary (the aggregate amount, $319,800), payable in a cash lump sum on or before April 15, 2017.

(b)Healthcare Continuation Coverage. Executive’s Company-provided health insurance benefits will end on March 31, 2017. If Executive elects to receive continued healthcare coverage pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall directly pay, or reimburse Executive for, the premiums for Executive and Executive’s covered dependents during the period commencing on the Effective Date and ending on the earlier to occur of (i) the nine-month anniversary of the Effective Date and (ii) the date Executive becomes eligible for comparable coverage under another employer’s plans. After the Company ceases to reimburse or pay premiums pursuant to the preceding sentence, Executive may, if eligible, elect to continue healthcare coverage at Executive’s expense in accordance with the provisions of COBRA.

(c)Time-Based Equity Awards. The unvested portions of the Executive’s (i) options to purchase shares of Company common stock granted on September 25, 2014, Februa1y 5, 2015, and February 26, 2016 (collectively, the “Time-Based Options”) and (ii) restricted stock unit awards granted on March 11, 2015 and Februa1y 26,2016 (together, the “RSU Awards”) at the time of the Effective Date shall continue to vest in accordance with the original vesting schedule of the applicable Time-Based Option or RSU Award while Executive is providing services to the Company pursuant to the Consulting Agreement. In addition, the vesting of the Time-Based Options and the RSU Awards shall accelerate upon the Effective Date in respect of that number of shares of Company common stock underlying such Time-Based Options and RSU Awards that would have vested had Executive’s employment with the Company continued through the nine-month anniversary of the Completion Date, in each case, as set forth on Exhibit A attached hereto. Should Executive satisfy the Consulting Agreement July 31, 2017, then a total of 28,434 options at a strike price of $8.04, 13,949 options at a strike price of $11.78, and 12,838 options at a strike price of $3.65 and 6,125 RSUs will vest on or before July 31, 2017. Any portion of the Time-Based Options and RSU Awards that remains unvested as of the Completion Date shall thereupon be forfeited for no consideration except as set forth in this paragraph. The vested portion of the Time-Based Options shall remain exercisable through the three-month anniversary of the Completion Date. Any vested Time-Based Options not exercised prior to the three-month anniversary of the Completion Date under the Consulting Agreement shall thereupon be forfeited. Executive acknowledges and agrees that to the extent any of Executive’s options to purchase Company common stock have an exercise price per share lower than the closing trading price of the Company’s common stock on the date this agreement is executed, such options shall cease to qualify as “incentive stock options” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”) as of the date this Agreement is signed. Executive further acknowledges and agrees that any options to purchase Company common stock that remain unexercised as of the three-month anniversary of the Effective Date shall thereupon constitute a non-qualified stock option.

(d)Performance-Based Equity Awards. To the extent any of the performance goals applicable to Executive’s options to purchase shares of Company common stock granted on September 25, 2014, February 5, 2015, and February 26, 2016 (collectively, the “Performance-Based Option”) are achieved prior to the Completion Date, the Performance-Based Option shall immediately vest in respect of that number of shares of Company common stock that correlates with such performance goal achievement, and Executive shall have until the three-month anniversary of the date Executive ceases to provide services under the Consulting Agreement to exercise the Performance-Based Option in respect of such shares. Any portion of the Performance-Based Option that remains unvested as of the Completion Date shall thereupon terminate. Any portion of the Performance-Based Option that vests and remains unexercised on the three-month anniversary of the Completion Date shall thereupon terminate.

(e)Taxes. Executive understands and agrees that all payments under this Agreement will be subject to appropriate tax withholding and other deductions. To the extent any taxes may be payable by Executive for the benefits provided to him by this Agreement beyond those withheld by the Company, Executive agrees to pay them himself and to indemnify and hold the Company and the other entities released herein harmless for any tax claims or penalties, and associated attorneys’ fees and costs, resulting from any failure by him to make required payments.

(f)Sole Separation Benefit. Executive agrees that the payments provided by this Section 3 are not required under the Company’s normal policies and procedures and are provided as a severance solely in connection with this Agreement. Executive acknowledges and agrees that the payments referenced in this Section 3 constitute adequate and valuable consideration, in and of themselves, for the promises contained in this Agreement.

4.Full Payment. Executive acknowledges that the payment and arrangements herein shall constitute full and complete satisfaction of any and all amounts properly due and owing to Executive as a result of his employment with the Company and the termination thereof. Executive further acknowledges that, other than the Confidentiality Agreement, the

Consulting Agreement and the Indemnification Agreement by and between the Company and Executive (the “Indemnification Agreement”), this Agreement shall supersede each agreement entered into between Executive and the Company regarding Executive’s employment, including, without limitation, any offer letter, employment agreement, severance and/or change in control agreement, and each such agreement other than the agreements evidencing Executive’s equity awards shall be deemed terminated and of no further effect as of the Effective Date.

5.Executive’s Release of the Company. Executive understands that by agreeing to the release provided by this Section 5 and by signing the Acceptance of Release in addition to executing this Agreement, Executive is agreeing not to sue, or otherwise file any claim against, the Company or any of its employees or other agents for any reason whatsoever based on anything that has occurred as of the date Executive signs the Acceptance of Release.

(a)Release. On behalf of Executive and Executive’s heirs, assigns, executors, administrators, trusts, spouse and estate, Executive hereby releases and forever discharges the “Releasees” hereunder, consisting of the Company, and each of its owners, affiliates, subsidiaries, predecessors, successors, assigns, agents, directors, officers, partners, employees, and insurers, and all persons acting by, through, under or in concert with them, or any of them, of and from any and all manner of action or actions, cause or causes of action, in law or in equity, suits, debts, liens, contracts, agreements, promises, liability, claims, demands, damages, loss, cost or expense, of any nature whatsoever, known or unknown, fixed or contingent (hereinafter called “Claims”), which Executive now has or may hereafter have against the Releasees, or any of them, by reason of any matter, cause, or thing whatsoever from the beginning of time to the date hereof, including, without limiting the generality of the foregoing, any Claims arising out of, based upon, or relating to Executive’s hire, employment, remuneration or resignation by the Releasees, or any of them, Claims arising under federal, state, or local laws relating to employment, Claims of any kind that may be brought in any court or administrative agency, including any Claims arising under Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. § 2000, et seq.; Americans with Disabilities Act, as amended, 42 U.S.C. § 12101 et seq.; the Rehabilitation Act of 1973, as amended, 29 U.S.C. § 701 et seq.; Age Discrimination in Employment Act, as amended, 29 U.S.C. § 621, et seq.; Civil Rights Act of I 866, and Civil Rights Act of 1991; 42 U.S.C. § 1981, et seq.; Equal Pay Act, as amended, 29 U.S.C. § 206(d); regulations of the Office of Federal Contract Compliance, 41 C.F.R. Section 60, et seq.; the Family and Medical Leave Act, as amended, 29 U.S.C. § 2601 et seq.; the Fair Labor Standards Act of 1938, as amended, 29 U.S.C. § 201 et seq.; the Employee Retirement Income Security Act, as amended, 29 U.S.C. § 1001 et seq.; the Worker Adjustment and Retraining Notification Act, as amended, 29 U.S.C. § 2101 et seq.; the California Fair Employment and Housing Act, as amended, Cal. Lab. Code§ 12940 et seq.; the California Equal Pay Law, as amended, Cal. Lab. Code§§ 1197.S(a),199.5; the Moore-Brown-Roberti Family Rights Act of 1991, as amended, Cal. Gov’t Code §§12945.2, 19702.3; California Labor Code §§ 110 I, I 1 02; the California WARN Act, California Labor Code§§ 1400 et. seq; California Labor Code§§ 1102.S(a),(b); claims for wages under the California Labor Code and any other federal, state or local laws of similar effect; the employment and civil rights laws of California; Claims for breach of contract; Claims arising in tort, including, without limitation, Claims of wrongful dismissal or discharge, discrimination, harassment, retaliation, fraud, misrepresentation, defamation, libel, infliction of emotional distress, violation of public policy, and/or breach of the implied covenant of good faith and fair dealing; and Claims for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney’s fees.

(b)ADEA Specific Waiver and Release. Executive acknowledges that Executive is knowingly and voluntarily waiving and releasing any rights Executive may have under the ADEA. Executive also acknowledges that the consideration given for the waiver and release in above is in addition to anything of value to which Executive was already entitled. Executive further acknowledges that Executive have been advised by this writing, as required by the ADEA, that: (a) Executive’s waiver and release do not apply to any rights or claims that may arise after Executive signs this Agreement; (b) Executive should consult with an attorney prior to signing this Agreement; (c) Executive has until twenty-one (21) days after the Effective Date within which to consider this Agreement (although Executive may choose to voluntarily sign this agreement earlier); (d) Executive has seven (7) days following the date Executive signs this Agreement to revoke the Agreement (the “Revocation Period”); and (e) this Agreement will not be effective until the date upon which the Revocation Period has expired, which will be the eighth day after this Agreement is signed by both parties. If Executive chooses to revoke this agreement, the revocation must be personally delivered or mailed to Zeryn Sarpangal, SVP of Corporate and People Strategy, by email (zsarpangal@achaogen.com) or by mail (7000 Shoreline Court, Suite 731, South San Francisco, CA 94080). If mailed, the revocation must be properly addressed to Ms. Sarpangal and postmarked no later than the last day of the Revocation Period. Executive understands that Executive’s acceptance of any severance benefit at any time after the Effective Date confirms that Executive did not revoke Executive’s assent to this Agreement and, therefore, that it is fully effective and enforceable.

(c)Notwithstanding the generality of the foregoing, Executive does not release the following claims:

(i)Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law;

(ii)Claims for workers’ compensation insurance benefits under the terms of any worker’s compensation insurance policy or fund of the Company;

(iii)Claims to continued participation in certain of the Company’s group benefit plans pursuant to the terms and conditions of COBRA;

(iv)Claims to any benefit entitlements vested as the date of Executive’s employment termination, pursuant to written terms of any Company employee benefit plan;

(v)Claims for indemnification under the Indemnification Agreement, the Company’s Bylaws, California Labor Code Section 2802 or any other applicable law; and

(vi)Executive’s right to bring to the attention of the Equal Employment Opportunity Commission claims of discrimination; provided, however, that Executive does release Executive’s right to secure any damages for alleged discriminatory treatment.

(d)EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE HAS BEEN ADVISED OF AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS:

“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM OR HER, MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.”

BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.

6.Non-Disparagement, Transition, Transfer of Company Property and Limitations on Service. Executive further agrees that:

(a)Non-Disparagement. Executive agrees that he shall not disparage, criticize or defame the Company or the released parties in any manner likely to be harmful to any of them or their business, business reputation or personal reputation, either publicly or privately. The Company agrees that it shall not, and it shall instruct its officers and members of its Board of Directors to not, disparage, criticize or defame Executive, either publicly or privately. Nothing in this Section 6(a) shall have application to any evidence or testimony required by any court, arbitrator or government agency. For purposes of this agreement, “disparage” shall mean to make, publish or communicate any negative, belittling or derogatory statement, whether oral or written. Executive agrees that the obligations under this Paragraph include (without limitation) refraining from publishing any disparaging remark on any blog, online social network or any other website (including, but not limited to, www.glassdoor.com), whether or not such comments are made anonymously. Notwithstanding the foregoing, Executive may respond accurately and fully to any question, inquiry or request for information when required by legal process. This provision does not in any way limit Executive’s right to file a charge with the EEOC or equivalent state or local agencies, or to investigations by any federal, state or local agencies.

(b)Non-Solicitation. For a period of one year following the Completion Date, Executive further acknowledges and reaffirms Executive’s obligation not to solicit Company employees to leave the Company, which also remain in full force and effect. Nothing in this Agreement is intended to interfere with or discourage a good faith disclosure to any governmental entity related to a suspected violation of the law. Executive cannot and will not be held criminally or civilly liable under any federal or state trade secret law for disclosing otherwise protected trade secrets and/or confidential or proprietary information as long as the disclosure is made in (i) confidence to a federal , state, or local government official, directly or indirectly, or to an attorney and solely for the purpose of reporting or investigating a suspected violation of law; or (ii) a complaint or other document filed in a lawsuit or other proceeding, as long as such filing is made under seal.

(c)Transition. Each of the Company and Executive shall use their respective reasonable efforts to cooperate with each other in good faith to facilitate a smooth transition of Executive’s duties to other executive(s) of the Company.

(d)Transfer of Company Property. On or before the Completion Date, Executive shall turn over to the Company all files, memoranda, records, and other documents, and any other physical or personal property which are the property of the Company and which he had in his possession, custody or control at the time he signed this Agreement.

7.Executive Representations. Executive warrants and represents that (a) he has not filed or authorized the filing of any complaints, charges or lawsuits against the Company or any affiliate of the Company with any governmental agency or court, and that if, unbeknownst to Executive, such a complaint, charge or lawsuit has been filed on his behalf, he will immediately cause it to be withdrawn and dismissed, (b) he has reported all hours worked as of the date of this Agreement and has been paid all compensation, wages, bonuses, commissions, and/or benefits to which he may be entitled and no other compensation, wages, bonuses, commissions and/or benefits are due to him, except as provided in this Agreement, (c) he has no known workplace injuries or occupational diseases and has been provided and/or has not been denied any leave requested under the Family and Medical Leave Act or any similar state law, (d) the execution, delivery and performance of this Agreement by Executive does not and will not conflict with, breach, violate or cause a default under any agreement, contract or instrument to which Executive is a party or any judgment, order or decree to which Executive is subject, and (e) upon the execution and delivery of this Agreement by the Company and Executive, this Agreement will be a valid and binding obligation of Executive, enforceable in accordance with its terms.

8.No Assignment by Executive. Executive warrants and represents that no portion of any of the matters released herein, and no portion of any recovery or settlement to which Executive might be entitled, has been assigned or transferred to any other person, firm or corporation not a party to this Agreement, in any manner, including by way of subrogation or operation of law or otherwise. If any claim, action, demand or suit should be made or instituted against the Company or any other Releasee because of any actual assignment, subrogation or transfer by Executive, Executive agrees to indemnify and hold harmless the Company and all other Releasees against such claim, action, suit or demand, including necessary expenses of investigation, attorneys’ fees and costs. In the event of Executive’s death, this Agreement shall inure to the benefit of Executive and Executive’s executors, administrators, heirs, distributees, devisees, and legatees. None of Executive’s rights or obligations may be assigned or transferred by Executive, other than Executive’s rights to payments hereunder, which may be transferred only upon Executive’s death by will or operation of law.

9.Governing Law. This Agreement shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of California or, where applicable, United States federal law, in each case, without regard to any conflicts of laws provisions or those of any state other than California.

10.Miscellaneous. This Agreement, collectively with the Confidentiality Agreement, the Indemnification Agreement and the agreements evidencing Executive’s equity awards comprise the entire agreement between the parties with regard to the subject matter hereof and supersedes, in their entirety, any other agreements between Executive and the Company with regard to the subject matter hereof. Executive acknowledges that there are no other agreements, written, oral or implied, and that he may not rely on any prior negotiations, discussions, representations or agreements. This Agreement may be modified only in writing, and such writing must be signed by both parties and recited that it is intended to modify this Agreement. This Agreement may be executed in separate counterparts, each of which is deemed to be an original and all of which taken together constitute one and the same agreement.

11.Company Assignment and Successors. The Company shall assign its rights and obligations under this Agreement to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise). This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns, personnel and legal representatives.

12.Maintaining Confidential Information. Executive reaffirms his obligations under the Confidentiality Agreement. Executive acknowledges and agrees that the payments provided in Section 3 above shall be subject to Executive’s continued compliance with Executive’s obligations under the Confidentiality Agreement.

13.Executive’s Cooperation. After the Completion Date, Executive shall cooperate with the Company and its affiliates, upon the Company’s reasonable request, with respect to any internal investigation or administrative, regulatory or judicial proceeding involving matters within the scope of Executive’s duties and responsibilities to the Company or its affiliates during his employment with the Company (including, without limitation, Executive being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company’s reasonable request to give testimony without requiring service of a subpoena or other legal process, and turning over to the Company all relevant Company documents which are or may have come into Executive’s possession during his employment);provided, however, that any such request by the Company shall not be unduly burdensome or interfere with Executive’s personal schedule or ability to engage in gainful employment.

14.Section 409A of the Code. This Agreement is intended, to the greatest extent permitted under law, to comply with the short-term deferral exemption and the separation pay exemption provided in Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and other interpretative guidance issued thereunder (“Section 409A”) such that no benefits or payments under this Agreement are subject to Section 409A. Notwithstanding anything herein to the contrary, the timing of any payments under this Agreement shall be made consistent with such exemption. Executive’s right to receive a series of installment payments under this Agreement, if any, shall be treated as a right to receive a series of separate payments. To the extent applicable, this Agreement shall be interpreted in accordance with Section 409A, including without limitation any such regulations or other guidance that may be issued after the Completion Date. Notwithstanding any provision of this Agreement to the contrary, in the event that the Company determines that any amounts payable hereunder may be subject to Section 409A, the Company may, to the extent permitted under Section 409A cooperate in good faith to adopt such amendments to this Agreement or adopt other appropriate policies and procedures, including amendments and policies with retroactive effect, that the Company determines are necessary or appropriate to avoid the imposition of taxes under Section 409A; provided, however, that this paragraph shall not create an obligation on the part of the Company to adopt any such amendment, policy or procedure or take any such other action, nor shall the Company have any liability for failing to do so. To the extent that any reimbursements payable pursuant to this Agreement are subject to the provisions of Section 409A, such reimbursements shall be paid to Executive no later than December 31 of the year following the year in which the expense was incurred, the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year, and Executive’s right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.

Executive hereby agrees to the terms and conditions set forth above.

IN WITNESS WHEREOF, the undersigned have caused this Transition and Separation Agreement to be duly executed and delivered as of the date indicated next to their respective signatures below.

		/s/ Ian Friedland
DATED:	3/14, 2017	Ian Friedland

		ACHAOGEN, INC.

DATED:	March 14, 2017	By:	/s/ Kenneth Hillan
		Name:	Kenneth Hillan
		Title:	Chief Executive Office

ACCEPTANCE OF RELEASE

BEFORE SIGNING MY NAME TO THE RELEASE, I STATE THE FOLLOWING: I HAVE READ THE RELEASE, INCLUDING BUT NO LIMITED TO SECTION 5 ABOVE, CONTAINED IN THIS AGREEMENT, I UNDERSTAND IT AND I KNOW THAT I AM GIVING UP IMPORTANT RIGHTS. I HAVE OBTAINED SUFFICIENT INFORMATION TO INTELLIGENTLY EXERCISE MY OWN JUDGMENT. I HAVE BEEN ADVISED THAT I SHOULD CONSULT WITH AN ATTORNEY BEFORE SIGNING IT, AND I HAVE SIGNED THE RELEASE KNOWINGLY AND VOLUNTARILY.

Date delivered to employee: March 14, 2017

Deadline for returning release: April 4, 2017

Executed this 14 day of March , 2017

/s/ Ian Friedland

Signature

EXHIBIT A

Exhibit BJ To

Consulting Agreement between Achaogen, Inc. and Planet Pharma, LLC

Dated March 15, 2013

This Exhibit BJ (“Exhibit”) effective as of March 16, 2017 (“Effective Date”), is between Achaogen, Inc. (“Achaogen”) and Planet Pharma, LLC (“Consultant”), and is issued pursuant to the Consulting Agreement between Achaogen and Consultant dated March 15, 2013 and amended January 1, 2016 and November 1, 2016 (“Agreement”). Achaogen and Consultant are sometimes hereinafter referred to jointly as the “Parties” to this Exhibit.

WHEREAS, the Parties wish to have Consultant perform for Achaogen the Services as described below.

NOW THEREFORE, the Parties agree to be bound by the terms and conditions of the Agreement and this Exhibit.

1.Contact. Consultant’s principal contact at Achaogen will be:

Name:Lynn Connolly

Title:VP Late Development

2.Assigned Resource. Consultant’s assigned resource at Achaogen will be:

Name:Dr. Ian Friedland

Title:Development and NDA Consultant

3.Services. Consultant will render to Achaogen the following Services (“Services”):

(i) Support for plazomicin NDA (non-CMC related): strategy discussions, review of key documents (CSR/Clin Overview), FDA interactions;

(ii) Med Affairs: scientific review of materials for ClinSci (platform, lexicon, ad board materials, publications) and support for Ad Boards;

(iii) Management of ARLG studies until NDA submission ready; and

(iv) C-Scape Phase 3 protocol.

4.Compensation.

(a)In consideration of the Services to be performed hereunder, Achaogen will pay Consultant $40,000 per month. The maximum compensation payable through July 31, 2017 for Services described in this Exhibit will not exceed $180,000.

(b)Consultant will submit a monthly invoice for services and expenses to Achaogen by regular mail or by email as noted below:

By regular mail:		Achaogen, Inc.
		Attn: Accounts Payable
		7000 Shoreline Court, Suite 371

Achaogen/Planet Pharma - Dr. Ian Friedland (TMV)

Consulting Agreement 2016 (non govt) Exhibit BJ

		South San Francisco, CA 94080
By email:		accounting@achaogen.com

(c)Consultant will submit all invoices for Services and expenses for Services conducted under this Exhibit separately from all other services conducted under the Agreement and any other associated exhibit(s) or amendment(s) thereto. Achaogen will pay each invoice within 30 days of receipt in the absence of a good faith dispute, provided that in case of a dispute the precise nature thereof will be provided to Consultant in writing within the 30-day payment period. In order to be eligible for payment by Achaogen, invoices must be submitted within six (6) months of the provision of services corresponding thereto. Invoices submitted by Consultant more than six (6) months after the provision of services listed in the invoice will not be considered by Achaogen for payment.

(d)Consultant will submit all invoices in a form approved by Achaogen and such invoices will be approved by the contact person listed above. The form shall include the following:

A brief description of Services performed;

ii.

Purchase Order Number 14455; and

iii.

The following statement: “Services performed pursuant to Exhibit BJ of the Consulting Agreement dated March 15, 2013 and associated with the program code 0.0.0.0.”

Achaogen/Planet Pharma - Dr. Ian Friedland (TMV)

Consulting Agreement 2016 (non govt) Exhibit BJ

IN WITNESS WHEREOF, the Parties hereto have executed this Exhibit on the date(s) set forth below and it will be effective as of the day and year first above written.

Achaogen, Inc.		Planet Pharma, LLC

By:	/s/ Kenneth Hillan	By:	/s/ Donald Kraus
	(signature)		(signature)

Name:	Kenneth Hillan	Name:	Donald Kraus

Title:	CEO	Title:	Senior Director

Date:	March 14, 2017	Date:

Achaogen/Planet Pharma - Dr. Ian Friedland (TMV)

Consulting Agreement 2016 (non govt) Exhibit BJ

EXHIBIT B

ACCELERATED EQUITY AWARDS


Name	ID	Grant Number	Grant Date	Plan/Type	Shares	Price	Vested

Time-based vesting
												Amount to
												vest
												monthly
												until last
Options										Last date of vest		date of vest
		000573	09/25/2014	2014/ISO	49,748	$8.04	32,128			9/25/18		1,036
		N00573	09/25/2014	2014/NQ	47,752	$8.04	30,839			9/25/18		995
		000649	02/05/2015	2014/NQ	51,500	$11.78	25,750			2/5/19		1,073
		000851	02/26/2016	2014/ISO	23,836	$3.65	1			2/26/20		497
		000852	02/26/2016	2014/NQ	20,164	$3.65	10,998			2/26/20		420


												Amount to
											Next vesting	vest at next
RSUs										Last date at vest	date	annual vest
		000655	03/11/2015	2014/RSU	15,000	$0.00	7,500			3/11/19	3/11/18	3,750
		000913	02/26/2016	2014/RSU	9,500	$0.00	2,375			2/26/20	2/26/18	2,375

Performance based vesting
												Amount to
												vested at
											Next vesting	next
										Expiration	threshold	threshold

Options		000577	09/25/2014	2014/NQ	52,500	$8.04	0	Perf based	1	9/25/24	33% at $33	17,500
		000858	02/26/2016	2014/NQ	20,000	$3.65	8,000	Perf based	2	2/26/26	40% at $25	8,000
RSUs		000917	02/26/2016	2014/RSU	4,000	$0.00	1,600	Perf based	2	2/26/26	40% at $25	1,600

				TOTAL	294,000

Perf based equity vesting:

1. 1/3 at $33, 1/3 at $55, $1/3 at $77

2. 40% at $12, 40% at $25, 20% at $55

EX-10.2 3 akao-ex102_989.htm EX-10.2 akao-ex102_989.htm

Exhibit 10.2

CONSULTING AGREEMENT

This Consulting Agreement (the “Agreement”) is made and entered into as of March 15, 2013 (the “Effective Date”), by and between ACHAOGEN, INC., a Delaware corporation with its principal place of business at 7000 Shoreline Court, Suite 371, South San Francisco, California 94080, USA (“Achaogen”), and PLANET PHARMA, LLC an Illinois corporation having a principal place of business at 800 Hillgrove Avenue, Suite 102, Western Springs, IL 60558 (“Consultant”). Achaogen desires to retain Consultant as an independent contractor to perform consulting services for Achaogen and Consultant is willing to perform such services, on terms set forth more fully below.

In consideration of the mutual promises contained herein, the parties agree as follows:

1.SERVICES AND COMPENSATION

(a)Consultant agrees to perform for Achaogen the services (“Services”) described in related Exhibit(s), attached hereto.

(b)Achaogen agrees to pay Consultant the compensation set forth in related Exhibit(s) for the performance of the Services.

2.CONFIDENTIALITY

(a)Definition. “Confidential Information” means any Achaogen proprietary information, technical data, trade secrets or know-how, including, but not limited to, research, product plans, products, services, customers, customer lists, markets, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, finances or other business information disclosed by Achaogen either directly or indirectly in writing, orally or by drawings or inspection of parts or equipment.

(b)Non-Use and Non-Disclosure. Consultant will not, during or subsequent to the term of this Agreement, use Achaogen’s Confidential Information for any purpose whatsoever other than the performance of the Services on behalf of Achaogen or disclose Achaogen’s Confidential Information to any third party. It is understood that said Confidential Information shall remain the sole property of Achaogen. Consultant further agrees to take all reasonable precautions to prevent any unauthorized disclosure of such Confidential Information including, but not limited to, having each employee of Consultant, if any, with access to any Confidential Information, execute a nondisclosure agreement containing provisions in Achaogen’s favor substantially identical to Sections 2, 3 and 5 of this Agreement. Confidential Information does not include information which (i) is known to Consultant at the time of disclosure to Consultant by Achaogen as evidenced by written records of Consultant, (ii) has become publicly known and made generally available through no wrongful act of Consultant, or (iii) has been rightfully received by Consultant from a third party who is authorized to make such disclosure. Without Achaogen’s prior written approval, Consultant will not directly or indirectly disclose to anyone the existence of this Agreement or the fact that Consultant has this arrangement with Achaogen.

(c)Former Employer’s Confidential Information. Consultant agrees that Consultant will not, during the term of this Agreement, improperly use or disclose any proprietary information or trade secrets of any former or current employer or other person or entity with which Consultant has an agreement or duty to keep in confidence information acquired by Consultant, if any, and that Consultant will not bring onto the premises of Achaogen any unpublished document or proprietary information belonging to such employer, person or entity unless consented to in writing by such employer, person or entity. Consultant will indemnify Achaogen and hold it harmless from and against all claims, liabilities, damages and expenses, including reasonable attorneys’ fees and costs of suit, arising out of or in connection with any violation or claimed violation of a third party’s rights resulting in whole or in part from Achaogen’s use of the work product of Consultant under this Agreement.

(d)Third Party Confidential Information. Consultant recognizes that Achaogen has received and in the future will receive from third parties their confidential or proprietary information subject to a duty on Achaogen’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. Consultant agrees that Consultant owes Achaogen and such third parties, during the term of this Agreement and thereafter, a duty to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying out the Services for Achaogen consistent with Achaogen’s agreement with such third party.

(e)Return of Materials. Upon the termination of this Agreement, or upon Achaogen’s earlier request, Consultant will deliver to Achaogen all of Achaogen’s property or Confidential Information that Consultant may have in Consultant’s possession or control.

3.OWNERSHIP

(a)Assignment. Consultant agrees that all inventions, improvements, developments, discoveries, copyrightable material, trade secrets, copyrightable material, notes, records, drawings and designs (collectively, “Inventions”) conceived, made or discovered by Consultant, solely or in collaboration with others, in connection with or as a result of performance of Services are the sole property of Achaogen. Consultant further agrees to assign (or cause to be assigned) and does hereby assign fully to Achaogen all Inventions, and all U.S. and foreign patents, patent applications, copyrights, copyright applications and mask work rights, and all other intellectual property rights relating thereto. Consultant will promptly disclose in writing to the Chief Executive Officer or Chief Scientific Officer of Achaogen, or to any other persons designated by Achaogen, all Inventions. Consultant will not disclose Inventions to any person outside Achaogen unless requested to do so in writing by the Chief Executive Officer or Chief Scientific Officer of Achaogen.

(b)Further Assurances. Consultant agrees to assist Achaogen, or its designee, at Achaogen’s expense, in every proper way to secure Achaogen’s rights in the Inventions and any patents, patent applications, copyrights, copyright applications and mask work rights, and all other intellectual property rights relating thereto in any and all countries, including the disclosure to Achaogen of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments which Achaogen shall deem necessary in order to apply for and obtain such rights and in order to assign and convey to

Achaogen/Planet Pharma, LLC

Consulting Agreement

Achaogen, its successors, assigns and nominees the sole and exclusive right, title and interest in and to such Inventions, and any patents, patent applications, copyrights, copyright applications and mask work rights, and all other intellectual property rights relating thereto. Consultant further agrees that Consultant’s obligation to execute or cause to be executed, when it is in Consultant’s power to do so, any such instrument or papers shall continue after the termination of this Agreement.

(c)Attorney in Fact. Consultant agrees that if Achaogen is unable because of Consultant’s unavailability, dissolution, mental or physical incapacity, or for any other reason, to secure Consultant’s signature to apply for or to pursue any application for any United States or foreign patents or mask work or copyright registrations covering the Inventions assigned to Achaogen above, then Consultant hereby irrevocably designates and appoints Achaogen and its duly authorized officers and agents as Consultant’s agent and attorney in fact, to act for and in Consultant’s behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of patents, copyright and mask work registrations thereon with the same legal force and effect as if executed by Consultant.

4.REPORTS

Consultant agrees that Consultant will from time to time during the term of this Agreement or any extension thereof keep Achaogen advised as to Consultant’s progress in performing the Services hereunder and that Consultant will, as reasonably requested by Achaogen, prepare written reports with respect thereto. It is understood that the time required in the preparation of such written reports shall be considered time devoted to the performance of the Services by Consultant. Reports prepared by Consultant shall be the sole property of Achaogen.

5.CONFLICTING OBLIGATIONS

(a)Consultant certifies that Consultant has no outstanding agreement or obligation that is in conflict with any of the provisions of this Agreement, or that would preclude Consultant from complying with the provisions hereof, and further covenants that Consultant will not enter into any such conflicting agreement during the term of this Agreement. Consultant has disclosed and, during the term of this Agreement, will disclose to the Chief Executive Officer of Achaogen any conflicts between this Agreement and any other agreements binding Consultant.

(b)The Services performed hereunder will not be conducted on time that is required to be devoted to any other third party. Consultant shall not use the funding, resources or facilities of any other third party, without the prior written consent of Achaogen, to perform Services hereunder and shall not perform the Services hereunder in any manner that would give any third party rights or access to the product of such Services.

(c)In view of Consultant’s access to Achaogen’s trade secrets and proprietary know-how, Consultant further agrees that Consultant will not, without Achaogen’s prior written consent, design identical or substantially similar designs as those developed under this Agreement for any third party during the term of this Agreement and for a period of twelve (12) months after the termination of this Agreement.

Achaogen/Planet Pharma, LLC

Consulting Agreement

6.TERM AND TERMINATION

(a)Term. This Agreement will commence on the Effective Date and will continue until the earlier of (i) Three (3) years from the Effective Date; or (ii) termination as provided below.

(b)Termination. Achaogen may terminate this Agreement upon giving two (2) weeks prior written notice thereof to Consultant. Any such notice shall be addressed to Consultant at the address shown above or such other address as Consultant may notify Achaogen and shall be deemed given upon delivery if personally delivered, or forty-eight (48) hours after deposited in the United States mail, postage prepaid, registered or certified mail, return receipt requested. Achaogen may terminate this Agreement immediately and without prior notice if Consultant refuses to or is unable to perform the Services or is in breach of any material provision of this Agreement.

(c)Survival. Upon such termination all rights and duties of the parties toward each other shall cease except:

(i)that Achaogen shall be obliged to pay, within thirty (30) days of the effective date of termination, all amounts owing to Consultant for Services completed and accepted by Achaogen prior to the termination date and related expenses, if any, in accordance with the provisions of Section 1 (Services and Compensation) hereof; and

(ii)Sections 2 (Confidentiality), 3 (Ownership), 5( c) (Development of Similar Products for Third Parties), 8 (Independent Contractor), 11 (Equitable Relief) and 13 (Non-Solicitation) shall survive termination of this Agreement.

7.ASSIGNMENT

Neither this Agreement nor any right hereunder or interest herein may be assigned or transferred by Consultant without the express written consent of Achaogen.

8.INDEPENDENT CONTRACTOR

It is the express intention of the parties that Consultant is an independent contractor. Nothing in this Agreement shall in any way be construed to constitute Consultant as an agent, employee or representative of Achaogen, but Consultant shall perform the Services hereunder as an independent contractor. Consultant agrees to furnish (or reimburse Achaogen for) all tools and materials necessary to accomplish this Agreement, and shall incur all expenses associated with performance, except as expressly provided on Exhibit A of this Agreement. Consultant acknowledges and agrees that Consultant is obligated to report as income all compensation received by Consultant pursuant to this Agreement, and Consultant agrees to and acknowledges the obligation to pay all self-employment and other taxes thereon. Consultant further agrees to indemnify and hold harmless Achaogen and its directors, officers, and employees from and against all taxes, losses, damages, liabilities, costs and expenses, including attorney’s fees and other legal expenses, arising directly or indirectly from (i) any negligent, reckless or intentionally wrongful act of Consultant or Consultant’s assistants, employees or agents, (ii) a determination by a court or agency that Consultant is not an independent contractor, or (iii) any breach by Consultant or

Achaogen/Planet Pharma, LLC

Consulting Agreement

Consultant’s assistants, employees or agents of any of the covenants contained in this Agreement.

9.NO DEBARMENT

Consultant represents and warrants that neither it nor any of its officers, directors, agents, affiliates, employees, independent contractors or subcontractors or any other person performing work on Consultant’s behalf in rendering Services is or has been under investigation by the United States Food and Drug Administration for debarment action or is presently debarred pursuant to the 21 USC § 335. Consultant shall notify Achaogen immediately upon any inquiry or the commencement of any such investigation or proceeding.

10.BENEFITS

Consultant acknowledges and agrees and it is the intent of the parties hereto that Consultant receive no Achaogen-sponsored benefits from Achaogen either as a Consultant or employee. Such benefits include, but are not limited to, paid vacation, sick leave, medical insurance, and 401 (k) participation. If Consultant is reclassified by a state or federal agency or court as an employee, Consultant will become a reclassified employee and will receive no benefits except those mandated by state or federal law, even if by the terms of Achaogen’s benefit plans in effect at the time of such reclassification Consultant would otherwise be eligible for such benefits.

11.EQUITABLE RELIEF.

The parties acknowledge that damages may in some cases not be an adequate remedy for grievances suffered under this Agreement, and accordingly may seek injunctive or other equitable relief from a court of appropriate jurisdiction.

12.NON-SOLICITATION

During the term of this Agreement and for a period of twelve (12) months thereafter Consultant will not directly or indirectly solicit, hire away, or induce to leave any employee or consultant of Achaogen.

13.GOVERNINGLAW

This Agreement shall be governed by the internal substantive laws, but not the choice of law rules, of the State of California.

14.ENTIREAGREEMENT

This Agreement is the entire agreement of the parties and supersedes any prior agreements between them, whether written or oral, with respect to the subject matter hereof. No waiver, alteration, or modification of any of the provisions of this Agreement shall be binding unless in writing and signed by duly authorized representatives ofthe parties hereto.

15.SEVERABILITY

The invalidity or unenforceability of any provision of this Agreement, or any terms

Achaogen/Planet Pharma, LLC

Consulting Agreement

thereof, shall not affect the validity of this Agreement as a whole, which shall at all times remain in full force and effect.

Achaogen/Planet Pharma, LLC

Consulting Agreement

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.


ACHAOGEN, INC.		PLANET PHARMA, LLC
By:	/s/ Dennis B. Hom	By:	/s/ Donald Kraus
	(signature)		(signature)

Name:	Dennis B. Hom	Name:	Donald Kraus

Title:	VP Finance & Corporate Development

Date:	April 8, 2013	Date:	4-1-2013

Achaogen/Planet Pharma, LLC

Consulting Agreement

Amendment One (1)

Consulting Agreement

Between Achaogen, Inc. And Planet Pharma, Llc

This Amendment 1 to the Consulting Agreement (the "Amendment") is dated as of January 1, 2016 (the "Effective Date"), and is issued pursuant to the Consulting Agreement (the "Agreement") dated March 15, 2013 by and between ACHAOGEN, INC. ("Achaogen") and PLANET PHARMA, LLC ("Consultant"). Achaogen and Consultant are jointly referred to as the "Parties" to this Amendment.

WHEREAS, the Parties wish to amend the Agreement by revising the Agreement's term; and

WHEREAS, the Parties agree to be bound by the terms and conditions of the Agreement as amended.

NOW THEREFORE, Subpart (a) of Section 6 of the Agreement, Term, is hereby deleted in its entirety and replaced with the following:

"(a)

This Agreement will commence on the Effective Date and will continue until December 31, 2017, unless such term is extended by the mutual written agreement of the Parties, or the Agreement is terminated earlier as provided below."

Other than as amended herein, the Agreement remains in full force and effect.

[Remainder of Page Intentionally Left Blank; Signature Page Follows]

Achaogen/Planet Pharma (CGL)

Consulting Agreement Amendment No. 1

IN WITNESS WHEREOF, the Parties hereto have executed this Amendment on the date(s) set forth below and it will be effective as of the Effective Date first above written.

Achaogen, Inc.		Planet Pharma LLC

By:	/s/ Blake Wise	By:	/s/ Nick Demling
Name:	Blake Wise	Name:	Nick Demling
Title:	COO	Title:	President
Date:	12/18/2015	Date:	12/16/2015

Achaogen/Planet Pharma (CGL)

Consulting Agreement Amendment No. 1

Amendment Two (2) To

Consulting Agreement Between

Achaogen, Inc. And Planet Pharma, Llc

This Amendment 2 (“Amendment”) effective as of November 1, 2016 (“Effective Date”), is by and between Achaogen, Inc. (“Achaogen”) and Planet Pharma, LLC (“Consultant), and issued pursuant to the Consulting Agreement dated March 15, 2013, as amended January 1, 2016 by and between Achaogen and Consultant (“Agreement”). Achaogen and Consultant are jointly referred to as the “Parties” to this Amendment.

WHEREAS, the Parties wish to amend the Agreement by revising the Agreement’s Term; and

WHEREAS, the Parties wish to amend the Agreement by adding Sections 16 and 17 as described below.

NOW THEREFORE, Achaogen and Consultant hereby agree to the following terms and conditions:

1). Subpart (a) of Section 6 of the Agreement, Term, is hereby deleted in its entirety and replaced with the following:

“(a)

This Agreement will commence on the Effective Date and will continue until December 31, 2020, unless such term is extended by the mutual written agreement of the Parties, or the Agreement is terminated earlier as provided below.”

2).Section 16 Direct Placements is hereby added to the Agreement.

“Section 16. Direct Placements

At Achaogen request, Consultant will present new candidates to Client for consideration of full time employment at Client’s organization.

Consultant fees are based on the candidate’s first year annual compensation exclusive of any signing bonus and any other paid, accrued, deferred or other compensation (“First Year Annual Compensation”). The base fee (“Fee”) amount is 25% of the First Year Annual Compensation. Fee is due in the event that a candidate referred to Achaogen is hired within twelve (12) months after referral.

All permanent placements are unconditionally guaranteed for Sixty (60) calendar days. In the event that the candidate resigns or is terminated for cause during the first Sixty (60) days of employment, the Fee shall be promptly refunded upon request. Implementation of the provisions of this paragraph is contingent upon our invoice being fully paid and payment remitted within ten (10) days after the employee commences employment.”


Achaogen/Planet Pharma (CGL)
Consulting Agreement Amendment No. 2	1

3).

Section 17, Restrictive Covenant and Right to Hire is hereby added to the Agreement:

“Section 17. Restrictive Covenant and Right to Hire

For Consultant contract employees, excluding Consultant payroll contract employees, if Company chooses to hire the employee, annual salary is based off the Contract Employee’s hourly rate (excluding mark-up) x 2,080 hours.


Hours of Placement	Conversion Fee
0-320	25%
321-519	20%
520-1039	15%
1040+	0

“

Other than as amended herein, the Agreement remains in full force and effect.

IN WITNESS WHEREOF, the Parties hereto have executed this Amendment on the date(s) set forth below and it will be effective as of the Effective Date first above written.

Achaogen, Inc.		Planet Pharma LLC

By:	/s/ Tobin Schilke	By:	/s/ Donald Kraus
Name:	Tobin Schilke	Name:	Donald Kraus
Title:	CFO	Title:	Senior Director
Date:	11/13/2016	Date:	11/4/2016


Achaogen/Planet Pharma (CGL)
Consulting Agreement Amendment No. 2	2

Exhibit BJ To

Consulting Agreement between Achaogen, Inc. and Planet Pharma, LLC

Dated March 15, 2013

WHEREAS, the Parties wish to have Consultant perform for Achaogen the Services as described below.

NOW THEREFORE, the Parties agree to be bound by the terms and conditions of the Agreement and this Exhibit.

1.Contact. Consultant’s principal contact at Achaogen will be:

Name:Lynn Connolly

Title:VP Late Development

2.Assigned Resource. Consultant’s assigned resource at Achaogen will be:

Name:Dr. Ian Friedland

Title:Development and NDA Consultant

3.Services. Consultant will render to Achaogen the following Services (“Services”):

(i) Support for plazomicin NDA (non-CMC related): strategy discussions, review of key documents (CSR/Clin Overview), FDA interactions;

(ii) Med Affairs: scientific review of materials for ClinSci (platform, lexicon, ad board materials, publications) and support for Ad Boards;

(iii) Management of ARLG studies until NDA submission ready; and

(iv) C-Scape Phase 3 protocol.

4.Compensation.

(b)Consultant will submit a monthly invoice for services and expenses to Achaogen by regular mail or by email as noted below:

Achaogen/Planet Pharma - Dr. Ian Friedland (TMV)

Consulting Agreement 2016 (non govt) Exhibit BJ

By regular mail:		Achaogen, Inc.
		Attn: Accounts Payable
		7000 Shoreline Court, Suite 371
		South San Francisco, CA 94080
By email:		accounting@achaogen.com

(d)Consultant will submit all invoices in a form approved by Achaogen and such invoices will be approved by the contact person listed above. The form shall include the following:

A brief description of Services performed;

ii.

Purchase Order Number 14455; and

iii.

The following statement: “Services performed pursuant to Exhibit BJ of the Consulting Agreement dated March 15, 2013 and associated with the program code 0.0.0.0.”

Achaogen/Planet Pharma - Dr. Ian Friedland (TMV)

Consulting Agreement 2016 (non govt) Exhibit BJ

IN WITNESS WHEREOF, the Parties hereto have executed this Exhibit on the date(s) set forth below and it will be effective as of the day and year first above written.

Achaogen, Inc.		Planet Pharma, LLC

By:	/s/ Kenneth Hillan	By:	/s/ Donald Kraus
	(signature)		(signature)

Name:	Kenneth Hillan	Name:	Donald Kraus

Title:	CEO	Title:	Senior Director

Date:	March 14, 2017	Date:

Achaogen/Planet Pharma - Dr. Ian Friedland (TMV)

Consulting Agreement 2016 (non govt) Exhibit BJ

EX-10.3 4 akao-ex103_831.htm EX-10.3 akao-ex103_831.htm

Exhibit 10.3

Confidential Treatment Requested by Achaogen, Inc.

VALIDATION AND MANUFACTURING AGREEMENT

THIS AGREEMENT is made and entered into this 5th day of March, 2017 (the “Effective Date”), by and between Achaogen, Inc., a company with its principal place of business at 7000 Shoreline Court, Suite 371, South San Francisco, CA, USA (“ACHAOGEN”) and Hovione Limited, a company with its principal place of business at Loughbeg, Ringaskiddy, Cork, County Cork, Ireland (“HOVIONE”). ACHAOGEN and HOVIONE may also hereinafter be referred to individually as a “Party” or collectively as the “Parties”.

RECITALS

WHEREAS, HOVIONE has expertise, available facilities, and experience related to the development, synthesis, formulation, testing, and production of active pharmaceutical ingredients, has both pilot plant and commercial scale facilities to manufacture same, and has been interested in providing such development and manufacturing services to ACHAOGEN; and

WHEREAS, ACHAOGEN wishes to engage the services of HOVIONE in a phased program whereby HOVIONE would carry out a Validation Program to confirm, validate and scale up ACHAOGEN technology to manufacture the active pharmaceutical ingredient “Plazomicin”, followed by certain post-submission development activities, and the manufacture of commercial quantities of the active pharmaceutical ingredient using the validated technology on a commercial scale in HOVIONE’s facility; and

WHEREAS, ACHAOGEN receives Federal funding from BARDA (as defined herein) in support of ACHAOGEN’s discovery and development of Plazomicin pursuant to the Prime Contract (as defined herein).

NOW, THEREFORE, in consideration of the acknowledgements, confirmations, representations, warranties, and covenants contained herein, ACHAOGEN and HOVIONE hereby agree as follows:

ARTICLE 1

DEFINITIONS

The following terms (in addition to such other terms as are specifically defined within the Agreement), whether used in the singular or plural, shall have the meanings assigned to them below for purposes of this Agreement:

1.1

“Acquisition Costs”, shall mean the [***] by a Party to any Third Party for acquiring any raw materials, packaging components and intermediates used exclusively in the Manufacture of the Product under this Agreement, including [***] by Party in connection with the acquisition of such materials, packaging components and intermediates.

1.2	“Affiliate”, with respect to a Party, shall mean any corporation or non-corporate entity which controls, is controlled by, or is under common control with a Party. A corporation or non-corporate entity shall be regarded as in control of another corporation if: (i) it

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by Achaogen, Inc.

owns, or directly or indirectly controls, at least fifty percent (50%) of the voting stock of the other corporation; or (ii) in the absence of the ownership of at least fifty percent (50%) of the voting stock of a corporation, or in the case of a non-corporate entity, it has the power to direct the direction of the management and policies of such corporation or non-corporate entity, as applicable.

1.3	“Agreement” shall mean this Validation and Manufacturing Agreement, incorporating all appendices, schedules, and exhibits, as may be amended from time to time.

1.4	“API” shall mean the active pharmaceutical ingredient PLAZOMICIN.

1.5

“Applicable Laws” shall mean all applicable ordinances, rules, regulations, laws, guidelines, guidance, statutes, requirements, and court orders of any kind whatsoever, as amended from time to time, including the bodies of law, regulations (including without limitation, cGMP or its equivalent) applicable to the Manufacturing activities for each Product, including but not limited to, in the US, the U.S. FDCA, and the laws of Canada and Western Europe.

1.6	“Approval” shall mean the first approval of the Product from the Facility for commercial sale by FDA or the EMA.

1.7	“Background Intellectual Property” shall mean any Intellectual Property either (i) owned or controlled by a Party prior to the Effective Date; or (ii) developed or acquired by a Party independently from the performance of the Manufacturing or Services hereunder during the Term of this Agreement.

1.8	“BARDA” means the Biomedical Advanced Research and Development Authority within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.

1.9	“Batch” shall mean a specific quantity or lot of the Product, as further described in Exhibit 2 hereto, that is intended to be of uniform character and quality, within specified limits, and is produced during the same cycle of Manufacture as defined by the Batch Record.

1.10	“Batch Records” shall mean the final executed batch production and control records for each Batch of the Product Manufactured under this Agreement in accordance with 21 CFR § 211.188.

1.11	“Business Day” shall mean a day other than a Saturday, Sunday, or a day on which commercial banks located in Ireland, Portugal or the United States of America shall be authorized or required by Applicable Laws to close.

1.12	“Calendar Year” shall mean the twelve (12) month period commencing on January 1 and ending on December 31 of each year during the Term.

Confidential Treatment Requested by Achaogen, Inc.

1.13

“cGMPs” shall mean current good manufacturing practices as established by the FDA and the European Union relating to the manufacture of medicinal products for human use, including, without limitation, current good manufacturing practices as specified in the ICH guidelines, including without limitation, ICH Q7, “ICH Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients”, the FDCA and the Guide to Good Manufacturing Practices for Medicinal Products as promulgated under European Directive 91/356/EEC.

1.14

“Certificate of Analysis” means, as further specified in Section 13.1, with respect to each Product, a controlled document prepared by HOVIONE that (a) lists all analytical tests and/or standards HOVIONE uses to evaluate a Product in order for such Product to be considered acceptable, and (b) certifying the accuracy of each of the foregoing.

1.15	“Certificate of Compliance” shall mean a document prepared by HOVIONE (a) listing the Manufacturing date, unique Batch number, and quantity of Product in such Batch; and (b) certifying that such Batch was Manufactured in accordance with the Master Batch Record and cGMP, if applicable.

1.16	“Commercially Reasonable” and “Commercially Reasonable Efforts” shall mean the level of diligence and/or efforts and commitment of resources consistent with the past practice of similarly situated pharmaceutical manufacturers with respect to comparable pharmaceutical products.

1.17	“Completion Date” shall mean the date of Batch Release for the Manufacture of Engineering, cGMP, Validation and Commercial Batches, or the date of report completion for analytical, lab and other Services.

1.18	“Confidential Information” shall have the meaning as set forth in Section 16.1.

1.19	“Delivery Date” shall mean a date on which the Product or other Services under this Agreement are designated to be ready for pick-up at the Hovione Facility set forth in the applicable Work Plan.

1.20

“Drug Master File” or “DMF” shall mean a drug master file providing detailed information about the Facility, the equipment, and Manufacturing Processes relating to the Product and such other information as required by Applicable Laws, including 21 C.F.R. Section 314.420, and to the extent applicable any equivalent requirement under Applicable Laws.

1.21	“Effective Date” shall mean the date first appearing at the beginning of this Agreement.

1.22	“EMA” shall mean the European Medicines Agency and any successor entity.

1.23	“Facility” shall means the Manufacturing facility of HOVIONE at a location specified in Section 2.9 (each of which is also referred to in this Agreement as a “Site”), or such other Manufacturing facility of HOVIONE as prior approved in writing by ACHAOGEN.

Confidential Treatment Requested by Achaogen, Inc.

1.24	“FDA” shall mean the United States Food and Drug Administration or any successor entity.

1.25	“FDA Approval” means regulatory approval by the FDA to market and sell a final product containing the Product in the United States of America.

1.26	“FDCA” shall mean the United States Federal Food, Drug and Cosmetic Act, including all regulations, guidelines, and guidances arising thereunder, as any of the same may be amended from time to time.

1.27	“Governmental Authority” shall mean any national, multinational, regional, state, or local regulatory agency in the United States, the European Union, or any other country in the Territory.

1.28	“Governmental Project” shall have the meaning set forth in Section 20.1.

1.29

“Improvements” means all discoveries, inventions, developments, modifications, innovations, updates, enhancements, or improvements to Technology (whether or not protectable under patent, trademark, copyright, or similar laws) that are conceived, discovered, invented, developed, created, made, or reduced to practice in the performance of the Parties’ obligations under this Agreement.

1.30	“Initial Term” shall have the meaning set forth in Section 12.1 hereof.

1.31

“Manufacture”, “Manufactured”, or “Manufacturing” shall mean all operations of HOVIONE in the scheduling, production, packaging, labeling, warehousing, quality control testing (including as requested all in-process, release, and stability testing), release, and shipping of the Product to meet the Specifications and other requirements for the Product hereunder.

1.32	“Minimum Annual Commitment” shall have the meaning set forth in Section 8.

1.33	“Prime Contract” means Contract No. HHSO 100201000046C between ACHAOGEN and BARDA (as modified).

1.34	“Process” shall mean the series of operations needed to convert the Starting Materials to the Product, including the testing thereof.

1.35

“Process Validation” shall mean any development activities conducted by HOVIONE intended to produce the documented evidence required to comply with cGMP requirements to establish that the Process, when operated within established parameters, performs effectively and reproducibly to commercially produce the Product meeting the Specifications.

1.36	“Product” shall means any active pharmaceutical ingredient Plazomicin [***] to be Manufactured by HOVIONE for ACHAOGEN under this Agreement.

Confidential Treatment Requested by Achaogen, Inc.

1.37

“Project Specific Raw Materials” shall mean the certain raw materials that are necessary for the Manufacture of the Product identified on Exhibit 5 and include the Starting Materials identified on Exhibit 6. For clarity and pursuant to Section 6.1, ACHAOGEN will be involved in the sourcing and planning for acquisition, but these raw materials will be planned, procured, and managed through HOVIONE’s supplier quality and purchasing departments.

1.38	“Relevant Information” has the meaning set forth in Section 20.3.

1.39	“Quality Agreement” shall have the meaning set forth in Section 2.5 hereof and be attached hereto as Exhibit 3 hereof.

1.40

“Regulatory Application” shall mean the new drug application or other submission made by ACHAOGEN to the FDA, or any equivalent regulatory agency in the Territory, seeking allowance to market, distribute, and sell the Product in the United States and/or elsewhere in the Territory, as such application may be amended or supplemented.

1.41

“Regulatory Authority(ies)” shall mean the regulatory entities with regulatory authority over the manufacture, storage, or testing of pharmaceutical products (including the Product), as well as any successor entity thereto. In the United States, “Regulatory Authority” includes the FDA. In the European Union, “Regulatory Authority” includes the EMA. In Canada, “Regulatory Authority” includes the Canadian Therapeutic Products Directorate.

1.42	“Services” shall mean the activities to be undertaken by HOVIONE related to the Manufacture of the Product hereunder pursuant to this Agreement and an applicable Work Plan.

1.43	“Specifications” shall mean the specifications for the Product as set forth in Exhibit 2 (as may be amended from time to time by written agreement of the Parties).

1.44

“Starting Materials” shall mean those materials identified on Exhibit 6. Starting Materials are certain Project Specific Raw Materials that have additional requirements as set forth in the Quality Agreement and shall meet the specifications set forth in the Regulatory Application. For clarity and pursuant to Section 6.1, ACHAOGEN will be involved in the sourcing and planning for acquisition, but the Starting Materials will be planned, procured and managed through HOVIONE’s supplier quality and purchasing departments.

1.45	“Successful Completion” in regard to the Validation Program shall mean ACHAOGEN’s acceptance of [***] Batches capable of being used for a submission of a marketing authorization as described in Section 4.2.

1.46	“Supply Failure” shall have the meaning set forth in Section 8.3 hereof.

Confidential Treatment Requested by Achaogen, Inc.

1.47	“Technology” means all methods, techniques, trade secrets, copyrights, know-how, data, documentation, hardware, software, and other intellectual property of any kind, whether or not protectable under patent, trademark, copyright, or similar law.

1.48	“Term” shall have the meaning set forth in Section 12.1 hereof.

1.49	“Territory” shall mean worldwide.

1.50	“Validation Batches” shall mean a series of [***] Batches capable of being used for a submission of a marketing authorization as described in Section 4.2.2.2.

1.51	“Validation Program” shall have the meaning set forth in Section 4.2 hereof.

1.52	“Work Plan” shall mean an individual contract agreed to by the Parties and executed under this Agreement that references this Agreement as containing the governing terms and conditions, to conduct additional Services related to the Manufacturing of Product.

ARTICLE 2

PERFORMANCE OF SERVICES

2.1

ACHAOGEN appoints HOVIONE to perform the development and Manufacturing of the Product under the terms and conditions set out in this Agreement. In addition, HOVIONE may provide additional services related to the development and Manufacturing of the Product under the terms and conditions of this Agreement and individual Work Plans executed under this Agreement (the “Services”). If Services are requested, this Agreement will serve as a general form of contract under which the Parties can contract individual Work Plans, substantially in the form as Exhibit 1, without having to renegotiate the basic terms and conditions contained in this Agreement. Each Work Plan shall be consecutively numbered beginning with C1 (e.g., “Work Plan C1”). This Agreement, as of the Effective Date, includes reference to six (6) Work Plans numbered C1 through Work Plan C6 (attached hereto as Exhibits 8 – 13). Work Plans [***] and [***] are finalized and are firm commitments. Although the details and technical specifications of the Work Plans [***] through [***] are still being negotiated for execution no later than [***], the tasks associated with these plans are firm commitments of work that ACHAOGEN will sponsor and the costs associated with these Work Plans cannot be amended by more than [***] without mutual written consent of the Parties; provided however, that the foregoing [***] cap shall not include or apply any costs associated with the [***] to be used by HOVIONE under this Agreement. The Parties shall mutually agree by no later than [***] on the costs associated with such [***].

2.2

In addition, this Agreement i) obligates ACHAOGEN to use HOVIONE to perform the Validation and Manufacturing (including, but not limited to, the related Validation Program) and Services set forth in the Agreement and Work Plans, and ii) as of the Effective Date, HOVIONE commits to make available a defined capacity at its Facility sufficient to meet ACHAOGEN’s forecasted demand for the Product and ACHAOGEN commits to pay the Minimum Annual Commitment in consideration for HOVIONE’s

Confidential Treatment Requested by Achaogen, Inc.

reservation of such capacity. For the avoidance of doubt, the commercial Manufacture and supply of Product shall be ordered through a purchase order in accordance with Article 5 and shall not require an additional Work Plan.

2.3

HOVIONE, or its Affiliates, shall diligently carry out the Services as provided in this Agreement and [***] the Manufacturing and any Services without any material defect and according to the established timelines set forth in the applicable Work Plan, or as otherwise agreed by the Parties. HOVIONE shall retain appropriately qualified and trained personnel with the requisite knowledge and experience to perform the Services in accordance with this Agreement.

2.3.1

Subcontracting. Other than analytical service agreed to in advance in writing by the Parties, no Manufacturing or Services will be subcontracted by HOVIONE without the written consent of ACHAOGEN. Such consent shall not be unreasonably conditioned, delayed or withheld by ACHAOGEN. All Manufacturing and Services shall be performed at the Facility, and any change in location or scope of Manufacturing or any Services must be approved in writing by both Parties. HOVIONE shall be liable for any subcontractors hereunder to the same extent as if HOVIONE itself performed or failed to perform.

2.4	Regulatory Matters.

2.4.1

HOVIONE shall be responsible for, at its own expense, filing and maintaining all necessary regulatory approvals to operate the Facility as a cGMP Manufacturing site for the Product.

2.4.2

HOVIONE shall immediately notify ACHAOGEN of any notification from a Governmental Authority or Regulatory Authority regarding a cGMP inspection of a Facility that is directly related to the Product. ACHAOGEN shall have the option to have a person on site during any inspection that is directly related to the Product as well as to have a person present during preapproval inspection preparations and overall site readiness that is directly related to the Product, [***]. Any ACHAOGEN personnel shall be required to follow all rules and procedures established by HOVIONE when on HOVIONE’s site. HOVIONE shall correct any cGMP deficiencies identified by any Governmental Authority or Regulatory Authority at HOVIONE’s expense.

2.4.3

Except as provided in Section 2.4.1, ACHAOGEN shall be responsible for filing and for maintaining all necessary regulatory approvals for the Product.

2.4.4

Drug Master File. HOVIONE will neither prepare nor file the Drug Master File (“DMF”), which shall be ACHAOGEN’s responsibility. ACHAOGEN shall own the DMF and shall be responsible for maintaining the DMF on file with the FDA, and amending the DMF, as may be required. During the Term, ACHAOGEN shall provide copies to HOVIONE of relevant portions of any regulatory filings that relate to HOVIONE’s Manufacturing of Product, and HOVIONE shall have [***] to review and comment on the portions of any regulatory filings (including,

Confidential Treatment Requested by Achaogen, Inc.

but not limited to Regulatory Applications) that reference HOVIONE’s Manufacturing of the Product or the Facility. For the avoidance of doubt, HOVIONE shall not be required to comply with any provisions of any regulatory filing it has not had the opportunity to review prior to ACHAOGEN’s submission to the applicable Regulatory Authority. For each regulatory filing proposed by ACHAOGEN, HOVIONE shall have the opportunity to inform ACHAOGEN that it cannot comply with the commitments required thereunder and HOVIONE shall not be deemed in breach of this Agreement for any failure to comply with any commitment in connection with the DMF that HOVIONE timely identifies under this Section 2.4.4 that it cannot comply.

2.4.5

Within [***] of HOVIONE’S receipt of a written request from ACHAOGEN [***], HOVIONE shall provide ACHAOGEN with any and all non-confidential documentation, records, and any and all non-confidential information (whatever the format) related to the Manufacture of the Product by HOVIONE to allow ACHAOGEN or its Affiliates to prepare and file, on a timely basis, supplements or amendments to Regulatory Applications or other government licenses for the Product and any annual reports to the FDA or other Regulatory Authority.

2.4.6

Support. The Parties shall provide each other with such assistance as they may reasonably request relating to their respective activities under this Agreement and in support of their respective regulatory applications and maintenance of regulatory approvals. If there are any support activities outside of the normal scope, then the requesting Party shall [***].

2.4.7

HOVIONE shall [***] any reasonable request by ACHAOGEN, [***], for feasible changes in the Specifications, Manufacturing Process, materials, and any change in analytical testing methods requested by ACHAOGEN, the FDA, or any other applicable Regulatory Authority.

2.5

Quality Agreement. In November 2016, the Parties agreed upon the terms of a Quality Agreement, which shall be incorporated into this Agreement, and attached hereto as Exhibit 3 (the “Quality Agreement”). Should the Parties require an additional or amended Quality Agreement in connection with the [***], the Parties agree to negotiate Commercially Reasonable terms as soon as practicable. In the event the Quality Agreement contains provisions which are not inconsistent with, but in addition to, the terms set forth herein, the Quality Agreement shall be supplemental to the terms and conditions set forth in this Agreement. Notwithstanding the foregoing or anything in this Agreement or the Quality Agreement to the contrary, however, in the event of any conflict or inconsistency between the provisions of this Agreement and the provisions of the Quality Agreement, the provisions of this Agreement shall govern.

2.6

Stability Testing. During the term of this Agreement, HOVIONE shall, [***], undertake such stability testing of the Product as ACHAOGEN may reasonably request [***] to be outlined in the Quality Agreement associated with applicable elements of the Manufacturing Services or as may otherwise be agreed in writing by the Parties or as stated in an executed Work Plan.

Confidential Treatment Requested by Achaogen, Inc.

2.7

Records. HOVIONE will maintain all materials, data, and documentation obtained or generated by HOVIONE in the course of performing the Manufacturing and Services under this Agreement, including all computerized records and files (the “Records”) in a secure area reasonably protected from fire, theft, and destruction for the longer of (a) a period of [***] following expiration or termination of this Agreement or (b) [***] past the last expiration date of the Product supplied under this Agreement, or, in each case, such longer period as is required by the Applicable Laws (the “Retention Period”). At the end of the Retention Period, all Records will, [***], either be delivered to ACHAOGEN or its designee in such form as they are then currently in the possession of HOVIONE, or disposed of, at the discretion and written request of ACHAOGEN. In no event will HOVIONE dispose of any Records without first giving ACHAOGEN at least [***] prior written notice of its intent to do so and an opportunity to have the Records transferred to ACHAOGEN. While in the possession and control of HOVIONE, Records shall be available during audits for inspection, examination and review by ACHAOGEN or its representatives. HOVIONE will also ensure that all Records are subject to secure, validated controls in accordance with applicable law, including cGMP.

2.8

Change Orders. In the event that any changes to a Work Plan are requested by ACHAOGEN, such changes must be mutually agreed upon by the Parties in a written change order prior to amendment of such Work Plan being effective. Each such change order shall constitute an amendment to the applicable Work Plan and the activities set forth therein.

2.9

Facility. HOVIONE shall perform all work contemplated under this Agreement, including but not limited to development and Manufacturing of the Product, at its Facilities (as defined below). For the avoidance of doubt, ACHAOGEN understands and acknowledges that small scale capacity (that is, less than [***] per year) and the initial validation of the Manufacturing of the Product shall take place at HOVIONE’s Facility in [***] and that larger scale validated commercial scale Manufacturing shall take place at HOVIONE’s Facility in [***] and the isolation step shall take place at HOVIONE’s Facility in [***] (the [***] shall be referred to herein individually as the “Facility” or collectively referred to as the “Facilities”).

2.10

No Subcontracting. Subject to 2.3.1, HOVIONE shall not subcontract to any third party any part of the work contemplated under this Agreement without the prior written consent of ACHAOGEN. In the event HOVIONE engages any agents for such outsourcing and or subcontracting of any portion of the Manufacturing or Services, HOVIONE will remain solely responsible for (a) skills, training, and supervision of such outsourced/subcontracted agents, and (b) payment to and liability, if any, for such agents. Notwithstanding anything herein to the contrary, HOVIONE will remain fully responsible to ACHAOGEN for all of its performance and obligations under the Agreement. If any HOVIONE approved subcontractor is placed on ‘Official Action Indicated’ status by FDA or a substantially similar status by FDA or another Regulatory Authority, then the Parties shall discuss and agree upon an action plan for resolving the use of such subcontractor or the use of an alternate subcontractor. The Parties mutually agree to the establishment of an action plan regarding the use of such subcontractor or the

Confidential Treatment Requested by Achaogen, Inc.

use of an alternate subcontractor within [***] from the date on which such HOVIONE approved subcontractor is placed on ‘Official Action Indicated’ status by FDA or a substantially similar status by FDA or another Regulatory Authority.

ARTICLE 3

DEVELOPMENT TEAM AND SUPPLY COMMITTEE

3.1

Development Project Team. Within [***] following the Effective Date, the Parties will establish a development project team (the “Development Project Team”), which shall consist of an equal number of personnel from each Party who are appropriately skilled and knowledgeable in relation to the development and manufacturing of the Product and who are deemed necessary to accomplish the development Services.

3.1.1

General Remit. The Development Project Team shall serve as the coordinating body for the development Services, including the Manufacture of the Validation Batches and other validation activities contemplated by this Agreement. The Development Project Team shall oversee and manage the development Services under the Validation Master Plan and shall communicate pertinent information related thereto (including the status thereof) to the Parties. The Development Project Team shall be dissolved [***] after the completion of the final activities in the Validation Master Plan, or earlier, upon mutual written agreement of the Parties.

3.1.2

Development Project Team Meetings. The Development Project Team shall determine how often it shall meet, but no less than once every [***]. Meetings may be held in person at either Party’s location or at another location mutually agreeable to the Parties, or telephonically. The meetings shall be co-chaired by the Parties’ designated project managers. The Development Project Team shall have the authority to make minor changes to the Validation Master Plan, and make recommendations to the Parties as to subsequent changes to the Validation Master Plan. But material changes to the Validation Master Plan shall require the written agreement of both Parties and, where applicable, an amendment to the applicable project plan and the Services set forth therein.

3.2

Supply Committee. Additionally, after the Effective Date, the Parties shall establish a general oversight committee (the “Supply Committee”). The Supply Committee shall be made up of an equal number of representatives from each Party having appropriate technical credentials, knowledge and experience.

3.2.1

General Remit. The Supply Committee shall serve as the coordinating body for the commercial Manufacturing of the Product and the related activities to be conducted under this Agreement, and for the transfer of information between the Parties relating to the commercial Manufacturing and commercialization of the Product.

Confidential Treatment Requested by Achaogen, Inc.

3.2.2

Meetings. The Supply Committee shall determine how often it shall meet, but no less than once every [***]. Meetings may be held in person at either Party’s facilities, at another location mutually agreed by the Parties, or telephonically. A quorum of at least [***] Supply Committee representatives appointed by each Party will be present at or will otherwise participate in each meeting. The Supply Committee shall act by unanimous agreement of its members, with each Party having one (1) vote.

3.2.3

At each Supply Committee meeting, the agenda shall include (a) an overall regulatory and commercial status of the Product, and a review of timelines for regulatory approval and commercialization, as appropriate; (b) anticipated market demand; (c) supply capability; (d) any anticipated capacity problems or prioritization issues; (e) any changes in the Product delivery or sourcing of Project Specific Raw Materials; and (f) any other matters which may impact or influence supply chain matters, Manufacturing, or any quality-related issues.

3.2.4

Not less than [***] each year, the Supply Committee shall hold or include in its meeting a business review meeting, with an agenda comprising; (a) evaluation of the collaboration; (b) long-term forecast; (c) capacity planning; and (d) performance improvement planning and investment.

3.3	Costs. Each Party shall be responsible for its own costs in respect of travel and accommodation expenses in attending meetings of the Development Project Team and Supply Committee.

ARTICLE 4

VALIDATION PROGRAM

4.1

Program Activities. ACHAOGEN acknowledges and confirms that it has provided or will provide HOVIONE with the most current technical package for the Manufacture of the Product, including process, analytical methods, and testing. HOVIONE shall keep and is keeping accurate and detailed records regarding its activities performed in respect of the Validation Program consistent with its internal policies and procedures.

4.2	Process Validation. Pursuant to the executed Work Plan #43, HOVIONE will conduct the following Process Validation activities under this Agreement, all of which shall comprise the “Validation Program”. The Process Validation activities shall include:

4.2.1

Validation Master Plan. HOVIONE and ACHAOGEN acknowledge that they will agree, in writing, on a validation master plan setting out the Process Validation activities to be conducted by HOVIONE under this Agreement (the “Validation Master Plan”). The process validation shall not commence until ACHAOGEN and HOVIONE confirm in writing that the Validation Master Plan is acceptable.

4.2.2

Validation Protocols/Validation Batches.

Confidential Treatment Requested by Achaogen, Inc.

4.2.2.1

HOVIONE will complete validation protocols setting forth the general parameters, testing and procedures as designated and will be mutually agreed upon in writing (the “Validation Protocols”). ACHAOGEN and HOVIONE acknowledge that the Process Validation will be separately completed for each process step as defined in the Validation Master Plan, thereby resulting in a separate validation report for each step.

4.2.2.2

HOVIONE will, in accordance with the Validation Protocols, the Specifications, the Quality Agreement, and cGMP, undertake Process Validation by Manufacturing [***] consecutive successful validation Batches of the Product (the “Validation Batches”). HOVIONE will conduct testing of the Validation Batches in accordance with the Validation Protocols. Except for price terms, all Validation Batches are governed by the same terms and conditions as the commercial Batches of the Product as set forth in this Agreement and the Quality Agreement, including the terms relating to shipment and delivery. The Project Specific Raw Materials for the Validation Batches have been provided by ACHAOGEN [***].

4.2.2.3

HOVIONE and ACHAOGEN acknowledge and confirm that, upon completion of the work defined in the particular Validation Protocol, HOVIONE will provide to ACHAOGEN a detailed report setting out the: (a) results for the Process step, including all executed Batch Records and test results, and comparing the results against the predetermined specifications and quality attributes for the resultant intermediate and/or the Product; and (b) Process for the relevant process step.

4.2.2.4

HOVIONE and ACHAOGEN acknowledge and confirm that, upon completion of the entire Process Validation campaign, HOVIONE shall provide to ACHAOGEN a detailed report summarizing the: (a) results of the entire Process Validation campaign, including any test results not addressed in the reports discussed above; (b) a Certificate of Analysis for each Batch of the Product with a comparison of these results to the predetermined specifications and quality attributes for the Product; (c) a Certificate of Compliance for each Batch of the Product; and (d) the Process.

4.3

Reporting/Transfer of Results. HOVIONE and ACHAOGEN acknowledge and confirm that, upon completion of each phase of the Validation Program and as specified in a Work Plan, HOVIONE will provide ACHAOGEN with a written report of the results obtained during the course of the Validation Program. HOVIONE will also promptly respond to ACHAOGEN’s reasonable inquiries regarding the status of the Validation Program on an ongoing basis and keep ACHAOGEN informed of interim results on an informal basis, including if requested, periodic meetings at HOVIONE’s Facility to discuss Validation Program results and progress.

Confidential Treatment Requested by Achaogen, Inc.

4.4	Audits. ACHAOGEN and/or its designee(s) shall be allowed, [*] and during normal business hours, to audit HOVIONE’s records [*] that are directly related to the Validation Program.

4.5

Milestone Payment. With respect to the Manufacture of Product at the [***] pursuant to this Agreement, ACHAOGEN shall pay HOVIONE a one-time non-refundable and non-creditable milestone payments, payable as follows: [***] payable to HOVIONE if, without any compromise in quality or standards, there is a Successful Completion of the Product Validation Program by no later than [***]. Such completion shall be evidence by delivery of the Final Validation Report and the payment will be made within [***] of ACHAOGEN’s acceptance of such report. The Parties agree and acknowledge that there may be factors beyond either Party’s control that prevent them from reaching this milestone. Provided that there is not a Successful Completion of the Validation Program by [***], no milestone shall be owed under this Agreement.

ARTICLE 5

COMMERCIAL MANUFACTURE AND SUPPLY OF THE PRODUCT

5.1

Manufacture and Supply. Upon Successful Completion of the Validation Program in accordance with this Agreement and ACHAOGEN’s decision to sell the Product, ACHAOGEN shall purchase an amount of the Product equal to: (a) at least eighty (80%) percent of the quantity of the Product required by ACHAOGEN’s in the Territory during the first three (3) Calendar Years following the first FDA Approval of the Product during the Term, and (b) after these three (3) years then (1) so long as the total annual quantity of the Product required by ACHAOGEN in the Territory is equal to or less than [***] then ACHAOGEN shall buy at least 66% of its requirements from HOVIONE, or (2) if ACHAOGEN’s said requirements exceed [***] it shall not buy from HOVIONE less than at the higher of [***] or forty (40%) percent of the quantity of the Product required by ACHAOGEN in the Territory for each Calendar Year during the balance of the Term, and HOVIONE shall Manufacture and supply the Product ordered by ACHAOGEN in accordance with this Agreement. Notwithstanding the foregoing, ACHAOGEN may (x) qualify a third party manufacturer in the Territory as an alternate or additional supplier of the Product for ACHAOGEN (such third party manufacturer being referred to herein as the “Alternate Supplier”); (y) require that HOVIONE provide to the Alternate Supplier, [***], all Manufacturing information (other than HOVIONE’s Confidential Information), including, without limitation, documentation, technical assistance, materials, and reasonable cooperation by appropriate employees of HOVIONE in order to Manufacture the Product for use in the Territory; and (z) without limiting the minimum purchase requirements set forth in subsections (a) and (b) above, purchase quantities of the Product for use in the Territory from such Alternate Supplier as necessary to maintain such Alternate Supplier as an alternate supplier.

Confidential Treatment Requested by Achaogen, Inc.

5.2	Forecasts.

5.2.1

Prior to First FDA Approval. No later than [***] prior to the anticipated date on which ACHAOGEN will require its first delivery of Product under this Agreement, ACHAOGEN shall provide HOVIONE with a non-binding forecast of its estimated requirements for Product for the first [***] of sales, broken down on a [***] basis. Every [***] thereafter but only prior to the first FDA Approval date of Plazomicin, ACHAOGEN shall provide HOVIONE with an updated non-binding forecast of its estimated requirements of Product for the first [***] of sales, broken down on a [***] basis.

5.2.2

After Approval. Within [***] after the first FDA Approval date, ACHAOGEN shall provide HOVIONE with a rolling [***] forecast of ACHAOGEN’s anticipated orders of the Product Batches and the forecast shall be updated no less frequently than [***] during the Term. The rolling forecast shall be made no later than [***] after [***] to assist HOVIONE in planning its production. The first [***] of each forecast shall constitute a binding order for the amounts of the Product set forth in such forecast; the balance of the forecast shall be non-binding on ACHAOGEN. In the event there are material changes to the lead-times and/or throughput times for the Manufacture of the Product, or of the Project Specific Materials and or the Starting Materials, the Parties shall work together in good faith to make appropriate adjustments to the length of the binding portion of the forecast.

5.3

Purchase Orders. ACHAOGEN shall place firm orders for the Product using the form of purchase orders mutually agreeable to ACHAOGEN and HOVIONE, setting forth the quantity of the Product required (which shall be in increments of full Batches), as well as its required Delivery Dates, which shall be in no event earlier than [***] from the date of the purchase order. HOVIONE will notify ACHAOGEN of its receipt of each purchase order within [***] thereafter. Such notice will include confirmation of the delivery date, which shall be not less than [***] and not more than [***] from the date of the ACHAOGEN purchase order issue date. If HOVIONE fails to notify ACHAOGEN of its receipt of such order within such [***] period, and subject to the limits set forth in Section 5.8, the order will be deemed to have been received and accepted; provided, however, that if the Parties mutually agree, HOVIONE may deliver a shipment of the Product prior to the date that is [***] after the date of the applicable purchase order. The expected time until the Delivery Date of Product made at each Facility shall take into account the total number of Batches that can be made at such Facility and other terms of Exhibit 7.

5.3.1

Within [***] after an initial ACHAOGEN purchase order issue date, ACHAOGEN may request that up to [***] of the Product be Manufactured under such purchase order, such additional quantity to be delivered not more than [***] after the initial ACHAOGEN purchase order issue date; provided, that only such quantity of the Product may be requested per purchase order issued hereunder unless otherwise agreed to in writing by HOVIONE.

Confidential Treatment Requested by Achaogen, Inc.

5.3.2

In the event of any conflict between the provisions of this Agreement and any purchase order, acknowledgement, invoice, bill of lading, acceptance, or other preprinted form provided by either Party, the provisions of this Agreement shall control. No additional provision in any such other document shall apply unless both Parties explicitly agree in writing signed by both Parties that such additional provision shall apply as an additional provision to the Parties rights and obligations under this Agreement.

5.4

HOVIONE agrees that no changes will be made to any materials, outside suppliers, equipment or methods of production or testing for the Supplied Compound without ACHAOGEN’s prior written approval, which shall not be unreasonably conditioned, delayed or withheld. Upon written approval or request of ACHAOGEN, HOVIONE shall make the approved or requested changes in manufacturing procedures in a manner consistent with cGMP and other Applicable Laws.

5.5

Quantities. HOVIONE shall be required to Manufacture, supply and deliver to ACHAOGEN such quantities of the Product as ACHAOGEN orders and HOVIONE receives pursuant to Section 5.3, including any additional quantities requested by ACHAOGEN and agreed to by HOVIONE in accordance with the terms and conditions of Section 5.3.1. Notwithstanding the foregoing, HOVIONE shall have no obligation to supply a quantity of the Product that is [***] or more than the amount set forth in ACHAOGEN’s most recent forecast. During the Term, and without limiting the Minimum Annual Commitment obligations set forth in Sections 5.7 to 5.9, beginning the calendar year following the FDA Approval date, the Parties acknowledge and agree that each order will include a minimum of [***].

5.6

The Parties agree that time is of the essence with respect to Manufacturing under the Agreement. Accordingly, should any condition arise in the course of this Agreement that is reasonably likely to delay Manufacturing or a Delivery Date, including but not limited to, disruption with suppliers, regulatory issues, or failure of any Batch, HOVIONE shall notify ACHAOGEN of such condition as soon as reasonably practicable. Similarly, should any ACHAOGEN responsibility be delayed in such a way to disrupt HOVIONE’s obligations under this Agreement, ACHAOGEN shall notify HOVIONE of such condition as soon as reasonably practicable.

5.7

Pre-FDA Approval Reservation Fee. As will be agreed in Work Plan 2, ACHAOGEN may request that HOVIONE reserve manufacturing capacity and procure the necessary Project Specific Raw Materials to Manufacture, supply and deliver up to [***] Batches to ACHAOGEN within the [***] after FDA approval. Upon ACHAOGEN’s request to reserve such capacity, HOVIONE may invoice ACHAOGEN a non-refundable reservation fee equal to [***] of the final costs of the Batches ordered. If ACHAOGEN does not receive FDA Approval or FDA Approval is delayed, ACHAOGEN may, with written notice to HOVIONE, cancel the Batches ordered under this Section 5.5. If ACHAOGEN does not cancel the Batches ordered under this Section 5.5, the reservation fee shall [***]. Notwithstanding the foregoing, for the avoidance of doubt, the provisions of this Section 5.5 shall in no way limit or credit against the firm commitments of ACHAOGEN under Work Plan [***] through Work Plan [***].

Confidential Treatment Requested by Achaogen, Inc.

5.8

Minimum Annual Commitment. Beginning the Calendar Year 2020 and continuing through the Initial Term, in consideration for HOVIONE’s reservation of sufficient Manufacturing capacity to meet ACHAOGEN’s forecasted demand for the Product under this Agreement, ACHAOGEN commits to purchase from HOVIONE an amount of Product in each of Calendar Year 2020 through Calendar Year 2024 that corresponds to the values set forth in Exhibit 7 attached hereto (“Minimum Annual Commitment).

5.9

Annual Commitment True Up. During the Initial Term and for Calendar Years 2020 through 2024 in which ACHAOGEN has a Minimum Annual Commitment under Section 5.6, on [***] of each such Calendar Year, if ACHAOGEN has not met its Minimum Annual Commitment for the applicable Calendar Year, HOVIONE shall invoice ACHAOGEN for the difference between the value of the sales of Product in such Calendar Year ([***] set out in Exhibit 7) and the Minimum Annual Commitment. The difference is the “Annual Shortfall”. The invoice for the Annual Shortfall shall be issued no later than [***] of the following Calendar Year and such invoice shall be paid in full within [***] by ACHAOGEN.

5.10

Production Commitments. After Successful Completion of the Validation Program in each of the Facilities, the Parties shall complete Exhibit 7 by setting out the production capabilities of each Facility, the throughput, the lead-time to order and the price for the Product from each Facility. Notwithstanding anything else set forth in this Agreement, HOVIONE commits to making available annual production capacities to ACHAOGEN of no more than:

•

[***] per year in the [***] as from [***] after Effective Date, in batches of [***] or [***] in batches of [***]. As soon as the [***] becomes an approved qualified source and the larger scale production enters routine production, the [***] shall become a back-up plant only.

And

•

[***] per year in the [***] and [***] as from the date that is [***] after the Effective Date. The Parties agree that when the [***] Manufactures the necessary intermediates, the new scaled-up facilities in [***] shall be planned.

ARTICLE 6

MATERIALS AND EQUIPMENT

6.1

Supply of Project Specific Raw Materials. ACHAOGEN shall, [***] certain raw materials (“Project Specific Raw Materials” and “Starting Raw Materials”) required to Manufacture the Product ordered by ACHAOGEN and shall, subject to the maximum shelf life of all such materials and based upon the rolling forecast provided under Section 5.2, order and maintain at all times a [***] supply of such materials necessary to Manufacture the Product from vendors that have been mutually agreed to and approved by the Parties. If HOVIONE obtains Project Specific Raw Materials and Starting Raw

Confidential Treatment Requested by Achaogen, Inc.

Materials as required by this Agreement in preparation for the Manufacture of Product hereunder, HOVIONE shall [***]. HOVIONE shall [***]. If at any time, [***].

6.1.1

Delivery and Risk of Loss. ACHAOGEN agrees to [***]. HOVIONE will at all times take such measures as in accordance with the industry standard to protect the Project Specific Raw Materials, Starting Materials and the Product from risk of loss or damage at all stages of Manufacturing, and except for normal in process yield losses, will immediately notify ACHAOGEN if at any time it believes any ACHAOGEN Project Specific Raw Materials or Products have been damaged, lost, stolen, or contain a non-conformity whether through the sampling and testing process or a latent defect.

6.1.2

Title. ACHAOGEN shall retain title to the Project Specific Raw Materials and Starting Materials while it is in the Facility. HOVIONE shall assume responsibility and risk for the safekeeping, storage, and handling for all shipments of Project Specific Raw Materials delivered hereunder and accepted by HOVIONE; provided however, ACHAOGEN at all times retains responsibility for any defects or non-conformities in the Project Specific Raw Materials and Starting Materials.

6.1.3

Project Specific Raw Materials and Starting Materials. HOVIONE shall be responsible for planning, managing, and procuring all Project Specific Raw Materials from qualified or specified manufacturers based on the forecasts it receives from ACHAOGEN. For such purchases, HOVIONE will not be liable or take responsibility if for any reason, other than because of a HOVIONE failure, the Supplier does not provide timely supplies. Should ACHAOGEN [***] HOVIONE for [***], HOVIONE shall have [***]. HOVIONE shall obtain a certificate of analysis or equivalent with each lot of Project Specific Raw Materials purchased. HOVIONE will store all Project Specific Raw Materials in a secure location under appropriate conditions.

6.1.4

[***]. HOVIONE shall hold and maintain a minimum of [***]. [***] will be based on [***]. HOVIONE shall rotate the [***] with each new Manufacturing Batch.

6.1.5

Testing. HOVIONE shall conduct release testing of the Project Specific Raw Materials and Starting Materials in accordance with internal policies and the Quality Agreement between ACHAOGEN and HOVIONE. HOVIONE will (a) account for all Project Specific Raw Materials; (b) not provide the Project Specific Raw Materials to any third party without the express prior written consent of ACHAOGEN; (c) not use the Project Specific Raw Materials for any purpose other than conducting the Services; and (d) destroy or return to ACHAOGEN all unused quantities of Project Specific Raw Materials according to ACHAOGEN’s written instructions [***].

6.2	HOVIONE-Sourced Materials. HOVIONE shall [*] plan, manage and procure all materials necessary for the Manufacturing of the Product [*]. HOVIONE shall ensure

Confidential Treatment Requested by Achaogen, Inc.

that all such materials are purchased from qualified or specified manufacturers. HOVIONE shall obtain a certificate of analysis or equivalent with each lot of materials purchased. HOVIONE will store all materials in a secure location under appropriate conditions. For the avoidance of doubt, [***] shall not [***].

6.3

HOVIONE Supplier Audits. ACHAOGEN shall have the right to attend and participate in HOVIONE’s routine or for cause audits of HOVIONE’s suppliers of any materials used to Manufacture the Product. HOVIONE shall give ACHAOGEN reasonable advance notice of any such audit in accordance with the Quality Agreement. HOVIONE shall work with its suppliers, when requested by ACHAOGEN, to ensure the appropriate confidentiality agreements or other necessary agreements are in place to allow ACHAOGEN to participate in HOVIONE’s audits of suppliers providing Project Specific Raw Materials or other HOVIONE-sourced materials.

6.4

HOVIONE Supplier Contracts. HOVIONE shall take all steps necessary to execute the contracts with its suppliers to ensure that HOVIONE can purchase the necessary quantities of Project Specific Raw Materials and Starting Materials in a timely manner to Manufacture the Product in the quantities required by Section 5.4., the terms of such contracts shall be known to ACHAOGEN. ACHAOGEN assures that should HOVIONE [***] ACHAOGEN shall [***].

6.5

Specialist or Capital Equipment. As of the Effective Date, the Parties acknowledge that to the best of their knowledge, no special or capital equipment will be needed in order for HOVIONE to provide the Manufacturing at HOVIONE’s Facilities except for i) the capital equipment needed for the [***], ii) the cost of [***] and related process development for [***], iii) the [***] for the [***] and iv) the process development and equipment such as [***] as can be found in Exhibits 10, 11 and 12. These budgets are based on current process knowledge, including but not limited to HOVIONE’s good faith efforts to estimate, based on information provided by ACHAOGEN, the Acquisition Cost for necessary capital investment. The Parties acknowledge, however, that there is insufficient information to allow for definitive pricing, and Parties agree that such final work plans shall be completed as soon as data is available and they shall be added to an amendment to the Agreement in no event later than [***] after such costs are identified. Allocation of costs for additional capital investment, if any, necessary to this Agreement shall be [***].

6.5.1

The initial estimate of the capital investment requried for the [***] outlined in Exhibits 10, 11 and 12, have been prepared based on HOVIONE’s current knowledge. Should new information be developed during the Validation Process or the process development of the purification step, HOVIONE shall promptly prepare a proposal for such capital investment and process development costs, and ACHAOGEN and HOVIONE shall negotiate in good faith on a Work Plan that sets out the scope of such capital investment requirements and determine which Party will be responsible for acquiring and/or paying for such capital equipment.

6.5.2

Should the scale-up to [***] batches and/or the technology transfer to [***] require additional equipment not reasonably predicted by HOVIONE’s current

Confidential Treatment Requested by Achaogen, Inc.

assessment or the proposal under 6.5.1, ACHAOGEN and HOVIONE will negotiate in good faith to determine (a) which Party will be responsible for acquiring and/or paying for any such equipment, and (b) any appropriate amendments to the consequences of expiration or termination of this Agreement.

6.5.3

To the extent that it is HOVIONE’s responsibility for acquiring and/or paying for the equipment, the Parties will [***] as appropriate. The value of the Work Plans shall be based on [***]. To the extent it is ACHAOGEN’s obligation to pay for any capital equipment acquired by HOVIONE pursuant to this Section 6.5, such obligation shall be set forth in a Work Plan and ACHAOGEN shall make payments and/or reimbursements to HOVIONE in accordance with the applicable Work Plan.

6.5.4

If the [***] ACHAOGEN’s manufacturing program, the Parties will negotiate in good faith to [***].

ARTICLE 7

OWNERSHIP AND TECHNOLOGY TRANSFER

7.1	Background Intellectual Property. As between the Parties:

7.1.1

[***]; and [***] except as [***].

7.1.2

[***]; and [***] except as [***].

7.2

Ownership of Tangible Materials. ACHAOGEN shall retain ownership of all information, documents, and materials which ACHAOGEN has provided or provides to HOVIONE, [***], in connection with the performance of the Validation Program hereunder. Further, ACHAOGEN shall solely own all reports, results, records (including Batch Records), documents, and other tangible materials which HOVIONE has provided or provides to ACHAOGEN in connection with the Validation Program and all other activities of HOVIONE pursuant to this Agreement and such materials, and such reports, records (including batch records), documents and other tangible materials shall be deemed ACHAOGEN’s Confidential Information. HOVIONE shall [***] any right, title, and interest in such tangible materials to ACHAOGEN; provided, however, that HOVIONE shall be entitled to retain one (1) copy of any such reports, records (including Batch Records), documents, and other tangible materials solely for archival purposes. For the avoidance of doubt, and notwithstanding anything to the contrary in this Agreement, the format of any tangible materials provided by HOVIONE hereunder shall, together with any other Confidential Information of HOVIONE, are and will remain Confidential Information of HOVIONE in accordance with the terms and condition of this Agreement. If and for so long as required under Applicable Law, all such reports, records (including Batch Records), documents, and other tangible materials shall be physically located by HOVIONE at the applicable Facility.

Confidential Treatment Requested by Achaogen, Inc.

7.3	Ownership of Intangible Materials. Between ACHAOGEN and HOVIONE, [*] shall [], and []. All [], including without limitation [] shall be [], subject only to [], and [] shall be deemed []. [], which has []; provided [*].

7.4

Technology Transfer. If ACHAOGEN elects to have the active pharmaceutical ingredient Plazomicin (the “API”) manufactured by an entity other than HOVIONE pursuant to the terms of this Agreement, or upon termination of this Agreement, the Parties shall undertake those actions necessary and useful to enable ACHAOGEN and the third party of ACHAOGEN’s choosing to manufacture and supply API in a manner and amount sufficient to satisfy ACHAOGEN’s demand for the API. It being clear that HOVIONE is only obligated to transfer information related to the API process that was developed for ACHAOGEN and paid for by ACHAOGEN. HOVIONE has no obligation to transfer information that belongs to its general knowhow of compliant GMP manufacture or of specialist technology operating knowhow. Such actions, [***], shall include:

7.4.1

Agreement. The technology transfer will be conducted in accordance with a separate agreement setting forth the terms and conditions for the transfer by ACHAOGEN of the Process for Manufacturing the API (the “Technology Transfer Agreement”).

7.4.2

Books and Records; Know-How. Pursuant to the Technology Transfer Agreement, HOVIONE shall make available or transfer, as applicable, to ACHAOGEN copies of all books and records (other than financial books and records) and HOVIONE intellectual property and HOVIONE improvements relating directly to the Manufacture and supply of the API, including documentation constituting development reports, and process validation reports, performance reports, batch records, analytical method development reports, analytical method operating procedures, shot practice, material specifications for HOVIONE-sourced materials and their quality control methods, applicable correspondence with Governmental Authorities, and any other material that is necessary or useful to enable ACHAOGEN or a third party of ACHAOGEN’s choosing to manufacture and supply the API provided that all such information is directly relevant to the process knowledge that is to be transferred. All such information was developed for ACHAOGEN and paid for by ACHAOGEN and shall be provided without additional cost to ACHAOGEN.

7.4.3

Assistance. Pursuant to the Technology Transfer Agreement, HOVIONE shall provide/allow HOVIONE designated employees knowledgeable of the ACHAOGEN’s manufacturing process and controls to meet with or be made available to employees or representatives of ACHAOGEN at the manufacturing facility of ACHAOGEN or the facility of the third party of ACHAOGEN’s choosing, to assist for a limited period -not to exceed a total of [***]- with the manufacture and supply of the API and with the training of ACHAOGEN’s personnel (or the personnel of a third party of ACHAOGEN’s choosing) to the extent reasonably necessary to enable ACHAOGEN or a third party of ACHAOGEN’s choosing to manufacture and supply the API. This support shall

Confidential Treatment Requested by Achaogen, Inc.

be provided during regular business hours for HOVIONE and ACHAOGEN shall [***].

7.4.4

Other Assistance. Pursuant to the Technology Transfer Agreement, HOVIONE shall provide such other assistance as ACHAOGEN may reasonably request to enable ACHAOGEN or its designated third party to manufacture and supply the API provided always that HOVIONE shall not be required to transfer information that (i) is not directly related to the Product; and (ii) is HOVIONE’s Background Intellectual Property and that this other assistance is provided at a time that would not inconvenience HOVIONE and for a price based on [***].

7.4.5

Nothing contained in 7.4 shall be construed as HOVIONE providing any assurance of success of the technology transfer to a third-party. Hovione only assures that it shall provide all API and API process information available resulting from the development and validation work performed for ACHAOGEN, provided however that nothing in this Agreement shall prevent ACHAOGEN from having access to information directly related to the Product, which is necessary for a Regulatory Authority to approve a second source of Product.

ARTICLE 8

EXCLUSIVITY BY HOVIONE

8.1

Exclusivity. Other than to fulfill its obligations hereunder and subject to Section 8.4, HOVIONE shall not knowingly, during the Term, and for a period expiring [***] after the termination of this Agreement: (a) supply API to any third party; or (b) consent to any third party’s reference to the DMF for the Product supplied by HOVIONE without ACHAOGEN’s prior written consent. Moreover, subject to Section 8.3, even after the expiration of the [***] referred to above, HOVIONE shall not be entitled to use any Confidential Information of ACHAOGEN to produce or sell API for any third party without ACHAOGEN’s prior written consent for a period of [***] after termination of this Agreement. The exclusivity obligations set forth in this Section 8.1 shall expire [***] after HOVIONE’s termination of this Agreement pursuant to Section 12.3 (ACHAOGEN breach) or Section 12.4 (ACHAOGEN bankruptcy).

8.2

Insufficient Supply. During the Term, HOVIONE shall [***] allocate its inventory and Manufacturing output of the Product so that, in the event HOVIONE has an insufficient Manufacturing capacity to satisfy all of its customers’ orders, HOVIONE’s allocation to ACHAOGEN’s on its orders will be as favorable as HOVIONE’s allocation to any and all other customers on their orders. If at any time during the Term, HOVIONE is, or expects that it will be, unable, in full or in part, to satisfy ACHAOGEN’s orders for the Product for any reason, including a Force Majeure Event (as defined in Section 17.1), HOVIONE shall so notify ACHAOGEN as soon as possible, detailing the extent to which it will not meet such orders. In the event that at any time HOVIONE is unable to meet ACHAOGEN’s requirements for the Product for more than [***], then ACHAOGEN will have the right, in its sole discretion, to either (i) cancel any and all outstanding purchase orders subject to such supply interruption without penalty and/or

Confidential Treatment Requested by Achaogen, Inc.

purchase any and all of its requirements of API from the Alternate Supplier until such time as HOVIONE notifies ACHAOGEN that HOVIONE is able to resume supplying ACHAOGEN’s requirements of the Product (provided, however, that HOVIONE’s right to resume supply of such requirements does not include amounts of API that ACHAOGEN is already committed to purchase from such Alternate Supplier); or (ii) terminate this Agreement upon sixty (60) days’ prior written notice to HOVIONE.

8.3

Supply Failure. A “Supply Failure” means (i) any notification from HOVIONE of an anticipated Product shortage or inability to fill [***] or more of a Purchase Order in either case for a period of [***] or more from the agreed upon Delivery Date; (ii) a Force Majeure Event or [***] that meets the Manufacturing Standards in accordance with this Agreement for a period of [***] or more from the agreed upon delivery date; or (iii) the occurrence on [***] or more occasions within a [***] period of a [***]. Notwithstanding any rights or obligations in the Agreement, should there be a Supply Failure and such failure is not due to the actions of ACHAOGEN, then (i) ACHAOGEN is permitted to [***] supply of Product from other sources even if such supply would otherwise be contrary to the terms of this Agreement, including but not limited to Section 5.1; and (ii) ACHAOGEN is excused from for any Minimum Annual Commitment for the remainder of the Term.

8.4

Supply to Third Parties. ACHAOGEN acknowledges that, notwithstanding anything to the contrary in this Agreement, HOVIONE shall have the right to (a) supply the Product and/or products containing the Product to ACHAOGEN or any licensee of ACHAOGEN for sale or use in products for sale in the Territory; and (b) (i) if ACHAOGEN (and its Affiliates) cease to have exclusive rights to sell the Product in the Territory, supply the Product and/or products containing the Product to ACHAOGEN or any licensee of ACHAOGEN for sale or use in products for sale in the Territory; and (ii) consent to ACHAOGEN’s or any licensee of ACHAOGEN’s reference to the DMF for the Product supplied by HOVIONE in the Territory. ACHAOGEN agrees that, solely in connection therewith, HOVIONE may use and disclose under an obligation of confidentiality (such obligation being at least as restrictive as the confidentiality provisions of this Agreement) any ACHAOGEN Confidential Information obtained prior to or during the Process Validation conducted in accordance with Letters of Authorization that is necessary or helpful to Manufacture the Product for such third parties.

ARTICLE 9

WARRANTIES; SPECIFICATIONS

9.1	Warranties. HOVIONE represents, warrants and covenants that:

9.1.1

All Product supplied to ACHAOGEN hereunder shall be Manufactured in accordance with cGMP and all other Applicable Laws, the Manufacturing Process, quality requirements, and the Specifications, and at the time of delivery shall have a shelf life no less than [***] or such longer period as equals the retest period (as ACHAOGEN may approve and communicate to HOVIONE with supporting documentation) minus [***]; provided, however, that ACHAOGEN

Confidential Treatment Requested by Achaogen, Inc.

provides HOVIONE with no less than [***] prior written notice of any such change in the shelf life of the Product.

9.1.2

All Product and HOVIONE’s Manufacture of the Product shall be performed in accordance with and conform in all respects to the Applicable Laws and industry standards governing the Manufacture and supply of the Product in the place where Manufactured and the Territory.

9.1.3

As of the date of this Agreement and to the best of its knowledge, all HOVIONE Background Intellectual Property is owned by HOVIONE or HOVIONE is otherwise entitled to use it for purposes of providing Manufacturing or the Services under this Agreement. HOVIONE will promptly notify ACHAOGEN in writing if it receives or is notified of a formal written claim from a third party that HOVIONE Background Intellectual Property or that the use by HOVIONE thereof infringes any intellectual property or other rights of any third party.

9.1.4

As of the date of this Agreement and to the best of its knowledge, all ACHAOGEN Background Intellectual Property is owned by ACHAOGEN or ACHAOGEN is otherwise entitled to use it for purposes of conducting the activities under this Agreement. ACHAOGEN will promptly notify HOVIONE in writing if it receives or is notified of a formal written claim from a third party that ACHAOGEN Background Intellectual Property or that the use by HOVIONE thereof infringes any intellectual property or other rights of any third party.

9.1.5

HOVIONE shall: (a) retain the minimum number of samples of the Product as are required and specified to comply with the retention requirements as set forth in the cGMPs, DMFs, and Regulatory Application; (b) report to ACHAOGEN any confirmed out-of-specification test results with respect to the delivered Product within [***]; and (c) make stability reports and findings available for reasonable inspection by ACHAOGEN and/or ACHAOGEN’s designees. HOVIONE shall retain all production records of the Process and Manufacture of the Product in accordance with Applicable Laws, including without limitation cGMP’s. HOVIONE shall perform stability testing as described and required to conform with the Product stability protocol to be agreed upon in writing by the Parties.

9.1.6

HOVIONE shall: (a) promptly report to ACHAOGEN and investigate all material out of specification events in Manufacturing and/or complaints by ACHAOGEN regarding non-conformance; (b) promptly report to ACHAOGEN and investigate all critical Manufacturing deviations; (c) keep ACHAOGEN apprised no less frequently than every [***] of the status of such investigations; and (d) share all investigative reports upon the conclusion of the investigation with ACHAOGEN.

9.1.7

Neither HOVIONE nor any of its officers or employees, nor any other person, consultant or contractor used by HOVIONE to perform Manufacturing or Services under this Agreement is: (a) an individual who has been debarred by the FDA pursuant to Section 306 of the FDCA, 21 U.S.C. § 335a (“Debarred Individual”); (b) a corporation, partnership or association that has been debarred

Confidential Treatment Requested by Achaogen, Inc.

by FDA pursuant to Section 306 of the FDCA, 21 U.S.C. § 335a (“Debarred Entity”); or (c) the subject of an FDA debarment investigation or proceeding (or similar proceeding of another regulatory agency); and HOVIONE will not retain or employ any personnel, and will not knowingly use the services of any contractor or consultant, who is debarred by the FDA or who is the subject of an FDA debarment investigation or proceeding (or similar sanction or investigation by another regulatory agency) in connection with performing any Manufacturing or Services. HOVIONE has no knowledge of any circumstances which may affect the accuracy of the foregoing representation, including, without limitation, any FDA investigations of, or debarment proceedings against, HOVIONE or any person or entity performing services or rendering assistance which is in any way related to activities taken pursuant to this Agreement. HOVIONE shall notify ACHAOGEN in writing as soon as possible if HOVIONE, at any time during the Term, becomes aware of any such circumstances.

9.2

Environmental Compliance. The generation, collection, storage, handling, transportation, movement, and release of hazardous materials and waste generated by or on behalf of HOVIONE or any of its Affiliates in connection with the Manufacture of the Product and other Services under this Agreement shall be the responsibility of HOVIONE, at HOVIONE’s cost and expense. Without limiting other legally applicable requirements, HOVIONE shall prepare, execute, and maintain as a generator of waste, all licenses, registrations, approvals, authorizations, notices, shipping documents and waste manifest required under applicable laws.

9.3

Specifications and Other Changes. ACHAOGEN represents and warrants that the Specifications shall be in conformance with the Regulatory Applications. In the event ACHAOGEN or any of its Affiliates changes the Specifications, ACHAOGEN shall promptly advise HOVIONE in writing of such changes, and HOVIONE shall promptly inform ACHAOGEN as to any scheduling and/or price adjustments which may reasonably result from such changes. In the event that HOVIONE wishes to propose any change to the Manufacturing (including without limitation components, equipment, Facility, or Process), the DMF, or the Specifications, it shall provide all relevant details related to such proposed change for review by ACHAOGEN, but shall not implement any such change prior to ACHAOGEN’s written approval and any necessary approval by the applicable Regulatory Authority. ACHAOGEN shall promptly provide HOVIONE with current, up-to-date copies of portions or sections of each applicable DMF or CMC from the NDA filing that relate to HOVIONE’s Manufacturing and Services that HOVIONE is expected to complete under this Agreement.

9.4	ACHAOGEN Warranties. ACHAOGEN represents and warrants that:

9.4.1

to the best of its knowledge, neither the Manufacture, supply, nor use of the Product as contemplated hereby will infringe on any patents or any other proprietary rights of third parties, except to the extent arising from any technology or process introduced and used by HOVIONE in the Manufacture of the Product, and neither ACHAOGEN, nor any of its Affiliates, has received any notice of any claimed infringement (including, without limitation, patent infringement) in

Confidential Treatment Requested by Achaogen, Inc.

connection with the Product and it will promptly notify HOVIONE in writing should it (or they) become aware of any claims asserting such infringement. For the avoidance of doubt, and without limiting any other provisions of this Agreement, ACHAOGEN understands and agrees that, if at any time HOVIONE reasonably determines, based on legal counsel, that the Manufacture and supply of Product as contemplated hereby does infringe on any patents or any other proprietary rights of third parties (except to the extent arising from any technology or process introduced and used by HOVIONE in the Manufacture of the Product), HOVIONE shall promptly provide ACHAOGEN with notice of such determination and, thereafter, HOVIONE may suspend the Manufacture and supply of Product under this Agreement without breaching any of HOVIONE’s obligations hereunder until ACHAOGEN has either (i) provided HOVIONE with sufficient justification for ACHAOGEN’s position that such suspected infringement is not the case, or (ii) provides evidence to HOVIONE that ACHAOGEN has secured the rights to rightfully practice the patents or any other proprietary rights of such third parties and that those rights are rightfully extended to HOVIONE under this Agreement, (iii) ACHAOGEN has confirmed irrevocably in writing that it shall cover all commercial losses that HOVIONE may owe to any 3^rd parties that allege infringement. In no event shall HOVIONE be in breach of this Agreement for its refusal to perform any manufacturing action that would amount to a criminal offense or be in contempt of court. If HOVIONE suspends the Manufacture of the Product under this Section, ACHAOGEN’S obligation to purchase Minimum Annual Commitments shall be suspended until restoration of the Manufacturing.

9.5	Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT.

9.6

ACHAOGEN as Party. The Parties acknowledge and agree that, in entering into this Agreement, ACHAOGEN (a) is making and providing only those acknowledgments, confirmations, representations, and warranties explicitly stated in this Agreement as made and provided by ACHAOGEN; (b) is not, and shall not be deemed as, making or providing any other acknowledgments, confirmations, representations, or warranties or undertaking covenants of any kind; and (c) is not, and shall not be deemed, in any way responsible or liable for (or jointly responsible or liable for), or the guarantor of, the acknowledgements, confirmations, representations, warranties, or covenants of ACHAOGEN in this Agreement.

ARTICLE 10

PRICE AND TERMS FOR THE COMMERCIAL PRODUCT

10.1	Price. The initial price for commercial Product supplied by HOVIONE to ACHAOGEN during the Term of this Agreement (excluding the Product from the validation Batches) is

Confidential Treatment Requested by Achaogen, Inc.

set forth in Exhibit 7. The price for the Product from the Validation Batches shall be included in the appropriate Work Plan.

10.2

Price Adjustments. As set forth in this Section, HOVIONE shall have the right to adjust prices [***] and HOVIONE and ACHAOGEN agree to meet at least [***] prior to the commencement of [***] during the Term to discuss the adjustment of the prices for Product hereunder. At such meeting, ACHAOGEN and HOVIONE shall formally review [***] and other factors positively or negatively impacting cost, including those resulting from experience in Manufacturing. ACHAOGEN and HOVIONE shall work together to obtain process improvements. Net savings or increases, such as in the costs of materials or labor or the economies of scale, shall be considered with respect reductions or increases respectively in the Purchase Price. Regardless of any cost savings considered hereunder, HOVIONE shall, [***] as follows: (i) with regard to the cost to Manufacture the Product (that is, all costs other than the cost of raw materials), HOVIONE may [***] of (B) [***] or (B) [***]; and (ii) with regard to the cost of raw materials, HOVIONE may [***]. Should such [***] become obsolete, the Parties will mutually agree in writing to a [***]. The [***] will be applicable on all orders placed [***] after such [***]. The Parties also agree to [***] a [***] price for all PRODUCT manufactured at the [***] but in no event shall the initial price of Product Manufactured at the [***] exceed the price of the most recent Product manufactured at the [***].

10.3

Product Delivery Terms. HOVIONE agrees to deliver all Product ordered by ACHAOGEN [***] (Incoterms 2010) at the Site designated in writing in any purchase orders. Title and risk of loss to the Product supplied hereunder shall [***]. All shipping instructions of ACHAOGEN shall be accompanied by the name and address of the recipient and the shipping date.

10.4	Invoices. The invoices for the fees under this Agreement shall be marked with the following information:

Purchase Order Number __________;

and the following statement:

“Manufacturing/Services performed under this Validation and Manufacturing Agreement and associated with the Work Plan:

HOVIONE shall invoice ACHAOGEN for Product upon the earlier to occur of (i) shipment of such Product, (ii) within [***] after Batch Release/Disposition by ACHAOGEN, or (iii) within [***] of HOVIONE’s Batch Release (as evidenced by the date of HOVIONE’s certificate of analysis), (iv) upon ACHAOGEN’s request. HOVIONE will submit its invoices for Manufacturing, Services, products, and expenses to ACHAOGEN by regular mail or by email as noted below:

If by regular mail:

Achaogen, Inc.
Attn: [***]

Confidential Treatment Requested by Achaogen, Inc.

7000 Shoreline Court, Suite 371
South San Francisco, CA 94080

If by electronic mail:

[***]

10.5

Method of Payment. All undisputed invoices shall be due and payable [***] from receipt by ACHAOGEN of the invoice; provided, however, that invoices for up-front fees shall be paid by ACHAOGEN within [***] after receipt thereof or as otherwise specified herein. In the event any payment is not made when due, HOVIONE shall notify ACHAOGEN of such nonpayment and, regardless of such notification, shall be entitled, in addition to its other rights and remedies, to charge interest on the unpaid amount at the rate of [***] per month. ACHAOGEN shall make all payments pursuant to this Agreement by wire transfer to a bank account as designated in writing by HOVIONE.

10.6	Reimbursement of Costs and Expenses. For any provision in this Agreement requiring ACHAOGEN to reimburse HOVIONE for its actual costs or expenses, including but not limited to [*], HOVIONE agrees to [] such amounts and to [**] any proposals by ACHAOGEN to reduce such amounts.

10.7	Currency: Currency Conversion. All payments to be made under this Agreement shall be made in US Dollars. The Parties agree to [*]. If and hen the [] hereunder, HOVIONE shall notify ACHAOGEN in writing and such [] (with such [*]).

10.8

Taxes. Any use, sales, excise or value added tax, duty, custom, inspection or testing fee, or any other tax, fee or charge of any nature whatsoever imposed by any governmental authority on or measured by the transaction between HOVIONE and ACHAOGEN (other than HOVIONE’s income tax), will be paid by ACHAOGEN in addition to the prices quoted or invoiced by HOVIONE. In the event HOVIONE is required to pay any such tax, fee, or charge, ACHAOGEN will reimburse HOVIONE for such payment, or in lieu of such payment, ACHAOGEN will provide HOVIONE at the time the order is submitted an exemption certificate or other document acceptable to the authority imposing the tax, fee or charge.

10.9

Import and Export. Without limiting the generality of any other provisions of this Agreement, and in addition to any other amounts due to HOVIONE under his Agreement, ACHAOGEN will be responsible for [***]. If applicable, HOVIONE will provide customary export documentation, as specified by ACHAOGEN in writing or by separate delivery and shipment documentation instructions, together with each shipment of Product (or such other deliverables). HOVIONE shall also provide ACHAOGEN with all relevant shipping information (e.g., carrier, shipment details, scheduled arrival date, quantity) prior to or coincident with shipping any Product (or such other deliverables) under this Agreement.

Confidential Treatment Requested by Achaogen, Inc.

ARTICLE 11

MANUFACTURING AUDITS

11.1

HOVIONE shall inform ACHAOGEN of any FDA or other Regulatory Authority inspection of the Facility in which the Product is Manufactured within [***] that such inspection is initiated or known by HOVIONE, and shall allow ACHAOGEN (or its designee) to attend and act as a consultant to HOVIONE in such audits if the inspection is directly related to the Manufacture of the Product (ACHAOGEN will have the right to be present on site, but not participate in, any such investigation or inspection).). HOVIONE shall, within [***] after receipt by HOVIONE, provide copies to ACHAOGEN of all inspection observation reports and other regulatory communications that may affect any of the Product or its Manufacture. HOVIONE shall also provide copies of HOVIONE’s proposed responses to such inspection observation reports and other regulatory communications within [***] of their preparation (the inspection observation reports, HOVIONE’s proposed and actual responses, and other regulatory communications are referred to collectively as “Regulatory Audit Materials”). ACHAOGEN will be allowed to review and comment on those Regulatory Audit Materials which pertain directly to the Product or the Manufacture thereof. HOVIONE shall promptly notify ACHAOGEN as to what corrective measure HOVIONE is taking, whether before or following any regulatory inspection or audit, and keep ACHAOGEN informed on a regular, ongoing, and periodic basis of related developments. For the avoidance of doubt, HOVIONE shall control and have full authority with regard to communications in connection with its Facilities with any Regulatory Authority.

11.2	Periodic Manufacturing Audit. Once every [*] during the Term, ACHAOGEN shall have the right to conduct one (1) Manufacturing Audit (as defined below) according to the terms specified in Section 11.4 hereof (such Manufacturing Audit to be hereinafter referred to as a “Periodic MA”). [*].

11.3

Event Manufacturing Audit. In addition to the Periodic MA referred to in Section 11.2 hereof, in the event that: (a) the Regulatory Authorities schedule a regulatory inspection of the Facility in which the Product is Manufactured; (b) HOVIONE shall receive a “Warning Letter” or Form 483 Observations from the FDA relating to the Manufacture of the Product by HOVIONE or compliance with cGMP’s at any Facility where the Validation Program, Manufacturing, or other activities related to the Product occurs; (c) ACHAOGEN has rejected a shipment of the Product for failure to meet Specifications; or (d) ACHAOGEN otherwise has reasonable concern regarding the quality or Manufacturing of the Product supplied by HOVIONE (individually or collectively, an “Event”), ACHAOGEN shall have the right to conduct additional Manufacturing Audits in respect of the Product according to the terms specified in Section 11.4 hereof (such Event Manufacturing Audit to be hereinafter referred to as an “Event MA”).

11.4

Audit. For purposes of this Agreement, the term “Manufacturing Audit” shall mean an audit of the relevant Manufacturing Facility to be conducted by ACHAOGEN or its designees. Each Manufacturing Audit shall be conducted during HOVIONE’s normal business hours and upon reasonable prior written notice to HOVIONE (“reasonable”, for

Confidential Treatment Requested by Achaogen, Inc.

purposes of this provision, shall be [***] for the Annual MA and [***] for the Event MA) and shall last no longer than [***]. During a Manufacturing Audit, upon ACHAOGEN’s request, HOVIONE shall make available for review and photocopying such documents as ACHAOGEN and its auditors may reasonably request provided they relate to the Product and its Manufacture by HOVIONE.

ARTICLE 12

TERM; TERMINATION

12.1

Term. The term of this Agreement shall commence on the Effective Date and shall expire on the seventh (7^th) annual anniversary of the first Delivery Date (the “Initial Term”) unless terminated earlier pursuant to the terms hereof. This Agreement shall be automatically renewed for successive additional two (2) year terms after the end of the Initial Term (each a “Renewal Term”), unless either Party provides written notice to the other at least twenty-four (24) months prior to the end of the Initial Term or twenty-four (24) months prior to the end of the Renewal Term, as the case may be, that this Agreement shall expire at the end of the Initial Term or such Renewal Term. The Initial Term and all Renewal Terms shall be collectively referred to herein as the “Term”.

12.2

Termination by ACHAOGEN. This Agreement may be terminated by ACHAOGEN in the event: (a) the FDA does not approve a Regulatory Application for Product or issue a letter indicating that such a Regulatory Application is approvable within [***] after ACHAOGEN submits its new drug application (“NDA”) to FDA for approval; (b) the Regulatory Application for Product as submitted for approval by the FDA is withdrawn, either by ACHAOGEN or any of its Affiliates or the Regulatory Authorities; (c) if ACHAOGEN, in its sole discretion, stops development of the Product; or (d) the Product is withdrawn from Sale throughout the Territory. Termination under this Section 12.2 shall be effective immediately upon ACHAOGEN’s delivery of written notice to HOVIONE.

12.3

Termination for Breach. This Agreement may be terminated by either Party in the event of the material breach by the other Party of the terms and conditions hereof; provided, however, the other Party shall first give to the defaulting Party written notice of the proposed termination or cancellation of this Agreement, specifying the grounds therefor. Upon receipt of such notice, the breaching Party shall have thirty (30) days to respond by curing such breach or by confirming to the other Party in writing that such breach is not capable of being cured within such sixty (60) day period and that the breaching Party is working diligently to cure such breach, but in no event shall the non-breaching Party be required to accept any cure period totaling greater than ninety (90) days. If the breaching Party does not so respond or fails to work diligently and to cure such breach within the additional time set forth above, then the other Party may terminate the Agreement. Termination of this Agreement pursuant to this Section 12.3 shall not affect any other rights or remedies which may be available to the non-breaching Party.

12.4	Bankruptcy; Insolvency. Either Party may terminate this Agreement upon: (a) the entry of a decree or order for relief by a court having jurisdiction in the premises in respect of

Confidential Treatment Requested by Achaogen, Inc.

such Party in an involuntary case under the U.S. Federal Bankruptcy Code, as now constituted or hereafter amended, or any other applicable federal or state insolvency or other similar law and the continuance of any such decree or order unstayed and in effect for a period of sixty (60) consecutive days; or (b) filing by such Party of a petition for relief under the U.S. Federal Bankruptcy Code, as now constituted or hereafter amended, or any other applicable federal or state insolvency or similar law.

12.5	Upon Assignment. HOVIONE may terminate this Agreement as set forth in Section 21.4(b).

12.6	Upon Termination. Except as set forth in this Agreement, upon termination or expiration of this Agreement, HOVIONE shall invoice ACHAOGEN, and ACHAOGEN shall promptly pay the following amounts to HOVIONE:

(a)

[***];

(b)

any outstanding, unpaid invoices issued by HOVIONE;

(c)

[***];

(d)

[***]; and

(e)

[***] as per the Work Plans numbered [***] to [***] found in Exhibits 8 to 13, that [***].

(f)

an amount equal to the sum of (i) the [***] in which the termination occurs, plus (ii) the [***] that would otherwise have been owed for the [***]; provided however, in the event this Agreement is terminated by ACHAOGEN pursuant to Section 12.2(a) (No FDA approval), the amount otherwise owed under this subsection (f) shall be [***].

(g)

For the avoidance of doubt, the amounts set forth in subsection 12.6(e) shall not be owed by ACHAOGEN in the event of a termination of this Agreement by ACHAOGEN pursuant Section 12.3 (HOVIONE breach), or Section 12.4 (HOVIONE bankruptcy).

ARTICLE 13

CONTROL SAMPLE; CLAIMS OF NON-CONFORMANCE

13.1

Certificate of Analysis and Control Sample. Each Batch of Product shipped to ACHAOGEN shall be accompanied by a Certificate of Analysis substantially in the form of Exhibit 4, approved by a responsible representative of the quality assurance function at HOVIONE. If requested by ACHAOGEN, each Batch shipped shall also include a control sample of each Batch shipped for analysis in a container provided or otherwise pre-approved by ACHAOGEN, or its designee to conduct quality control release testing.

Confidential Treatment Requested by Achaogen, Inc.

Such control sample must be from, and representative of, the lot of the Product actually shipped.

13.2

Inspection. Every Batch of Product supplied by HOVIONE shall be delivered in accordance with Section 10.3, subject to ACHAOGEN’s inspection, and may be rejected if any such Product fails to conform at the time of delivery in accordance with Section 10.3 with any warranty of HOVIONE, the Specifications or the other requirements set forth herein, including but not limited to, delivery without a Certificate of Analysis. Such a rejection shall be communicated in writing to HOVIONE within [***] of delivery of such Product and will provide sufficient detail for the reasons for such rejection to permit HOVIONE to investigate the alleged non-conformity. ACHAOGEN shall be deemed to have accepted each Batch in a shipment of Product if HOVIONE does not receive written notice to the contrary within such [***] period as set forth in this Section 13.2. ACHAOGEN shall have the right to reject a Batch or part thereof by notifying HOVIONE in writing within such [***] period after delivery to ACHAOGEN of any non-conforming Batch or part of a Batch of Product containing obvious defects discoverable without affecting the integrity of the Product’s packaging. In addition, ACHAOGEN will have the right to reject a Batch or part thereof by notifying HOVIONE within [***] from its discovery of any latent defects in a Batch or part thereof; provided that HOVIONE will not be responsible for any latent defects that ACHAOGEN discovers in any Product that has been further processed in any way (except to the extent any such defect is shown to have been present in such Product at the time of delivery in accordance with Section 10.3) or that cannot be shown to have been present at the time of delivery in accordance with Section 10.3. If there is a disagreement between the Parties as to whether any Product conforms to the requirements of this Agreement, then samples, Batch records and other information, as appropriate, from the Batch in dispute will be submitted for testing and evaluation to an independent cGMP testing laboratory agreed to in writing by both Parties. The determination of such laboratory as to conformance will be binding upon the Parties. If it is determined by such laboratory that the Product conformed to the requirements herein at the time of delivery in accordance with Section 10.3, the cost of any testing and evaluation by the testing laboratory will be borne by ACHAOGEN. If the Product is determined to have been non-conforming at the time of delivery in accordance with Section 10.3, the cost of any testing and evaluation by the testing laboratory will be borne by HOVIONE, and [***] or, [***]. Nothing in this Section 13.2 shall in any way limit the indemnification obligations of either Party set forth in this Agreement. HOVIONE shall not have liability for latent defects in the Products in the absence of HOVIONE’s gross negligence, willful misconduct or breach of this Agreement.

ARTICLE 14

RECALLS; CMC DOCUMENTATION

14.1	Recalls and Returned Product. In the event: (a) ACHAOGEN or any of its Affiliates reasonably determines that Product or a product containing Product should be recalled for any reason; (b) any Regulatory Authority issues a request, directive, or order that Product

Confidential Treatment Requested by Achaogen, Inc.

be recalled or otherwise withdrawn from any country in the Territory; or (c) a court of competent jurisdiction orders such a recall or withdrawal (either (b) or (c) together, an “Order”), the Parties shall take all appropriate corrective actions reasonably requested by the other Party or any Regulatory Authority. To the extent such recall or withdrawal results from HOVIONE’s: (i) [***], including but not limited to [***]; (ii) the [***]; or (iii) [***], then HOVIONE shall be responsible for: (x) its [***]; (y) [***] for such recall or withdrawal; and (z) [***]. If ACHAOGEN believes that the recall results from any reason defined in (i), (ii), and/or (iii) above, then ACHAOGEN and its Affiliates may proceed with such recall [***] (subject to the following sentence) and will hold a [***] to ensure the [***]. If HOVIONE agrees, or a final determination is made in an arbitration, that the recall results from any reason defined in (i), (ii), and/or (iii) above, then HOVIONE shall be responsible for its and ACHAOGEN’s expenses as set forth above; provided that HOVIONE’s aggregate liability to ACHAOGEN under this Section 14.1 for any recall shall be [***]. If the recall results from any other reason, [***]. For purposes of this Agreement, [***] of such recall or withdrawal shall be [***]. The Parties each have the right to audit such recall costs. ACHAOGEN shall be responsible for coordinating any and all such recall or withdrawal activities with the Regulatory Authorities, its customers, or otherwise.

14.2

CMC Documentation. Upon ACHAOGEN’s written request, HOVIONE shall supply, [***], all information required by ACHAOGEN in support of the Chemistry, Manufacturing & Control (“CMC”) Section of any NDA or other filings to be filed by ACHAOGEN or its Affiliates in the Territory with the Regulatory Authorities for any product, containing Product Manufactured by HOVIONE, under this Agreement. HOVIONE shall co-operate with, and provide support and assistance to, [***], any consultant that ACHAOGEN or its Affiliates selects to write the documentation in the CMC section.

ARTICLE 15

INDEMNIFICATION; INSURANCE

15.1

Indemnification by ACHAOGEN. ACHAOGEN shall indemnify, defend and hold harmless HOVIONE, its Affiliates, and their respective directors, officers, employees, agents, successors, and assigns from and against any damages, judgments, claims, suits, actions, liabilities, costs, and expenses (including, but not limited to, reasonable attorneys’ fees) (collectively a “Claim”) made by any third party to the extent arising out of: (a) any breach of any representation or warranty made by ACHAOGEN in this Agreement; (b) any failure by ACHAOGEN to perform any covenant, agreement, or undertaking on the part of ACHAOGEN contained in this Agreement; (c) the gross negligence or willful misconduct of ACHAOGEN or its Affiliates (or their respective directors, officers, employees, and agents); (d) the marketing, distribution, import, use, or sale by ACHAOGEN or its Affiliates of a Product (including without limitation [***] and any product liability claims); or (e) any [***], except to the extent that such claim or suit results from or arises out of any act or omission for which HOVIONE is obligated to indemnify ACHAOGEN or its Affiliates pursuant to Section 15.2. Notwithstanding the

Confidential Treatment Requested by Achaogen, Inc.

foregoing, ACHAOGEN shall have no such indemnity obligation to the extent that such third party claims are based on, arise out of, or are caused by: (x) the gross negligence or willful misconduct of HOVIONE or its Affiliates (or their respective directors, officers, employees, agents, contractors, successors, and assigns); (y) any breach of any representation or warranty made by HOVIONE in this Agreement; or (z) any failure by HOVIONE to perform any covenant, agreement, or undertaking on the part of HOVIONE contained in this Agreement.

15.2

Indemnification by HOVIONE. HOVIONE shall indemnify, defend and hold harmless ACHAOGEN, its Affiliates, and their respective directors, officers, employees, agents, successors, and assigns from and against any Claims made by any third party to the extent arising out of: (a) any breach of any representation or warranty made by HOVIONE in this Agreement; (b) any failure by HOVIONE to perform any covenant, agreement, or undertaking on the part of HOVIONE contained in this Agreement; (c) the gross negligence or willful misconduct of HOVIONE or its Affiliates (or their respective directors, officers, employees, agents, and contractors); or (d) any [***]. Notwithstanding the foregoing, HOVIONE shall have no such indemnity obligation to the extent that such third party claims are based on, arise out of, or are caused by: (x) the gross negligence or willful misconduct of ACHAOGEN or its Affiliates (or their respective directors, officers, employees, agents, successors, and assigns); (y) any breach of any representation or warranty made by ACHAOGEN in this Agreement; or (z) any failure to perform any covenant, agreement, or undertaking on the part of ACHAOGEN contained in this Agreement.

15.3

Indemnification Procedures. A Party who intends to claim indemnification under Section 15.1 or 15.2 hereof (the “Indemnitee”) shall promptly notify the other Party (the “Indemnitor”) in writing of any claim for which the Indemnitee intends to seek indemnification hereunder. The Indemnitor shall have the exclusive right and authority to conduct the defense or settlement of any such claim at the Indemnitor’s sole expense and the Indemnitee shall cooperate with the Indemnitor therewith; provided, however, that the Indemnitee shall be entitled to provide consultation in the defense of such matter and to employ counsel at its expense to assist Indemnitee in providing such consultation. The Indemnitee shall provide the Indemnitor with such information and assistance as the Indemnitor may reasonably request, at the expense of the Indemnitor.

15.4	Insurance.

15.4.1

ACHAOGEN’s Insurance. ACHAOGEN will, throughout the Term of this Agreement and for [***] after the latest expiration date of any Product Manufactured pursuant to this Agreement, obtain and maintain at its own cost and expense, commercial general liability insurance and product liability insurance. Such policies will provide protection against any and all types of claims, demands, and causes of action that could arise under this Agreement. The minimum amount of coverage required by this Agreement will be:

(a)

Excess products liability with a combined single limit in an amount of not less than U.S. [***] per occurrence and U.S. [***] in the aggregate during

Confidential Treatment Requested by Achaogen, Inc.

the clinical and development phase of the Project; and not less than U.S. [***] per occurrence and U.S. [***] in the aggregate upon the Product receiving its first Regulatory Approval but prior to any commercial sale;

(b)

workers’ compensation insurance in accordance with Applicable Laws;

(c)

commercial general liability including premises operations, blanket contractual liability, personal injury, and advertising injury including fire, legal liability for bodily injury, and property damage in an amount not less than [***] per occurrence and [***] in the aggregate; and

(d)

employer’s liability with a limit of liability in an amount of not less than the statutory limits.

ACHAOGEN agrees to furnish within [***] after execution of this Agreement, and upon each policy renewal thereafter, and upon written request of HOVIONE, a certificate of insurance or self-insurance evidencing that such insurance is in effect. ACHAOGEN will provide HOVIONE [***] prior written notice of cancellation, non-renewal, or material change in the insurance required by this Agreement.

15.4.2

HOVIONE’s Insurance. HOVIONE agrees to maintain, during the Term and for [***] thereafter, at its own expense (a) commercial liability insurance in an amount not less than U.S. [***] per occurrence and U.S. [***] annual aggregate; and (b) worker’s compensation insurance in full compliance with Applicable Laws. HOVIONE shall submit to ACHAOGEN, from an insurer with an A.M. Best rating of A- or better or, if less than A-, otherwise acceptable to ACHAOGEN, a certificate of insurance evidencing that the required insurance is in force and effect. HOVIONE will provide ACHAOGEN [***] prior written notice of cancellation, non-renewal, or material change in the insurance required by this Agreement.

15.5

Disclaimer of Damages. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR INDIRECT DAMAGES ARISING OUT OF THIS AGREEMENT, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY. THIS LIMITATION SHALL APPLY EVEN IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE; PROVIDED, HOWEVER, THAT THIS LIMITATION SHALL NOT APPLY TO DAMAGES RESULTING FROM BREACHES BY A PARTY OF ITS DUTY OF CONFIDENTIALITY AND NON-USE IMPOSED UNDER ARTICLE 16 OR TO ITS INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE 15. Notwithstanding anything to the contrary in this Section 15.5, the total aggregate liability of HOVIONE to ACHAOGEN for all losses under this Agreement in relation to liabilities, damages, indemnities, or recall costs, of any type and pursuant to any legal theories or remedies, shall be limited to the lesser of (a) the aggregate amount of Commercial Liability Insurance and Contract Liability Insurance (U.S. [***]) required to be maintained under

Confidential Treatment Requested by Achaogen, Inc.

this Agreement; or (b) the amount of consideration actually paid by ACHAOGEN to HOVIONE under this Agreement in the [***] period immediately preceding the date of the Claim.

ARTICLE 16

CONFIDENTIALITY; INSIDER TRADING

16.1

Definition. “Confidential Information” means any scientific, technical, trade, or business information which is disclosed by one Party (“Disclosing Party”) to the other (“Receiving Party”) and which is treated by the Disclosing Party as confidential or proprietary. Confidential Information does not include information that (a) is in possession of the Receiving Party at the time of disclosure, as reasonably demonstrated by written records and without obligation of confidentiality; (b) is part of the public domain at the time of the Receiving Party’s public disclosure through no fault of the Receiving Party; (c) is received by the Receiving Party from a third party who has no obligation of confidentiality to the Disclosing Party; or (d) is developed independently by the Receiving Party without use of, reference to, or reliance upon the Disclosing Party’s Confidential Information. The Disclosing Party will, to the extent practical, use reasonable efforts to label or identify as confidential, at the time of disclosure all such Confidential Information that is disclosed in writing or other tangible form. Confidential Information of HOVIONE includes, but is not limited to, HOVIONE’s Background Intellectual Property, HOVIONE’s Technology, and HOVIONE’s Improvements, whether or not labeled confidential. Confidential Information of ACHAOGEN includes, but is not limited to, ACHAOGEN’s Background Intellectual Property, ACHAOGEN’s Technology, and Refinements, whether or not labeled confidential. This Agreement shall be Confidential Information of both Parties.

16.2

Restrictions . The Receiving Party agrees (a) to keep confidential the Confidential Information of the Disclosing Party and the terms of this Agreement; (b) not to disclose the Disclosing Party’s Confidential Information to any third party without the prior written consent of such Disclosing Party; and (c) to use such Confidential Information only as necessary to fulfill its obligations or in the reasonable exercise of rights granted to it hereunder. A Receiving Party, however, may disclose Confidential Information of the Disclosing Party to its employees and consultants and to those of its Affiliates, in each case who have a specific need to know such Confidential Information and who are bound by a like obligation of confidentiality and restriction on use. Neither Party will use the other Party’s Confidential Information in support of regulatory filings without the express written consent of the other Party.

16.3

Compelled Disclosure. In the event that the Receiving Party is required (by oral questions, interrogatories, request for information or documents, subpoena, civil investigative demand, or similar legal or regulatory process, or by rule of any stock exchange or listing entity) to disclose any of the Disclosing Party’s Confidential Information, the Receiving Party shall give the Disclosing Party prompt notice thereof so that the Disclosing Party may seek an appropriate protective order. Recipient shall

Confidential Treatment Requested by Achaogen, Inc.

reasonably cooperate with the Disclosing Party in its efforts to seek such a protective order.

16.4

Term of Restriction. The obligations of the Receiving Party under this Agreement with respect to each item of Confidential Information that is subject to the nondisclosure and non-use provisions set forth above shall extend for a period of [***] from the date of initial disclosure to the Disclosing Party of such item; provided, however, that with respect to information provided (a) which constitutes chemical structures; or (b) which is in written form under this Agreement and specifically identified by the Disclosing Party as trade secret information, the Receiving Party’s obligations shall extend thereafter until such information no longer constitutes a trade secret under Applicable Laws.

16.5

No Public Disclosure. Except to the extent required by Applicable Laws or any rule of any stock exchange or listing entity and as otherwise provided in this ARTICLE 16, neither Party shall make any public statements or releases concerning this Agreement or the transactions contemplated by this Agreement without obtaining the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed. Notwithstanding anything herein to the contrary, ACHAOGEN shall be free to use HOVIONE’s name and make mention of the existence of this Agreement as necessary or appropriate in connection with any regulatory filings, approvals, or other regulatory matters, and ACHAOGEN shall be free to disclose information concerning this Agreement as reasonably necessary to ensure and/or exercise its intellectual property rights under this Agreement, and in discussions relating to the Product with potential or actual collaborators/investors and counsel.

16.6

Insider Trading. The Receiving Party acknowledges that during the performance of this Agreement it may come into possession of certain material information about the Disclosing Party or its Affiliates that has not yet been disclosed to the public. The Receiving Party agrees to comply with the rules and regulations of the United States Securities and Exchange Commission, including those relating to insider trading, for as long as the Receiving Party is in the possession of such material, non-public information about the Disclosing Party or its Affiliates. The Receiving Party is hereby notified that it should not trade in securities of the Disclosing Party that might be issued in the future, either on its own behalf or on the behalf of others while in possession of any such material, non-public information.

ARTICLE 17

FORCE MAJEURE

17.1

Effects of Force Majeure. Except for the obligation to pay any amounts due under this Agreement, neither Party shall be held liable or responsible for failure or delay in fulfilling or performing any of its obligations under this Agreement in case such failure or delay is due to any condition beyond the reasonable control of the affected Party including, without limitation, acts of God, acts of war or terrorism, fire, explosion, flood, earthquake, embargoes, shortages, epidemics, quarantines, civil commotion, strikes, or acts, omissions, or delays in acting, by any Governmental Authority (which acts,

Confidential Treatment Requested by Achaogen, Inc.

omissions, or delays do not arise from such Party’s breach of this Agreement), and labor disputes (a “Force Majeure Event”). Such excuse shall continue as long as the Force Majeure Event continues. Upon cessation of such Force Majeure Event, such Party shall promptly resume performance hereunder.

17.2

Notice of Force Majeure Event. Each Party agrees to give the other Party written notice, promptly following its first knowledge of any Force Majeure Event, as to the nature thereof, and the extent to which the affected Party expects to be unable fully to perform its obligations hereunder. The Party experiencing any such Force Majeure Event further agrees (a) to use Commercially Reasonable Efforts to promptly correct the Force Majeure Event; (b) to give the other Party periodic updates including notice when it expects to be fully able to perform such obligations; and (c) to continue to perform its obligations to the extent feasible given the Force Majeure Event. In the event a Force Majeure Event continues for more than [***], the non-affected Party may terminate this Agreement upon ten (10) days’ written notice. The Parties acknowledge and agree that in the event of a Force Majeure Event, if ACHAOGEN determines, based upon a convincing demonstration by HOVIONE, that HOVIONE can fulfill its obligations hereunder through the use of an alternate facility owned by HOVIONE at no additional cost to ACHAOGEN or delay relative to ACHAOGEN’s or its Affiliates’ market inventory needs, then HOVIONE may use such facility until such Force Majeure Event has been resolved.

ARTICLE 18

MUTUAL REPRESENTATIONS

18.1	Each Party hereby represents, warrants and covenants to the other Party as follows throughout the Term of this Agreement:

18.1.1

Organization. It is duly organized, validly existing and in good standing under the laws of the jurisdiction of incorporation or organization. Such Party has the requisite legal and corporate power and authority to conduct its business as presently being conducted, and as proposed to be conducted by it, and is duly qualified to do business in those jurisdictions where its ownership of property or the conduct of its business requires.

18.1.2

Authority. It has all requisite legal and corporate power and authority to enter into this Agreement and to perform the services contemplated hereunder. All corporate actions on the part of such Party, the boards of directors or managers, or similar governing body of such Party and the equity holders of such Party necessary for: (a) the authorization, execution, delivery, and performance by such Party of this Agreement; and (b) the consummation of the transactions contemplated hereby, have been duly taken.

18.1.3

Binding Obligation. This Agreement is a legally valid and binding obligation of such Party, enforceable against such Party in accordance with its terms.

Confidential Treatment Requested by Achaogen, Inc.

18.1.4

No Conflicts. None of the execution and delivery of this Agreement, the consummation of the transactions provided for herein or contemplated hereby, or the fulfillment by such Party of the terms hereof or thereof, will (with or without notice or passage of time or both): (a) conflict with or result in a breach of any provision of the certificate or articles of incorporation or formation, by-laws, statutes, operating agreement, or other governing documents of such Party; (b) result in a breach, constitute a breach under, give rise to any right of termination, cancellation or acceleration, or require any consent or approval (other than approvals that have heretofore been obtained) of any Governmental Authority or under any of the terms, conditions, or provisions of any material note, bond, mortgage, indenture, loan, arrangement, license, agreement, lease, or other instrument or obligation to which such Party is a party or by which its assets may be bound; or (c) violate any law or regulation applicable to such Party or any of its assets.

18.1.5

Consents and Approvals. All material consents, approvals, qualifications, orders or authorizations of, filings with, or notices to any Governmental Authority or any other person required in connection with such Party’s execution, delivery, or performance of: (a) this Agreement; and (b) the consummation of any other transaction contemplated on the part of such Party hereby, have been obtained, made or given.

18.1.6

No Violation of Law; Permits. Such Party is not in violation of any law or regulation (nor is such Party aware of any violation of any law or regulation by any other person), which violation could reasonably be expected to adversely affect such Party’s performance of its obligations hereunder or the ability of the other Party to realize the intended benefits to such other Party under this Agreement, and, except as otherwise contemplated hereby, such Party holds each of the licenses, permits, approvals, or authorizations necessary with respect to its current business and operations (and its rights and obligations contemplated hereby) in compliance with all laws and regulations.

ARTICLE 19

DISPUTE RESOLUTION

19.1

Dispute Resolution. The Parties recognize that bona fide disputes may arise which relate to the Parties’ rights and obligations under this Agreement. Except as otherwise expressly set forth in this Agreement including, prior to proceeding under Section 19.2, try to settle such dispute amicably among themselves by referring such dispute, controversy or claim (a “Dispute”) (a) to the Development Project Team or the Supply Committee for resolution; and (b) if the Development Project Team or the Supply Committee fails to come to consensus on such Dispute within [***] of referral, then referring such Dispute to the Parties’ respective chief executive officers, or any other executive officer designated by such chief executive officer (the “Executive Officers”). A dispute shall be referred to such Executive Officers upon one Party providing the other Party with written notice of referral of such Dispute to the Executive Officers. The Parties agree to attempt

Confidential Treatment Requested by Achaogen, Inc.

to resolve such Dispute through good faith discussions. If the Executive Officers fail to come to consensus on such Dispute within [***] of receipt of such written notice then either Party is free to initiate the dispute resolution procedures set forth in this ARTICLE 19.

19.2

Arbitration. Except as otherwise expressly set forth in this Agreement, all controversies, disputes, or claims arising out of or relating to this Agreement or any alleged breach hereof, will be settled by binding arbitration administered by the American Arbitration Association (“AAA”) in accordance with the then current Commercial Arbitration Rules of the American Arbitration Association except that, to the extent such rules are inconsistent with this ARTICLE 19, this ARTICLE 19 will control. The following rules will apply to any such arbitration:

(a)

Any demand for arbitration must be made in writing to the other Party.

(b)

There will be [***], [***] and [***]. If the [***] cannot agree on the appointment of the [***] within [***], then the AAA shall select the arbitrator. [***] will have at least (i) [***] of dispute resolution experience (including judicial experience); or (ii) [***] legal or business experience in the biotech or pharmaceutical industry. Any arbitration involving patent rights, other intellectual property rights, or intellectual property will be heard by arbitrators who are experienced in such areas.

(c)

The arbitration will be held in [***], or such other place as the Parties agree. The arbitrators will apply the substantive law specified in Section 21.13 except that the interpretation and enforcement of this arbitration provision will be governed by the United States Federal Arbitration Act, 9 U.S.C. Section 1 et. seq.

(d)

Electronic documents shall normally be furnished on the basis of generally available technology in a searchable format that is usable by the Party receiving it and convenient and economical for the producing Party. When the cost and burden of e-discovery are disproportionate to the likely importance of the requested materials, the arbitrators may deny the requests or require that the requesting Party advance the reasonable cost of production to the other side.

(e)

The arbitrators shall not have the authority to modify any provision of this Agreement or to award punitive damages. In no event shall either party be liable for special, consequential, or incidental damages, or lost profits. The arbitrators shall have the power to issue mandatory orders and restraint orders in connection with the arbitration.

(f)

There shall be a stenographic record of the proceedings. The decision of the arbitrators will be final and binding upon both Parties. The arbitrators will render a written opinion setting forth findings of fact and conclusions of law on each issue. Each Party agrees that, notwithstanding any provision of applicable law, it will not request, and the arbitrators shall have no authority to award damages

Confidential Treatment Requested by Achaogen, Inc.

against any Party that exceed the limits set forth in Section 15.5, to the extent applicable.

(g)

A final award shall be issued no later than [***] from the date the claimant Party files its demand for arbitration.

(h)

The expenses of the arbitration will be [***]. Each Party will [***].

(i)

The award shall be final and binding on the Parties, and judgment upon the award rendered by the arbitrators may be entered in any court of competent jurisdiction. The proceedings and the final award shall be confidential.

(j)

During the continuance of any arbitration proceeding, the Parties shall continue to perform their respective obligations under this Agreement to the greatest extent practicable.

19.3

Arbitrability. The question of arbitrability and whether a claim, dispute, or other matter in question would be barred by the applicable statute of limitations, which statute of limitations also shall apply to any claim or disputes subject to arbitration under this Agreement, shall be determined by binding arbitration pursuant to this ARTICLE 19.

19.4

Injunctive Relief. Notwithstanding anything to the contrary in this ARTICLE 19, a Party may seek immediate injunctive or other interim relief from any court of competent jurisdiction, without resort to dispute resolution under this Article as necessary to enforce and prevent infringement of Intellectual Property Rights owned or Controlled by a Party or its Affiliates, or to prevent breach of ARTICLE 16 (Confidentiality).

ARTICLE 20

BARDA REQUIREMENTS

20.1

Government Projects. For certain Services, ACHAOGEN may engage HOVIONE as a subcontractor to certain projects under the Prime Contract by mutual execution of a Work Plan. Any Work Plan under which HOVIONE is acting as a subcontractor shall be a “Government Project”, and such Government Projects will be expressly identified as such within the applicable Work Plan. For the avoidance of doubt, the commercial Manufacturing and supply of the Product shall not be a Government Project.

20.2

Government Contract Clauses. HOVIONE acknowledges that when performing a Government Project, HOVIONE will be subject to and must abide by the terms set forth at Appendix A known as “Government Contract Clauses.” The Government Contract Clauses shall only be amended by the mutual written agreement of the Parties.

20.3

Government Inspections; Correspondence. Notwithstanding the provisions of ARTICLE 11, in the event the Facility is inspected by representatives of the FDA or other U.S. Government agency, and such inspection relates to HOVIONE’s processes for the Manufacture of the Product or any portion of the Facility directly related to the

Confidential Treatment Requested by Achaogen, Inc.

Manufacture of the Product, HOVIONE shall notify ACHAOGEN as soon as reasonably practicable, but in no event later than [***] (by telephone, and if possible, in writing) upon learning of such inspection. HOVIONE shall provide ACHAOGEN (which ACHAOGEN will provide to BARDA) with electronic copies of all written materials and correspondence received from or sent to the FDA or other U.S. Government agency relating to any such inspection; provided however, that the documentation contains information relating to any of HOVIONE’s manufacturing process(es) used in the Manufacture of the Product or which may have an effect on HOVIONE’s ability to supply the Product to ACHAOGEN (“Relevant Information”) and provided further, that HOVIONE may redact any information that does not qualify as Relevant Information. To the extent reasonably practicable, HOVIONE shall share with ACHAOGEN drafts of any written materials in advance of submitting such materials to the FDA or other U.S. Government agency so as to allow for review and comment by ACHAOGEN and/or BARDA. The Parties shall consult regarding the nature, extent, duration, and possible impact of such inspection on the development and manufacture of the Product so as to determine whether ACHAOGEN and/or BARDA may have an interest to send representatives to the Facility and be present for any part of such inspection.

20.4

All BARDA requirements applicable to HOVIONE as contained in this Agreement shall only be applicable for so long as ACHAOGEN has ongoing obligations to BARDA. ACHAOGEN agrees to notify HOVIONE as soon as reasonably practicable for any BARDA requirements that are no longer applicable after commercial launch of the Product.

ARTICLE 21

MISCELLANEOUS

21.1

Independent Contractors. The relationship between ACHAOGEN and HOVIONE is that of independent contractors and nothing herein shall be deemed to constitute the relationship of partners, joint ventures, nor of principal and agent between ACHAOGEN and HOVIONE. Neither Party shall have an express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any contract, agreement or undertaking with any third party.

21.2

Cooperation with Collaboration Partner. HOVIONE acknowledges that ACHAOGEN may have a collaboration partner in conjunction with certain sales of Product outside the United States. HOVIONE agrees to cooperate with such partner as required in matters relating to supply for and regulatory compliance in jurisdictions outside the United States. ACHAOGEN shall [***].

21.3	Performance by Affiliates. The Parties agree that either Party’s rights or obligations hereunder may be exercised or performed by one or more of that Party’s Affiliates; provided that the Party shall remain liable for the performance of any such obligations by any of its Affiliates.

21.4	Assignment.

Confidential Treatment Requested by Achaogen, Inc.

(a)

This Agreement may not be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which shall not be unreasonably withheld); provided, however, either Party may, without such consent, assign this Agreement: (i) to an Affiliate whose performance is guaranteed by such Party; or (ii) in connection with the transfer or sale of all or substantially all of the assets of such Party or the line of business to which this Agreement relates. Any purported assignment in violation of the preceding sentence shall be void. Any permitted assignee shall assume all obligations of its assignor under this Agreement.

(b)

For the avoidance of doubt, in the event ACHAOGEN licenses the Product to one or more third parties, or if ACHAOGEN sells or assigns the business or assets to which this Agreement relates (whether by merger, consolidation, stock sale, asset sale, or otherwise), ACHAOGEN shall not do anything to change the rights and obligations of HOVIONE under this Agreement or to impair HOVIONE’s interests in connection with such assignment. If HOVIONE believes, [***], that any such assignment does impair HOVIONE’s interests, HOVIONE shall have the right to terminate this Agreement by providing ninety (90) days’ written notice to ACHAOGEN (or its assignee or successor) and ACHAOGEN has a further 90 days after the end of written notice of such impairment to cure or ameliorate to HOVIONE’s satisfaction such impairment, if possible.

21.5	Continuing Obligations. Termination, assignment or expiration of this Agreement shall not relieve either Party from full performance of any obligations incurred prior thereto.

21.6	Waiver. Neither Party’s waiver of any breach or failure to enforce any of the terms and conditions of this Agreement, at any time, shall in anyway affect, limit, or waive such Party’s right thereafter to enforce and compel strict compliance with every term and condition of this Agreement.

21.7

Survival. Expiration or termination of this Agreement for any reason shall not relieve either Party of any obligation accruing prior to such expiration or termination, or of any rights and obligations of the Parties that by their terms survive termination or expiration of this Agreement, including, without limitation, Sections 2.7, 8.1, 12.6 and ARTICLE 7 (Ownership and Technology Transfer), ARTICLE 9 (Warranties; Specifications), ARTICLE 11 (Audits), ARTICLE 14 (Recalls; CMC Documentation); ARTICLE 15 (Indemnification; Insurance), ARTICLE 16 (Confidentiality; Insider Trading), ARTICLE 19 (Dispute Resolution), ARTICLE 20 (BARDA Requirements), and this ARTICLE 21 (Miscellaneous).

21.8

Severability. Each Party hereby expressly agrees that it has no intention to violate any public policy, statutory or common laws, rules, regulations, treaty, or decision of any Governmental Authority or executive body thereof of any country or community or association of countries, and that if any word, sentence, paragraph, clause, or combination thereof in this Agreement is found by a court or executive body with judicial powers having jurisdiction over this Agreement or either Party hereto, in a final unappealed order, to be in violation of any such provisions in any country or community

Confidential Treatment Requested by Achaogen, Inc.

or association of countries, such words, sentences, paragraphs, clauses, or combination shall be inoperative in such country or community or association of countries and the remainder of this Agreement shall remain binding upon the Parties, so long as enforcement of the remainder does not violate the Parties’ overall intentions in this transaction.

21.9	Headings and Construction. The headings in this Agreement are for convenience of reference only and shall not affect its interpretation. Both Parties participated equally in the formation of this Agreement, and the language of this Agreement shall not be presumptively construed against either Party

21.10

Exhibits. All exhibits referred to herein form an integral part of this Agreement and are incorporated into this Agreement by such reference.

21.11

Notices. All notices required to be given under this Agreement shall be in writing and shall be delivered personally or sent by: (i) registered or certified mail, return receipt requested; (ii) a nationally-recognized courier service guaranteeing next-day delivery, charges prepaid; or (iii) electronically (with the original sent within [***] by either of the two foregoing manners), and shall be deemed to have been given when delivered if delivered personally, by mail or by courier, or electronically, as the case may be. Any such notices shall be addressed to the receiving Party at such Party’s address set forth below, or at such other address as may from time to time be furnished by similar notice by either Party.

If to HOVIONE:

Hovione LLC
40 Lake Drive
East Windsor, NJ 08520
USA
Attn: [***]
Email:[***]

And to:

[***]
Attn: [***]
Email: [***]

If to ACHAOGEN:

Achaogen, Inc.
7000 Shoreline Court, Suite 371
South San Francisco, CA 94080
USA
Attn: [***]
Email: [***]

With a copy to:

Achaogen, Inc.
7000 Shoreline Court, Suite 371
South San Francisco, CA 94080

Confidential Treatment Requested by Achaogen, Inc.

USA
Attn: [***]

Email: [***]

21.12

Counterparts. This Agreement and any amendment or supplement hereto may be executed in any number of counterparts, and any Party hereto may execute any such counterpart, each of which when executed and delivered shall be deemed to be an original and all of which counterparts taken together shall constitute but one and the same instrument. The execution of this Agreement and any such amendment or supplement by any Party hereto will not become effective until counterparts hereof have been executed by both Parties hereto.

21.13

Compliance with Anti-Corruption Practices. Each Party represents and warrants that it and its subsidiaries, officers, directors, agents, and subcontractors (collectively “Affiliates”) are aware of the provisions of the United States Foreign Corrupt Practices Act of 1977, as amended (15 U.S.C. § 78 et seq.) (“FCPA”). The Parties have not and will not commit any violation of the FCPA and/or any other anti-corruption or anti-bribery laws applicable to ACHAOGEN or HOVIONE in any other jurisdiction (the FCPA and such other similar laws, collectively, “Anti-Corruption Laws”) or any act or omission which could cause the Parties to be in violation of any Anti-Corruption Laws with respect to any activities related to the Agreement. Each Party further represents and warrants that it and its Affiliates will not, directly or indirectly, pay, promise to pay, or authorize the payment or giving of anything of value to any official or employee of any government except in exchange for legitimate services provided.

21.14

Governing Law. The validity, interpretation and performance of this Agreement shall be governed and construed in accordance with the laws of the State of New York, without regard to the conflicts of law provisions thereof. The Parties agree that the provisions of the United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement, and are hereby expressly excluded.

21.15

Entire Agreement. This document, along with the Exhibits, constitute the full understanding of the Parties and a complete and exclusive statement of the terms of the Parties’ agreement with respect to the subject matter herein. Without limiting the generality of the foregoing, this Agreement supersedes in its entirety the Confidentiality Agreement [***], and entered into by and between ACHAOGEN and HOVIONE (it being agreed that disclosures under the Confidentiality Agreement shall be treated confidentially after the Effective Date as though they were made under this Agreement). No terms, conditions, understanding, or agreement purporting to modify or vary the terms of this Agreement shall be binding unless hereafter made in writing and signed by the Parties. No modification to this Agreement shall be effected by the acknowledgment or acceptance of any purchase order or shipping instruction forms or similar documents containing terms or conditions at variance with or in addition to those set forth herein.

21.16

Further Action. Each Party hereto shall take, or cause to be taken, all actions, and do, or cause to be done, all things reasonably necessary, proper or advisable under applicable laws and regulations, and execute and deliver such further documents as may be

Confidential Treatment Requested by Achaogen, Inc.

reasonably requested by the other Party in connection with the operation of this Agreement.

THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK

Confidential Treatment Requested by Achaogen, Inc.

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as of the Effective Date.

ACHAOGEN, INC.

By: /s/ Blake Wise

Title: COO

Date: 3/9/17

HOVIONE LIMITED

By: /s/ Guy Villax

Title: Chief Executive

Date: Zurich, 6^th March 2017

Confidential Treatment Requested by Achaogen, Inc.

Exhibit 1

Sample Validation Program Work Plan

Work Plan No. C-XX

This Work Plan No. C-[#] (the “Work Plan”), dated _______________ (the “Effective Date”), is by and between Achaogen, Inc., a company with its principal place of business at 7000 Shoreline Court, Suite 371, South San Francisco, CA, USA (“ACHAOGEN”) and Hovione Limited, a company with its principal place of business at Loughbeg, Ringaskiddy, Cork, County Cork, Ireland (“HOVIONE”), and upon execution by both Parties, shall be incorporated into the Validation and Manufacturing Agreement between ACHAOGEN and HOVIONE dated _____ November, 2016 (the “Manufacturing Agreement”). Capitalized terms used in this Order shall have the meanings ascribed to them in the Agreement.

ACHAOGEN hereby engages HOVIONE to provide Services as follows:

1.	Work Plan. This agreement constitutes a “Work Plan” under the Manufacturing Agreement, and this Work Plan and the Services contemplated herein are subject to the terms and provisions of the Manufacturing Agreement.

2.	Services and Payment of Fees and Expenses. The specific services contemplated by this Work Plan (the “Services”) and the related payment terms and obligations are set forth on the following attachments, which are incorporated herein by reference:

SCOPE OF WORKAttachment 1

PROJECT BUDGETAttachment 2

PAYMENT SCHEDULEAttachment 3

3.	Delivery Date. HOVIONE shall [***] deliver to ACHAOGEN [description of the deliverable] by not later than [delivery date(s) or schedule of delivery dates] and a final report by not later than [delivery date(s) or schedule of delivery dates.

4.	Price. As consideration for HOVIONE conducting the Services described in this Order, ACHAOGEN shall pay to HOVIONE an amount not to exceed [Insert written amount; include shipping and taxes, if applicable] US dollars ($ numerical amount])

[Insert payment schedule if not [***].]

5.	Term. The term of this Work Plan shall commence on the Effective Date and shall continue until the Services described in Attachment 1 are completed, unless this Work Plan is terminated in accordance with the following terms:

Exhibit 1-1

Confidential Treatment Requested by Achaogen, Inc.

Upon termination of a Work Plan under this Section 5(a), HOVIONE will immediately: (i) cease work under the Work Plan; (ii) prepare and submit to ACHAOGEN an itemization of all completed and partially completed deliverables and Services; (iii) deliver to ACHAOGEN any and all work completed under the Work Plan up to the date of termination at the agreed upon prices; and (iv) deliver upon request any work in process.

In no event shall ACHAOGEN be liable for lost or anticipated profits, unabsorbed indirect costs or overhead, or for any sum in excess of the total Work Plan price.

In the event of a material breach of this Work Plan by either Party, the other Party may terminate this Agreement immediately if the material breach is not cured within thirty (30) days’ written notice.

In the event of termination of any Work Plan, ACHAOGEN will compensate HOVIONE for all Services performed thereunder, [***] under this subsection.

If the Manufacturing Agreement is terminated or expires, but this Work Plan is not terminated or completed, then the terms of the Manufacturing Agreement shall continue to apply to this Work Plan until the Work Plan is either terminated or completed.

6.	Project Contacts.

The primary contact at ACHAOGEN will be [name, title], [email], [phone].

The primary contact at HOVIONE will be [name, title], [email], [phone].

7.	Government Projects. Pursuant to ARTICLE 20 of the Manufacturing Agreement, this Work Plan is/is not a “Government Project”.

8.	Entire Agreement. This Work Plan, along with the Attachments and the Manufacturing Agreement, constitute the full understanding of the Parties and a complete and exclusive statement of the terms of the Parties’ agreement with respect to the subject matter herein.

9.	Amendments. No modification, amendment, or waiver of this Work Plan shall be effective unless in writing and duly executed and delivered by each party to the other.

Following the full execution of this Order, any change to the price must be agreed to in writing by the parties. [***]

Exhibit 1-2

Confidential Treatment Requested by Achaogen, Inc.

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized representatives as of the Effective Date.

ACHAOGEN, INC.

By:

Title:

Date:

HOVIONE LIMITED

By:

Title:

Date:

Exhibit 1-3

Confidential Treatment Requested by Achaogen, Inc.

Exhibit 2

Specifications

[TBD]

Exhibit 2-1

Confidential Treatment Requested by Achaogen, Inc.

Exhibit 3

Quality Agreement

To Be Subsequently Attached
No Later Than March 31, 2017

QUALITY AGREEMENT

between

HOVIONE [***] (hereafter HOVIONE")

and

ACHAOGEN,INC,

located at 7000 Shoreline Court. #371, South San Francisco, CA 94080, United States of

America (hereafter “ACHAOGEN”)

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

1 of 40

Exhibit 3-1

Confidential Treatment Requested by Achaogen, Inc.

Approvals

[***]

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

2 of 40

Exhibit 3-2

Confidential Treatment Requested by Achaogen, Inc.

Table of Contents

1.	Introduction/Purpose/Scope	6

	Introduction	6

	Purpose	6

	Scope of the Agreement	6

	Product Covered by the Quality Agreement	6

	Applicable Laws	6

	Term of Agreement	7

2.	Definitions and Abbreviations	7

3.	Roles and Responsibilities	8

3.1.	Training	8

3.2.	Facilities	8

3.3.	Manufacturing Equipment	8

3.4.	HAPIs	9

3.5.	Qualification / Validation	9

3.6.	Batch Manufacturing	10

3.7.	Stability	10

3.8.	Controlled Documents	11

3.9.	Change Control	12

3.10.	Retention of records/documentation	13

3.11.	Annual Product Quality Review	13

3.12.	Subcontracting	14

3.13.	Access to Manufacturing Facilities	14

3.14.	Resolution of Quality Issues	14

4.	General Requirements	14

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

3 of 40

Exhibit 3-3

Confidential Treatment Requested by Achaogen, Inc.

4.1.	Specifications	14

4.2.	Analytical methods	15

4.3.	Reference standards	15

4.4.	Raw materials	15

4.5.	Starting Materials	16

4.6.	Process Validation Program	17

4.7.	Undesirable contaminants	17

4.8.	Deviations / OOS (incl. stability)	17

4.9.	Reference (Product) and Retention of samples (final Product)	19

4.10.	Storage and Distribution	19

4.11.	Certificate of Analysis	19

4.12.	Product Release	20

4.13.	Reprocessing	21

4.14.	Reworking	21

4.15.	Packaging	21

4.16.	Labelling	21

4.17.	Product Rejection	22

4.18.	Laboratory Control	22

5.	Complaints and Recalls	22

5.1.	Complaints	22

5.2.	Recall	23

6.	Compliance and Regulatory Requirements	23

6.1.	Applicable GMP Standard	23

6.2.	Regulatory documents	24

7.	Audits and Inspections	24

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

4 of 40

Exhibit 3-4

Confidential Treatment Requested by Achaogen, Inc.

7.1.	ACHAOGEN’s Right to Audit	24

7.2.	Authority Inspections	25

8.	Miscellaneous Provisions	26

8.1.	Assignment	26

8.2.	Related agreements	26

8.3.	Confidentiality	27

8.4.	Choice of Law	27

8.5.	Debarment Certification	27

8.6.	BARDA Requirements	27

8.7.	Entire Agreement	28

8.8.	Amendments and Supplements	28

9.	Contacts	29

10.	List of Appendices	29

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

5 of 40

Exhibit 3-5

Confidential Treatment Requested by Achaogen, Inc.

1.	Introduction/Purpose/Scope

Introduction

ACHAOGEN and HOVIONE are Parties to this Quality Agreement (the “Quality Agreement”). The Quality Agreement covers the validation, manufacturing, analytical testing, stability, packaging and supply of the Drug Substance (as defined below), as well as certain regulatory activities for Drug Substance.

Purpose

The purpose of this Quality Agreement is to define the roles and responsibilities of each Party under the Validation and Manufacturing Agreement, between ACHAOGEN and Hovione International Limited, an Affiliate of HOVIONE, still under discussion (the “Manufacturing Agreement”). This Quality Agreement will also define the required technical quality arrangements between HOVIONE and ACHAOGEN for managing the quality systems.

The purpose of this agreement is to establish the Quality Agreement, required by Section 2.4 of the Manufacturing Agreement, regarding the validation, manufacturing, testing, packaging and supply of the drug substance (DS), Plazomicin [***]. This agreement outlines the responsibilities of HOVIONE and ACHAOGEN with respect to the quality of the aforementioned OS and the interface between the parties.

Scope of the Agreement

The scope of this Quality Agreement is to cover the essential quality requirements pertinent to the manufacture of Drug Substance intended to be used as the registration / validation batches, and Drug Substance for commercial production. It includes all aspects of process development, manufacturing, analytical testing, storage, release, stability and regulatory activities. This agreement delineates the responsibilities and the channels of communication between the Parties.

Product Covered by the Quality Agreement

This Quality Agreement covers the following Product

Product: Plazomlcin [***]

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

6 of 40

Exhibit 3-6

Confidential Treatment Requested by Achaogen, Inc.

Applicable Laws

HOVIONE shall manufacture Product and control Product quality in compliance with the technical information provided by ACHAOGEN and in compliance with Applicable Laws.

Term of Agreement

This Quality Agreement shall become effective and binding upon the date of the final approval signature and shall remain in effect until two (2) years after the last delivery of Product by HOVIONE to ACHAOGEN under the Manufacturing Agreement, unless the Parties specifically agree in writing an extension of the Quality Agreement.

2.	Definitions and Abbreviations

Capitalized terms used but not defined herein are used as defined in the Manufacturing Agreement. The following terms (in addition to such other terms as are specifically defined within the Quality Agreement), whether used in the singular or plural, shall have the meanings assigned to them below for purposes of this Agreement:

Drug substance (DS): Any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient.

HOVIONE’s Quality System: The Quality System for management of facilities, personnel and procedures, including current SOPs.

Intermediate Drug Substance (IDS): A material produced during steps of the processing of an Active Pharmaceutical Ingredient (API) or Drug Substance that undergoes further molecular change or purification before it becomes an API. May or may not be isolated.

Major/Critical Change: A change to a validated system or process that has the potential to impact Product quality. Additionally, any change that has the potential to impact the regulatory filing.

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

7 of 40

Exhibit 3-7

Confidential Treatment Requested by Achaogen, Inc.

Major/Critical Deviation: A deviation that has the potential to impact the quality of the Product. Additionally, it includes a deviation that has the potential to impact the stability program or regulatory filing.

Out-of-specification (OOS) result: any test result that does not conform to the current specification limit.

Raw materials (RM): A general term used to denote starting materials, reagents, excipients, solvents and primary and secondary packaging material intended for use in the production of any DS or DP.

Specifications: The analytical release criteria defined in the technical agreement by which the Product will be accepted by ACHAOGEN.

3.	Roles and Responsibilities

3.1.

Training

HOVIONE shall insure that all personnel engaging in the manufacture, testing, processing, packing, or storage of the Product have the required education, training, and experience or any combination thereof, to perform the assigned functions. All training relative to a specific task will be completed prior to the initiation of the task. Training will be conducted with sufficient frequency meeting cGMP requirements applicable to the position and function. Training records shall be readily available for review and audits.

3.2.

Facilities

Facilities shall be properly maintained, including general cleanliness, maintenance and monitoring of water and environmental control systems (as appropriate) per cGMP requirements. HOVIONE shall perform qualification/validation (revalidation requirements), monitoring, calibration and maintenance (preventative and repair) for all plant utility systems, including but not limited to purified water, HVAC, clean steam and process compressed air, and QC equipment. Such work to be conducted within the established timeframes appropriate to the significance of the system and the equipment.

HOVIONE will follow its Facility and manufacturing processes, which are designed and operated to minimize risk of contamination (general), microbial contamination, cross-over contamination (between products) and/or carry-over contamination (between batches of the Product). This includes robust cleaning

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

8 of 40

Exhibit 3-8

Confidential Treatment Requested by Achaogen, Inc.

methods for manufacturing equipment, line/room clearance procedures and change-over (between product campaign) procedures. Product shall be manufactured in a GMP manufacturing area.

The product will be manufactured, packaged, labeled, tested, and stored, if agreed upon, at the HOVIONE’s Facility covered by this Quality Agreement. HOVIONE shall not use third parties or other sites for the manufacturing, packaging, labeling, testing and storage of the Product without prior written agreement by ACHAOGEN.

ACHAOGEN must be notified in advance of any modifications to the Facility that directly impact the Product or the Product’s regulatory filings. Modifications that impact the Product’s regulatory filings must be pre-approved by ACHAOGEN.

3.3.

Manufacturing Equipment

All equipment used for the manufacture of Product shall be qualified before use. For all manufacturing, testing, packaging, storage, equipment and facilities, HOVIONE shall operate per written, approved procedures such as equipment qualification/validation, preventative maintenance, instrument calibration, cleaning, and revalidation requirements.

HOVIONE shall perform cleaning verification for manufacturing equipment used for Product manufacturing. For non-dedicated equipment, this shall include potential impact from other products using the same equipment.

All equipment used for the manufacture of the Product shall undergo equipment cleaning per HOVIONE’s Standard Operating Procedures ("SOPs") and requirements and be verified clean by HOVIONE as meeting the required specifications for residual active ingredient and residual cleaning agent before use.

HOVIONE shall be responsible for completing and maintaining records of equipment usage, calibration, qualification and cleaning.

HOVIONE shall notify ACHAOGEN of any Major/Critical Changes or modifications to equipment that directly impact the Product quality and obtain ACHAOGEN’s approval before the equipment is used to Manufacture the Product.

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

9 of 40

Exhibit 3-9

Confidential Treatment Requested by Achaogen, Inc.

3.4.

HAPIs

HOVIONE shall not conduct production and handling of highly sensitizing materials (such as penicillins, cytotoxics or cephalosporins) in the equipment being used for the manufacturing of Product. Manufacturing of such materials in the same building being used for the Product is permitted only if performed in a closed and dedicated system.

For any other type of materials manufactured by HOVIONE in the same facilities as used for Product, validated inactivation and/or cleaning procedures and appropriate containment shall be in place.

3.5.

Qualification / Validation

HOVIONE shall insure that equipment qualification, process validation, analytical methods validation and validation of computerized systems, if applicable, are in place and covered by change control. Validation documentation related to the process and/or analytical method validation shall be reviewed and approved by ACHAOGEN. On request, ACHAOGEN will get copies or summaries from the validation reports, as applicable.

3.6.

Batch Manufacturing

All Master Batch Records ("MBR") will be created by HOVIONE, and submitted to ACHAOGEN Technical, Regulatory Affairs (RA) and QA representatives for review and approval. Once approved by both HOVIONE and ACHAOGEN, HOVIONE Manufacturing and QA will submit the MBR to Document Control for approval, issuance and security.

In the event of a deviation that directly impacts product quality during processing, ACHAOGEN Technical and QA Representative shall be notified to ACHAOGEN within [***] and an investigation is to be initiated. Review and approvals of deviation reports are required from both HOVIONE and ACHAOGEN Technical and QA.

Executed batch records ("EBR") shall be reviewed by manufacturing and approved by HOVIONE and ACHAOGEN QA to determine completeness and compliance with all established, approved written procedures and specifications.

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

10 of 40

Exhibit 3-10

Confidential Treatment Requested by Achaogen, Inc.

Any unexplained discrepancy (including a percentage of theoretical yield exceeding the maximum or minimum percentages if established in MBR) or the failure of a batch to meet any of its specifications shall be thoroughly investigated, and the documentation will become part of the EBR.

HOVIONE will complete the analytical release testing and review of the records and related documents within [***] of the completion of production date. A copy of the HOVIONE reviewed production record and lot-specific analytical results will be sent to ACHAOGEN after HOVIONE review is complete. The final supplied production record should contain copies of the following documents:

•

HOVIONE-reviewed and approved EBR and all supporting documentation (raw material and packaging materials CoA, environment monitoring records, etc.);

•

Deviation or investigation reports related to the lot as required;

•

Release Certificate of Analysis reviewed by HOVIONE QA, including raw data as requested.

3.7.

Stability

HOVIONE is responsible for performing stability studies for the product as per ICH guidelines and ACHAOGEN requirements, approved stability protocols and as per internal procedures.

HOVIONE is responsible for assigning re-evaluation dates to the Product or extending the retest date of the Product and for determining suitable storage and shipping conditions, based upon stability studies and ACHAOGEN approval.

HOVIONE is responsible for generating stability protocols, methods and specifications.

HOVIONE and ACHAOGEN is responsible for approving stability protocols, stability reports, methods and specifications in a timely manner.

HOVIONE will upon request or at least [***] provide updated data from the stability program to ACHAOGEN.

HOVIONE will inform ACHAOGEN if there are any adverse trends that could impact on current retest date.

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

11 of 40

Exhibit 3-11

Confidential Treatment Requested by Achaogen, Inc.

Stability Protocol: The material will be placed on stability only after the stability protocol for that lot of the Product has been signed and approved by HOVIONE and ACHAOGEN. The number of Batches to be placed on stability will required discussion between Hovione and ACHAOGEN.

Stability Testing & Report: Hovione will conduct the stability testing as per the approved stability protocol and current approved test methods for the lot. After HOVIONE review of the stability results is complete, a copy of the analytical results summary and the updated stability table summarizing all the stability results for that lot with HOVIONE review signatures will be sent to ACHAOGEN Technical and QA Representatives for review and approval. Once the stability study is completed, a final stability report will be prepared by HOVIONE and sent to ACHAOGEN for review and approval.

Deviation/OOS/Other Investigation: In the event of any stability incident, HOVIONE shall communicate issue and proposed actions to ACHAOGEN within [***] of confirmation. HOVIONE shall conduct the investigation per HOVIONE’s SOP and report results to ACHAOGEN as soon as investigation is complete, but not to exceed [***] from confirmation, unless otherwise mutually agreed to.

3.8.

Controlled Documents

All documents used in the production of the Product, from the receiving of raw material to the releasing of the Product are considered controlled documents. Controlled documents consist of the following: receiving documents, test methods, including in-process methods, SOPs, specifications, including in-process specifications, production records, batch records, testing data/records, product reports and protocols, stability protocols and stability reports, and all product support documents. These shall be under revision control (as appropriate) and shall be filed in such a manner as to be traceable. Current SOPs and test methods will be readily accessible to production personnel or QC chemists.

3.9.

Change Control

HOVIONE shall have a documented and effective change control system in place. HOVIONE shall provide advanced notification to ACHAOGEN of any changes to the process, specifications and analytical methods (drug product, API/drug substance, intermediates and Project Specific Raw Materials), storage, labelling,

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

12 of 40

Exhibit 3-12

Confidential Treatment Requested by Achaogen, Inc.

primary packaging, stability protocols and equipment, which may have an impact on the quality of the Product, and/or on any regulatory applications related to the Product to allow ACHAOGEN to assess the impact of the change(s) for approval prior to implementation.

Principles:

☐

Product produced by the new process shall not be accepted unless the process change has first been reviewed and approved by ACHAOGEN.

☐

Change requests shall be supported by appropriate technical documents to support the change and to confirm that technical performance has not been altered.

☐

Modifications relating to Product Specifications shall only take place by mutual consent between the Parties.

☐

For those changes required to comply with Applicable Laws and Regulatory Authority requirements, HOVIONE shall promptly notify ACHAOGEN of such requirements after HOVIONE becomes aware of the need for such change.

☐

ACHAOGEN shall assess any change request received from HOVIONE in a timely manner. Unless there are justified scientific and/or compliance reasons to reject the change request, ACHAOGEN shall not unreasonably withhold its approval of the request.

☐

ACHAOGEN is responsible for the submission of all necessary change notifications to all Regulatory Authorities in full compliance with the applicable regulations, respectively.

☐

ACHAOGEN will inform HOVIONE of the receipt of the necessary acknowledgement of the validity of the regulatory notification and, depending on the type of change, the acceptance or approval of the change by the competent authorities.

☐

ACHAOGEN will notify HOVIONE of any changes to the manufacturing process and/or components supplied by ACHAOGEN used for the manufacturing of the product.

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

13 of 40

Exhibit 3-13

Confidential Treatment Requested by Achaogen, Inc.

☐

ACHAOGEN will provide to HOVIONE copies of the relevant sections of the INDs or NDAs or other regulatory filings and changes thereof.

☐

ACHAOGEN shall provide advanced notification to HOVIONE of any changes to the process, specifications and analytical methods, storage, labelling, primary packaging, stability protocols, which may have an impact on HOVIONE Quality System and/or on any regulatory applications related to the Product to allow HOVIONE to assess the impact of the change upon the product supplied or its Quality System.

3.10.

Retention of records/documentation

HOVIONE will store the original master batch records, the executed batch records, and all other original documentation that is related to the manufacture of Product and that is required to be maintained under cGMP, protected from destruction and unauthorized access, for the time period outlined below:

☐

DS with retest date: for [***] after the batch is completely distributed by HOVIONE;

HOVIONE will retain the original records related to the manufacture of the Product for the entire term of the Manufacturing Agreement. The documentation shall be kept for a minimum of [***] after the Batch is completed. ACHAOGEN will be notified prior to the destruction of any documents to determine disposition of documents at the end of the specified storage period. Upon termination of the Manufacturing Agreement, HOVIONE will provide upon request ACHAOGEN with the original manufacturing records. For the archiving of data, media, diskettes, etc., the original media and backup copies shall be kept in a separate location protected against damage, destruction, and or disposal during the required time of storage. Data media shall be readable for the entire period that the documentation is retained, and will be compliant with 21 CFR §11, as applicable.

HOVIONE will keep the latest version of test methods and/or Specifications and will invalidate the previous, superseded versions.

3.11.

Annual Product Quality Review

HOVIONE shall conduct [***] Product Quality Review ("PQR.) for the Product, per the requirements of the applicable guidelines as defined in Section 6.1 and any

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

14 of 40

Exhibit 3-14

Confidential Treatment Requested by Achaogen, Inc.

additional requirements mutually agreed between the Parties. HOVIONE shall present the findings from its annual PQR to ACHAOGEN in a clear format, which makes it possible to identify quality problems, deviations and trends and/or to substantiate consistent quality of the Product.

3.12.

Subcontracting

HOVIONE will use its established cGMP systems for evaluation, approval and maintenance of all subcontracted services with a cGMP impact on the Product manufactured.

HOVIONE shall not subcontract to a third party any of the work entrusted to them under this Quality Agreement without ACHAOGEN’s prior written approval in accordance with Section 2.9 of the Manufacturing Agreement. If such an agreement is given, HOVIONE shall nonetheless remain fully responsible for the quality of the materials or services provided by subcontractors and for all commitments as agreed upon with this Quality Agreement. This must be assured through quality agreements with the respective subcontractors and technical delivery specifications.

A list of currently approved subcontractors related to the manufacture of the product is provided in Appendix C. In case that HOVIONE would like to use a new subcontractor, this list will be updated and will be review and approved by ACHAOGEN. Any change in subcontracting shall follow the established change control procedure.

3.13.

Access to Manufacturing Facilities

HOVIONE shall have appropriate control procedures in place to ensure that only authorized personnel have access to HOVIONE’s manufacturing facilities.

3.14.

Resolution of Quality Issues

Representatives from both ACHAOGEN and HOVIONE Quality Assurance (QA) departments will be involved in decision-making and resolution of quality issues. All action items and resolutions shall be documented in writing. Any dispute between the Parties arising from or with respect to this Agreement shall be resolved through the Dispute Resolution provisions of the Manufacturing Agreement.

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

15 of 40

Exhibit 3-15

Confidential Treatment Requested by Achaogen, Inc.

4.	General Requirements

4.1.

Specifications

Specifications for the Product are detailed In Appendix B.

All raw materials, starting materials, intermediates, Product packaging materials must be tested and released per approved specifications.

No changes in any Specifications for starting materials, intermediates, or API, starting material sources, Product-specific analytical methods, production records, or any other changes that would affect ACHAOGEN’s current regulatory filings shall be made without prior written approval of ACHAOGEN via the formal change control system (See Section 3.9).

4.2.

Analytical methods

Analytical methods used for testing the product: Compendial analytical methods’ suitability shall be established and documented under actual conditions of use and all others shall be validated prior to use.

Any Major/Critical Changes to these analytical methods shall be approved by ACHAOGEN via a formal change control system (See Section 3.9).

4.3.

Reference standards

All reference standards shall be stored in accordance with the HOVIONE’s recommended storage conditions and used within the assigned expiry or retest date.

HOVIONE or ACHAOGEN is responsible for the purchase and certification of the reference standards.

(In case, HOVIONE is responsible) HOVIONE shall provide to ACHAOGEN reasonable quantities of any non-compendial or not commercially available reference standards necessary to perform the tests included in the Specifications.

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

16 of 40

Exhibit 3-16

Confidential Treatment Requested by Achaogen, Inc.

(In case, ACHAOGEN is responsible) ACHAOGEN shall provide to HOVIONE reasonable quantities of any non-compendial or not commercially available reference standards necessary to perform the tests included in the Specifications.

4.4.

Raw materials

HOVIONE shall be responsible for the purchase, storage, handling, sampling, testing and approval or rejection of materials used in manufacturing the Product pursuant to this agreement, except for any material supplied by ACHAOGEN.

HOVIONE shall have in place a vendor qualification program to evaluate the suppliers of critical materials. HOVIONE shall only purchase materials from qualified suppliers. As part of the PQR, HOVIONE shall provide a list of changes in vendors HOVIONE is using to purchase materials and any changes the existing vendors make to the material they are sourcing.

HOVIONE shall utilize approved material inspection plans and testing procedures. The results of this inspection and testing shall be in accordance with specifications filed by ACHAOGEN.

HOVIONE shall inspect and/or test all materials on a batch-by-batch basis.

Raw materials supplied by qualified vendors and those supplied by ACHAOGEN can be subject to reduced testing but a minimum ID testing (or visual examination in case of hazardous or highly toxic raw materials) needs to be performed for each delivery and each lot.

HOVIONE shall store and handle materials used in manufacturing the Product pursuant to this Agreement under appropriate conditions, consistent with cGMPs, all applicable laws, rules and regulations, and industry standards. ACHAOGEN shall inform HOVIONE on the storage conditions of any material supplied to HOVIONE.

HOVIONE shall have all necessary and appropriate controls in place to prevent cross contamination of the raw materials and intermediates used in the manufacture of the Product from other chemicals stored, used, or manufactured by HOVIONE.

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

17 of 40

Exhibit 3-17

Confidential Treatment Requested by Achaogen, Inc.

When materials are supplied by ACHAOGEN, HOVIONE shall receive sufficient amount of material to manufacture the quantities of batches ordered. ACHAOGEN warrants that any material supplied to HOVIONE shall comply with the agreed specifications. A Certificate of Analysis and a MSDS shall be submitted to HOVIONE and shall accompany each shipment. The specification in force for the ACHAOGEN-supplied material is attached as Appendix B. ACHAOGEN shall be responsible for the maintenance and storage of appropriate retain samples of any material supplied to HOVIONE.

If HOVIONE believes that any shipment received of ACHAOGEN-supplied material does not meet specification, HOVIONE shall notify ACHAOGEN in writing, including a detailed explanation of the non-conformity. ACHAOGEN shall investigate such alleged non-conformity and, if agrees, such material is not conforming and ACHAOGEN will replace it or the Product will be manufactured at the sole risk of ACHAOGEN. If ACHAOGEN disagrees, it shall be notified to HOVIONE in writing. Consequently, the manufacturing of the Product will be at the sole risk of ACHAOGEN. HOVIONE shall not be responsible for materials defects or not meeting specifications.

4.5.

Starting Materials

The regulatory starting materials of the manufacturing process are [***].

4.6.

Process Validation Program

Program Activities: ACHAOGEN acknowledges and confirms that it has provided or will provide HOVIONE with the most current technical package for the manufacture of the Product, including process, analytical methods, and testing. HOVIONE shall keep and is keeping accurate and detailed records regarding its activities performed in respect of the Validation Program consistent with its internal policies and procedures.

Process Validation: HOVIONE shall conduct the following process validation activities as part of the Validation Program, including:

Validation Master Plan: HOVIONE and ACHAOGEN acknowledge that they will agree, in writing, on a validation master plan for the Process Validation activities to be conducted by HOVIONE (the "Validation Master Plan") and the

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

18 of 40

Exhibit 3-18

Confidential Treatment Requested by Achaogen, Inc.

process validation shall not commence until the Validation Master Plan has been approved by both ACHAOGEN and HOVIONE.

4.7.

Undesirable contaminants

HOVIONE shall upon request provide to ACHAOGEN a BSE/TSE certificate for the Product in accordance with the current EMA/410/01 Note for Guidance. The certificate shall indicate if the Product is (are) of human or animal origin, and if materials of human or animal origin are used during the manufacturing process of the Product. An updated BSE/TSE certificate must be issued if the previous statement changes after any change to the manufacturing process which involves new raw materials or for raw materials that have been sourced from a different supplier.

Any contaminants found in the routine analysis will be investigated as per the procedure in place. HOVIONE shall inform ACHAOGEN if there is any investigation as soon as detected and that could impact on product quality.

4.8.

Deviations / OOS (incl. stability)

HOVIONE must have a formal procedure for handling deviations as well as non-conforming laboratory test results (OOS results) that is in accordance with cGMP.

HOVIONE shall notify ACHAOGEN promptly (target: [***] after any Critical Deviation or OOS confirmation, excluding stability results) in the event of any Critical Deviation(s) that can potentially affect the integrity of the Product.

For all confirmed OOS stability test results that indicate that the product has failed to remain within specifications, HOVIONE shall notify ACHAOGEN promptly ([***] after stability OOS confirmation) and provide the stability data. ACHAOGEN may participate in any investigation concerning the OOS results and may need to inform Regulatory Authority. HOVIONE shall implement any agreed corrective and/or preventive actions arising out of the completed investigation report to avoid the reoccurrence of similar issues in the future.

In all cases, HOVIONE shall investigate any confirmed OOS result and forward a copy of the completed investigation report to ACHAOGEN within a reasonable period of time.

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

19 of 40

Exhibit 3-19

Confidential Treatment Requested by Achaogen, Inc.

All Product related deviations and OOS shall be reviewed and approved by ACHAOGEN.

Unplanned Deviations

The following procedure for notification and approval will be followed for any unplanned deviation that may have an impact on the quality of the product during the manufacturing, storage or testing of starting materials, intermediates or the Products:

If an ACHAOGEN representative is present on site, HOVIONE will promptly communicate the deviation and proposed corrective action to the representative verbally.

If an ACHAOGEN representative is not present on site, HOVIONE will communicate verbally via telephone or by email to [***] (as a first choice) the deviation and proposed corrective action to ACHAOGEN Technical Representative within [***] or as soon as possible.

OOS Results

HOVIONE shall verbally communicate (via e-mail to [***]) the OOS and proposed actions to ACHAOGEN within [***] and [***] or as soon as possible of confirmation of the OOS. HOVIONE shall conduct the investigation as per their internal OOS procedure and report the results to ACHAOGEN as soon as the investigation is complete, but not to exceed [***] from date of confirmation of OOS, unless otherwise mutually agreed to.

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

20 of 40

Exhibit 3-20

Confidential Treatment Requested by Achaogen, Inc.

4.9.

Reference (Product) and Retention of samples (final Product)

HOVIONE shall store product reference samples to perform at least [***] full specification analyses, in containers that are equivalent to or more protective than the commercial packaging. Samples are to be retained for the time period outlined below:

☐

General Starting Materials at least for [***] after the batch release by HOVIONE (other than water, compressed gases, cleaning solvents and highly volatile compounds) if their stability allows;

☐

API/Drug Substance Starting Material at least for [***] after the expiration date of the last batch of the drug substance;

☐

Product with retest date: for [***] after the Batch is completely distributed by HOVIONE;

HOVIONE shall store final Product retention sample, representative from the Batch for identification purpose. The quantity of retention samples shall allow at least [***] full specification analyses.

HOVIONE shall make Product retention samples available to ACHAOGEN promptly upon ACHAOGEN’s justified request.

The samples shall be stored in a controlled manner until further authorization by ACHAOGEN. HOVIONE shall notify ACHAOGEN prior to destroying retain samples.

4.10.

Storage and Distribution

HOVIONE shall make commercially reasonable efforts to exclude, during packaging, storage, and shipping of the Product, the possibility of deterioration, contamination, or mix-ups with any other material.

Per shipment HOVIONE shall provide an up-to-date MSDS to ACHAOGEN, and a certificate of analysis.

This agreement does not absolve HOVIONE from complying with any legal requirements in relation to the transportation of the product.

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

21 of 40

Exhibit 3-21

Confidential Treatment Requested by Achaogen, Inc.

4.11.

Certificate of Analysis

A Certificate of Analysis is required for each Batch of Product shipped on behalf of ACHAOGEN.

The Certificate of Analysis shall be produced by a computer system which provides a degree of control equivalent to that given by a signature. The Certificate of Analysis states that the batch is suitable for release, and it shall include- as a minimum:

☐

HOVIONE name, address and telephone number,

☐

Product name and grade (if applicable),

☐

HOVIONE batch/lot number,

☐

Reference to the Specification (approved current version),

☐

Test parameters and corresponding specification requirements,

☐

Test results (numerical, where applicable) for each chemical, physical or microbiological test performed,

☐

Date of manufacture, retest date and release date of the Product (if applicable).

☐

A statement that the batch was:

analyzed in accordance with the tests listed in the Certificate of Analysis and conforms to the latest HOVIONE specification;

produced in accordance with the current Good Manufacturing Practices.

4.12.

Product Release

HOVIONE will perform initial review of EBR and lot-specific related documents. Review and approval by HOVIONE QA must include closure/resolution of all associated deviations and/or out-of-specification (OOS) related to the batch. Once HOVIONE QA has approved the production documentation, the documentation will be forwarded to ACHAOGEN.

HOVIONE Quality Assurance Director/delegate or Qualified Person (depending if it is a Drug Substance or Drug Product and the HOVIONE site local law) has the responsibility to release the Product for disposition by ACHAOGEN.

HOVIONE shall not ship any Product to any destination, as identified by ACHAOGEN, until the product is dispositioned by ACHAOGEN for shipment,

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

22 of 40

Exhibit 3-22

Confidential Treatment Requested by Achaogen, Inc.

unless prior written approval has been received from ACHAOGEN to perform such a shipment under quarantine.

Unless otherwise authorized by ACHAOGEN, HOVIONE shall not deliver to any destination any product under quarantine conditions.

HOVIONE shall be responsible for the issuance of a product Certificate of Analysis per batch (see also Section 11.2).

HOVIONE shall answer all inquiries for the batch quality as promptly as possible; and make the complete batch documentation available to ACHAOGEN upon its and/or a Regulatory Authority’s request.

4.13.

Reprocessing

Reprocessing shall be performed per the current regulatory dossier, if applicable, and reported to ACHAOGEN. Reasons for reprocessing shall be investigated, and the results shall be communicated to ACHAOGEN.

Reprocessed Batches shall be reported and agreed with ACHAOGEN.

4.14.

Reworking

Reworking is only possible after approval by ACHAOGEN. Any reworking process shall be validated. Additional stability tests and analytical testing of reworked Batches may be required.

Reworked Batches shall be reported and approved by ACHAOGEN. Reworking process could be part of the experience through process development.

4.15.

Packaging

The following shall apply to the packaging of the final product:

The specifications for packaging materials including tamper evident seals must be in accordance with the regulatory documentation related to the product.

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

23 of 40

Exhibit 3-23

Confidential Treatment Requested by Achaogen, Inc.

4.16.

Labelling

HOVIONE shall comply with the requirements related to labelling:

☐

Master of shipping label shall be approved by ACHAOGEN

☐

Labelling operations shall be conducted to prevent mix ups,

☐

Labels shall be checked for accuracy before application.

The shipping label may include additional information (e.g., ACHAOGEN material code); details may be defined in the supply agreement if required by ACHAOGEN.

This agreement does not absolve HOVIONE from complying with any legal requirements in relation to the transportation of the product.

4.17.

Product Rejection

If there is any issue which likely to cause rejection of the Product, ACHAOGEN shall communicate to HOVIONE as soon as possible, but in any case, within [***] of release of the Product from HOVIONE to ACHAOGEN.

4.18.

Laboratory Control

•

General: Any specifications, standards, sampling plans, test procedures, validation protocols, reports or other laboratory control mechanisms, including any change in such specifications, standards, sampling plans, test procedures, or other laboratory control mechanisms, should be prepared and approved by HOVIONE.

•

Laboratory Equipment: All laboratory equipment used to perform cGMP operations should be calibrated/qualified and maintained in a controlled state by HOVIONE.

•

Reference Standards: See Section 4.3.

•

Specifications: See Section 4.1.

5.	Complaints and Recalls

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

24 of 40

Exhibit 3-24

Confidential Treatment Requested by Achaogen, Inc.

5.1.

Complaints

All complaints related to the Product reported, regardless of source (e.g., consumers, doctors, pharmacists, sales representatives) shall be handled by ACHAOGEN. If a complaint relates to the activities or processes carried out or controlled by HOVIONE, ACHAOGEN shall communicate the complaints to HOVIONE.

HOVIONE shall be responsible for recording and Investigating all quality-related complaints on the Product and will maintain the complete complaint database and complaint files, as per internal procedures.

HOVIONE shall complete their investigation and respond to ACHAOGEN in writing to all complaints within [***] of receipt.

A formal written report on the complaint detailing identifiable root causes and corrective and preventive actions where applicable shall be prepared by HOVIONE and sent to ACHAOGEN.

In case the investigation could not be finalized within [***], HOVIONE shall provide an interim report to ACHAOGEN. HOVIONE is responsible for implementing a corrective and/or preventive action plan to correct any deficiencies identified during an investigation.

ACHAOGEN shall make relevant information and samples of the affected product available to assist HOVIONE investigation.

HOVIONE shall provide complaint files for ACHAOGEN product to ACHAOGEN within [***], if they are required during a Regulatory Authority inspection.

5.2.

Recall

If HOVIONE believes that a recall of the product may be necessary or appropriate, HOVIONE shall immediately, i.e. within [***], notify ACHAOGEN. The Parties will take joint decisions on the disposition of the Product or user information, where required.

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

25 of 40

Exhibit 3-25

Confidential Treatment Requested by Achaogen, Inc.

ACHAOGEN is responsible for the final decision and the coordination of any recalls or field alert activities.

HOVIONE shall provide any information required by ACHAOGEN relating to recall or field alert activities within [***] of the request, if such information is readily available at HOVIONE.

HOVIONE shall not initiate any notifications to health authorities concerning a (potential) nonconformance without the prior agreement of ACHAOGEN.

HOVIONE shall collaborate, if needed, in any recall of a defective Batch of Product.

HOVIONE and ACHAOGEN shall immediately inform each other of any recall actions concerning the Product. Relevant contact persons are listed in Quality contacts.

6.	Compliance and Regulatory Requirements

6.1.

Applicable GMP Standard

HOVIONE shall manufacture the Product in compliance with current Good Manufacturing Practices of all applicable health authorities including without limitation, the FDA applicable rules, regulations, guides and guidance, such as 21 CFR Parts 11, 210-211, the EU GMP Guide Part I and/or Part II and respective guidance documents and ICH respective guidance including but not limited to ICH Q7 and legislation of other countries, as applicable.

6.2.

Regulatory documents

ACHAOGEN shall be responsible for preparation of registration documents related to Product and submission of such registration documents to any Regulatory Authority, including maintaining such submissions (hereafter altogether called ‘Regulatory Submissions’).

Upon request by, and in mutual consultation with ACHAOGEN, HOVIONE shall be responsible for preparation of documentation on manufacture of Product as required for the Regulatory Submissions of ACHAOGEN, limited to HOVIONE’s activities under this agreement.

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

26 of 40

Exhibit 3-26

Confidential Treatment Requested by Achaogen, Inc.

ACHAOGEN shall provide portions of Regulatory Submissions, related to Product and HOVIONE’s activities performed under this agreement, to HOVIONE for review and written consent, prior to submission to any Regulatory Authority.

HOVIONE shall review and comment to ACHAOGEN on such portions of Regulatory Submissions, within [***] from receipt or other period previously agreed by the Parties.

ACHAOGEN shall, upon submission to any Regulatory Authority, provide HOVIONE with current copies of portions of Regulatory Submissions, including amendments and supplements thereto, related to the Product and HOVIONE’s activities performed under this Quality Agreement.

HOVIONE shall provide, in mutually agreed timelines, all other information related to the product that ACHAOGEN may reasonably request for its Regulatory Submissions, including any data for annual reports (e.g. annual stability reports for the product.

When a change is known to require, or has the potential to require a Regulatory Submission, ACHAOGEN will develop a joint strategy to secure the appropriate regulatory approval prior to implementation of the change at HOVIONE and ACHAOGEN. For change control see Section II.3 of Manufacturing Agreement.

7.	Audits and Inspections

7.1.

ACCHAOGEN’s Right to Audit

Routine GMP audit: In accordance with Article 11 of the Manufacturing Agreement, HOVIONE shall allow ACHAOGEN’s representatives including but not limited to third party audit companies under the scope of audit sharing programs (e.g. Rx-360, API Institute), to carry out the routine GMP audit. [***] during the routine GMP audit, HOVIONE shall permit ACHAOGEN all reasonable access to the manufacturing, packaging, warehousing and laboratory areas related to the manufacture of the Product including pertinent documentation.

The results of the audit and the observation(s) shall be sent to HOVIONE by means of a written report. HOVIONE will ensure a satisfactory follow up to the observations made during the audit performed by the ACHAOGEN within [***]

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

27 of 40

Exhibit 3-27

Confidential Treatment Requested by Achaogen, Inc.

after receipt of the report, and take corrective/preventive actions designed to address non-conformities with the applicable guidelines and mutually agreed upon by the Parties. All other observations shall be evaluated and actions may be defined and implemented if considered that they bring added value to HOVIONE Quality System.

The frequency of the routine GMP audit shall depend upon the results of the audit and the quality performance of HOVIONE. In the absence of any Major/Critical Changes or Critical Deviations being found by ACHAOGEN’s audits or reported by HOVIONE, the frequency shall be not more than [***] targeting every [***].

For-Cause Audit: In accordance with Section 11.3 of the Manufacturing Agreement, HOVIONE shall permit ACHAOGEN and its representatives to perform a for-cause audit for certain causes including whenever any Major/Critical Changes or /Critical Deviations have been identified. HOVIONE shall permit all reasonable access to the plant area and to all data and documents related to the product with the objective to understand the root cause and to define corrective and/or preventive actions with the collaboration of the ACHAOGEN. HOVIONE shall work with any permitted subcontractors to ensure that the appropriate agreements are in place to allow ACHAOGEN to participate in any for-cause audit related to the subcontractor’s performance, if so required.

Person-In-Plant: HOVIONE shall permit ACHAOGEN to have manufacturing, technical and/or quality representatives present during the Product’s manufacturing and processing operations. ACHAOGEN shall provide prior notification of their intention to witness the production. No more than [***] ACHAOGEN representatives will be permitted to be present in the manufacturing area, and only [***] in the actual processing room. ACHAOGEN representatives in the plant shall adhere to HOVIONE quality and safety procedures. HOVIONE shall also provide a key contact person at their facility to communicate the production and product quality related issues during the production.

7.2.

Authority Inspections

In accordance with Section 11.1 of the Manufacturing Agreement, HOVIONE shall notify ACHAOGEN of regulatory inspections that relate to the Product. During the Pre-Approval Inspection (PAI), not more than [***] representatives from ACHAOGEN may be on-site for consultation purposes only (direct

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

28 of 40

Exhibit 3-28

Confidential Treatment Requested by Achaogen, Inc.

interaction with Regulatory Agency personnel is the sole responsibility of HOVIONE).

HOVIONE shall release any records required to be made available to the inspecting or inquiring authority by law or regulation, but shall not release any ACHAOGEN’s Confidential Information not required by law to be provided for inspection or copying without specific written consent of ACHAOGEN.

Each party shall promptly notify the other of any information or notice it receives or becomes aware of, including without limitation, any threatened or pending action by the FDA or other regulatory authority, concerning the safety or efficacy of the API. ACHAOGEN will notify HOVIONE of any regulatory actions on the APIor ACHAOGEN that may impact HOVIONE.

HOVIONE shall reasonably assist ACHAOGEN in its efforts to secure and maintain government regulatory filings for the Product and shall participate as is reasonably necessary in resolving the concerns of FDA or other regulatory authority arising with respect to HOVIONE’s manufacture of the Product for ACHAOGEN.

8.	Miscellaneous Provisions

8.1.

Assignment

Neither Party shall have the right to assign any or all its rights or obligations under this Quality Agreement without the other Party’s prior written consent, which consent shall not unreasonably be withheld. The foregoing notwithstanding, prior written consent shall not be required (i) in case of an assignment of rights or obligations to an Affiliate of the assignor (optional extension: provided that the assignor procures that any such Affiliate assigns such rights back to the assignor immediately before ceasing to be an Affiliate of the assignor), or (ii) in connection with a merger, consolidation, or a sale of all or substantially all of party’s assets to a third Party, except if such merger, consolidation or sale is with a competitor of the other Party.

8.2.

Related agreements

In the event of a conflict between any of the provisions of the Manufacturing Agreement and the Quality Agreement with respect to quality-related activities, including compliance with cGMP, the provisions of the Quality Agreement shall

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

29 of 40

Exhibit 3-29

Confidential Treatment Requested by Achaogen, Inc.

control. In the event of a conflict between any of the provisions of the Manufacturing Agreement and the Quality Agreement with respect to any commercial or other matters, including the allocation of risk, liability, and financial responsibility, the provisions of the Manufacturing Agreement shall control.

8.3.

Confidentiality

All communications and documentation exchanged between the Parties, including the terms of this Agreement, shall be considered proprietary and confidential, and its use is subject to the terms and conditions of the Manufacturing Agreement.

Each Party may share with the other Party and Affiliates copies of confidential documents to facilitate their mutual understanding and in support of the development and quality activities under this Quality Agreement. Neither Party shall use the other Party’s Confidential Information in support of regulatory filings without the express written consent of the other Party.

8.4.

Choice of Law

The Parties agree that this Quality Agreement shall be governed by and construed in accordance with the law applicable to the Manufacturing Agreement.

8.5.

Debarment Certification

Neither HOVIONE nor any of its officers or employees, nor any other person, consultant or contractor used by HOVIONE to perform Manufacturing or Services under this Quality Agreement is: (a) an individual who has been debarred by the FDA pursuant to section 306 of the FDCA, 21 U.S.C. § 335a ("Debarred Individual"), (b) a corporation, partnership or association that has been debarred by FDA pursuant to section 306 of the FDCA, 21 U.S.C. § 335 a ("Debarred Entity"), or (c) the subject of an FDA debarment investigation or proceeding (or similar proceeding of another regulatory agency); and HOVIONE will not retain or employ any personnel, and will not knowingly use the services of any contractor or consultant, who is debarred by the FDA or who is the subject of an FDA debarment investigation or proceeding (or similar sanction or investigation by another regulatory agency) in connection with performing any Manufacturing or Services. HOVIONE has no knowledge of any circumstances which may affect the accuracy of the foregoing representation, including, without

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

30 of 40

Exhibit 3-30

Confidential Treatment Requested by Achaogen, Inc.

limitation, any FDA investigations of, or debarment proceedings against, HOVIONE or any person or entity performing services or rendering assistance which is in any way related to activities taken pursuant to this Agreement. HOVIONE shall notify ACHAOGEN in writing as soon as possible if HOVIONE, at any time during the Term, becomes aware of any such circumstances.

8.6.

BARDA Requirements

For certain Services, including those covered by this Quality Agreement, ACHAOGEN may engage HOVIONE as a subcontractor to certain projects under the Prime Contract by mutual execution of a Work Plan. Any Work Plan under which HOVIONE is acting as a subcontractor shall be a "Government Project", and such Government Projects will be expressly identified as such within the applicable Work Plan.

8.7.

Entire Agreement

This Quality Agreement and the Manufacturing Agreement constitute the entire agreement between the Parties with respect to the subject matter hereof, and supersedes all other prior agreements, understandings, warranties, or any other representation between the Parties with respect thereto. If there is a conflict between the terms of this Quality Agreement and the Manufacturing Agreement, the terms of the Manufacturing Agreement shall govern on all matters except quality, in which cases this Quality Agreement shall govern.

8.8.

Amendments and Supplements

Any amendment or supplement to this Quality Agreement shall be documented and approved in writing by both Parties.

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

31 of 40

Exhibit 3-31

Confidential Treatment Requested by Achaogen, Inc.

Contacts

HOVIONE

[***]

ACHAOGEN

[***]

10.List of Appendices

Appendix A – Responsibility Matrix

Appendix B – Product specification

Appendix C – Subcontractors list

Appendix D – Quality Agreement change control record

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

32 of 40

Exhibit 3-32

Confidential Treatment Requested by Achaogen, Inc.

Appendix A

Responsibility Matrix

[***]

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

33 of 40

Exhibit 3-33

Confidential Treatment Requested by Achaogen, Inc.

1 – When material is supplied by ACHAOGEN

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

34 of 40

Exhibit 3-34

Confidential Treatment Requested by Achaogen, Inc.

[***]

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

35 of 40

Exhibit 3-35

Confidential Treatment Requested by Achaogen, Inc.

Signatories

[***]

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

36 of 40

Exhibit 3-36

Confidential Treatment Requested by Achaogen, Inc.

APPENDIX B

Product Specification (Current Spec Doc. [***])

Test Name	Specification
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]
[***]	[***]

Informative tests
[***]	[***]
[***]	[***]

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

37 of 40

Exhibit 3-37

Confidential Treatment Requested by Achaogen, Inc.

Signatories

[***]

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

38 of 40

Exhibit 3-38

Confidential Treatment Requested by Achaogen, Inc.

APPENDIX C

Subcontractors list

Service(s) Provided	Company name and address

Storage of Stability Samples	[***]

Determination of elemental impurities, By ICP-MS-Final Product Release	[***]

Signatories

[***]

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

39 of 40

Exhibit 3-39

Confidential Treatment Requested by Achaogen, Inc.

APPENDIX D

Change Control

Revision no.	Reason	Effective date
000	First execution of this Agreement.

Signatories

[***]

HQ.QSD.MA711.4.EN – [***] – Contract Manufacturing

Prepared based on APIC version [***]

HOVIONE/ACHAOGEN – version 00 – [***]

40 of 40

Exhibit 3-40

Confidential Treatment Requested by Achaogen, Inc.

Exhibit 4

Certificate of Analysis

See attached.

Exhibit 4-1

Confidential Treatment Requested by Achaogen, Inc.

Exhibit 5

Project Specific Raw Materials

[***]

Long lead time raw material:

•

[***]

The Project Specific Raw Materials in Exhibit 5 are included in Raw Materials.

Exhibit 5-1

Confidential Treatment Requested by Achaogen, Inc.

Exhibit 6

Starting Materials

[***]

Exhibit 6-1

Confidential Treatment Requested by Achaogen, Inc.

Exhibit 7

Pricing and Production Performance

AND MINIMUM ANNUAL COMMITMENT

[***]

validation campaign based on the average process performance. Accordingly, all amounts are subject to change pending confirmation following completion of the Validation Process campaigns.

All forecasting and ordering lead-times set out in the Agreement shall take production performance into consideration [***]. For clarity a delivery date in a purchase orders shall be defined as [***]

[***]

Exhibit 7-1

Confidential Treatment Requested by Achaogen, Inc.

EXHIBIT 8

TABLE OF WORK PLANS

[***]

Exhibit 8-1

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

Exhibit 9

Program Work PLAN - WORK Plan No. C-1

[***]

Work Plan No. C-01

Version [***]

[***]

Reference: [***]

This Work Plan No. C-01 (the “Work Plan”), dated [***] (the “Order Date”), is by and between [***] Hovione Limited, (“Hovione”) and Achaogen, Inc., a Delaware corporation, having a principle place of business at 7000 Shoreline Court, Suite 371, South San Francisco, California 94080, U.S.A. ("Customer"), and upon execution by both parties, shall be incorporated into the Validation and Manufacturing Agreement between Customer and Hovione Limited with an effective date of [***] (the “Agreement”). Customer, [***] and Hovione Limited hereby acknowledge and agree to all terms in both this Work Plan and the Agreement. Capitalized terms used in this Work Plan shall have the meanings ascribed to them in the Agreement.

1.	Background:

This Work Plan is based on Hovione’s historical experience with the Plazomicin [***] program and on detailed discussions between the Customer and Hovione’s project teams. All information and content herein reflects information known at the time of the Order Date.

The Validation Program for Customer’s proprietary compound Plazomicin [***] (the “Product”) will occur at Hovione’s Loures site in Portugal (the “Facility”). Assuming that all process optimization and PAR/NOR activities are completed in a timely manner, the anticipated start date for the Validation Program of the Product will be [***] with completion of the Manufacture of the Validation Program anticipated for [***]. Since [***], [***]. For sake of clarity, the [***] are covered under separate Work Plans executed under the Master Services Agreement between Customer and Hovione International Limited with an effective date of [***], amended on [***] and on [***] (collectively, the “MSA”), and are not included herein.


Achaogen-Hovione Validation and Manufacturing Agreement	1
Work Plan [***]]	CONFIDENTIAL

Exhibit 9-1

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

The scale of the Validation Program in this Work Plan is anticipated to be [***] per Batch.

This Work Plan does not include any [***]. If such work is requested, it will be covered in a separate Work Plan(s).

Tasks:

This Work Plan covers the Product Validation Program to be run in the projected equipment train [***] at the Facility. The reserved equipment train during the below- listed timeslot will be used to perform the Validation Program of the Product. It is anticipated that this Validation Program will consist of [***] engineering batch followed by [***] validation batches [***]. It is anticipated that all [***] batches will target the same batch size. It is also anticipated that a Demo run of the [***] step will be run at [***] to [***], prior to conducting the engineering batch’s [***] step. At the time that this Work Plan is issued, the projected batch size is confirmed to target [***]. The total targeted output for this validation campaign is [***].

Timeline:

Hovione confirms that the Product Validation Program would start in [***] (subject to PO issuance). The deadline for delivery of the Final Validation Report (the “Final Deliverable”) to Customer is [***] (the “Deadline”). Any changes to the timeline shall be made in writing signed by both Parties.

At the time this Work Plan was prepared, the following is anticipated:

•

It will take approximately [***] to execute the demonstration/engineering batch [***] and approximately [***] to execute the [***] validation batches [***].

•

Following completion of manufacture, QC/QA release testing is expected to take [***] weeks.

•

Campaign report writing (PVR, CVR) is expected to take at least [***] weeks after the batches are completed.

•

Upon execution of this Work Plan, Hovione will reserve a minimum of a [***] of production time for Customer’s validation campaign of [***].


Achaogen-Hovione Validation and Manufacturing Agreement	2
Work Plan [***]]	CONFIDENTIAL

Exhibit 9-2

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

Deliverables:

Hovione shall prepare the following deliverables for Customer under this Work Plan (collectively the “Deliverables”).

•

[***] Demonstration batch of [***] of [***], based on an input of [***] (previously manufactured at Hovione) under GMP Commercial conditions (suitable for Validation and Commercial supply)

•

[***] Engineering batch of [***], based on an input of [***], produced under GMP Commercial conditions (suitable for Validation and Commercial supply)

•

[***] Process Validation batches of [***], based on an input of [***] per batch, produced under GMP Commercial conditions (suitable for Validation and Commercial supply)

•

Testing of the [***] batches including a CoA for each batch and the completed batch records in the release package

•

VMP (Validation Master Plan), [***] PVPs (Process Validation Protocols), [***] PVRs (Process Validation Reports), [***] CVPs (Cleaning Validation Protocols), CVR (Cleaning Validation Reports), FVR (Final Validation Report)

•

Master Batch Production Records

•

Completed Batch Production Records

•

Campaign summary report

Compensation and Payment Terms

5.1

Labor & Equipment

In consideration of these Services performed by Hovione, Achaogen shall pay Hovione [***] for the Tasks outlined in Section 2 and the Deliverables set forth in Section 4 (the “Service Fees”).

5.2

Reports and Deliverables

All Deliverables are included in the Service Fees above.

5.3

Project Specific Materials

Project Specific Materials are raw materials and reagents (including solvents) used in the conduct of the tasks described in Section 2 and that


Achaogen-Hovione Validation and Manufacturing Agreement	3
Work Plan [***]]	CONFIDENTIAL

Exhibit 9-3

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

Hovione must procure specifically in the course of the project to conduct the Services.

The total cost of Project Specific Materials described in this Work Plan shall not exceed [***] where a maximum of [***] is for the procurement of [***], where a maximum of [***] is for the procurement of [***] of the [***] and a maximum of [***] for procurement of [***].

Hovione will not use Project Specific Materials on any other project. Project Specific Materials may be shipped to Achaogen at Achaogen’s written request and expense.

General Chemicals, Materials, and Supplies constitute items such as [***] which are used routinely in all operations and widely across projects at Hovione. The total cost for General Chemicals, Materials and Supplies is approximately [***].

5.4

Shipping

[***]. Hovione will use a dedicated shipping account provided by Achaogen for these charges. Compounds will be shipped by [***] unless otherwise requested by Achaogen. Hovione estimates that the shipping costs inclusive of customs, shipping and packing materials will not exceed [***]. [***].

All materials shipped by Hovione on behalf of Achaogen will follow [***].

5.5

Travel Costs

The fee above does not account for nor does it include any travel costs. Customer will only reimburse Hovione for reasonable out-of-pocket expenses actually incurred in connection with the Services that are approved in writing in advance by Customer and supported by receipts and documentation. All out-of-pocket expenses shall be invoiced to Customer without mark-up.


Achaogen-Hovione Validation and Manufacturing Agreement	4
Work Plan [***]]	CONFIDENTIAL

Exhibit 9-4

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

5.6

Other Costs

Not applicable at the time of Work Plan issuance. If Other Costs need to be incurred, these will be discussed and agreed in writing by both the Customer and Hovione prior to their expenditure.

5.7

Invoices

Payment will be made according to the terms of the Agreement, and as outlined below.

5.7.1

Milestones: Hovione will invoice Achaogen according to the following payment milestone schedule:

5.7.1.1.

[***] of this Work Plan and issuance of the PO, Hovione will issue an invoice for [***].

5.7.1.2.

[***] Master Batch Records for Achaogen’s review, Hovione will issue an invoice for [***].

5.7.1.3.

[***] of the Validation Master Plan (VMP) and Process Validation Protocols (PVP) for [***], Hovione will issue an invoice for [***].

5.7.1.4.

[***] of the [***] of [***], Hovione will issue an invoice for [***].

5.7.1.5.

[***] of the [***] of [***], Hovione will issue an invoice for [***].

5.7.1.6.

[***] of the [***] of [***], Hovione will issue an invoice for [***].

5.7.1.7.

[***] of the [***] of [***], Hovione will issue an invoice for [***].

5.7.1.8.

[***] of the [***] of [***] to [***], Hovione will issue an invoice for [***].

5.7.1.9.

[***] of the [***] of [***] to [***], Hovione will issue an invoice for [***].


Achaogen-Hovione Validation and Manufacturing Agreement	5
Work Plan [***]]	CONFIDENTIAL

Exhibit 9-5

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

5.7.1.10.

[***] of the [***] of [***] to [***], Hovione will issue an invoice for [***].

5.7.1.11.

[***] of the [***] of [***] to [***], Hovione will issue an invoice for [***].

5.7.1.12.

[***] of the [***] of [***] to [***], Hovione will issue an invoice for [***].

5.7.1.13.

[***] of the [***] of [***] to [***], Hovione will issue an invoice for [***].

5.7.1.14.

[***] of the [***] of [***] to [***], Hovione will issue an invoice for [***].

5.7.1.15.

[***] of the [***] of [***] to [***], Hovione will issue an invoice for [***].

5.7.1.16.

[***] of the [***] of [***] to [***], Hovione will issue an invoice for [***].

5.7.1.17.

[***] of the [***] of [***] to [***], Hovione will issue an invoice for [***].

5.7.1.18.

[***] of the [***] of [***] to [***], Hovione will issue an invoice for [***].

5.7.1.19.

[***] of the [***] of [***] to [***], Hovione will issue an invoice for [***].

5.7.1.20.

[***] of the [***] of [***] to [***], Hovione will issue an invoice for [***].

5.7.1.21.

[***] of the [***], Hovione will issue an invoice for [***].

5.7.1.22.

[***] of the [***], Hovione will issue an invoice for [***].

5.7.1.23.

[***] of the [***], Hovione will issue an invoice for [***].

5.7.1.24.

[***] of the [***], Hovione will issue an invoice for [***].


Achaogen-Hovione Validation and Manufacturing Agreement	6
Work Plan [***]]	CONFIDENTIAL

Exhibit 9-6

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

5.7.1.25.

[***] of the [***], Hovione will issue an invoice for [***]

5.7.1.26.

[***] of the [***], Hovione will issue an invoice for [***].

5.7.1.27.

[***] of the [***], Hovione will issue an invoice for [***].

5.7.1.28.

[***] of the [***], Hovione will issue an invoice for [***].

5.7.1.29.

[***] of the [***], Hovione will issue an invoice for [***].

5.7.1.30.

[***] of the [***], Hovione will issue an invoice for [***].

5.7.1.31.

[***] of the [***], Hovione will issue an invoice for [***].

5.7.2 Project Specific Materials and Shipping. Hovione will issue invoices for reimbursement of Project Specific Material and shipping costs as these costs are incurred.

5.7.2.1.

[***] of this Work Plan, Hovione has purchased [***] of Project Specific Materials.

5.7.2.2.

In reference to the [***], Hovione has purchased [***].

5.7.2.3.

In reference to [***], Hovione has purchased [***].

5.7.2.4.

In reference to [***], Hovione has purchased [***].

5.7.2.4.

[***], Hovione will invoice Achaogen the remaining budget for Project Specific Materials, which will not exceed [***], without Achaogen’s prior written consent.

5.7.2.5

[***], Hovione will invoice Achaogen up to [***] for shipping costs incurred during the campaign.

5.7.3. Invoice Markings. All invoices for payments to be made to Hovione for services under this Exhibit shall be marked with:

5.7.3.1.

the following unique Purchase Order number: .

5.7.3.2.

the statement “Work Plan C-01 entitled, [***].”


Achaogen-Hovione Validation and Manufacturing Agreement	7
Work Plan [***]]	CONFIDENTIAL

Exhibit 9-7

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

Ceiling Price

The ceiling price for the services covered under this Work Plan C-01 is [***] of which no more than [***] shall be for services (6.1), [***] for the final report (6.2), [***] for General and Project-Specific Materials (6.3), and [***] for shipping costs (6.4). Achaogen shall not be obligated to pay Hovione any amount in excess of this ceiling price, unless and until an additional agreement that raises this price has been negotiated and signed by both Parties.

Under Work Plan [***], Customer has paid Hovione a reservation fee of [***]. The monies paid under Work Plan [***] have been applied to the ceiling price in this Work Plan C-01 (in particular they have covered the cost of the General and Project-Specific Materials (6.3) in the amount of [***]. The total invoiceable amount under this Work Plan is [***].

Government Sponsored Project:

Pursuant to Article 20 of the Manufacturing Agreement, this Work Plan is a “Government Project”.


8.	Commercial Contact:	Project Management Contact:
	Hovione:	Hovione:
	[***]	[***]
	Tel: [***]	Tel: [***]
	[***]	[***]

	Achaogen:	Achaogen
	[***]	[***]
	Tel: [***]	Tel: [***]
	[***]	[***]

Term:

9.1

The term of this Work Plan shall commence on the Order Date and shall continue until the Services described in Section 2 are completed, unless this Work Plan is terminated in accordance with the following terms:

(a)

Upon termination of a Work Plan under Section 3(a), Hovione will immediately: (i) cease work under the Work Plan; (ii) prepare and submit to Customer an itemization of all completed and partially


Achaogen-Hovione Validation and Manufacturing Agreement	8
Work Plan [***]]	CONFIDENTIAL

Exhibit 9-8

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

completed deliverables and Services; (iii) deliver to Customer any and all work completed under the Work Plan up to the date of termination at the agreed upon prices; and (iv) deliver upon request any work in process.

(b)

In no event shall Customer be liable for lost or anticipated profits, unabsorbed indirect costs or overhead, or for any sum in excess of the total Work Plan price.

(c)

(d)

In the event of termination of any Work Plan, Customer will compensate Hovione for all Services performed thereunder, as well as [***], provided Hovione [***].

9.2

If the Agreement is terminated or expires, but this Work Plan is not terminated or completed, then the terms of the Agreement shall continue to apply to this Work Plan until the Work Plan is either terminated or completed.

9.3

If this Work Plan is cancelled after [***] and before the planned start date of the Validation Campaign, Customer will compensate Hovione with [***] of the total value of this Work Plan [***].

9.4

If this Work Plan is cancelled after the start of the Validation Campaign, a cancellation fee of [***] of the total value of this Work Plan [***] plus [***] of the Work Plan value for each started and completed batches.

10.

Miscellaneous:

10.1

Each Party represents that it has full power and authority to enter into this Work Plan.

10.2

This Work Plan, together with the Agreement, sets forth the entire understanding among the Parties with respect to the subject matter of this Work Plan. This Work Plan supersedes all previous oral or written agreements and understandings on this subject matter between the Parties or their respective Affiliates.


Achaogen-Hovione Validation and Manufacturing Agreement	9
Work Plan [***]]	CONFIDENTIAL

Exhibit 9-9

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

10.3

This Work Plan may be executed in counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when joined, shall together constitute one and the same agreement. Any photocopy or electronic exchange of this Work Plan, or of any counterpart, shall be deemed the equivalent of an original.

ORDER PREPARED BY:
Hovione Inter Limited
Name:		[***]
Title:		[***]
Date:		[***]

ORDER AGREED TO AND ACCEPTED BY:

Achaogen, Inc.		Hovione Limited

By:	/s/ [***]	By:	/s/ [***]
Name:	[***]	Name:	[***]

Title:	[***]	Title:	[***]
Date:	[***]	Date:	[***]


Achaogen-Hovione Validation and Manufacturing Agreement	10
Work Plan [***]]	CONFIDENTIAL

Exhibit 9-10

Confidential Treatment Requested by Achaogen, Inc.

Exhibit 10

Program Work PLAN - WORK Plan No. C-2

[***]

(TO BE AGREED TO SEPARATELY)

Exhibit 10-1

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requestred with respect to the omitted portions.

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

Exhibit 11

Program Work PLAN - WORK Plan No. C-3

[***]

Work Plan No. C-03

Version [***]

[***]

Reference: [***]

This Work Plan No. C-03 (the “Work Plan”), dated [***] (the “Order Date”), is by and between [***] Hovione Limited, (“Hovione”) and Achaogen, Inc., a Delaware corporation, having a principle place of business at 7000 Shoreline Court, Suite 371, South San Francisco, California 94080, U.S.A. (“Customer”), and upon execution by both parties, shall be incorporated into the Validation and Manufacturing Agreement between Customer and Hovione Limited with an effective date of [***] (the “Agreement”). Customer, [***] and Hovione Limited hereby acknowledge and agree to all terms in both this Work Plan and the Agreement. Capitalized terms used in this Work Plan shall have the meanings ascribed to them in the Agreement.

1.	Background:

In order to meet Customer’s commercial demand for [***] and produce API in larger batch sizes, Customer and Hovione recommend [***]

The current [***] process has been developed and dimensioned to produce batches of [***] of final product. This [***]. The current forecast requires a significant increase in the batch scale and consequently it is necessary to further scale-up [***]. The current [***]. Using current process yields and the known properties of a [***]. The following [***] are expected for various batch sizes (Table 1.)


Achaogen-Hovione Validation and Manufacturing Agreement	1
Work Plan #[***]	CONFIDENTIAL

Exhibit 11-1

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

Table 1.

[***]
[***]
[***]
						[***]
[***]	[***]	[***]	[***]	[***]	[***]

[***]	[***]	[***]	[***]	[***]	[***]	[***]
[***]	[***]	[***]	[***]	[***]	[***]	[***]
[***]	[***]	[***]	[***]	[***]	[***]	[***]
[***]	[***]	[***]	[***]	[***]	[***]	[***]
[***]	[***]	[***]	[***]	[***]	[***]	[***]
[***]	[***]	[***]	[***]	[***]	[***]	[***]
[***]	[***]	[***]	[***]	[***]	[***]	[***]
[***]	[***]	[***]	[***]	[***]	[***]	[***]

The most [***]) is estimated to take [***] and utilizes at least [***]. The following workplan is directed to [***] as well as other steps in the [***].

This Work Plan does not include the [***]. At the moment, the costs included in this Work Plan cover the various stages of [***]. Though it is expected that the chemistry and engineering teams from the Customer and Hovione will meet to provide a list of user requirements for a [***]. If a [***], a separate Work Plan will be prepared [***]. The following activities will have to be carried out [***]:

[***]

Tasks:

This Work Plan covers the tasks listed below. These tasks cover the various stages of column [***].

[***]


Achaogen-Hovione Validation and Manufacturing Agreement	2
Work Plan #[***]	CONFIDENTIAL

Exhibit 11-2

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

•

[***]

•

[***]

•

[***]

Note:

These changes could [***] The [***] It is expected that [***] The [***]

[***]

[***] Note: if the [***]

[***]

•

[***]

•

[***]

•

[***]

•

[***]

•

[***]

•

[***]


Achaogen-Hovione Validation and Manufacturing Agreement	3
Work Plan #[***]	CONFIDENTIAL

Exhibit 11-3

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

•

[***]

Timeline:

Hovione anticipates that the implementation of activities outlined in Section 2 above will take:

•

[***]

•

[***]

•

[***]

•

[***]

During this time, [***]

4.	Deliverables:

Hovione shall prepare the following deliverables for Customer under this Work Plan (collectively the “Deliverables”).

4.1

Meetings and Project Oversight

Hovione will provide effective project monitoring and oversight to ensure work is proceeding diligently and that all assigned Hovione staff are conducting the work on the project as directed by Customer. Project timelines will be reviewed on a [***] basis during the regular team teleconferences. An additional project oversight teleconference will be held every [***] during which timelines, budgets and resource allocation will be reviewed and discussed.

Project meetings will occur [***] by teleconference. Leaders of the project from both Achaogen and Hovione will be required to attend these [***] status meetings, and other members will make reasonable efforts to attend, as needed. Hovione will send (electronically) [***] reports to Customer at least [***] prior to the [***] status meetings detailing progress on the project. Hovione will reasonably tailor the [***] reports as directed by Customer as needed. On a [***]


Achaogen-Hovione Validation and Manufacturing Agreement	4
Work Plan #[***]	CONFIDENTIAL

Exhibit 11-4

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

basis, the reports will include the tracking of resources and project budget. These updates will be discussed during the [***] teleconference between both Parties.

4.2

Final Report

Hovione shall provide a comprehensive Final Report in writing to Customer approximately [***] after the completion of the Tasks. This Report (as an electronic Adobe acrobat file) shall consist of a written, comprehensive description of the development results and calculations including relevant analytical data.

4.3

Other Project Data and Information

At Customer’s request, Hovione shall provide any data or information generated in the course of performing the Tasks, including but not limited to, analytical data, meeting notes, photographs, drawings, and designs, regardless of the media containing the information. Hovione shall provide all information or data pertaining to a Customer request using commercially reasonable efforts within a commercially reasonable timeframe.

5.	Compensation and Payment Terms

5.1

Labor & Equipment

In consideration of these services performed by Hovione, Customer shall pay Hovione at a rate of [***] based on [***]. This rate includes General Chemicals, Materials, and Supplies, and hazardous waste disposal, as well as routine use of general dedicated instrumentation and [***]. The total estimated cost of labor for the scope of work outlined in this Work Plan is [***].

5.2

Reports and Deliverables

In consideration for the provision of the final report (4.2), Customer shall pay Hovione a fixed fee of [***].

5.3

Project Specific Materials

Project Specific Materials are raw materials and reagents (including solvents) used in the conduct of the tasks described in Section 2 and that Hovione must procure specifically in the course of the project to conduct the Services. The cost for Project Specific Materials is estimated to total [***].


Achaogen-Hovione Validation and Manufacturing Agreement	5
Work Plan #[***]	CONFIDENTIAL

Exhibit 11-5

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

General Chemicals, Materials, and Supplies constitute items such as [***] which are used routinely in all operations and widely across projects at Hovione.

Customer will [***]. All Project Specific Materials will be ordered by Hovione from commercial sources.

Hovione will not use Project Specific Materials on any other project. Project Specific Materials may be shipped to Customer at Customer’s written request and expense.

5.4

Shipping

[***]. Hovione will use a dedicated shipping account provided by Customer for these charges. Compounds will be shipped by [***] unless otherwise requested by Customer.

Each billing period, Hovione will provide an itemized list of shipping costs being charged, in addition to copies of all associated invoices.

5.5

Travel Costs

5.6

Other Costs

Not applicable at the time of Work Plan issuance. If Other Costs need to be incurred, these will be discussed and agreed in writing by both the Customer and Hovione prior to their expenditure.


Achaogen-Hovione Validation and Manufacturing Agreement	6
Work Plan #[***]	CONFIDENTIAL

Exhibit 11-6

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

5.7

Invoices

Payment will be made according to the terms of the Agreement, and as outlined below.

5.7.1

Milestones: Hovione will invoice Customer according to the following payment milestone schedule:

5.7.1.1

[***], Hovione will invoice Customer [***] for execution of Stage 1 (Task 1).

5.7.1.2

[***], Hovione will invoice Customer [***].

5.7.1.3

[***], Hovione will invoice Customer [***].

5.7.1.4

[***], Hovione will invoice Customer [***].

5.7.1.5

[***], Hovione will invoice Customer [***].

5.7.1.6

Hovione will invoice [***].

5.7.2

Invoice Markings. All invoices for payments to be made to Hovione for services under this Exhibit shall be marked with:

5.7.2.1.

the following unique Purchase Order number: ___________________.

5.7.2.2.

the statement “Work Plan #C-03 entitled, [***].”

6.	Ceiling Price:

The ceiling price for the services covered under this Work Plan [***] is [***] of which no more than [***] shall be for services (Section 2), [***] for the Final Report (4.2) and [***] for Project Specific Materials (5.3). Customer shall not be obligated to pay Hovione any amount in excess of this ceiling price, unless and until an additional agreement that raises this price has been negotiated and signed by both Parties.

7.	Government Sponsored Project:

Pursuant to Article 20 of the Manufacturing Agreement, this Work Plan is a “Government Project”.


Achaogen-Hovione Validation and Manufacturing Agreement	7
Work Plan #[***]	CONFIDENTIAL

Exhibit 11-7

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]


8.	Commercial Contact:	Project Management Contact:
	Hovione:	Hovione:
	[***]	[***]
	Tel: [***]	Tel: [***]
	[***]	[***]
	Achaogen:	Achaogen
	[***]	[***]
	Tel: [***]	Tel: [***]
	[***]	[***]

Term:

9.1

If this Work Plan is cancelled greater than or equal to [***] prior to the planned start of the campaign, Customer will compensate Hovione with [***] of the total value of this Work Plan [***].

9.2

If this Work Plan is cancelled after the start of activities in Section 2, a cancellation fee of [***] of the total value of this Work Plan [***] plus pro-rata per time worked over total estimated time for the balance of [***] of the Work Plan ([***] pro-rated for every [***] or part thereof worked).

9.3

10.	Miscellaneous:

10.1

Each party represents that it has full power and authority to enter into this Work Plan.

10.2

This Work Plan, together with the Agreement, sets forth the entire understanding among the parties with respect to the subject matter of this Work Plan. This Work Plan supersedes all previous oral or written agreements and understandings on this subject matter between the Parties or their respective Affiliates.


Achaogen-Hovione Validation and Manufacturing Agreement	8
Work Plan #[***]	CONFIDENTIAL

Exhibit 11-8

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

10.3

ORDER PREPARED BY:
Hovione Limited
Name:		[***]
Title:		[***]
Date:		[***]

ORDER AGREED TO AND ACCEPTED BY:

Achaogen, Inc.		Hovione Limited

By:	/s/ [***]	By:	/s/ [***]
Name:	[***]	Name:	[***]

Title:	[***]	Title:	[***]
Date:	[***]	Date:	[***]


Achaogen-Hovione Validation and Manufacturing Agreement	9
Work Plan #[***]	CONFIDENTIAL

Exhibit 11-9

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

Exhibit 12

Program Work PLAN - WORK Plan No. C-4

[***]

Work Plan No. C-04

Version [***]

[***]

Reference: [***]

This Work Plan No. C-04 (the “Work Plan”), dated [***] (the “Order Date”), is by and between Hovione Limited, having a place of business at Loughbeg, Ringaskiddy, Cork, County Cork, Ireland (“Hovione”) and Achaogen, Inc., a Delaware corporation, having a principle place of business at 7000 Shoreline Court, Suite 371, South San Francisco, California 94080, U.S.A. (“Customer”), and upon execution by both parties, shall be incorporated into the Validation and Manufacturing Agreement between Customer and Hovione Limited with an effective date of [***] (the “Agreement”). Customer and Hovione Limited hereby acknowledge and agree to all terms in both this Work Plan and the Agreement. Capitalized terms used in this Work Plan shall have the meanings ascribed to them in the Agreement.

1.	Background:

In order to meet Customer’s commercial demand for [***] and [***], Hovione recommends [***]

This purpose of this Work Plan is to confirm that both Parties will discuss and agree in good faith on a Work Plan that will cover [***].

This Work Plan does not include [***]. The [***] is covered in a separate Work Plan.

Tasks:

In order to ensure that the Facility is ready in time to support the [***], the Parties will discuss and agree in good faith on a Work Plan which covers the specific tasks and business terms for the engineering and qualification activities at the Facility by [***].

In order to ensure that the [***] is available and qualified to support the Manufacture of Plazomicin outlined in Work Plan [***] and Work Plan [***], the Parties will discuss and agree in good faith on a Work Plan which covers the [***] by [***].


Achaogen-Hovione Validation and Manufacturing Agreement	1
Work Plan #C-[***]	CONFIDENTIAL

Exhibit 12-1

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

Timeline:

Work Plan to support [***] at Facility: due [***]. Work Plan to support purification scale-up and qualification activities: due [***]

4.	Deliverables:

Work Plans to support [***]

Work Plan to support [***]

5.	Compensation and Payment Terms

5.1

Labor & Equipment

Not applicable for this Work Plan.

5.2

Reports and Deliverables

Work Plan for [***]

5.3

Project Specific Materials

Not applicable for this Work Plan.

5.4

Shipping

Not applicable for this Work Plan.

5.5

Travel Costs

Not applicable for this Work Plan.

5.6

Other Costs

Not applicable for this Work Plan.

5.7

Invoices

Not applicable for this Work Plan.


Achaogen-Hovione Validation and Manufacturing Agreement	2
Work Plan #C-[***]	CONFIDENTIAL

Exhibit 12-2

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

6.	Ceiling Price

Not applicable for this Work Plan.

7.	Government Sponsored Project:

Pursuant to Article 20 of the Manufacturing Agreement, this Work Plan is a “Government Project”.

8.	Commercial Contact: Hovione:	Project Management Contact: Hovione:
	[***]	[***]
	Tel: [***]	Tel: [***]
	[***]	[***]

	Achaogen: [*] Tel: [] [**]	Achaogen [*] Tel: [] [**]

9.Term:

9.1

10.Miscellaneous:

10.1

Each party represents that it has full power and authority to enter into this Work Plan.

10.2

10.3


Achaogen-Hovione Validation and Manufacturing Agreement	3
Work Plan #C-[***]	CONFIDENTIAL

Exhibit 12-3

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

electronic exchange of this Work Plan, or of any counterpart, shall be deemed the equivalent of an original.

ORDER PREPARED BY:
Hovione Limited
Name:		[***]
Title:		[***]
Date:		[***]

ORDER AGREED TO AND ACCEPTED BY:

Achaogen, Inc.		Hovione Limited

By:	/s/ [***]	By:	/s/ [***]
Name:	[***]	Name:	[***]

Title:	[***]	Title:	[***]
Date:	[***]	Date:	[***]


Achaogen-Hovione Validation and Manufacturing Agreement	4
Work Plan #C-[***]	CONFIDENTIAL

Exhibit 12-4

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

Exhibit 13

Program Work PLAN - WORK Plan No. C-5

[***]

Work Plan No. C-05

Version [***]

[***]

Reference: [***]

This Work Plan No. C-05 (the “Work Plan”), dated [***] (the “Order Date”), is by and between Hovione Limited, having a place of business at Loughbeg, Ringaskiddy, Cork, County Cork, Ireland (“Hovione”) and Achaogen, Inc., a Delaware corporation, having a principle place of business at 7000 Shoreline Court, Suite 371, South San Francisco, California 94080, U.S.A. ("Customer"), and upon execution by both parties, shall be incorporated into the Validation and Manufacturing Agreement between Customer and Hovione Limited with an effective date of [***] (the “Agreement”). Customer and Hovione Limited hereby acknowledge and agree to all terms in both this Work Plan and the Agreement. Capitalized terms used in this Work Plan shall have the meanings ascribed to them in the Agreement.

1.	Background:

This Work Plan is based on Hovione’s historical experience with the Plazomicin [***] program and on discussions between the Customer and Hovione. All information and content herein reflects information known at the time of the Order Date.

The [***] for Customer’s proprietary compound Plazomicin [***] (the “Product”) will occur at [***] with the [***] at [***], individually referred to as the “Facility” and collectively referred to as the “Facilities.” This is covered in Work Plan [***].

This Work Plan will cover the Manufacture of one [***] referenced above. It will cover the manufacture of [***] covered in Work Plan [***]. The [***]

This Work Plan does not include any [***]. If such work is requested, it will be covered in a separate Work Plan(s).


Achaogen-Hovione Validation and Manufacturing Agreement	1
Work Plan [***]	CONFIDENTIAL

Exhibit 13-1

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

Tasks:

This Work Plan covers the [***]. The batch will be produced in the [***] in [***]. It is anticipated that batch [***]. It is anticipated that [***] will occur at [***].

Timeline:

Hovione confirms that the [***] would commence in [***]. The Manufacture of this batch is anticipated to be completed by [***]. Any changes to the timeline shall be made in writing and signed by both Parties.

At the time this Work Plan was prepared, the following is anticipated:

•

[***]

•

[***]

4.	Deliverables:

Hovione shall prepare the following deliverables for Customer under this Work Plan (collectively the “Deliverables”).

•

[***]

•

Master Batch Production Records

•

Completed Batch Production Records

•

Campaign summary report

5.	Compensation and Payment Terms

5.1

Labor & Equipment

In consideration of these Services performed by Hovione, Customer shall pay Hovione [***] for the Tasks outlined in Section 2 and the Deliverables set forth in Section 4 (the “Service Fees”).

5.2

Reports and Deliverables

All Deliverables are included in the Service Fees above.


Achaogen-Hovione Validation and Manufacturing Agreement	2
Work Plan [***]	CONFIDENTIAL

Exhibit 13-2

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

5.3

Project Specific Materials

The total cost of Project Specific Materials described in this Work Plan shall not exceed [***] where a maximum of [***] is for the procurement of [***] and a maximum of [***] for procurement of [***]. The [***] has been purchased under a separate Work Plan.

Hovione will not use Project Specific Materials on any other project. Project Specific Materials may be shipped to Customer at Customer’s written request and expense.

5.4

Shipping

[***]. Hovione will use a dedicated shipping account provided by Customer for these charges. Compounds will be shipped by [***] unless otherwise requested by Customer. Hovione estimates that the shipping costs inclusive of customs, shipping and packing materials will not exceed [***]. [***].

All materials shipped by Hovione on behalf of Customer will follow [***].

5.5

Travel Costs

5.6

Other Costs

Not applicable at the time of Work Plan issuance. If Other Costs need to be incurred, these will be discussed and agreed in writing by both the Customer and Hovione prior to their expenditure.


Achaogen-Hovione Validation and Manufacturing Agreement	3
Work Plan [***]	CONFIDENTIAL

Exhibit 13-3

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

5.7

Invoices

Payment will be made according to the terms of the Agreement, and as outlined below.

5.7.1

Milestones: Hovione will invoice Customer according to the following payment milestone schedule:

5.7.1.1.

[***] and issuance of the PO, Hovione will issue an invoice for [***] for the purchase of Project Specific Materials, General Chemicals, Materials and Supplies and the reservation of capacity and resources.

5.7.1.2.

[***], Hovione will issue an invoice for [***].

5.7.1.3.

[***], Hovione will issue an invoice for [***].

5.7.1.4.

[***], Hovione will issue an invoice for [***].

5.7.1.5.

[***], Hovione will issue an invoice for [***].

5.7.1.6.

[***], Hovione will invoice Customer up to [***].

5.7.2.

Invoice Markings. All invoices for payments to be made to Hovione for services under this Exhibit shall be marked with:

5.7.2.1.

the following unique Purchase Order number: .

5.7.2.2.

the statement “Work Plan #C-05 entitled, [***].”

6.	Ceiling Price

The ceiling price for the services covered under this Work Plan C-05 is [***] of which no more than [***] shall be for services (6.1), [***] for the final report (6.2), [***] for General and Project-Specific Materials (6.3), and [***] for shipping costs (6.4). Customer shall not be obligated to pay Hovione any amount in excess of this ceiling price, unless and until an additional agreement that raises this price has been negotiated and signed by both Parties.


Achaogen-Hovione Validation and Manufacturing Agreement	4
Work Plan [***]	CONFIDENTIAL

Exhibit 13-4

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

7.	Government Sponsored Project:

Pursuant to Article 20 of the Manufacturing Agreement, this Work Plan is a “Government Project”.

8.	Commercial Contact: Hovione:	Project Management Contact: Hovione:
	[***]	[***]
	Tel: [***]	Tel: [***]
	[***]	[***]

	Achaogen: [*] Tel: [] [**]	Achaogen [*] Tel: [] [**]

Term:

9.1

If this Work Plan is cancelled greater than or equal to [***] prior to the planned start of the campaign, Customer will compensate Hovione with [***] of the total value of this Work Plan [***].

9.2

If this Work Plan is cancelled less than [***] prior to the planned start of the campaign, Customer will compensate Hovione with [***] of the total value of this Work Plan [***].

9.3

If this Work Plan is cancelled after the start of the campaign, Customer will compensate Hovione with a cancellation fee of [***] of the total value of this Work Plan.

9.4

10.	Miscellaneous:

10.1

Each party represents that it has full power and authority to enter into this Work Plan.


Achaogen-Hovione Validation and Manufacturing Agreement	5
Work Plan [***]	CONFIDENTIAL

Exhibit 13-5

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

10.2

10.3

ORDER PREPARED BY:
Hovione Limited
Name:		[***]
Title:		[***]
Date:		[***]

ORDER AGREED TO AND ACCEPTED BY:

Achaogen, Inc.		Hovione Limited

By:	/s/ [***]	By:	/s/ [***]
Name:	[***]	Name:	[***]

Title:	[***]	Title:	[***]
Date:	[***]	Date:	[***]


Achaogen-Hovione Validation and Manufacturing Agreement	6
Work Plan [***]	CONFIDENTIAL

Exhibit 13-6

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

Exhibit 14

Program Work PLAN - WORK Plan No. C-6

[***]

Work Plan No. C-06

Version [***]

[***]

Reference: [***]

This Work Plan No. C-06 (the “Work Plan”), dated [***] (the “Order Date”), is by and between Hovione Limited, having a place of business at Loughbeg, Ringaskiddy, Cork, County Cork, Ireland (“Hovione”) and Achaogen, Inc., a Delaware corporation, having a principle place of business at 7000 Shoreline Court, Suite 371, South San Francisco, California 94080, U.S.A. ("Customer"), and upon execution by both parties, shall be incorporated into the Validation and Manufacturing Agreement between Customer and Hovione Limited with an effective date of [***] (the “Agreement”). Customer and Hovione Limited hereby acknowledge and agree to all terms in both this Work Plan and the Agreement. Capitalized terms used in this Work Plan shall have the meanings ascribed to them in the Agreement.

1.	Background:

The [***] for Customer’s proprietary compound [***] (the “Product”) will occur at [***], individually referred to as the “Facility” and collectively referred to as the “Facilities.” Assuming that all [***] are completed in a timely manner, the anticipated timing for the [***] of the Product will be [***]. Additional process development such as [***] will be covered under a separate Work Plan and is anticipated to be [***].

This Work Plan does not include any [***]. If such work is requested, it will be covered in a separate Work Plan(s).


Achaogen-Hovione Validation and Manufacturing Agreement	1
Work Plan C-[***]	CONFIDENTIAL

Exhibit 14-1

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

2.Tasks:

This Work Plan covers the Validation Program to be run in the [***]. It is anticipated that [***]. It is anticipated that this campaign will consist of [***]

Timeline:

Hovione confirms that the [***] would commence in [***]. The deadline for delivery of the [***] (the “Final Deliverable”) to Customer is [***] following [***] (the “Deadline”). The Manufacturing campaign is anticipated to be completed by [***]. Any changes to the timeline shall be made in writing and signed by both Parties.

At the time this Work Plan was prepared, the following is anticipated:

•

[***]

•

[***]

•

[***]

•

[***]

4.	Deliverables:

Hovione shall prepare the following deliverables for Customer under this Work Plan (collectively the “Deliverables”).

•

[***]

•

[***]

•

[***]

•

[***]

•

Master Batch Production Records

•

Completed Batch Production Records

•

Campaign summary report

5.	Compensation and Payment Terms

5.1

Labor & Equipment

In consideration of these Services performed by Hovione, Customer shall pay Hovione [***] for the Tasks outlined in Section 2 and the Deliverables set forth in Section 4 (the “Service Fees”).


Achaogen-Hovione Validation and Manufacturing Agreement	2
Work Plan C-[***]	CONFIDENTIAL

Exhibit 14-2

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

5.2

Reports and Deliverables

All Deliverables are included in the Service Fees above.

5.3

Project Specific Materials

The total cost of Project Specific Materials described in this Work Plan shall not exceed [***] where a maximum of [***] is for the procurement of [***] and a maximum of [***]. The [***] has been purchased under a separate Work Plan.

Hovione will not use Project Specific Materials on any other project. Project Specific Materials may be shipped to Customer at Customer’s written request and expense.

5.4

Shipping

All materials shipped by Hovione on behalf of Customer will follow [***]

5.5

Travel Costs


Achaogen-Hovione Validation and Manufacturing Agreement	3
Work Plan C-[***]	CONFIDENTIAL

Exhibit 14-3

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

5.6

Other Costs

Not applicable at the time of Work Plan issuance. If Other Costs need to be incurred, these will be discussed and agreed in writing by both the Customer and Hovione prior to their expenditure.

5.7

Invoices

Payment will be made according to the terms of the Agreement, and as outlined below.

5.7.1

Milestones: Hovione will invoice Customer according to the following payment milestone schedule:

5.7.1.1.

[***], Hovione will issue an invoice for [***] for the purchase of Project Specific Materials, General Chemicals, Materials and Supplies and the reservation of capacity and resources.

5.7.1.2.

[***], Hovione will issue an invoice for [***].

5.7.1.3.

[***], Hovione will issue an invoice for [***].

5.7.1.4.

[***], Hovione will issue an invoice for [***].

5.7.1.5.

[***], Hovione will issue an invoice for [***].

5.7.1.6.

[***], Hovione will issue an invoice for [***].

5.7.1.7.

[***], Hovione will issue an invoice for [***].

5.7.1.8.

[***], Hovione will issue an invoice for [***].

5.7.1.9.

[***], Hovione will issue an invoice for [***].

5.7.1.10.

[***], Hovione will issue an invoice for [***].

5.7.1.11.

Upon issuance of the [***], Hovione will issue an invoice for [***].

5.7.1.12.

[***], Hovione will issue an invoice for [***].


Achaogen-Hovione Validation and Manufacturing Agreement	4
Work Plan C-[***]	CONFIDENTIAL

Exhibit 14-4

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

5.7.1.13.

[***], Hovione will issue an invoice for [***].

5.7.1.14.

[***], Hovione will issue an invoice for [***].

5.7.1.15.

[***], Hovione will invoice Customer up to [***] for shipping costs incurred during the campaign.

5.7.2.Invoice Markings. All invoices for payments to be made to Hovione for services under this Exhibit shall be marked with:

5.7.2.1.

the following unique Purchase Order number: .

5.7.2.2.

the statement “Work Plan #C-06 entitled, [***].”

6.	Ceiling Price

The ceiling price for the services covered under this Work Plan C-06 is [***] of which no more than [***] shall be for services (6.1), [***] for the final report (6.2), [***] for General and Project-Specific Materials (6.3), and [***] for shipping costs (6.4). Customer shall not be obligated to pay Hovione any amount in excess of this ceiling price, unless and until an additional agreement that raises this price has been negotiated and signed by both Parties.

7.	Government Sponsored Project:

Pursuant to Article 20 of the Manufacturing Agreement, this Work Plan is a “Government Project”.

8.	Commercial Contact: Hovione:	Project Management Contact: Hovione:
	[***]	[***]
	Tel: [***]	Tel: [***]
	[***]	[***]

	Achaogen: [*] Tel: [] [**]	Achaogen [*] Tel: [] [**]


Achaogen-Hovione Validation and Manufacturing Agreement	5
Work Plan C-[***]	CONFIDENTIAL

Exhibit 14-5

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

9.Term:

9.1

If this Work Plan is cancelled greater than or equal to [***] prior to the planned start of the campaign, Customer will compensate Hovione with [***] of the total value of this Work Plan [***].

9.2

If this Work Plan is cancelled less than [***] prior to the planned start of the campaign, Customer will compensate Hovione with [***] of the total value of this Work Plan [***].

9.3

If this Work Plan is cancelled after the start of the campaign, a cancellation fee of [***] of the total value of this Work Plan [***] of the Work Plan value for each started and completed batches [***].

9.4

10.	Miscellaneous:

10.1

Each party represents that it has full power and authority to enter into this Work Plan.

10.2

10.3


Achaogen-Hovione Validation and Manufacturing Agreement	6
Work Plan C-[***]	CONFIDENTIAL

Exhibit 14-6

Confidential Treatment Requested by Achaogen, Inc.

Achaogen

Plazomicin

[***]

ORDER PREPARED BY:
Hovione Limited
Name:		[***]
Title:		[***]
Date:		[***]

ORDER AGREED TO AND ACCEPTED BY:

Achaogen, Inc.		Hovione Limited

By:	/s/ [***]	By:	/s/ [***]
Name:	[***]	Name:	[***]

Title:	[***]	Title:	[***]
Date:	[***]	Date:	[***]


Achaogen-Hovione Validation and Manufacturing Agreement	7
Work Plan C-[***]	CONFIDENTIAL

Exhibit 14-7

Confidential Treatment Requested by Achaogen, Inc.

Exhibit 15

Project Time-Line that describes the planned scheduling of the activities and tasks by Hovione from the effective date of this agreement ti^ªll up to and including [***]

Exhibit 15-1

Confidential Treatment Requested by Achaogen, Inc.

APPENDIX A

Government Contract Clauses

1.	The Terms and Conditions explicated in this Appendix are applicable to the Service Provider for all Government Projects conducted by HOVIONE on behalf of ACHAOGEN.

Referenced Clauses. The following provisions are incorporated by reference and have the same force and effect as if set forth in full text. Clauses listed in this Section that are incorporated by reference have the same force and effect as if they were given in full text. References are to the Federal Acquisition Regulation (FAR) and to the Defense Federal Acquisition Regulation Supplement (DFARS). Full text is available at http://farsite.hill.af.mil/. For purposes of this Agreement, the term “contract” shall mean this Agreement; the term “Contractor” shall mean HOVIONE; the term “prime contractor” shall mean ACHAOGEN; and the terms “Government” and “Contracting Officer” shall mean ACHAOGEN or the United States Government depending on the context in which the term is used.


Clause	Date	Title
FAR 52.203-5	Sep-06	Covenant Against Contingent Fees (Over $100,000)
FAR 52.203-6	Sep-06	Restrictions on Subcontractor Sales to the Government (Over $100,000)
FAR 52.203-7	Jul-95	Anti-Kickback Procedures (Over $100,000)
FAR 52.215-2	Mar-09	Audit and Records-Negotiation (Over $100,000) Insert “and Achaogen” after “Contracting Officer” and “Comptroller General of the United States”.
FAR 52.215-12	Oct-97	Subcontractor Cost or Pricing Data (Over $650,000)
FAR 52.215-21	Oct-97	Requirements for Cost or Pricing Data or Information Other Than Cost or Pricing Data-Modifications. Substitute “Achaogen” for “Contracting Officer” throughout this clause.
FAR 52.219-8	May-04	Utilization of Small Business Concerns (Over $100,000)
FAR 52.222-35	Sept-06	Equal Opportunity for Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans (Over $100,000)
FAR 52.222-37	Sep-06	Employment Reports on Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans (Over $100,000)
FAR 52.222-50	Feb-09	Combating Trafficking in Persons Substitute “Achaogen” for “Contracting Officer” throughout this clause. In paragraph I, insert “and Achaogen” after “Government”.
FAR 52.225-13	Jun-08	Restrictions on Certain Foreign Purchases
FAR 52.227-1	Dec-07	Authorization and Consent, Alternate I (Apr 1984) (Over $100,000)

Confidential Treatment Requested by Achaogen, Inc.


Clause	Date	Title
FAR 52.227-2	Dec-07	Notice and Assistance Regarding Patent and Copyright Infringement (Over $100,000)
FAR 52.227-11	Dec-07	Patent Rights – Ownership by the Contractor (Note: In accordance with FAR 27.303(b)(2), paragraph I is modified to include the requirements in FAR 27.303(b)(2)(i) through (iv). The frequency of reporting in (i) is annual
FAR 52.230-3	Aug-96	Disclosure and Consistency of Cost Accounting Practices, with the exception of clause (b).
FAR 52.230-6	Mar-08	Administration of Cost Accounting Standards
FAR 52.244-6	Jun-10	Subcontracts for Commercial Items
FAR 52.247-64	Feb-06	Preference for Privately Owned U.S.-Flag Commercial Vessels
FAR 52.247.67	Feb-06	Submission of Transportation Documents for Audit
FAR 252.203-7001	Dec-04	Prohibition on Persons Convicted of Fraud or Other Defense-Contract-Related Felonies
FAR 252.204.7000	Dec-91	Disclosure of Information
FAR 252.227.7013	Nov-95	Rights to Technical Data-Noncommercial Items
FAR 252.227.7016	Jun-95	Rights in Bid or Proposal Information
FAR 252.227.7037	Sep-99	Validation of Restrictive Markings on Technical Data
FAR 252.247.7023	May-02	Transportation of Supplies by Sea
FAR 252.247.7024	Mar-00	Notification of Transportation of Supplies by Sea

Referenced Clauses for Lower Tier Contracts. Notwithstanding any other language in this Agreement, including any clauses incorporated by reference, HOVIONE agrees as a subcontractor to a Federal prime contract to incorporate only the following Government Contract Clauses, as applicable, with all subcontracts HOVIONE negotiates in association with the services materials provided to ACHAOGEN as an aspect of a Government Project.


Clause	Date		Title
FAR 52.230-6		Mar-08	Administration of Cost Accounting Standards
FAR 52.244-6		Sep-06	Subcontracts for Commercial Items
FAR 52.247-64		Feb-06	Preference for Privately Owned U.S.-Flag Commercial Vessels
FAR 52.247.67		Feb-06	Submission of Transportation Documents for Audit
FAR 252.203-7001		Dec-04	Prohibition on Persons Convicted of Fraud or Other Defense-Contract-Related Felonies
FAR 252.204.7000		Dec-91	Disclosure of Information
FAR 252.227.7013		Sep-99	Validation of Restrictive Markings on Technical Data
FAR 252.227.7016		Nov-05	Subcontracts for Commercial Items and Commercial Components

Confidential Treatment Requested by Achaogen, Inc.

Protecting the Government’s Interests when Subcontracting with Contractors Debarred, Suspended, or Proposed for Debarment (reference: FAR 52.209-6). As a condition of this Agreement, HOVIONE certifies that, it or any of its principles (as defined in FAR 52.209-5(a)(2)) are not currently debarred, suspended, or proposed for debarment by the Federal Government. HOVIONE agrees to provide immediate written notice to ACHAOGEN if, at any time prior to termination, HOVIONE learns that its certification was erroneous when submitted or has become erroneous by reason of changed circumstances.

5.	Certification and Disclosure Regarding Payments to Influence Certain Federal Transactions (Reference: FAR 52.203-11). As a condition of this Agreement, HOVIONE certifies that:

5.1

no Federal appropriated funds have been paid or will be paid to any person for influencing or attempting to influence in the extension, continuation, renewal, amendment, or modification of any Federal contract, grant, loan, or cooperative agreement;

5.2

for any funds other than Federally appropriated funds, HOVIONE shall complete and submit, with its offer, OMB standard form LLL, “Disclosure of Lobbying Activities”, for transmittal to the Contracting Officer; and

5.3

HOVIONE will include the language of this certification in all subcontracts, at any tier, negotiated in association with the services and materials provided to ACHAOGEN under this Agreement, and require that all recipients of subcontract awards in excess of $100,000 certify and, if required, disclose accordingly.

6.	Government Right to Inspection of Research and Development (Reference: FAR 52.246-8).

6.1

HOVIONE recognizes that the Government has the right to inspect and test all work called for by this Agreement, to the extent practicable at all places and times, including the period of performance, and in any event before its termination. The Government may also inspect the plant or plants of the contractor or its subcontractors engaged in Prime Contract performance. The Government shall perform inspections and tests in a manner that will not unduly delay the work.

6.2

If the Government performs any inspection or test on its premises, HOVIONE shall furnish all reasonable facilities and assistance for the safe and convenient performance of these duties.

7.	Registration in the Central Contractor Registration (“CCR”) Database (Reference: FAR 52.204-7).

Confidential Treatment Requested by Achaogen, Inc.

7.1

HOVIONE shall be registered in the CCR database prior to signing, during performance, and through final payment of this Agreement

7.2

HOVIONE will include this requirement in all subcontracts, at any tier, negotiated in association with the services and materials provided to ACHAOGEN under this Agreement, and require that all recipients of subcontract awards in excess of $100,000 register accordingly.

8.	Government Interface.

8.1

As the Government is not in privity with HOVIONE, HOVIONE employees may not interface with any Government employee without advance consent from ACHAOGEN.

8.2

If ACHAOGEN allows HOVIONE or HOVIONE employees access to Government employees, HOVIONE is not authorized to accept Government instruction on behalf of ACHAOGEN. HOVIONE is not authorized to make offers, commitments, or otherwise negotiate with the government on ACHAOGEN’s behalf or its own behalf in its capacity as a subcontractor to ACHAOGEN. In case of occurrence of any such offense, HOVIONE shall

8.2.1

suggest to the Government representative that ACHAOGEN be involved in all such discussions, and

8.2.2

immediately report to ACHAOGEN any attempt by Government personnel to provide such instruction or conduct such negotiations.

8.3

If HOVIONE interfaces with the Government, HOVIONE’s regular reports to list all data exchanged and shall summarize all significant technical discussions with the Government personnel during the reporting period.

8.4

Under no circumstances shall HOVIONE initiate contact with ACHAOGEN’s Procuring Contracting Officer (“PCO”), Administrative Contracting Officer (“ACO”), Contracting Officer’s Representative (“COR”), or their respective support staff, with respect to any matters pertaining to this agreement or the Prime Contract, without the advance consent of ACHAOGEN.

Disputes.

9.1

Disputes Involving the Prime Contract and/or the Government:

9.1.1

In the event of: (i) a claim by HOVIONE against the Government; (ii) a claim by the Government against HOVIONE; (iii) a claim by the Government against ACHAOGEN; (iv) a claim by ACHAOGEN against the Government; or (v) in appealable finding of fact or law or judgment by the Government or a court, to the extent that such claim, finding, or judgment arises from or is related to the Prime Contract and materially

Confidential Treatment Requested by Achaogen, Inc.

affects ACHAOGEN’s interests, ACHAOGEN will promptly notify HOVIONE and, at its option, as permitted by the terms of the Prime Contract, follow one of the following procedures:

9.1.1.1

ACHAOGEN will prosecute, defend, or appeal all claims to the extent of ACHAOGEN’s interest. HOVIONE will assist ACHAOGEN in every reasonable manner, including but not limited to furnishing all documents, statements, witnesses as may be in its employ, and other pertinent information, as required by ACHAOGEN.

9.1.1.2

ACHAOGEN will authorize HOVIONE to prosecute, defend, or appeal in ACHAOGEN’s name, to the extent of HOVIONE’s interest. ACHAOGEN will assist HOVIONE in every reasonable manner, including but not limited to furnishing all relevant documents, statements, witnesses as may be in its employ, and other pertinent information as deemed necessary.

9.1.2

Effect of Decisions.

9.1.2.1

All preliminary and final decisions and judgments issued by the Government or a court pursuant to claims or appeals within the scope of paragraph 9.1.1 of this Section shall be binding upon HOVIONE to the extent binding on ACHAOGEN, whether or not HOVIONE was a party to the prosecution, defense, or appeal.

9.1.2.2

If, as the result of any decision or judgment which is binding upon ACHAOGEN and HOVIONE, ACHAOGEN is unable to obtain reimbursement from the Government under the Prime Contract for, or is required to refund or credit to the government any amount with respect to any item of cost or fee for which ACHAOGEN has reimbursed HOVIONE, HOVIONE shall, on demand, promptly repay such amount to ACHAOGEN.

EX-10.4 5 akao-ex104_711.htm EX-10.4 akao-ex104_711.htm

Exhibit 10.4

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

1. CONTRACT ID CODE

PAGE OF PAGES

2. AMENDMENT/MODIFICATION NO.

0026

3. EFFECTIVE DATE

See Block 16C

4. REQUISITION/PURCHASE REQ. NO.

5. PROJECT NO. (If applicable)

6. ISSUED BYCODE

ASPR-BARDA

7. ADMINISTERED BY (If other than Item 6)CODE

ASPR-BARDA

ASPR-BARDA
200 Independence Ave., S.W.
Room 640-G
Washington DC 20201

ASPR-BARDA
200 Independence Ave., S.W.
Room 638-G
Washington DC 20201

8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)

(X)

9A. AMENDMENT OF SOLICITATION NO.

ACHAOGEN, INC. 1361331
ACHAOGEN, INC. 7000 SHORELINE
7000 SHORELINE CT STE 371
SOUTH SAN FRANCISCO CA 940801957

9B. DATED (SEE ITEM 11)

10A. MODIFICATION OF CONTRACT/ORDER NO.

HHSO100201000046C

CODE1361331

FACILITY CODE

10B. DATED (SEE ITEM 13)

09/01/2010

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

☐

The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers

☐ is extended

☐ is not extended

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:  (a) By completing
Items 8 and 15, and returning _______________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By
separate letter or telegram which includes a reference to the solicitation and amendment numbers.  FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT
THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER.  If by
virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes
reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

12. ACCOUNTING AND APPROPRIATION DATA (If required)

See Schedule

13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

CHECK ONE

A.THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT
ORDER NO. IN ITEM 10A.

B.THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office,
appropriation date. etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

C.THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

D.OTHER (Specify type of modification and authority)

Bilateral: Mutual Agreement of the Parties and FAR Clause 52.217-7

E. IMPORTANT:

Contractor

☐ is not

☒ is required to sign this document and return 2 copies to the issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

Tax ID Number: 68-0533693

DUNS Number: 167293153

A.The purpose of this bi-lateral modification is to update the list of Key Personnel.

Under Article G.3., Key Personnel, the current list of contract Key Personnel is hereby

deleted and replaced with a list of the following Achaogen employees:

1. Lynn Connolly, VP, Late Development, Principal Investigator

2. Anne Keane, Sr. Dir. Regulatory & Quality, Regulatory Director

3. Neil Andersen, Dir. Process Chemistry, Drug Substance Manufacturing Manager

4. Matthew Metz, Dir. Alliance Management, BARDA Liason

Continued…

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A. NAME AND TITLE OF SIGNER (Type or print)

Tobin C. Schilke CFO

16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

THOMAS P. HASTINGS

15B. CONTRACTOR/OFFEROR

/s/ Tobin Schilke
(Signature of person authorized to sign)

15C. DATE SIGNED

3/30/17

16B. UNITED STATES OF AMERICA

/s/ Thomas P. Hastings
(Signature of Contracting Officer)

16C. DATE SIGNED

3/30/2017

NSN 7540-01-152-8070
Previous edition unusable

STANDARD FORM 30 (REV. 10-83)
Prescribed by GSA
FAR (48 CFR) 53.243


CONTINUATION SHEET		REFERENCE NO. OF DOCUMENT BEING CONTINUED HHSO100201000046C/0026				PAGE OF
CONTINUATION SHEET						2	2
NAME OF OFFEROR OR CONTRACTOR ACHAOGEN, INC. 1361331
ITEM NO. (A)	SUPPLIES/SERVICES (B)	QUANTITY (C)	UNIT (D)	UNIT PRICE (E)	AMOUNT (F)
	5. Jim Kirchner, Dir. Process Chemistry, Drug Product Manufacturing and Drug Registration Manager B. This is a bi-lateral, no cost modification. The total amount obligated and all other terms and conditions remain unchanged. Period of performance: 09/19/2010 to 12/31/2017


NSN 7540-01-152-8067		OPTIONAL FORM 336 (4-86) Sponsored by GSA FAR (48 CFR) 53.110

EX-10.5 6 akao-ex105_830.htm EX-10.5 akao-ex105_830.htm

Exhibit 10.5

Confidential Treatment Requested by Achaogen, Inc.

COLLABORATIVE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

This Collaborative Development and Commercialization Agreement (“Agreement”) is entered into as of April 26, 2016 (“Effective Date”) by and between Microgenics Corporation (hereinafter “Microgenics”), having its principal place of business at 46500 Kato Road, Fremont, California 94538, and Achaogen Inc. (hereinafter “Achaogen”), having a place of business at 7000 Shoreline Court, #371, South San Francisco, California 94080. Both Microgenics and Achaogen are referred to herein individually as a “Party” and collectively as the “Parties.”

WHEREAS, Achaogen possesses certain intellectual property rights and know-how relating to drug compound Plazomicin;

WHEREAS, Microgenics has certain expertise and know-how relating to the development, manufacture and sale of immunoassays for in vitro diagnostic use;

WHEREAS, the Parties are undertaking, as of the Effective Date, activities under that certain Antibody Development Agreement, dated [***] (the “Antibody Development Agreement”), for the purpose of identifying and developing antibodies against Plazomicin and this Agreement is the “Assay Commercialization Agreement” referred to in Section 2.6 of the Antibody Development Agreement; and

WHEREAS, the Parties desire to collaborate on the development and commercialization of a therapeutic drug monitoring assay for the measurement of concentrations of Plazomicin in biological fluids.

NOW THEREFORE, in consideration of the foregoing premises and the covenants and promises contained herein, the Parties intending to be bound, hereby agree as follows:

1.Definitions

For the purposes of this Agreement and the Exhibits hereto, the following words and phrases shall have the following meanings (words defined in the Agreement shall have the meaning ascribed to them in that Section):

1.1“Achaogen Know-How” shall mean all proprietary, technical and clinical information, data and know-how relating to Plazomicin and haptens and polyclonal antibodies related directly to Plazomicin, whether or not patentable, which is Controlled as of the Effective Date or acquired during the Term by Achaogen.

1.2“Achaogen Materials” shall mean the materials set forth in Exhibit A.

1.3“Achaogen Patents” shall mean the Patents and Patent applications set forth in Exhibit B hereto.

1.4“Affiliate” shall mean, with respect to a Party, any corporation, or other business entity which directly controls, is controlled by or is under common control with that Party. A person or entity shall be regarded as in control of another entity if it owns, directly or indirectly, fifty percent (50%) or more of the outstanding equity securities of the subject entity which is entitled to vote in the election of directors, or a fifty percent (50%) or greater interest in the net assets or profits of the subject entity if such entity is not a corporation.

Confidential Treatment Requested by Achaogen, Inc.

1.5“Applicable Law” shall mean all applicable provisions of all statutes, laws, rules, regulations, administrative codes, ordinances, decrees, orders, decisions, injunctions, awards judgments, permits and licenses of or from governmental authorities, including those relating to or governing the use or regulation of the subject item and the listing standards or agreements of any national or international securities exchange.

1.6“Assay” shall mean an antibody-based immunoassay or immunoassays used for the in vitro measurement of Plazomicin concentration in human blood and other body fluids, [***], that (a) uses or otherwise would infringe Immunoassay Technologies, (b) is developed by Microgenics and its Affiliates under this Agreement, and (c) [***].

1.7“Commercially Reasonable Efforts” shall mean efforts and resources normally utilized by a Party for a product owned by it or to which it has rights, which is of similar market potential at a similar stage in its product life, taking into account the competitiveness of the marketplace, the proprietary position of the product, the regulatory structure involved, the profitability of the applicable products, the relative benefit that accrues to actual and potential patients and other relevant factors; provided, that, in any event, “Commercially Reasonable Efforts” under this Agreement require that a Party (a) [***], (b) [***], and (c) [***].

1.8“Confidential Information” shall mean all proprietary and confidential business, technical, scientific, and/or regulatory information relating to the Assay, Plazomicin, and/or the purpose of, or activities under, this Agreement, that is provided by or on behalf of a Disclosing Party to a Receiving Party hereunder, whether disclosed in writing or orally.

1.9“Control” shall mean with respect to any (a) item of information, including know-how, or (b) intellectual property right, the possession (whether by ownership or license) by a Party of the ability to grant to the other Party access and/or a license as provided herein under such item or right without violating the terms of any agreement or other arrangements with any Third Party existing before or after the Effective Date.

1.10“Development and Manufacturing Phase” shall mean that phase of the Research Program set forth in the Project Plan relating to the optimization of the Assay and the manufacture and validation of [***] ([***]) production lots of the Assay that meet the Specifications [***].

1.11“Feasibility Study Phase” shall mean that phase of the Research Program set forth in the Project Plan comprising all studies conducted by Microgenics to establish the feasibility for developing the Assay by demonstrating (a) [***], (b) [***], (c) [***], (d) [***], (e) [***], and (f) [***].

1.12“First Commercial Sale” shall mean (a) with respect to the Assay, the initial sale by or on behalf of Microgenics (or its Affiliates) of the Assay and (b) with respect to Plazomicin, the initial sale by or on behalf of Achaogen (or its Affiliates) of Plazomicin, in each case, to a Third Party in exchange for cash or some equivalent to which value can be assigned; provided, that a sale of the Assay or Plazomicin, as applicable, in connection with [***] of the Assay or Plazomicin, as applicable, or for [***] therefor will not constitute First Commercial Sale.

1.13“Good Clinical Practice” or “GCP” shall mean the then current standard for clinical trials for assays, as set forth in the United States Federal Food, Drug and Cosmetics Act and applicable regulations

Page 2 of 60

Confidential Treatment Requested by Achaogen, Inc.

promulgated thereunder, as amended from time to time and such standards of good clinical practice as are required by the European Union and other organizations and governmental agencies in countries where the Assay is intended to be sold, to extent such standards are no less stringent than United States GCP.

1.14“Good Laboratory Practice” or “GLP” shall mean the then current standards for laboratory activities for assays, as set forth in the United States Federal Food, Drug and Cosmetics Act and applicable regulations promulgated thereunder, as amended from time to time and such standards of good laboratory practice as are required by the European Union and other organizations and governmental agencies in countries where the Assay is intended to be sold, to extent such standards are no less stringent than United States GLP.

1.15“Good Manufacturing Practices” or “GMP” shall mean the then current standards for the manufacture of assays, as set forth in the United States Federal Food Drug and Cosmetics Act and applicable regulations promulgated thereunder, as may be amended from time to time and such standards of good manufacturing practice as are required by the European Union and other organizations and governmental agencies in countries where the Assay is intended to be sold, to extent such standards are no less stringent than United States GMP.

1.16“Immunoassay Technologies” shall mean technologies, including any patentable or unpatentable intellectual property rights appurtenant thereto, Controlled by Microgenics or its Affiliates suitable for developing and manufacturing assays, calibrators and controls for application on [***], including [***] assay technology, [***] technology, [***] technology, [***] immunoassay, the Microgenics Cell Line, and Microgenics [***] Antibodies.

1.17“Microgenics Cell Line” shall mean those certain cell lines (a) that were developed under the Antibody Development Agreement, or (b) that produce Microgenics [***] Antibodies and are Controlled by Microgenics and listed in Exhibit C, as such Exhibit may be amended from time to time upon the mutual written agreement of the Parties.

1.18“Microgenics Know-How” shall mean all proprietary, technical information, data and know-how relating to the Assay or Immunoassay Technologies and reagents for use therewith which are Controlled as of the Effective Date or acquired or developed during the Term by Microgenics or its Affiliates.

1.19“Microgenics [***] Antibodies” shall mean [***] antibodies developed by, or Controlled by, Microgenics or its Affiliates and directed to Plazomicin.

1.20“Patent” shall mean any existing or future: (a) national, regional or international patent or patent application in any jurisdiction (including any provisional, divisional, continuation, continuation-in-part, non-provisional, converted provisional, or continued prosecution application, any utility model, petty patent, design patent and/or certificate of invention), (b) any extension, restoration, revalidation, reissue, re-examination and extension (including any supplementary protection certificate and the like) of any of the foregoing patents or patent applications, and (c) any ex-U.S. equivalents corresponding to any of the foregoing.

1.21“Plazomicin” shall mean Achaogen’s aminoglycoside antibiotic that is in Phase 3 clinical development as of the Effective Date and having the chemical structure shown on Exhibit D, and [***] thereof, regardless of commercial name.

Page 3 of 60

Confidential Treatment Requested by Achaogen, Inc.

1.22“Primary Countries” shall mean (a) the countries set forth on Exhibit E and (b) any other country in the Territory which the Parties mutually agree in writing shall be a Primary Country in accordance with Section 4.2.5, in each case, for which the Parties intend to pursue initial registration, commercialization and launch of the Assay.

1.23“Project Plan” shall mean the plan of work to be conducted under the Research Program pursuant to Section 2.1 (Project Plan) hereof as attached as Exhibit F.

1.24“Regulatory Approval” shall mean all authorizations, registrations or clearances with or by the appropriate Regulatory Authorities which are required for the marketing, promotion, pricing and sale of either the Assay or Plazomicin, as applicable, in any country or regulatory jurisdiction in the Territory.

1.25“Regulatory Authority” shall mean any national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity involved in the granting of Regulatory Approval, including the United States Food and Drug Administration.

1.26“Research Program” shall mean the collaborative program of research relating to the development of the Assay to be carried out by the Parties pursuant to this Agreement.

1.27“Secondary Countries” shall mean all countries in the Territory, other than the Primary Countries.

1.28“Shortfall License” shall mean a temporary, fully-paid up, royalty-free, worldwide non-exclusive license granted by Microgenics (including on behalf of its Affiliates as appropriate), under Section 4.3.2.3, to (a) the Immunoassay Technologies and (b) all other intellectual property rights (including Patent applications, Patents, trade secrets, copyrights, and trademarks) (i) of Microgenics (or its Affiliates as appropriate) arising out of the performance of this Agreement or the Antibody Development Agreement, or (ii) Controlled by Microgenics (or its Affiliates as appropriate) that are necessary or desirable for or used in the manufacture and commercialization of the Assay, which license would be for the manufacture, use, sale, offer for sale and import of the Assay. Such license shall be fully sub-licensable to any Third Party for purposes of manufacturing and commercializing the Assay (including the components thereof) under Section 4.3.2.3.

1.29“Specifications” shall mean the specifications applicable to the Assay, as set forth on Exhibit G.

1.30“Territory” shall mean the world.

1.31“Third Party(ies)” shall mean any person(s) or entity(ies) other than Achaogen, Microgenics or their respective Affiliates.

1.32“Trademarks” shall mean all registered and unregistered trademarks (including all common law rights thereto), service marks, trade names, brand names, logos, taglines, slogans, certification marks, Internet domain names, trade dress, corporate names, business names and other indicia of origin, together with the goodwill associated with any of the foregoing and all applications, registrations, extensions and renewals thereof throughout the world, and all rights therein provided by international treaties and conventions.

Page 4 of 60

Confidential Treatment Requested by Achaogen, Inc.

1.33“Transfer License” shall mean a royalty-bearing, worldwide exclusive license granted by Microgenics (including on behalf of its Affiliates as appropriate), under Section 9.4.4.1, to (a) the Immunoassay Technologies and (b) all Patent applications, Patents, trade secrets and other know-how, (i) of Microgenics (or its Affiliates as appropriate) arising out of the performance of this Agreement or the Antibody Development Agreement, or (ii) Controlled by Microgenics (or its Affiliates as appropriate) as of the termination date of this Agreement that are necessary for or used in the development, manufacture, and commercialization of the Assay, which license would be solely for the development, manufacture, use, sale, offer for sale and import of the Assay in connection solely with the use of Plazomicin. Such license shall be fully sub-licensable to any Third Party for purposes of manufacturing and commercializing the Assay (including the components thereof) [***].

1.34Additional Definitions. Each of the following definitions is set forth in the Section of the Agreement indicated below.


Definition	Section
AAA	13.8.2
Abandoned Commercialization	4.2.7.1
Abandoned Development	4.2.7.1
Achaogen	Preamble
Achaogen Indemnified Parties	11.2
Achaogen Inventions	8.1
Agreement	Preamble
Alliance Manager	5.1.1
Antibody Development Agreement	Recitals
Assay Commercialization Plan	4.2.4
Audit Outcome	4.4.2
Back-up Supplier	4.3.2.2
Binding Forecast	4.2.2
Commercial Leader	5.3.1
Convicted Entity or Convicted Individual	10.4.4
Debarred Entity	10.4.2
Debarred Individual	10.4.1
Development Leader	5.3.1
Disclosing Party	12.1
Dispute	13.8.1
Effective Date	Preamble
Excluded Entity or Excluded Individual	10.4.3
FDA	10.4.5
FDA Disqualified/Restricted List	10.4.5
Force Majeure Event	13.1
Functional Leaders	5.3.1
Joint Project Team or JPT	5.3.1
JSC	5.2
[***] Products	8.1
Joint Patent	8.2.2
Launch Plan	4.2.4
Losses	11.1

Page 5 of 60

Confidential Treatment Requested by Achaogen, Inc.


Definition	Section
Microgenics	Preamble
Microgenics Indemnified Parties	11.1
Microgenics Inventions	8.1
Minimum Threshold	4.2.3
Minimum Threshold Period	4.2.3
Party or Parties	Preamble
Plazomicin Commercialization Plan	4.2.1
Receiving Party	12.1
Regulatory Finding	3.3.1.2
Regulatory Leader	5.3.1
Responsible Party	8.3.1
Review Party	8.3.1
Supply Resumption Date	4.3.2.2
Term	9.1
Third Party Claims	11.1
VAT	7.3.2

2Research and Development Collaboration

2.1Project Plan. The Parties shall collaborate on the Research Program in accordance with the Project Plan, as set forth as Exhibit F. As may be necessary or reasonable from time-to-time, the JPT may suggest appropriate revisions to the Project Plan to the JSC for its review in accordance with Section 5.3.2 and, if approved by the JSC in accordance with Section 5.1, the Project Plan may be amended from time to time by the JSC.

2.2Party Responsibilities.

2.2.1General. Microgenics and Achaogen shall each perform their respective obligations under the Research Program, using Commercially Reasonable Efforts, in accordance with the Project Plan and in compliance with Applicable Law.

2.2.2Achaogen. Achaogen shall supply to Microgenics, [***], (a) Achaogen Materials, including Plazomicin and Plazomicin clinical patient samples, in such quantities as are set forth in Exhibit A or otherwise mutually agreed by the Parties or set forth in the Project Plan; and (b) all necessary and in Achaogen’s possession Plazomicin pharmacological and biochemical information, including [***] etc., to enable the JPT to correctly design the Assay and Microgenics to work with the appropriate Regulatory Authorities to secure Regulatory Approval for the Assay. Microgenics shall not transfer any portion of the Achaogen Materials to any Third Party or use the Achaogen Materials for any purpose other than the purposes of performing its obligations under, and in accordance with, this Agreement and the applicable Project Plan. Microgenics shall hold, store and transport all supplies of the Achaogen Materials in compliance with all Applicable Laws and [***]. Microgenics shall maintain complete and accurate records relating to the disposition of all Achaogen Materials.

2.2.3Microgenics. Subject to the provisions of this Agreement (including Article 3 (Regulatory Submissions and Meetings)), Microgenics shall be responsible for the research, development, manufacture and sale of the Assay. Microgenics shall manufacture the Assay according to the Specifications

Page 6 of 60

Confidential Treatment Requested by Achaogen, Inc.

attached hereto as Exhibit G (which may be amended from time to time by the JSC in accordance with Section 5.1) and in accordance with the timelines set forth in the Project Plan. Without limiting the foregoing, Microgenics shall develop and commercialize the Assay such that it is capable of being run on no less than [***] ([***]) distinct [***] platforms, which [***] platforms shall be mutually agreed upon by the Parties in good faith.

2.3Information Exchange, Records and Compliance.

2.3.1Technology Transfer. Achaogen shall provide Microgenics with all Achaogen Know-How [***] reasonably necessary for Microgenics to carry out its responsibilities under the Research Program and to obtain Regulatory Approvals for the Assay. Microgenics shall provide Achaogen with all Microgenics Know-How [***] reasonably necessary for Achaogen to carry out its responsibilities under the Research Program and to conduct clinical trials of Plazomicin. All information exchanged shall be subject to the confidentiality requirements set forth in Article 12 (Confidentiality) hereof.

2.3.2Record Keeping/Compliance. During the Term and for a period of [***] ([***]) years thereafter (or such longer period of time as required by Applicable Laws), each Party shall maintain records in sufficient detail and in good scientific manner appropriate for obtaining and maintaining Regulatory Approvals. Achaogen shall have the right (either by itself or through a Third Party reasonably acceptable to Microgenics), during normal business hours and upon reasonable notice, to inspect records pertinent to Microgenics’ obligations under this Agreement. To the extent such records contain Confidential Information of Microgenics, Achaogen shall maintain such Confidential Information disclosed therein in confidence in accordance with Article 12. Achaogen shall have the right to arrange for its employee(s) and/or consultant(s) involved in the activities contemplated hereunder, during normal business hours and upon reasonable notice, to discuss the development activities and results contemplated under this Agreement in detail with the technical personnel and consultant(s) of Microgenics. Each Party shall comply with all applicable GLP, GCP, GMP, ISO 9001 and ISO 13485:2003 requirements and other Applicable Laws in the conduct of the Research Program and in the activities contemplated under this Agreement, including the development, manufacture and commercialization of the Assay.

2.4Installation and Training. Upon Achaogen’s request, Microgenics shall, [***], install any necessary equipment and train appropriate staff at clinical sites designated by Achaogen for the performance of clinical trials by Achaogen, in connection with obtaining Regulatory Approval for Plazomicin, and in order to enable such sites to use the Assay in connection with such use of Plazomicin and provide training for such sites’ personnel on how to operate such equipment. For clarity, [***] shall be [***] responsible for the costs of (a) any clinical trials conducted for purposes of obtaining Regulatory Approval for the Assay (as opposed to Regulatory Approval for Plazomicin) and (b) any activities conducted in a given country in the Territory following the receipt of Regulatory Approval for the Assay for such country (e.g. commercial activities).

2.5Quality Agreement. No later than [***] ([***]) days after the Effective Date (or such later date as may be otherwise agreed upon by the Parties in writing), the Parties shall enter into a quality agreement defining the commitments of both Parties to ensure that the Assay and related services developed and commercialized under this Agreement satisfy the quality and regulatory requirements required by this Agreement. Microgenics shall manage all Achaogen Materials (including clinical patient samples) according to customer property requirements described in such quality agreement.

2.6BARDA Requirements. The Parties acknowledge and agree that Achaogen receives funding

Page 7 of 60

Confidential Treatment Requested by Achaogen, Inc.

from the United States government through the Biomedical Advanced Research and Development Authority within the office of the Assistance Secretary for Preparedness and Response in the United States Department of Health and Human Services (BARDA) in connection with Achaogen’s development of new antibacterial treatment of MDR gram-negative bacterial infection. In connection with the foregoing, the terms and conditions of this Agreement shall be subject in their entirety to the terms and conditions set forth on Appendix A of Exhibit H. In the event of any conflict between the terms and conditions of the main body of this Agreement and Appendix A of Exhibit H, Appendix A of Exhibit H shall control.

3Regulatory Submissions and Meetings

3.1Coordination. Achaogen and Microgenics shall [***] coordinate the therapeutic and diagnostic regulatory filings and communications with Regulatory Authorities in the Territory. Achaogen will be responsible for all activities regarding the Regulatory Approval of Plazomicin (and, as between the Parties, Achaogen shall retain ownership of all regulatory filings and Regulatory Approvals for Plazomicin), and, subject to the terms and conditions of this Agreement, [***] will be responsible for all activities regarding the Regulatory Approval of [***] (and, as between the Parties, [***] shall retain ownership of all regulatory filings and Regulatory Approvals for [***]). For the avoidance of doubt, the Parties acknowledge and agree that, notwithstanding anything herein to the contrary, but subject to Section 3.2 and Section 4.2.7, (a) Achaogen shall have the sole discretion, at any time during the Term, to determine whether to conduct any clinical trial or make any regulatory filing, submission or correspondence with respect to Plazomicin; and (b) [***], subject to Section 4.2.7, at any time during the Term, to conduct any clinical trial (provided, that, in the event of a clinical trial that involves the use or administration of [***], [***]) or make any regulatory filing, submission or correspondence with respect to [***].

3.2Reporting and Consultation. [***] shall keep [***] regularly informed in connection with the preparation of all regulatory filings, submissions or correspondence related to [***] and [***] shall have the right to review and comment on any regulatory filing, submission or correspondence related to [***] (including any [***]), to be submitted to any health authority by [***]. In connection therewith, [***] shall provide to [***] for review the text of any such regulatory filing, submission or correspondence for [***] prior to submission and [***] shall consider in good faith all comments provided by [***]; provided that any disputes with respect to comments provided by [***] shall be resolved by the JSC. In addition, [***] shall consult with [***] with respect to all material matters required for regulatory filings, submissions or correspondence, under this Agreement; provided, however, that, subject to Section 3.1, [***] shall have sole responsibility hereunder for all regulatory filings (including [***] or their ex-United States equivalent), submissions or correspondence, including preparing and analyzing all [***] information required pursuant to any and all Applicable Laws, and preparing and analyzing any additional data and information required by any applicable Regulatory Authority (other than any data or information regarding [***]). Upon written request from [***], [***] shall promptly provide to [***] copies of all submitted regulatory filings, submissions, and material correspondence to and from any Regulatory Authorities; provided, that [***] may redact from such copies information that does not relate to the Assay, Plazomicin or this Agreement and the activities hereunder.

3.3Correspondence from Regulatory Authority.

3.3.1.1If either Party receives any material communication from the Regulatory Authorities relating to [***] or has any meetings (telephonic or in person) with any Regulatory Authority for any material reason regarding [***], such Party shall promptly notify the other Party and, upon mutual agreement, decide whether it is necessary for the other Party to be present in any

Page 8 of 60

Confidential Treatment Requested by Achaogen, Inc.

discussions with the Regulatory Authorities regarding [***]; provided, however, that, notwithstanding the foregoing, Achaogen shall have the right to participate in (a) [***], (b) [***], or (c) [***] pertaining to Achaogen Materials or Achaogen Know-How. For clarity, as between the Parties, [***] shall be responsible for leading any meetings or other discussions with the [***]. [***] shall not make any representations or discuss the uses of [***] with any Regulatory Authority except to the extent it relates to [***]. Neither Party shall disclose, without the other Party’s prior written consent, Confidential Information of such other Party in any regulatory filing, submission or correspondence or at a meeting with any Regulatory Authority, except to the extent required by Applicable Laws or otherwise under the Project Plan.

3.3.1.2In addition, Microgenics shall notify Achaogen within [***] ([***]) business days of any regulatory finding or violation identified by a Regulatory Authority that may potentially impact the activities contemplated under the Project Plan or the development, manufacture or commercialization of the Assay (a “Regulatory Finding”). With respect to each Regulatory Finding, if any, Microgenics shall provide (1) (a) [***], or (b) [***], or (c) [***] and (2) Microgenics’ [***]; provided, that, in each case of clauses (a), (b), and (c), Microgenics’ may redact from such copies or reports information that does not relate to the Assay, Plazomicin or this Agreement and the activities hereunder. Without limiting the next to last sentence of Section 3.5, Microgenics shall notify Achaogen promptly of any notification or information received from a Regulatory Authority, that: (i) would reasonably be expected to impair the integrity or reputation of Plazomicin or the Assay; (ii) raises any material concerns regarding the safety or efficacy of Plazomicin or the Assay; (iii) indicates or suggests a potential material liability of either Party to Third Parties in connection with Plazomicin or the Assay; (iv) is reasonably likely to lead to a recall or market withdrawal with respect to Plazomicin or the Assay; or (v) [***].

3.4Package Insert Information. Notwithstanding anything to the contrary contained herein, but subject to any applicable review and comment rights of the other Party, and dispute resolution escalation procedures set forth in Section 13.8, [***] shall have final decision making authority on all package insert language directed [***], and [***] shall have final decision making authority on all Assay package insert language directed [***].

3.5Filings. On a country-by-country basis, a Regulatory Approval from the applicable Regulatory Authority(ies) is required for the Assay prior to launch in such country. Upon Achaogen’s request, Microgenics shall reasonably cooperate with Achaogen with respect to any regulatory filings, submissions, or correspondence made by Achaogen related to Plazomicin in any country in the Territory, including promptly providing data, information and advice regarding the Assay, including the manufacture (including any recall information) and use thereof. This Agreement generally assumes that there is a current 510(k) pathway for obtaining Regulatory Approval for the Assay; provided, that, if a PMA pathway is required, the Parties acknowledge and agree that [***] reviewed by the Parties and may need to be adjusted to the extent agreed upon between the Parties and subject to the proviso in the foregoing sentence. For the avoidance of doubt, Achaogen shall have sole right to control any such regulatory filings, submissions, correspondence or other matters related to Plazomicin including any joint submissions or filings, but not [***], and to communicate with Regulatory Authorities related thereto. No later than [***] (or such later date as otherwise agreed to by the Parties), the Parties shall enter into an agreement setting forth the Parties respective responsibilities for adverse event and complaint reporting, the exchange of safety data and, to the extent agreed by the Parties to be appropriate and relevant, recall matters.

3.6Right of Reference. [***] hereby grants to [***] a non-exclusive, non-transferable (except

Page 9 of 60

Confidential Treatment Requested by Achaogen, Inc.

in connection with a permitted assignment, sublicense or subcontract) “right of reference” (as defined in 21 CFR 314.3(b)) with respect to clinical trial data and results related to [***], solely as necessary for [***] to prepare, submit and maintain regulatory submissions related to [***] and Regulatory Approvals for [***]. [***] hereby grants to [***] a non-exclusive, non-transferable (except in connection with a permitted assignment, sublicense or subcontract) “right of reference” (as defined in 21 CFR 314.3(b)) with respect to [***] clinical trial data (including [***]), information (including the [***], as applicable) and results related to [***], solely as necessary for [***] to prepare, submit and maintain regulatory submissions related to [***] and Regulatory Approvals for [***].

3.7[***]. In connection with the [***] of [***] in any [***] in the Territory, [***] shall [***] of the [***] in [***] in [***] with such [***] of [***]. The Parties shall discuss in good faith (via the JPT) and mutually agree as to [***] shall [***] for [***], which discussion and decision shall occur no later than [***] ([***]) year [***]. In the event that the Parties later agree to [***] for [***] in a [***], the Parties (through the JPT and JSC) shall amend the Project Plan to [***], subject to [***], and [***] shall [***].

4Manufacture and Commercialization of Assay

4.1Manufacture. Except as provided elsewhere in this Agreement, including Section 4.3 (Supply) and Section 9.4.4 (Effect of Termination), during the Term, Microgenics shall be solely and exclusively responsible for the worldwide manufacture of the Assay in accordance with GMP standards, the Specifications and Applicable Law. For clarity, from and after the expiration or termination of this Agreement, nothing in this Agreement shall restrict Microgenics from developing, manufacturing or commercializing the Assay as and to the same extent as any third party.

4.2Commercialization. Upon successful completion of the Development and Manufacturing Phase and upon receipt of the applicable Regulatory Approval in a given country in the Territory required in order to sell the Assay in such country, Microgenics shall use Commercially Reasonable Efforts to exclusively commercialize and market the Assay, under the Thermo Scientific tradename and packaging and utilizing Microgenics’ and its Affiliate’s commercial infrastructure, in each country within the Territory in which Achaogen is commercializing Plazomicin for so long as Achaogen is commercializing Plazomicin in such country. Solely to the extent Achaogen elects to promote an assay which may be capable of measuring Plazomicin in a given Primary Country ([***]) in the Territory, and subject to receipt and conditions of any applicable Regulatory Approvals, Achaogen shall prioritize the promotion of the Assay relative to any other assay which may be capable of measuring Plazomicin, in its marketing and sales efforts in such Primary Country; provided, however, that in the event (a) Microgenics [***] is unable to supply the Assay in quantities sufficient to meet each applicable Binding Forecast, including [***], or (b) [***], Achaogen may prioritize the promotion of assays capable of measuring Plazomicin in the affected country(ies). For clarity, and notwithstanding anything to the contrary in this Agreement, including this Section 4.2, Achaogen expressly reserves and retains the right to, directly or indirectly (including through contractors or collaborators), research, develop, manufacture, use or commercialize assays capable of measuring Plazomicin other than the Assay; provided, that, Achaogen may not, directly or indirectly (including through contractors or collaborators) commercialize any immunoassay [***], other than the Assay in accordance herewith, [***]; provided, further, that the restriction on Achaogen’s right to commercialize immunoassays [***], other than the Assay, shall be of no force or effect if Microgenics is unable to supply the Assay for [***] ([***]) days at any time [***] or if the Parties mutually determine that Microgenics will not be able to supply the Assay. Additional commercialization and supply terms may be added to this Agreement in the form of an amendment. Without limiting the foregoing:

Page 10 of 60

Confidential Treatment Requested by Achaogen, Inc.

4.2.1Plazomicin Commercialization Plan. As soon as commercially reasonable, but no later than [***] ([***]) days after the Effective Date of this Agreement, Achaogen shall share its global commercialization plans for Plazomicin with Microgenics (“Plazomicin Commercialization Plan”). The Plazomicin Commercialization Plan shall include the list of countries consistent with the Primary Country list for commercialization of Plazomicin, anticipated launch timing, initial volume forecasts and such other information as may be determined by the JPT. Microgenics will develop timelines on a country basis to the extent it receives adequate Plazomicin Commercialization Plan details with respect to a given country. Achaogen agrees to keep such Plazomicin Commercialization Plan updated via regular communication with the JSC. For clarity, (a) the Plazomicin Commercialization Plan shall be Confidential Information of Achaogen hereunder, and (b) Achaogen [***] in preparing and conducting activities under the Plazomicin Commercialization Plan.

4.2.2Volumes and Pricing.

4.2.2.1On a regular basis, beginning at least [***] ([***]) months prior to the anticipated date of the First Commercial Sale of Plazomicin in the Territory, Achaogen will share confidential, non-binding (except as described below) good faith volume forecasts in units for the Assay and updates thereof in the Plazomicin Commercialization Plan through the JSC in order for the Parties to develop a [***] market introduction including achieving Regulatory Approval [***] for the Assay in all relevant countries and regions. Thereafter, and on a [***] basis, Achaogen shall supply Microgenics with a confidential, good faith rolling [***] ([***]) month forecast (in units, broken-down by country (or regions)) as to Achaogen’s estimated unit demand for worldwide commercial demand for the Assay (it being agreed and understood that such forecasts shall be Confidential Information of Achaogen hereunder); provided, however, only the first [***] ([***]) months of each [***] ([***]) month forecast shall be binding (a “Binding Forecast”) and the remaining [***] ([***]) months of such forecast shall be non-binding (for clarity, when each [***] forecast update is provided, [***] of the previous forecast (i.e., [***] of the Binding Forecast previously submitted) shall not be changed as they become [***] of the current forecast and [***] of the current Binding Forecast). For clarity, except as otherwise provided in this Agreement with respect to the Binding Forecast, Achaogen shall have no liability whatsoever with respect to such forecasts, including no liability for any Assay manufactured or materials ordered by or on behalf of Microgenics based on such forecasts. Microgenics shall supply the quantities of the Assay set forth in the applicable Binding Forecasts and shall use Commercially Reasonable Efforts to ensure that [***], in each case, in accordance with Section 4.3; provided, however, [***].

4.2.2.2The Parties acknowledge and agree that [***] shall have [***] with respect to the pricing of the Assay in any country in the Territory; provided, however, [***] shall [***] to price the Assay in a given country at an amount no greater than (i) (a) $[***] in the United States or (b) $[***] in any other country, or (ii) [***] percent ([***]%) of the applicable list price of any other [***] assay marketed in such country; provided, further, that [***] shall [***] to take into account [***]. In the event that (x) [***] to price the Assay at an amount greater than the foregoing subclauses (i) and (ii), then the JSC shall review the available data and discuss the Assay price in accordance with Section 5.2.1(h), and/or (y) the Assay pricing [***], the JSC will review the available data and discuss various alternative solutions.

4.2.3Minimum Thresholds. In the event that, during the applicable Minimum Threshold Periods (as defined below), Microgenics does not receive the applicable Minimum Threshold Revenue (as defined below) during a given calendar year, Achaogen agrees to pay [***] Microgenics for such region during such calendar year (on a prorated basis, as applicable). For purposes of this Section 4.2.3,

Page 11 of 60

Confidential Treatment Requested by Achaogen, Inc.

4.2.3.1The “First Minimum Threshold Period” shall begin on the [***] ([***]) anniversary of the date on which the First Commercial Sale of the Assay in [***] occurred and shall end on the [***] ([***]) anniversary of the date on which the First Commercial Sale of the Assay in [***] occurred. For example, if the First Commercial Sale of the Assay in [***] occurred on [***] then the First Minimum Threshold Period would begin on [***] and would end on [***];

4.2.3.2The “Second Minimum Threshold Period” shall begin on the [***] ([***]) anniversary of the earlier of the date on which the First Commercial Sale of the Assay occurred in (i) [***] of the following countries – [***] (each an “[***] Country”); or (ii) an [***] Country and [***]; or (iii) [***] ([***]) of the Primary Country list ([***]) (subclause (i), (ii), or (iii), as applicable, the “Start Date”), and shall end on the earlier of (a) the [***] ([***]) anniversary of the Start Date or (b) the date this Agreement expires or terminates;

4.2.3.3“Minimum Threshold Revenue” shall mean, with respect to each of the First Minimum Threshold Period and the Second Minimum Threshold Period, USD $[***] of annual gross revenue received by Microgenics from sales of the Assay in the Territory (for clarity, during any overlap between the First Minimum Threshold Period and the Second Minimum Threshold Period, the total Minimum Threshold Revenue would be USD $[***]); provided, however, that the Minimum Threshold Revenue (i) shall be determined by [***] for a given Assay, less [***] directly associated with such sale and Assay and permitted to be taken in accordance with generally accepted accounting principles in the United States, and (ii) that in the event the Minimum Threshold Period begins or ends during a given calendar year, the Minimum Threshold Revenue for such calendar year shall be prorated accordingly.

4.2.4Market Introduction. The Parties will reasonably agree regarding details related to commercialization of the Assay once the [***] are clarified by Achaogen in the Plazomicin Commercialization Plan. Within [***] ([***]) months of receiving the initial Plazomicin Commercialization Plan, Microgenics will provide Achaogen with (a) a detailed market introduction plan for the Assay (the “Launch Plan”) and (b) a global commercialization plan for the Assay, in a form to be determined by the JSC (the “Assay Commercialization Plan”). During the Term, Microgenics shall provide Achaogen [***] with (i) an updated Launch Plan [***], and (ii) an updated Assay Commercialization Plan [***]. For clarity, (i) the Launch Plan and Assay Commercialization Plan shall be Confidential Information of Microgenics hereunder, and (ii) Microgenics is [***] in preparing and conducting activities under the Launch Plan and Assay Commercialization Plan.

4.2.5Geographies. Other than the Primary Countries set forth on Exhibit E, the Parties shall mutually agree upon any Secondary Countries where Achaogen plans to introduce Plazomicin, which such Secondary Countries shall thereafter be deemed to be Primary Countries and included in the Plazomicin Commercialization Plan and the Assay Commercialization Plan, in all cases no later than [***] prior to the anticipated launch of Plazomicin in any such country; provided, however, the parties agree that actual product registration may take longer than [***] ([***]) months.

4.2.6Selling, Marketing and Customer Support to Clinical Labs. Microgenics will establish and maintain a commercial infrastructure for the supply of the Assay, as well as adequate product support, customer support and regulatory support in each market where the Assay is introduced, including [***]. For clarity, Achaogen [***] the Assay to physicians and other prescribers and related individuals and organizations; provided, that, for clarity, Microgenics [***] of the Assay to any such physicians or other prescribers or related individuals and organizations.

Page 12 of 60

Confidential Treatment Requested by Achaogen, Inc.

4.2.7Abandoned or Uninitiated Development or Commercialization of Assay.

4.2.7.1If, during the Term, Achaogen determines in good faith that Microgenics has ceased to develop, commercialize and market the Assay in a specific country within the Territory in which Achaogen has obtained or is in the process of obtaining Regulatory Approval for Plazomicin for a period of at least [***] ([***]) months (“Abandoned Commercialization” or “Abandoned Development,” as applicable), then Achaogen may deliver to Microgenics written notice that Achaogen deems Microgenics to have Abandoned Commercialization. If Achaogen delivers such written notice to Microgenics, such notice shall set forth the basis for Achaogen’s good faith determination. If Microgenics disagrees with Achaogen’s determination that Microgenics has Abandoned Commercialization, then the Parties will meet within [***] ([***]) business days to discuss such disagreement. If the Parties cannot agree after such discussion, then the terms of Section 13.8 shall apply to resolve such Dispute.

4.2.7.2If it is finally determined pursuant to the procedures set forth in Section 4.2.7.1 that Microgenics has Abandoned Commercialization, then, within [***] ([***]) business days of such determination, Microgenics will commercialize and market the Assay for [***] ([***]) months after the written determination is received. After the [***] ([***]) months period has expired, Microgenics will continue to supply the Assay to Achaogen or its distributor pursuant to the terms of a supply agreement that the Parties will negotiate during the first [***] ([***]) months of the [***] month period described in the prior sentence; provided, that such supply agreement shall include an initial (i.e., for a period of no less than [***] ([***]) months) supply price that is no greater than [***] ([***]%) of the lowest price at which Microgenics has made the Assay available to its distributors, or any Third Party if there is no distributor, in the affected country. Microgenics shall [***] promptly assist Achaogen (and/or its designee) in obtaining all necessary Regulatory Approvals and/or modifying and/or transferring existing Regulatory Approvals to enable Achaogen (and/or its designee) to develop, make, have made, use, market, distribute, import, sell and offer for sale the Assay ([***]) in any applicable country.

4.2.7.3Solely in the event of Abandoned Development, the Parties acknowledge and agree that this Agreement does not supersede Section 5.3 of the Antibody Development Agreement and that Achaogen reserves all of its rights under Section 5.3 of the Antibody Development Agreement, including in the event of Abandoned Development.

4.3Supply.

4.3.1Clinical Supply. Microgenics shall supply to Achaogen the amount of Assay ordered by Achaogen, if any, for use in any clinical trials or other development of Plazomicin in accordance with the delivery and shipment terms set forth in the Project Plan to the extent applicable. Achaogen shall provide to Microgenics confidential, non-binding good faith clinical trial and other development supply forecasts for each [***] ([***]) month period starting on [***] and [***] of each calendar year and shall deliver each forecast in writing at least [***] ([***]) days prior to the commencement of the applicable [***] ([***]) month period. The Parties shall agree on the exact date for the delivery of such Assay. Achaogen shall reimburse Microgenics at (a) a price of USD $[***] per patient result used to make diagnostic decisions for the applicable patient or (b) in the event the Assay is being commercialized at the time of supply, [***]; provided, however, in each case, if Microgenics utilizes any data from any clinical trial or other study conducted by Achaogen with Assay supplied under this Section 4.3.1, Achaogen shall have no obligation to reimburse Microgenics for such Assay.

Page 13 of 60

Confidential Treatment Requested by Achaogen, Inc.

4.3.2Continued Supply.

4.3.2.1Microgenics shall ensure the continued worldwide supply of the Assay in quantities at least sufficient to meet each applicable Binding Forecast. Without limiting the foregoing, Microgenics agrees to maintain a safety stock of rare reagents sufficient to meet each applicable Binding Forecast for the Assay. Microgenics shall provide Achaogen at least [***] ([***]) months (or [***]) prior written notice of any possible shortfall in meeting each applicable Binding Forecast or other commercial demand for the Assay, and the Parties shall promptly meet and discuss all reasonable commercial resolutions if Microgenics is unable to assure supply as needed to meet each applicable Binding Forecast pursuant to the terms set forth in Section 4.3.2.2.

4.3.2.2In addition, in order to ensure security of supply of the Assay, within [***] of Microgenics’ receipt of the first Regulatory Approval for the Assay in any country in the Territory, Microgenics shall designate [***] (the “Back-up Supplier”) which such Back-up Supplier shall be and remain qualified as a manufacturer of the Assay for the supply of the Assay for sale in the Territory. Microgenics shall [***] ensure that the Back-up Supplier can supply the Assay for sale in the Territory within [***] days. Microgenics will develop a manufacturing transition plan that will highlight [***] needed to complete the transition to the back-up supplier. This plan will be presented to the JSC prior to first commercial launch of the Assay.

4.3.2.3If, for any reason, [***], both Microgenics and the Back-up Supplier (as applicable) are unable to supply the Assay in quantities sufficient to meet the quantities of the Assay either (a) as set forth in each applicable Binding Forecast or (b) based on such other measure of commercial demand as agreed to by the Parties in writing, in either case, during any given [***] ([***]) month period for a given country in the Territory, then Microgenics hereby grants Achaogen or its designee a Shortfall License, which license shall survive until [***] ([***]) months following the date that either Microgenics or the Back-up Supplier (as applicable) is in a position again to fulfill such demand (as such positioning is demonstrated [***]) (the “Supply Resumption Date”). The Shortfall License shall expire automatically [***] ([***]) months after the Supply Resumption Date; provided, however, that (a) Achaogen shall be entitled to use, sell, offer for sale, and import any assay that are in inventory prior to the expiration of the Shortfall License (even if such activity occurs after expiration of the Shortfall License). Additionally, [***], Microgenics shall (i) make its personnel available for a reasonable period of time (not to exceed [***] ([***]) months) to effect a successful technology transfer with respect to the manufacture and commercialization of such Assay under the terms of this paragraph, (ii) provide Achaogen with copies of the physical embodiment of all processes, protocols, procedures, methods, tests and other intellectual property rights licensed to Achaogen under the Shortfall License, as applicable, related to Assay (including the manufacture thereof), (iii) supply [***] (including [***]) reasonably required to perform [***] as may be required by the applicable Regulatory Authorities, and upon request by Achaogen, [***], provide Achaogen (and/or its designee) with [***] related to the Assay, and (iv) promptly assist Achaogen (and/or its designee) in obtaining all necessary Regulatory Approvals and/or modifying and/or transferring existing Regulatory Approvals to enable Achaogen (and/or its designee) to develop, make, have made, use, market, distribute, import, sell and offer for sale the Assay ([***]).

4.4Audit Rights.

4.4.1[***] during the Term, commencing on the [***] ([***]) [***] of the Effective Date, Achaogen shall have the right to inspect and audit [***] per calendar year (either by itself or through a Third Party reasonably acceptable to Microgenics) the Assay manufacturing process, facilities, procedures,

Page 14 of 60

Confidential Treatment Requested by Achaogen, Inc.

and records upon reasonable notice (which shall be no less than [***] ([***]) calendar days prior notice, unless a shorter period is mutually agreed to by the Parties), and during normal business hours. Notwithstanding the foregoing, Achaogen shall have the right to conduct “for cause” audits (either by itself or through a Third Party reasonably acceptable to Microgenics) [***] during normal business hours of the [***], including in the event of a failure to supply the Assay as specified under Section 4.3.2. Any information shared with Achaogen or a Third Party under this Section 4.4.1 shall be considered Confidential Information. In connection with any such inspection or audit, Microgenics shall have no obligation to provide Achaogen and/or a Third Party access to Microgenics’ Confidential Information related to any product other than the Assay.

4.4.2Additionally, during the Term, Microgenics shall inform Achaogen within [***] ([***]) business days after receipt of any notice of an audit or inspection by ay Regulatory Authority which directly or indirectly relates to the Assay or the Assay manufacturing or distribution operations and Microgenics shall promptly provide to Achaogen in writing the results of any such audit or inspection within [***] ([***]) business days of receipt, including (a) a copy of any inspection reports, Form 483s, warning letters or similar such reports or warnings (“Audit Outcome”), to the extent such Audit Outcome solely addresses the Assay, or (b) a summary of such Audit Outcome, including verbatim text copies of portions thereof pertaining to the Assay, to the extent such Audit Outcome addresses the Assay and other matters, or (c) a summary of such Audit Outcome, to the extent that the Assay is not mentioned in such Audit Outcome; provided, that, in each case of clauses (a), (b), and (c), Microgenics’ may redact from such copies or reports information that does not relate to the Assay, Plazomicin or this Agreement and the activities hereunder, and a summary of Microgenics proposed strategy for addressing any issues or violations noted during the course of such audit or inspection.

4.5Labeling.

4.5.1Assay Labeling. Microgenics shall be responsible for ensuring that all Assay packaging and labeling are in compliance with its Regulatory Approvals and Applicable Law.

4.5.2Information for Labeling and Promotional Materials for Plazomicin. At the request of Achaogen, Microgenics shall provide to Achaogen such information related to the Assay which is in Microgenics’ possession, for Achaogen’s use and reference in the packaging and labeling (including package insert) and promotional materials for Plazomicin.

4.5.3Changes to Labeling. Achaogen will promptly notify Microgenics of any changes to Plazomicin labeling relevant for the Assay, including [***]. [***], such changes will be implemented by Achaogen with [***] in order to allow Microgenics to change any labeling on the Assay as a result of such changes to Plazomicin labeling. Similarly, Microgenics will promptly notify Achaogen of any changes to the Assay labeling, and Microgenics will implement such changes with [***] in order to allow Achaogen to change any labeling on Plazomicin as a result of such changes to the Assay labeling; provided, however, that Microgenics shall not make any such changes directed to Plazomicin (including, [***]) or which would otherwise require a change to the labeling for Plazomicin, without Achaogen’s prior written approval.

5Governance.

5.1Alliance Managers.

5.1.1No later than [***] ([***]) days after the Effective Date, each of the Parties shall

Page 15 of 60

Confidential Treatment Requested by Achaogen, Inc.

appoint one (1) representative as its alliance manager (“Alliance Manager”). The Alliance Managers shall have the right to attend all JSC and JPT meetings as non-voting participants and may bring to the attention of the JSC or JPT any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as set forth in Section 5.1.2 or as the Parties may mutually agree. Each Party may replace its Alliance Manager at any time or may designate different Alliance Managers by notice in writing to the other Party.

5.1.2The Alliance Managers shall have responsibility for creating and maintaining a constructive work environment between the Parties. Without limiting the generality of the foregoing, each Alliance Manager shall:

5.1.2.1identify and bring disputes and issues, including disputes that cannot be resolved by the JPT, that may result in disputes to the attention of the JSC in a timely manner, and function as the point of first referral in all matters of conflict resolution. In doing so, it is not intended that the Alliance Manager(s) act as a substitute for, or insert any delay in, the formal dispute resolution mechanisms set forth in Section 13.8, but rather that the Alliance Manager(s) shall endeavor to maintain a positive and constructive relationship between the Parties at the working level;

5.1.2.2provide a single point of communication for seeking consensus both internally within the Parties’ respective organizations and between the Parties;

5.1.2.3plan and coordinate cooperative efforts, internal communications and external communications between the Parties with respect to this Agreement; and

5.1.2.4take responsibility for ensuring that meetings and the production of meeting agendas and minutes occur as set forth in this Agreement, and that relevant action items resulting from such meetings are appropriately carried out or otherwise addressed.

5.2Joint Steering Committee. The Parties agree that the Research Program shall be managed by a Joint Steering Committee (“JSC”) and that the JSC shall otherwise have responsibility for the general oversight of activities hereunder. No later than [***] ([***]) days after the Effective Date, each of the Parties shall appoint two (2) representatives to the JSC. The JSC shall be led by two (2) co-chairs, one (1) appointed by Microgenics and one (1) appointed by Achaogen. The JSC will make decisions by consensus, with Microgenics and Achaogen each having one vote. In the event of an impasse, the matter shall be resolved pursuant to Section 5.2.3 (Decision-Making). A Party may change any of its representatives at any time by giving [***] ([***]) days prior written notice to the other Party.

5.2.1Responsibilities. In addition to its general responsibility to oversee and coordinate the development of the Assay according to the Project Plan and to assure the regular flow of information between the Parties, the JSC shall:

(a)

develop the Project Plan, monitor the progress of the Research Program, and review and approve all proposed changes to the Project Plan;

(b)

amend the Specifications for the Assay;

(c)

review and approve the [***] in accordance with Section [***] hereof;

(d)

oversee the activities of the JPT;

(e)

review and approve the most appropriate regulatory pathway for obtaining Regulatory

Page 16 of 60

Confidential Treatment Requested by Achaogen, Inc.

Approval of the Assay;

(f)

review and approve the contents of all applications for Regulatory Approval and related and supporting submissions to Regulatory Authorities;

(g)

develop and manage clinical samples supply;

(h)

discuss pricing policy for the Assay in the Territory, including [***] and similar matters, to the extent permitted under Applicable Law; provided that, for clarity, [***];

(i)

resolve disputes escalated by the Alliance Managers; provided that, if after [***], the JSC is unable to resolve any such dispute, such dispute shall be resolved in accordance with Section 5.2.3.2;

(j)

confirm completion of each event described in Section 7.1 if the Joint Project Team has not agreed that a Milestone has been completed; and

(k)

manage and coordinate the supply and commercialization of the Assay, including the initial commercial launch of the Assay and monitoring the progress of the Assay Commercialization Plan and Launch Plan.

5.2.2Meetings. The JSC shall meet at least [***] during the Term at such place and time as is agreed upon by the Parties; provided, however, that in the event of an emergent situation, including a situation in which a decision by the JSC is required, a meeting shall be held within [***] ([***]) days after written request for such meeting by either Party. Meetings of the JSC may be conducted in person, by telephone or videoconference as agreed by the JSC or the Parties. When held in person, the location of the meetings shall alternate between Achaogen’s facilities and Microgenics’ facilities, unless otherwise mutually agreed by the Parties. The Alliance Managers shall be responsible for planning and scheduling the meetings and preparing the agenda. The Alliance Managers will record the minutes of each meeting (alternating between Achaogen and Microgenics). Minutes of each meeting of the JSC shall be exchanged for review, comment and approval by the members; provided that, if after [***] ([***]) days following the distribution of the minutes, neither Party has raised any objection, the minutes shall be deemed to have been approved by the Parties. Thereafter, the minutes shall be signed by the co-chairs and distributed to each of the Parties. Additionally, upon invitation by the JSC, the Functional Leaders (or other JPT members) may attend JSC meetings as non-voting members, and each JSC member may reasonably invite other guests to the meetings, in order to discuss special technical or commercial topics relevant to the applicable agenda; provided, that any guests are subject to the confidentiality provisions set forth in Article 12 (Confidentiality).

5.2.3Decision-Making.

5.2.3.1All decisions of the JSC shall be made in good faith in the interest of furthering the purposes of this Agreement and the JSC members shall use good faith efforts to make decisions unanimously.

5.2.3.2If the JSC is unable to agree on any matter after good faith attempts to resolve such disagreement [***], then for matters that are [***], the JSC may refer the disagreement to a meeting between a senior executive (other than a JSC member) representing each Party (currently [***] for Achaogen and [***] for Microgenics) which meeting shall take place as soon as practicable, but in no event later than [***] ([***]) days after the date of the relevant referral. If the senior executives for Achaogen and Microgenics cannot resolve such disagreement over such [***] matter in a mutually acceptable manner within [***] ([***]) business days after such meeting then the matter shall be decided in accordance with Section 13.8.2. Notwithstanding the foregoing, except as otherwise provided in, and subject to the terms and conditions of, this Agreement: (a) [***], with appropriate consideration of the interests of [***], will have [***] that impact the development,

Page 17 of 60

Confidential Treatment Requested by Achaogen, Inc.

manufacture or marketing of [***] and (b) [***], with appropriate consideration of the interests of [***], will have [***] that [***] impact the development, manufacture or marketing of [***]; provided, that, [***] shall not have decision-making authority regarding (i) [***], or (ii) [***], which such decisions shall require the mutual agreement of the Parties, or (iii) [***] (which the Parties acknowledge will be ultimately dictated by [***]), or (iv) [***].

5.2.4Expenses. Microgenics and Achaogen shall be responsible for all expenses incurred by its JSC members in connection with performing their duties hereunder, including all costs of travel, lodging and meals.

5.2.5No Authority to Amend. For the avoidance of doubt, the JSC (and any Party exercising decision-making authority under Section 5.2.3.2) shall not have the authority to amend this Agreement, but the JSC shall have authority to amend the Project Plan and the Specifications as expressly set forth herein (and, for clarity, [***] shall not have decision-making authority with respect to any [***]).

5.3Joint Project Team; Functional Leaders.

5.3.1Formation. The Parties shall form a joint project team (the “Joint Project Team” or “JPT”). The JPT shall be comprised of a total of six (6) project team members from Microgenics and Achaogen, with Microgenics and Achaogen each designating a development leader, a regulatory leader, and a commercial leader (respectively, the “Development Leader”, the “Regulatory Leader” and the “Commercial Leader”, and collectively, the “Functional Leaders”) who shall be the principal point of contact for each Party for matters relating to its respective function, and shall be responsible for implementing and coordinating, on a day-to-day basis, all activities and facilitating the exchange of information between the Parties regarding the Project Plan for his or her function. Notwithstanding the foregoing, the Regulatory Leaders and Commercial Leaders may be appointed at such time as the Parties deem appropriate to facilitate the development of the Assay and a successful commercial launch of Plazomicin and the Assay.

5.3.2Responsibilities. The JPT shall have responsibility for coordinating all development, regulatory, commercial and other business and technical activities under this Agreement. In addition to its general responsibility to deliver the development of the Assay according to the Project Plan and to assure the regular flow of information between the Parties, the JPT shall:

(a)

recommend changes to the Project Plan, Launch Plan and Assay Commercialization Plan to the JSC,

(b)

monitor the activities vs budget to the JSC,

(c)

recommend changes to the Specifications for the Assay to the JSC;

(d)

communicate progress to the JSC;

(e)

plan the regulatory pathway for obtaining Regulatory Approval of the Assay; and

(f)

prepare all applications for Regulatory Approval and related and supporting submissions to Regulatory Authorities.

5.3.3Members. No later than [***] ([***]) days after the Effective Date, each Party shall provide the other with the names of its JPT members and Functional Leaders (other than the Regulatory Leaders and Commercial Leaders). Microgenics and Achaogen may replace its JPT members and Functional Leaders at any time and for any reason upon written notice to the other Party.

5.3.4Sub-Teams. The JPT and Functional Leaders may delegate tasks and

Page 18 of 60

Confidential Treatment Requested by Achaogen, Inc.

responsibilities to sub-managers, working groups and other team members as they deem appropriate to efficiently and effectively perform their respective obligations hereunder.

5.3.5Meetings. The JPT shall meet as soon as practicable after the Effective Date and thereafter during the performance of the Project Plan, at least [***], and at such additional times as the JPT or the Parties reasonably deem appropriate; provided, that, following the completion of the Project Plan, the JPT shall continue to meet no less frequently than [***]. Meetings of the JPT may be conducted in person, by telephone or videoconference as agreed by the JPT or the Parties. Additionally, the JPT and the Functional Leaders (or their designees) shall maintain close regular communications with each other as to the status of the ongoing and planned activities under the Project Plan, Launch Plan and Assay Commercialization Plan. Each JPT member may reasonably invite other guests to the meetings, in order to discuss special technical or commercial topics relevant to the applicable agenda; provided, that any guests are subject to the confidentiality provisions set forth in Article 12.

5.3.6No Authority to Amend. Neither the JPT nor the Functional Leaders (or their designees) shall have authority to amend this Agreement or the Project Plan, but may make recommendations regarding such amendments to the JSC.

5.3.7Dispute Resolution. The JPT and the Functional Leaders will cooperate with each other and work in good faith to resolve any disagreements between them or their respective teams. Any such disagreements that are not resolved by the JPT shall be raised to the Alliance Managers for internal escalation if needed.

5.3.8Records. The JPT shall keep accurate and complete records of their activities and meetings and shall, from time to time as requested by the JSC, provide the JSC with appropriate updates and information to keep the JSC apprised of the progress of the Project Plan, Launch Plan and Assay Commercialization Plan. All records of the JPT that are disclosed to the other Party and which relate to the Project Plan shall be available at all times to the JSC and to each Party on a confidential basis solely for use with respect to such Party’s activities conducted pursuant to this Agreement.

5.3.9Expenses. Microgenics and Achaogen shall be responsible for all expenses incurred by its JPT members in connection with performing their duties hereunder, including all costs of travel, lodging and meals.

5.4Reporting. The Parties shall keep each other promptly informed on an ongoing basis through the Joint Project Team and the JSC on the progress of the Project Plan, the Launch Plan and the Assay Commercialization Plan, including forecasts of expected performance and completion of activities. Without limiting the foregoing, within [***] ([***]) days following [***] of each calendar year during the Term, Microgenics shall provide to Achaogen a written progress report in English, in a form to be agreed upon by the JSC, which shall include any information required under the Project Plan and as otherwise reasonably determined by the JSC relating to the progress of the goals or performance of the development, commercialization and other activities under the Project Plan, the Launch Plan and the Assay Commercialization Plan.

6Grant of License

6.1Exclusive License by Achaogen. During the Term, and without limiting Section 4.2, Achaogen hereby grants to Microgenics a royalty-free, exclusive, worldwide license to use the Achaogen

Page 19 of 60

Confidential Treatment Requested by Achaogen, Inc.

Know-How, Achaogen Patents, and Achaogen Materials to research, develop, manufacture, use, market and sell the Assay in the Territory. [***].

6.2License by Microgenics. During the Term, Microgenics hereby grants to Achaogen and its Affiliates a royalty-free, non-exclusive, sub-licenseable, worldwide license, under and with respect to the Immunoassay Technologies, Microgenics Know-How and any Patents or Patent applications Controlled by Microgenics or its Affiliates to the extent reasonably necessary for Achaogen to perform its obligations or exercise its rights under this Agreement or as is otherwise reasonably necessary to make, have made, use, sell, offer for sale, import and otherwise commercialize Plazomicin. For the avoidance of doubt, the foregoing license grant does not provide any license or right for Achaogen to make, have made, use, sell, offer for sale, import or otherwise commercialize the Assay, except in connection with Achaogen’s exercise of the Shortfall License or Transfer License.

6.3[***] Products and Joint Patents. Each Party shall be entitled to grant non-exclusive licenses to any Third Party under its interest in a [***] Products or Joint Patent [***]. [***], and if in certain countries the grant of a license, in order to be effective, requires declarations from the other Party, the other Party shall reasonably cooperate and provide the necessary declarations.

6.4No Implied License. Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How. Microgenics retains all rights in and to the Immunoassay Technologies and Microgenics Know-How. Only the licenses and other rights expressly granted by one Party to the other Party under terms of this Agreement are of any legal force or effect. No other licenses or other rights are granted, conveyed or created (whether by implication, estoppel or otherwise).

7Consideration to Microgenics

7.1Development Payments. In consideration of the development efforts of Microgenics under the Research Program, Achaogen shall pay to Microgenics the following one-time payments upon the occurrence of the corresponding events:

(a)

USD $[***] upon the successful completion of Phase 0: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for Phase 0;

(b)

USD $[***] upon the successful completion of Phase 1: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for Phase 1;

(c)

USD $[***] upon the successful completion of Phase 2: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for Phase 2;

(d)

USD $[***] upon the successful completion of Phase 3: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for Phase 3;

(e)

USD $[***] upon the successful completion of the first milestone of Phase 4: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of

Page 20 of 60

Confidential Treatment Requested by Achaogen, Inc.

all deliverables required by the Project Plan for the first milestone of Phase 4;

(f)

USD $[***] upon the successful completion of the second milestone of Phase 4: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for the second milestone of Phase 4;

(g)

USD $[***] upon the successful completion of the third milestone of Phase 4: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for the third milestone of Phase 4;

(h)

[***], USD $[***] upon the successful completion of the fourth milestone of Phase 4: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for the fourth milestone of Phase 4;

(i)

USD $[***] upon the successful completion of the first milestone of Phase 5: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for the first milestone of Phase 5;

(j)

USD $[***] upon the successful completion of the second milestone of Phase 5: [***] as determined in accordance with the Project Plan, including delivery by Microgenics of all deliverables required by the Project Plan for the second milestone of Phase 5;

(k)

[***]; and

(l)

[***] and assuming [***], USD $[***] upon [***]; provided, however, this amount [***].

Thereafter, no additional payments shall be due and payable to Microgenics by Achaogen for any Assay [***].

7.2Invoices; Mechanism of Payment. Upon the completion of each event as described in Section 7.1, Microgenics will invoice Achaogen within [***] ([***]) business days. Microgenics agrees to submit invoices to Achaogen (on a timely basis) for all payments due hereunder. Invoices shall reference Achaogen’s contract number and the purchase order number. The invoices due under this Agreement shall be submitted to:

Achaogen Inc.

7000 Shoreline Court, #371

South San Francisco, CA 94080

Reference: Achaogen Contract No. _____________, Attn.: _______

Email:

All payments due Microgenics under this Agreement shall be made by Achaogen in United States dollars within [***] ([***]) days after receipt of the applicable invoice by ACH transfer to the credit and account of Microgenics at the following account: [***].

Page 21 of 60

Confidential Treatment Requested by Achaogen, Inc.

7.3Taxes.

7.3.1Withholding. Microgenics shall be liable for all income and other taxes (including interest) imposed upon any payments made by Achaogen to Microgenics under this Agreement. In the event that any Applicable Law requires Achaogen to withhold taxes with respect to any payment to be made by Achaogen pursuant to this Agreement, Achaogen will notify Microgenics of such withholding requirement prior to making the payment to Microgenics and provide such assistance to Microgenics, including the provision of such documentation as may be required by a tax authority, as may be reasonably necessary in Microgenics’ efforts to claim an exemption from or reduction of such taxes. Achaogen will, in accordance with such Law withhold taxes from the amount due, remit such taxes to the appropriate tax authority, and furnish Microgenics with proof of payment of such taxes within [***] ([***]) days following the payment. If taxes are paid to a tax authority, Achaogen shall provide reasonable assistance to Microgenics to obtain a refund of taxes withheld, or obtain a credit with respect to taxes paid.

7.3.2VAT. All payments due to Microgenics from Achaogen pursuant to this Agreement shall be paid exclusive of any value-added tax (“VAT”) (which, if applicable, shall be [***]). If Microgenics is required to report any such tax, Achaogen shall promptly provide Microgenics with applicable receipts and other documentation necessary or appropriate for such report.

8Intellectual Property Rights; Ownership

8.1Ownership of Discoveries and Inventions. Achaogen shall own all discoveries and inventions made by one or both of the Parties as part of the Research Program, whether or not patentable, relating (i) solely to Plazomicin, the Achaogen Patents, the Achaogen Know-How, and Achaogen Materials or (ii) [***] (each of (i) and (ii), “Achaogen Inventions”). Microgenics shall own all inventions and discoveries made by one or both of the Parties as part of the Research Program, whether or not patentable, relating solely to Microgenics Cell Lines, Microgenics [***] Antibodies, the Assay, Immunoassay Technologies and Microgenics Know-How (“Microgenics Inventions”). For all other inventions and discoveries, whether or not patentable, made by the Parties as part of the Research Program, whether individually or jointly, inventorship shall be determined pursuant to the inventorship principles arising under the patent laws of the United States of America, [***] (“[***] Products”). Each Party shall ensure that each of its employees and other representatives performing activities hereunder has agreed to assign to it all discoveries and inventions made by such employee or other representative in the course of his or her employment.

8.2Patent Procurement.

8.2.1Achaogen and Microgenics shall each disclose to the other any inventions and discoveries made during the course of the Research Program. Achaogen shall be responsible for the prosecution and maintenance of any Patent applications and Patents claiming or covering any Achaogen Inventions, and Microgenics shall be responsible for the prosecution and maintenance of any Patent applications and Patents claiming or covering any Microgenics Inventions; provided, that [***] shall not, without first obtaining [***] prior written consent, file any Patent claiming or covering the [***]; provided, further, that, in the event that any such Patent applications covering or claiming any [***] are filed without first obtaining [***] prior written consent, then [***] hereby grants [***] a perpetual, irrevocable, fully paid-up, royalty-free, worldwide, sublicenseable, non-exclusive license under such Patent applications and any Patents issuing therefrom or related thereto for the purpose of developing, manufacturing, using or commercializing [***].

Page 22 of 60

Confidential Treatment Requested by Achaogen, Inc.

8.2.2With respect to any Patent applications and Patents claiming or covering any [***] Products, the Parties shall meet to determine in what countries, if any, Patent applications claiming such [***] Products should be filed and the appropriate filing Party (a “Joint Patent”). The Parties shall [***] by the Party filing such patent applications in connection with any Joint Patents. If a Party elects [***] related to any Joint Patent, the other Party shall provide written notice upon the decision to [***] and the Party not giving such notice shall have the right to assume responsibility for any such prosecution or maintenance, [***].

8.3Prosecution, Review, Cooperation.

8.3.1The Party responsible for prosecuting and maintaining a given Patent pursuant to Section 8.2.1 or 8.2.2 (i.e., Microgenics with respect to Patents claiming or covering any Microgenics Inventions and the Assay Patent and the Party agreed to by the Parties with respect to Joint Patents) (the “Responsible Party”) shall keep the other Party (the “Review Party”) reasonably informed regarding the status of the filing, prosecution and maintenance of each applicable Patents, and shall provide the Review Party with copies of all documentation concerning each applicable Patent, including all correspondence to and from any Governmental Authority relating thereto. Prior to filing an applicable Patent application for, or material prosecution documents or other submissions relating to, an applicable Patent, the Responsible Party shall provide the Review Party with a reasonable opportunity to review and comment on the proposed application, document or submission, and the Responsible Party shall reasonably consider all such comments and incorporate such comments. In the event that the Responsible Party elects to abandon any applicable Patent, the Responsible Party shall notify the Review Party in writing (such notice, an “Abandonment Notice”) at least [***] ([***]) days prior to any filing or payment due date or any other due date that requires action to prevent loss of rights, and in the event that the Review Party provides the Responsible Party with written notice within [***] ([***]) days of receipt of the applicable Abandonment Notice, the Review Party shall thereafter have the right, [***], to conduct such filing, prosecution and maintenance for the applicable Patent.

8.3.2Each of the Parties shall execute or have executed by its employees, representatives and agents such documents as may be reasonably necessary to obtain, perfect, or maintain any Patent rights which would be filed pursuant to this Agreement and to cooperate with the other Party, [***], as reasonably necessary with respect to the prosecution of such Patent rights.

8.4Ownership. The Achaogen Patents, Achaogen Know-How and the Achaogen Materials shall at all times remain the sole property of Achaogen. Microgenics shall not use the Achaogen Know-How or the Achaogen Materials to develop or market, or have developed or marketed, any Assay for any Third Party. The Microgenics Cell Lines, Microgenics [***] Antibodies, Immunoassay Technologies and Microgenics Know-How shall remain the sole property of Microgenics. Except as may otherwise be expressly permitted pursuant to the terms and conditions of this Agreement, Achaogen shall not use the Microgenics Cell Lines, Microgenics Monoclonal Antibodies, Immunoassay Technologies and Microgenics Know-How to develop, manufacture, or market, or have developed, manufactured, or marketed, the Assay or any additional assay(s) for Plazomicin or any other compound/substance.

8.5Enforcement. Each Party shall immediately notify the other if it becomes aware of any infringement, anywhere in the world, of any issued Patent within the Joint Patents. The Parties shall mutually determine whether to take action to obtain a discontinuance of infringement or bring suit against a Third Party infringer of any Joint Patents within [***] ([***]) days from the date of notice; provided that neither

Page 23 of 60

Confidential Treatment Requested by Achaogen, Inc.

Party shall be obligated to join any such action. In the event that either Party does not want to join as a Party plaintiff, then the Party not seeking to enforce such infringement claims shall have the right to assign the relevant Joint Patents to the other Party; provided that such assignment is solely and sufficient for purposes of commencing and maintaining the action. The Party seeking to enforce such infringement claims [***] of any suit brought by it claiming infringement of any Joint Patent. The Parties will reasonably cooperate, at the expense of the Party seeking to enforce such infringement claim, in any such suit and shall have the right to consult with the other Party and to participate in and be represented by independent counsel in such litigation [***]. Any recoveries obtained by Achaogen or Microgenics, as applicable, as a result of any proceeding against such a Third Party infringer shall be allocated as follows: (a) such recovery shall first be used to reimburse each Party for all reasonable attorney fees and other litigation costs actually incurred in connection with such litigation by that Party, and (b) any remainder shall be shared [***] by the Parties.

8.6Patent Infringement. Each Party shall immediately notify the other if a claim or other proceeding is brought against either Party alleging infringement of Third Party Patent rights based upon the manufacture, use or sale of the Assay. The Parties shall immediately consult on how to proceed with respect to defending against any such claim of infringement.

8.7Third Party Licenses. Microgenics shall be solely responsible, at its own expense, for obtaining rights under any Third Party intellectual property necessary for Microgenics to perform its obligations under this Agreement and Achaogen shall be under no obligation to provide support therefor, financial or otherwise.

8.8Trademarks. As between the Parties, Microgenics shall own all right, title and interest in and to any Trademarks developed by or for Microgenics for use in connection with the Assay. Microgenics hereby grants to Achaogen a royalty-free non-exclusive right to use such Trademarks in connection with advertising, promoting and marketing Plazomicin, subject to Section 12.5 (Non-Use of Names). All use of Microgenics’ Trademarks by Achaogen shall inure to the sole benefit of Microgenics. As between the Parties, Achaogen shall own all right, title and interest in and to all Trademarks developed by or for Achaogen for use in connection with Plazomicin.

9Term and Termination

9.1Term.This Agreement shall be effective as of the Effective Date and unless terminated earlier by mutual written agreement of the Parties or pursuant to Section 9.2 (Termination At Will) or Section 9.3 (Termination for Cause) below, the term of this Agreement shall continue in effect until Achaogen ceases development and commercialization of Plazomicin (“Term”).

9.2Termination At Will. Achaogen may terminate this Agreement in its entirety, for any reason, by providing at least sixty (60) days prior written notice to Microgenics.

9.3Termination for Cause.This Agreement may be terminated in its entirety by written notice by either Party at any time:

9.3.1For material breach by the other Party, which breach remains uncured for ninety (90) days from the date written notice of such breach is given to the breaching Party, or, if such breach is not susceptible of cure within such ninety (90) day period and the breaching Party uses diligent good faith efforts to cure such breach, for one hundred eighty (180) days after written notice to the breaching Party if such breach remains uncured; or

Page 24 of 60

Confidential Treatment Requested by Achaogen, Inc.

9.3.2Upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party, or in the event a receiver or custodian is appointed for such Party’s business, or if a substantial portion of such Party’s business is subject to attachment or similar process; provided, however, that in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the proceeding is not dismissed within sixty (60) days after the filing thereof.

9.4Effect of Termination. Upon termination of this Agreement pursuant to Sections 9.1 (Term), Section 9.2 (Termination At Will) or 9.3 (Termination for Cause):

9.4.1All rights and licenses granted under Section 6.1 (License by Achaogen) of this Agreement shall terminate and all rights to the Achaogen Patents and Achaogen Know-How shall revert to Achaogen.

9.4.2All rights and licenses granted under Section 6.2 (License by Microgenics) of this Agreement shall terminate and, subject to Section 9.4.4, all rights to the Immunoassay Technologies and Microgenics Know-How shall revert to Microgenics.

9.4.3Microgenics shall promptly return or destroy (as directed by Achaogen) to Achaogen all Achaogen Know-How and Achaogen Materials provided to Microgenics hereunder, and, subject to Section 9.4.4, Achaogen shall promptly return to Microgenics all Microgenics Know-How provided to Achaogen hereunder;

9.4.4Solely in the case of termination of this Agreement by Achaogen under Section 9.3 (Termination for Cause):

9.4.4.1Microgenics hereby grants Achaogen a Transfer License; provided, that, Achaogen covenants not to use the Transfer License beyond the scope set forth in Section 1.33. In the event that Microgenics reasonably believes that Achaogen has breached the foregoing covenant, Microgenics shall provide written notice thereof, including reasonable supporting evidence, and, in the event that Achaogen agrees with such written notice and does not indicate to Microgenics that it will conform its activities to the scope of the Transfer License within [***] ([***]) business days after receiving the written notice, then the Transfer License shall be void as of the end of [***] period described in this sentence. If Achaogen indicates that it will so conform its activities, then the Transfer License shall remain in full force and effect. In the event that Achaogen disagrees with such written notice and advises Microgenics of such disagreement, the Parties shall submit this matter to the Dispute resolution process in 13.8. For purposes of resolving any disputes regarding the Transfer License, the Parties agree to complete the Dispute resolution process in 13.8 within [***] from the date of Microgenics’ first written notice of the breach of the covenant found in the proviso to the first sentence of this Section 9.4.4.1(i). If after concluding the Dispute resolution process in 13.8 it is determined that the covenant found in the proviso was breached, then the Transfer License shall terminate immediately. In the event that the Transfer License is granted, Achaogen shall owe no payments to Microgenics for the first [***] ([***]) months that any Assay commercialized under the Transfer License is commercialized and shall pay a [***] percent ([***]%) royalty on its net sales (i.e., gross sales less all deductions, reductions and offsets reasonably taken in accordance with generally accepted accounting principles in the United States) of Assays commercialized under the Transfer License following the end of such [***] ([***]) month

Page 25 of 60

Confidential Treatment Requested by Achaogen, Inc.

period.

9.4.4.2Microgenics shall (a) make its personnel available for a reasonable period of time (not to exceed [***] ([***]) months) to effect a successful technology transfer with respect to the manufacture and commercialization of the Assay, (b) provide Achaogen with copies of the physical embodiment of all processes, protocols, procedures, methods, tests and other intellectual property rights licensed to Achaogen under the Transfer License, as applicable, related to the Assay (including the manufacture thereof), (c) supply [***] (including [***]) reasonably required to perform [***] as may be required by the applicable Regulatory Authorities, and upon request by Achaogen, [***], provide Achaogen (and/or its designee) with [***] related to the Assay, and (d) promptly assist Achaogen (and/or its designee) in obtaining all necessary Regulatory Approvals and/or modifying and/or transferring existing Regulatory Approvals to enable Achaogen (and/or its designee) to develop, make, have made, use, market, distribute, import, sell and offer for sale the Assay ([***]).

9.4.4.3If, at the date of the actual termination of this Agreement, Microgenics is commercializing the Assay, such termination shall be suspended, and Microgenics shall continue to supply the Assay to the market, until [***]; provided that (i) such period shall not extend beyond an additional [***] ([***]) months from the date of the actual termination of this Agreement, (ii) Achaogen, itself or through or in conjunction with a Third Party, may commercialize another assay for use in conjunction with Plazomicin (i.e., Microgenics shall lose its commercial exclusivity), and (iii) Section 4.2.3 shall be of no force or effect during any such suspended termination.

9.4.5If this Agreement is terminated during the Term at any time by Achaogen under Section 9.2 (Termination At Will) or by Microgenics under Section 9.3 (Termination for Cause), the following terms shall apply:

9.4.5.1Solely to the extent the expiration or termination of this Agreement occurs prior to the payment of all development payments described in Section 7.1, Achaogen shall pay to Microgenics an amount equal to the first applicable unpaid development payment as described in Section 7.1 (Development Payments) for the period in which the Agreement is terminated or expires (for illustrative purposes only, if Achaogen provides notice of termination under Section 9.1 (Term) prior to the completion of the Phase 3: [***], then Achaogen shall pay an amount equal to USD $[***] to Microgenics pursuant to the terms of Section 7.2 (Invoices; Mechanism of Payment)); provided, that, notwithstanding the foregoing, no payment shall be due under this Section 9.4.5.1 in the event that this Agreement is terminated by Achaogen under Section 9.2 (Termination At Will) at any time in connection with the failure to obtain, or maintain, Regulatory Approval for Plazomicin; and

9.4.5.2for a period of two (2) years after the expiration or termination date of this Agreement pursuant to Section 9.4.5, in the event Achaogen decides to continue to develop and commercialize Plazomicin, Achaogen shall provide written notice thereof to Microgenics and, upon Achaogen’s receipt of a written proposal from Microgenics, the Parties shall use good faith efforts to negotiate a definitive agreement for the continued development, manufacture, supply and sale of the Assay by Microgenics on commercially reasonable terms; provided, however, that nothing in this Section 9.4.5.2 shall (a) obligate Achaogen to enter into any new agreement with Microgenics with respect to the development, manufacture, supply or sale of the Assay or (b) prohibit Achaogen from negotiating or entering into an agreement with any Third Party with respect to the development, manufacture, supply or sale of any assay.

Page 26 of 60

Confidential Treatment Requested by Achaogen, Inc.

9.4.6The termination, expiration or non-renewal of this Agreement shall not relieve either Party from any obligation that accrues pursuant to this Agreement before the effective date of the termination or expiration nor shall it release the Parties from any obligation that may have been incurred as a result of operations conducted under this Agreement.

9.5Survival. Termination of this Agreement for whatever reason in accordance with the provisions hereof or expiration of this Agreement shall not affect the accrued rights of the Parties, and shall not limit remedies that may be otherwise available in law or equity. Article 1 (Definitions), Section 4.1 (Manufacture), 8 (Intellectual Property Rights; Ownership) (except for Section 8.8 (Trademarks) (unless Achaogen intends to commercialize the Assay upon termination)), 11 (Indemnification), 12 (Confidentiality), and 13 (Miscellaneous) and Section 3.6 (Right of Reference) (but only in the event that Achaogen intends to commercialize the Assay upon termination), 9.4 (Effect of Termination) and 9.5 (Survival) shall survive expiration or termination of this Agreement for any reason. All other rights and obligations will terminate upon expiration of this Agreement.

10Representations and Warranties

10.1Representations and Warranties of Each Party. Each of Achaogen and Microgenics hereby represents, warrants and covenants to the other Party hereto as follows:

10.1.1it is a corporation or other entity duly organized and validly existing under the laws of the state or other jurisdiction of incorporation or formation;

10.1.2the execution, delivery, and performance of this Agreement by such Party has been duly authorized by all requisite corporate action and does not require any shareholder action or approval;

10.1.3no consent, approval, order or authorization of, or registration, declaration or filing with, or exemption by, any Third Party or any governmental entity is required by or with respect to such Party in connection with the execution, delivery and performance of this Agreement;

10.1.4this Agreement constitutes a valid and legally binding obligation of such Party, enforceable against such Party in accordance with its respective terms, except as may be limited by (a) applicable bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and (b) the effect of rules of law governing the availability of equitable remedies;

10.1.5the execution, delivery and performance of this Agreement do not and will not conflict with, or result in any violation of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation that would result in the creation of any encumbrance upon any of the assets owned by such Party under, any material provision of Applicable Law, of such Party’s organizational documents or of any agreement, judgment, injunction, order, decree, or other instrument binding on such Party or any assets owned by such Party; and

10.1.6it shall comply with all material Applicable Laws relating to its activities under this Agreement.

10.2Representations and Warranties of Microgenics. In addition to the representations and

Page 27 of 60

Confidential Treatment Requested by Achaogen, Inc.

warranties made by Microgenics under Section 10.1 (Representations and Warranties of Each Party) above, Microgenics further represents and warrants to Achaogen that:

10.2.1it has the capacity and resources (including [***]) to (i) develop, manufacture and supply the Assay in and for the Territory, and (ii) commercialize the Assay in the Primary Countries;

10.2.2and further covenants that, the Assay shall be developed, manufactured, commercialized, and shall function, in accordance with applicable GMP, Specifications and Applicable Laws;

10.2.3it has the capacity and resources to develop (including [***]), manufacture and commercialize the Assay in accordance with this Agreement, including in accordance with the Project Plan;

10.2.4to the best of its knowledge, the development, manufacture, use and sale of the Assay will not infringe any issued Patents in the Territory owned or controlled by any Third Party; and

10.2.5it owns or controls all rights to the Microgenics Cell Lines, Microgenics [***] Antibodies, and Immunoassay Technologies.

10.3Representations and Warranties by Achaogen. In addition to the representations and warranties made by Achaogen under Section 10.1 (Representations and Warranties of Each Party) above, Achaogen further represents and warrants to Microgenics that:

10.3.1it owns, controls or has the right and ability to grant Microgenics the licenses under its (and its Affiliates) rights in the Achaogen Patents (as listed in Exhibit B hereto) related to the use of Plazomicin, pursuant to this Agreement; and

10.3.2it owns, controls or has the right and ability to provide to Microgenics the Achaogen Materials for development, manufacture, marketing, and sale of the Assay pursuant to this Agreement.

10.4Debarment and Exclusion. Achaogen and Microgenics represent and warrant that neither it, nor any of its employees or agents working on the subject matter of this Agreement, has ever been, is currently, or is the subject of a proceeding that could lead to it becoming, as applicable, a Debarred Entity or Debarred Individual, an Excluded Entity or Excluded Individual or a Convicted Entity or Convicted Individual, nor are they listed on the FDA’s Disqualified/Restricted List for clinical investigators. Each Party further covenant, represent and warrant that if, during the Term, it, or any of its employees or agents working on their behalf, becomes or is the subject of a proceeding that could lead to that Party with respect to the subject matter hereof, becoming, as applicable, a Debarred Entity or Debarred Individual, an Excluded Entity or Excluded Individual or a Convicted Entity or Convicted Individual, or added to FDA’s Disqualified/Restricted List for clinical investigators, the Party shall immediately notify the other Party. This provision shall survive termination or expiration of this Agreement. For purposes of this provision, the following definitions shall apply:

10.4.1A “Debarred Individual” is an individual who has been debarred by the FDA pursuant to 21 U.S.C. §335a (a) or (b) from providing services in any capacity to a person that has an approved or pending drug product application.

10.4.2A “Debarred Entity” is a corporation, partnership or association that has been debarred by the FDA pursuant to 21 U.S.C. §335a (a) or (b) from submitting or assisting in the submission of

Page 28 of 60

Confidential Treatment Requested by Achaogen, Inc.

any abbreviated drug application, or a subsidiary or Affiliate of a Debarred Entity.

10.4.3An “Excluded Individual” or “Excluded Entity” is (a) an individual or entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in federal health care programs such as Medicare or Medicaid by the Office of the Inspector General (OIG/HHS) of the U.S. Department of Health and Human Services, or (b) is an individual or entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in federal procurement and non-procurement programs, including those produced by the U.S. General Services Administration (GSA).

10.4.4A “Convicted Individual” or “Convicted Entity” is an individual or entity, as applicable, who has been convicted of a criminal offense that falls within the ambit of 42 U.S.C. §1320a – 7(a), but has not yet been excluded, debarred, suspended or otherwise declared ineligible.

10.4.5“FDA’s Disqualified/Restricted List” is the list of clinical investigators restricted from receiving investigational drugs, biologics or devices if the United State Food and Drug Administration (“FDA”) has determined that the investigators have repeatedly or deliberately failed to comply with regulatory requirements for studies or have submitted false information to the study sponsor.

10.5Disclaimer. EXCEPT FOR THE EXPRESS REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS AGREEMENT, NEITHER MICROGENICS NOR ACHAOGEN MAKES, AND EACH HEREBY EXPRESSLY DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED, WHETHER IN FACT OR IN LAW, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.

10.6No Representations Regarding Approval or Commercial Success. Neither Party makes any representations or warranties as to: (a) whether Plazomicin or the Assay will be approved for commercial sale by the applicable Regulatory Authorities; or (b) the commercial potential or success of Plazomicin or the Assay.

11Indemnification

11.1Indemnification by Achaogen. Achaogen shall indemnify, defend and hold harmless Microgenics and its Affiliates and each of its and their respective employees, officers, directors and agents (each a “Microgenics Indemnified Party”) from and against any and all liabilities, damages, penalties, expenses and/or losses (including reasonable legal expenses and attorneys’ fees) (collectively, “Losses”), resulting from any Third Party suits, claims, actions or demands (collectively, “Third Party Claims”), to the extent arising out of or relating to: (a) the breach by Achaogen of any representation, warranty or covenant contained in this Agreement; (b) the willful misconduct or negligent acts or omissions of Achaogen, its Affiliates or any of their respective employees, officers, directors or agents; (c) the manufacture, promotion, distribution, use, testing, marketing or sale of pharmaceutical products containing Plazomicin by Achaogen or its Affiliates; or (d) claims of infringement of Third Party Patents based upon the manufacture, use or sale of Plazomicin; except, in each case, to the extent such Losses result from clauses (a), (b), (c) or (d) of Section 11.2 (Indemnification by Microgenics).

11.2Indemnification by Microgenics. Microgenics shall indemnify, defend and hold harmless Achaogen and its Affiliates and each of its and their respective employees, officers, directors and agents (each a “Achaogen Indemnified Party”) from and against any and all Losses, resulting from any Third Party

Page 29 of 60

Confidential Treatment Requested by Achaogen, Inc.

Claims, to the extent arising out of or relating to: (a) the breach by Microgenics of any representation, warranty or covenant contained in this Agreement; (b) the willful misconduct or negligent acts of Microgenics, its Affiliates or any of their respective employees, officers, directors, or agents; (c) the manufacture, promotion, distribution, use, testing, marketing or sale of the Assay; or (d) claims of infringement of Third Party Patents based upon the manufacture, use or sale of the Assay; except, in each case, to the extent such Losses result from clauses (a), (b) (c) or (d) of Section 11.1 (Indemnification by Achaogen).

11.3Conditions to Indemnification The obligations of the indemnified Party under Sections 11.1 (Indemnification by Achaogen) and 11.2 (Indemnification by Microgenics) are conditioned upon the delivery of written notice to the indemnifying Party of any potential liability promptly after the indemnified Party become aware of such potential liability; provided, however, that the failure to give such notice promptly shall not impair a Party’s right to indemnification under this Section 11.3 (Conditions to Indemnification) unless the delay in providing such notice has a material adverse effect on the ability of the indemnifying Party to defend against such liability. The indemnifying Party shall have the right to assume the defense of any suit or claim relating to the liability if it has assumed responsibility for the suit or claim in writing; however, if in the reasonable judgment of the indemnified Party, such suit or claim involves an issue or matter which could have a material adverse effect on the business operation or assets of the indemnified Party, the indemnified Party may waive its rights to indemnity under this Agreement and control the defense or settlement thereof, but in no event shall any such waiver be construed as a waiver of any rights such indemnified Party may have against any Third Party at law or in equity. If the indemnifying Party defends the suit or claim, the indemnified Party shall cooperate with the indemnifying Party in such defense and the indemnified Party or Parties may participate in (but not control) the defense thereof at its sole cost and expense.

11.4Settlements. Neither of the Parties may settle a claim or action related to a Third Party Claim without the consent of the other Party, if such settlement would impose any monetary obligation on the other Party, or would require the other Party to submit to an injunction or otherwise limit the other Party’s rights under this Agreement. Any payments made by a Party to settle any such claim or action shall be at its own costs and expense, except in the event such payment was made with the prior written consent of an indemnifying Party, in which case such payment shall be subject to the obligations of the Parties as set forth in Sections 11.1 (Indemnification by Achaogen), 11.2 (Indemnification by Microgenics), and 11.3 (Conditions to Indemnification).

11.5Limitation of Liability. except with respect to damages that arise due to a Party’s breach of confidentiality (article 12) or indemnification obligations (article 11), in no event will either Party be liable to the other for consequential, indirect, special, exemplary or punitive damages for any cause of action, whether in contract, tort or otherwise, including lost revenues, profits or business opportunities arising out of or in connection with this Agreement, whether or not the other Party was or should have been aware of the possibility of these damages. except with respect to damages that arise due to a Party’s breach of confidentiality (article 12) or indemnification obligations (article 11), the liability of either Party under this Agreement (whether by reason of breach of contract, tort, or otherwise) with respect to a given claim shall not exceed an amount equal to [***].

11.6Insurance. Each Party shall maintain, through self-insurance or commercially-placed insurance, adequate commercial general liability and products liability insurance, including contractual liability coverage, necessary to satisfy its obligations hereunder and consistent with pharmaceutical and

Page 30 of 60

Confidential Treatment Requested by Achaogen, Inc.

diagnostic industry practices.

12Confidentiality

12.1Nondisclosure. During the Term, and for a period of [***] ([***]) years thereafter, all Confidential Information disclosed to a Party hereto or its Affiliates (the “Receiving Party”) by the other Party or its Affiliates (the “Disclosing Party”) shall be deemed confidential and shall be treated as such by the Receiving Party (meaning that the Receiving Party shall take the same steps to protect such information as it does to protect its own confidential information, which in any event shall be no less than the reasonable protective measures for the industry) and shall only be used for the purposes of this Agreement. Notwithstanding the foregoing, Confidential Information shall not include information that is:

(a)

known by the Receiving Party at the time of its receipt and not through a prior disclosure by the Disclosing Party;

(b)

at the time of disclosure or thereafter, becomes published or otherwise part of the public domain through no breach of this Agreement by the Receiving Party;

(c)

subsequently disclosed to the Receiving Party by a Third Party having the right to make such a disclosure; or

(d)

developed by the Receiving Party, as evidenced by its records, independently of information received by it from the Disclosing Party hereunder.

12.2Permitted Disclosure. Information provided under this Agreement may be disclosed to employees, agents or consultants of the Receiving Party, but only to the extent required to accomplish the purposes of this Agreement and only after the Receiving Party obtains the prior agreement of its employees, agents and consultants to whom disclosure is to be made to hold in confidence and not to make use of such information for any purpose other than that permitted by this Agreement. In addition to the foregoing exceptions, either Party may disclose Confidential Information to the extent it is required to be disclosed under Applicable Law, or in connection with any application by the Receiving Party for any Regulatory Approvals; provided, however, that the Receiving Party shall furnish the Disclosing Party with as much prior written notice of such disclosure requirement as reasonably practicable, so as to permit the Disclosing Party, in its sole discretion, and at its sole expense, to take appropriate action, including seeking a protective order, in order to prevent the Disclosing Party’s Confidential Information from passing into the public domain or becoming generally available to the public.

12.3Publicity. The Parties agree to make a joint public release of the having entered into this Agreement upon the successful completion of Phase I as described in Exhibit F. The public release must however not contain any Confidential Information of any kind such as scientific, commercial or financial which both Parties have not agreed to include in writing. No public announcement concerning the existence, terms or subject matter of this Agreement shall be made, either directly or indirectly, by any Party, without first obtaining the prior written approval of the other Party and agreement upon the nature and text of such public announcement which such agreement and approval shall not be unreasonably withheld. Notwithstanding the foregoing, if, in the opinion of legal counsel for the Party desiring to make such public announcement, such disclosure is required under Applicable Law, subject to Section 12.2 (Permitted Disclosure) above, the Party required to make such public announcement shall inform the other Parties of the proposed announcement or disclosure in reasonably sufficient time prior to public release, which shall be not

Page 31 of 60

Confidential Treatment Requested by Achaogen, Inc.

less than [***] ([***]) business days (or such shorter period as may be required under Applicable Law) prior to release of such proposed public announcement, and shall provide the other Parties with a written copy thereof in order to allow such other Parties to comment upon such public announcement. The Receiving Party shall reasonably cooperate with the Disclosing Party (at the Disclosing Party’s expense) with respect to all disclosures regarding this Agreement required under Applicable Law, including requests for confidential treatment of proprietary information of the Disclosing Party included in any such disclosure.

12.4Applicable Law. Nothing in this Agreement shall be construed as preventing or in any way inhibiting any Party from complying with Applicable Law governing activities and obligations undertaken pursuant to this Agreement, in any manner which it reasonably deems appropriate, including, for example, by disclosing to Regulatory Authorities confidential or other information received from the other Parties, subject to Sections 12.2 (Permitted Disclosure) and 12.3 (Publicity).

12.5Non-Use of Names. Except as otherwise provided in this Agreement, neither Party (or its Affiliates) shall use, either directly or indirectly, the Trademarks of the other Party (or their Affiliates), or the names of any of their officers, employees or board members in any publicity, marketing advertising or other documents (or other disclosures) unless (a) such use is consistent with, and permitted under, the Project Plan or (b) a copy or transcript of the proposed disclosure is submitted to and approved in advance in writing by the other Party (each in its sole discretion), except in the case in which a governmental authority requires the use of the Trademark by a Party in the sale or distribution of the Assay or Plazomicin. Each Party will use good faith efforts to review and approve any proposed disclosure within [***] ([***]) business days of its receipt from the other Party of a copy or transcript of the proposed disclosure. If a Party approves the other Party’s usage of its Trademarks (or its Affiliates), or the names of any of their officers, employees or board members in accordance with this Section 12.5 (Non-Use of Names), the other Party shall comply with any usage guidelines or requirements imposed by the approving Party.

12.6Publications. Publication in a journal, paper, magazine or any other such similar disclosure relating to the development, manufacture or commercialization of the Assay will not take place without the prior written agreement of both Achaogen and Microgenics, which shall not be unreasonably withheld. Any draft article intended to be submitted for publication by Microgenics or Achaogen (or a clinical trial site utilized by Achaogen) hereto shall first be sent to the other Party in order to allow such Party to preserve its intellectual property rights by delaying such publication (but not for more than [***] ([***]) days) and/or removing its Confidential Information. Achaogen’s and/or Microgenics’ contribution shall be acknowledged in any publication by co-authorship or acknowledgment, whichever is appropriate. Republication of any article, in whole or in part, which has previously been approved by the Parties shall not require subsequent approval, provided that the content is substantially unchanged. These restrictions are not applicable to Plazomicin; provided, however, that, for clarity, Microgenics shall have no right to publish with respect to Plazomicin.

12.7Prior CDAs. This Agreement supersedes that certain Confidential Disclosure Agreement between the Parties dated [***]; provided, however, that all Confidential Information disclosed or received by the Parties thereunder will be deemed Confidential Information hereunder and will be subject to the terms and conditions of this Agreement. For clarity, this Agreement does not supersede the Antibody Development Agreement.

13Miscellaneous

13.1Force Majeure. Neither Party shall be liable to the other for delay or failure in the

Page 32 of 60

Confidential Treatment Requested by Achaogen, Inc.

performance of the obligations on its part contained in this Agreement if and to the extent that such failure or delay is due to government action, war, terrorism, fire, explosion, flood, strike, lockout, embargo, shortage of materials or utilities, vendor failure to supply, act of God, or any other cause beyond the control and without the fault or negligence of the defaulting Party (a “Force Majeure Event”), provided that the Party claiming Force Majeure Event has exerted all Commercially Reasonable Efforts to avoid or remedy such force majeure. Such excuse shall continue as long as the condition preventing the performance continues. Upon cessation of such Force Majeure Event, the affected Party shall promptly resume performance hereunder. Each Party agrees to give the other Party prompt written notice of the occurrence of any such Force Majeure Event, the nature thereof, and the extent to which the affected Party will be unable to perform its obligations hereunder. Each Party further agrees to use all Commercially Reasonable Efforts to correct the Force Majeure Event [***] and to give the other Party prompt written notice when it is again fully able to perform its obligations hereunder.

13.2Assignment. Neither Party may assign this Agreement to a Third Party unless both Parties have agreed to such assignment in a writing signed by an authorized representative of each Party hereto; provided, however, that upon providing written notice, (i) either Party may, without the other Party’s consent, assign this Agreement to an Affiliate or to any Third Party entity that acquires all or substantially all of its assets to which this Agreement relates and (ii) Achaogen may, without Microgenics’ consent, assign this Agreement (in whole or in part) to a Third Party licensee of Achaogen’s rights with respect to Plazomicin. This Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties. Any assignment not in accordance with this Section 13.2 (Assignment) shall be void.

13.3No Waiver. The failure of either Party to require performance by the other Party of any of that other Party’s obligations hereunder shall in no manner affect the right of such Party to enforce the same at a later time. No waiver by any Party hereto of any condition, or the breach of any provision, term, representation or warranty contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such condition or breach, or of any other condition or of the breach of any other provision, term, representation or warranty hereof.

13.4Severability. If a court or other tribunal of competent jurisdiction should hold any term or provision of this Agreement to be excessive, or invalid, void or unenforceable, the offending term or provision shall be deleted, and, if possible, replaced by a term or provision which, so far as practicable, achieves the legitimate aims of the Parties. In the event that such provisions cannot be agreed upon, the invalidity, illegality or unenforceability of one or more provision of this Agreement shall not affect the validity of this Agreement as a whole.

13.5Relationship Between the Parties. Both Parties are independent contractors under this Agreement. Nothing herein contained shall be deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party. Neither Party shall have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever.

Page 33 of 60

Confidential Treatment Requested by Achaogen, Inc.

13.6Correspondence and Notices. Correspondence, reports, documentation and any other communication in writing between the Parties in the course of implementation of this Agreement shall be in writing and sent by internationally recognized overnight delivery service that maintains records of delivery, or by facsimile confirmed by prepaid registered or certified air mail letter, and shall be deemed to have been properly served to the addressee upon the date delivered by hand or transmitted by facsimile (with transmission confirmed) or on the second business day (at the place of delivery) after deposit with an internationally recognized overnight delivery service. The proper address for communication and for all payments shall be:

To Microgenics:With a copy to:

Microgenics CorporationThermo Fisher Scientific

Attn: VP & General ManagerAttn: SDG General Counsel

46500 Kato Road81 Wyman Street

Fremont, CA 94538Waltham, MA 02451

Fax: Fax: (781) 622-1283

To Achaogen:With a copy to:

Achaogen Inc.

7000 Shoreline Court, #371

South San Francisco, CA 94080

Fax:

13.7Choice of Law. This Agreement is subject to and governed by the laws of the State of Delaware, U.S.A. (without regard to conflict of law principles).

13.8Dispute Resolution.

13.8.1Executive Resolution. In the event of a dispute with respect to (a) the validity, interpretation or construction of this Agreement, (b) compliance with this Agreement or (c) a breach of this Agreement (a “Dispute”), a Party may provide the other Party with written notice of the Dispute, and the Parties agree to exercise reasonable efforts to resolve the Dispute in good faith by promptly engaging in discussions with duly authorized representatives of the Parties. If the Dispute cannot be resolved by such authorized representatives of the Parties within [***] ([***]) business days, the authorized representatives shall refer the Dispute to a meeting between a senior executive representing each Party (currently the [***] for Achaogen, and the [***] for Microgenics), which such senior executives shall participate in at least one in person meeting as soon as practicable, but in no event later than [***] ([***]) days after the date of the relevant referral. If the senior executives for Achaogen and Microgenics cannot resolve such Dispute in a mutually acceptable manner within [***] ([***]) business days after such meeting, then the Dispute shall be resolved exclusively by final and binding arbitration in accordance with Section 13.8.2.

13.8.2Arbitration. Arbitration will be conducted exclusively in the State of Delaware by arbitration administered by the American Arbitration Association (“AAA”) under its Commercial Arbitration Rules and Supplementary Procedures for Large Complex Disputes, and judgment on the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof. [***]. Notwithstanding anything in this Agreement to the contrary, each Party shall have the right, at its election, to seek injunctive or other equitable relief in any court of competent jurisdiction to enforce or obtain compliance with any provision of

Page 34 of 60

Confidential Treatment Requested by Achaogen, Inc.

this Agreement without first submitting such matter to arbitration. All rights and remedies hereunder shall be cumulative, may be exercised singularly or concurrently and, unless otherwise stated herein, shall not be deemed exclusive.

13.9Entire Agreement; Amendment. Except as otherwise set forth in Section 12.7, this Agreement and the Antibody Development Agreement, including the Exhibits and Schedules hereto and thereto and all the covenants, promises, agreements, warranties, representations, conditions and understandings contained herein and therein sets forth the complete, final and exclusive agreement between the Parties and supersedes and terminates all prior and contemporaneous agreements and understandings between the Parties, whether oral or in writing. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth in this Agreement and the Antibody Development Agreement. No subsequent alteration, amendment, change, waiver or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. No understanding, agreement, representation or promise, not explicitly set forth herein, or in the Antibody Development Agreement, has been relied on by either Party in deciding to execute this Agreement. Notwithstanding anything to the contrary contained herein or in the Antibody Development Agreement, nothing in the Antibody Development Agreement shall be deemed to modify or diminish the representations, warranties, covenants and obligations of the Parties under this Agreement and in the event of any conflict between the terms and conditions of this Agreement and the terms and conditions of the Antibody Development Agreement, this Agreement shall govern except with respect to Section 4.2.7.3 of this Agreement which shall be subject to the Antibody Development Agreement.

13.10Headings. The headings and captions used in this Agreement are solely for the convenience of reference and shall not affect its interpretation.

13.11Counterpart. This Agreement may be executed in one or more counterparts, each of which shall be an original, and all of which shall constitute together the same document. Each Party acknowledges that an original signature or a copy thereof transmitted by facsimile (or .pdf file) shall constitute an original signature for purposes of this Agreement.

13.12Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement including any filings with any antitrust agency which may be required.

13.13Affiliates. Both Parties shall have the right, in their sole discretion, to perform some or all of its obligations and exercise some or all of its rights under this Agreement through its Affiliates.

13.14Joint Negotiation. This Agreement is the joint product of Microgenics and Achaogen, and each provision hereof has been subject to the mutual consultation, negotiation and agreement of the Parties and their respective legal counsel and advisers and any rule of construction that a document shall be interpreted or construed against the drafting Party shall not be applicable.

13.15Construction. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). All references to a “business day” or “business days” in this Agreement means any day other than a day which is a Saturday, a Sunday or any day banks are authorized or required to be closed in the United States. The words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation”. The word “will” shall be construed to have the same

Page 35 of 60

Confidential Treatment Requested by Achaogen, Inc.

meaning and effect as the word “shall.” The words “herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof. All currency herein shall refer to United States dollars, unless specifically provided otherwise. All exhibits to this Agreement are hereby made a part of this Agreement.

13.16Use of Third Parties. All obligations under this Agreement shall be performed by the Party designated to perform such obligations under this Agreement and such obligations may not be performed by a Third Party on such Party’s behalf, unless (a) the other Party has consented in writing which shall not be unreasonably be withheld or delayed, (b) the Party engaging such Third Party performs appropriate qualification and oversight of such Third Party in accordance with the Applicable Law, including applicable GMP, GCP, and GLP requirements, and (c) the Party engaging such Third Party ensures that such Third Party complies with the terms and conditions of this Agreement, and provided that such performance of activities by a Third Party is consistent with the rights and obligations of the Parties under this Agreement. Notwithstanding any such consent, each Party shall remain at all times fully liable for its respective responsibilities under this Agreement. Each Party hereby expressly waives any requirement that the other Party exhaust any right, power or remedy, or proceed against such subcontractor for an obligation or performance hereunder, prior to proceeding directly against the Party engaging such subcontractor.

[Signature Page to Follow]

Page 36 of 60

Confidential Treatment Requested by Achaogen, Inc.

IN WITNESS WHEREOF, duly authorized representatives of the Parties have duly executed this Agreement to be effective as of the Effective Date.

ACHAOGEN INC.MICROGENICS CORPORATION


By: /s/ Blake Wise	By: /s/ Marc Tremblay
Name: Blake Wise	Name: Marc Tremblay
Title: COO	Title: President, Clinical Diagnostics
Date: 4/26/16	Date: 4/26/2016

Signature Page to Collaborative Development and Commercialization Agreement

DB2/ 26356633.19

Confidential Treatment Requested by Achaogen, Inc.

Exhibit A

Achaogen Materials


Achaogen Materials	Estimated Amount	Estimated Development Phase Required
[***]

(1)

[***]

Page 38 of 60

DB2/ 26356633.19

Confidential Treatment Requested by Achaogen, Inc.

Exhibit B

Achaogen Patents

[***]

Page 39 of 60

DB2/ 26356633.19

Confidential Treatment Requested by Achaogen, Inc.

Exhibit C

Microgenics’ Cell Lines

[***]


Clone #	Clone ID

[***]

[***]


Clone #	Clone ID

[***]

[***]


Clone #	Clone ID

[***]

[***]


Rabbit	Identity	Immunogen
[***]

[***]

Page 40 of 60

DB2/ 26356633.19

Exhibit D

Plazomicin Chemical Structure

Page 41 of 60

Confidential Treatment Requested by Achaogen, Inc.

Exhibit E

Primary Countries


Achaogen Primary Country List
Country	Country
[***]

Page 42 of 60

DB2/ 26356633.19

Confidential Treatment Requested by Achaogen, Inc.

Exhibit F

Project Plan Timeline and Deliverables


Plazomicin TDM Immunoassay Development Project Plan Timeline and Deliverables
Deliverables		Start	End	Duration (M)
Phase 0	[***]	[***]	[***]	[***]
[***]
[***]
Phase 1	[***]	[***]	[***]	[***]
•[***]
•[***]
Phase 2	[***]	[***]	[***]	[***]
[***]
[***]
Phase 3	[***]	[***]	[***]	[***]
[***]
[*] [*]
[***]
Phase 4	[***]	[***]	[***]	[***]
Milestone 1: [***]		[***]	[***]	[***]
[***]
Milestone 2: [***]		[***]	[***]	[***]
[***]
Milestone 3: [***]		[***]	[***]	[***]
Milestone 3A: [***]		[***]	[***]	[***]
[***]
Milestone 3B: [***]		[***]	[***]	[***]
[***]
[***]
[***]		[***]	[***]	[***]
[***]
Phase 5	[***]	[***]	[***]	[***]
Milestone 1: [***]		[***]	[***]	[***]
[***]
Milestone 2: [***]		[***]	[***]	[***]
[***]

Page 43 of 60

DB2/ 26356633.19

Confidential Treatment Requested by Achaogen, Inc.

Exhibit G

Specifications

[***]

Performance Attributes

Desired Value(s)

Acceptable Value(s)

[***]

Page 44 of 60

DB2/ 26356633.19

Confidential Treatment Requested by Achaogen, Inc.

Exhibit H - BARDA Requirements

1.0	Additional Terms and Conditions for this Agreement as a Federal Subcontract

1.1

Purpose. This Agreement is a subcontract under the following Achaogen Government Contract(s):

•

Contract No. HHSO100201000046C (BARDA 0046C Contract) between Achaogen, Inc. and Department of Health and Human Services, Biomedical Advanced Research and Development Authority;

The purpose of this Section 1.0 is to incorporate by reference certain government (“ Government”) contract clauses (flow downs) associated with the Achaogen Government Contract(s) specified above, that Achaogen, as a prime contractor, must include, and by which Microgenics, as a subcontractor, must abide.

1.2

Incorporated Government Contract Clauses

(a)

For BARDA Contract. This Agreement incorporates by reference Appendix A, “Government Provisions for Commercial Item Subcontracts Under Contract No. HHSO100201000046C (BARDA 0046C Contract).” Microgenics agrees to abide by all of the provisions listed in Appendix A hereto as a condition of performance of services pursuant to any duly-executed Exhibit under this Agreement.

1.3

Changes to Government Contracts Provisions

Microgenics agrees that upon the request of Achaogen it will negotiate in good faith with Achaogen amendments to this Agreement to incorporate additional provisions herein or to change provisions hereof, as Achaogen may reasonably deem necessary in order to comply with the provisions of the applicable Achaogen Government Contract or with the provisions of amendment(s) to such Achaogen Government Contract. If any such amendment to this Agreement causes [***], an equitable adjustment shall be made pursuant to the “Changes” clause of this Agreement.

1.4

RESERVED [Not applicable]

1.5

Government Right to Inspection of Research and Development (Reference: FAR 52.246-9)

(a)

Microgenics recognizes that the Government has the right to inspect and evaluate work performed or being performed under the Achaogen Government Contract, including any such work performed or being performed under this Agreement, to the extent practicable at all reasonable places and times and in a manner that will not unduly delay the work, including the period of performance, and in any event before its termination.

(b)

If the Government performs any inspection or test on Microgenics’ premises, Microgenics shall furnish all reasonable facilities and assistance for the safe and convenient performance of these duties.

1.6

Representations and Certifications

Page 45 of 60

DB2/ 26356633.19

By executing this Agreement, Microgenics represents and certifies that:

(a)

neither it, nor any of its Principals (as defined hereinafter), is presently debarred, suspended, proposed for debarment or otherwise declared ineligible for participating in any federal or state procurement action by any federal, state, or local government or agency;

(b)

neither it, nor any of its Principals, has within the last three years, been convicted of, or had a civil judgment rendered against it, for any of the following: (i) the commission of fraud or a criminal offense in connection with obtaining, attempting to obtain, or performing a federal, state or local government contract or agreement; (ii) a violation of federal or state antitrust statutes relating to the submission of offers; or (iii) the commission of embezzlement, theft, forgery, bribery, falsification or destruction of records, making false statements, tax evasion, or receiving stolen property;

(c)

it will comply with all applicable Federal laws and regulations regarding ethics in public acquisitions and procurement and performance of contracts;

(d)

RESERVED

(e)

it has not made or solicited and will not make or solicit kickbacks in violation of FAR 52.203-7 or the Anti-Kickback Act of 1986 (41 USC 51-58);

(f)

that (i) no federal appropriated funds have been paid or will be paid to any person for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress on his or her behalf in connection with the awarding of this Agreement; (ii) if any funds other than federal appropriated funds (including profit or fee received under a covered federal transaction) have been paid, or will be paid, to any person for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress on his or her behalf in connection with this Agreement, Microgenics shall complete and submit, with its offer, OMB standard form LLL, Disclosure of Lobbying Activities, to the Contracting Officer; and (iii) it will include the language of this certification in all subcontract awards at any tier and require that all recipients of subcontract awards in excess of $150,000 shall certify and disclose accordingly (the definitions and prohibitions contained in the clause at FAR 52.203-12, Limitation on Payments to Influence Certain Federal Transactions, included in this Subsection 12.7 (f) and will be included in all such certifications);

(g)

that (i) if Microgenics has participated in a previous contract or subcontract subject to the Equal Opportunity clause (FAR 52.222-26), Microgenics has filed all required compliance reports; and (ii) representations indicating submission of required compliance reports, signed by proposed subcontractors, will be obtained before subcontract awards; and

(h)

that to the best of the Microgenics's knowledge and belief, there are no relevant facts or circumstances which could give rise to an organizational conflict of interest, as defined in FAR Subpart 9.5.

Microgenics agrees to provide immediate written notice to Achaogen if, at any time prior to termination, Microgenics learns that its certification was erroneous when submitted or has become erroneous by reason of changed circumstances. For the purpose of paragraphs (a)

Page 46 of 60

and (b) above, “Principal” means an officer; director, owner; partner; or a person having primary management or supervisory responsibilities within a business entity.

2.0	Government Interface

2.1

Microgenics employees may not communicate with any Government employee, including Achaogen’s contracting officer (“Contracting Officer”), Contracting Officer’s representative or their respective support staff, concerning any work performed pursuant to this Agreement or any associated Exhibit or appendix, without advance written consent from Achaogen.

2.2

Under no circumstances may Microgenics accept Government instruction on behalf of Achaogen. Microgenics is not authorized to make offers, commitments, or otherwise negotiate with the Government on Achaogen’s behalf or its own behalf in its capacity as a subcontractor to Achaogen. In case of occurrence of any such events, Microgenics shall:

(a)

suggest to the Government representative that Achaogen be involved in all such discussions, and

(b)

immediately report to Achaogen any attempt by Government personnel to provide such instruction or conduct such negotiations.

2.3

If Microgenics communicates with the Government regarding a Project, Microgenics’s monthly contract management reports shall list all data exchanged and shall summarize each and every significant discussion with Government personnel during the reporting period.

3.0

Disputes

3.1

Disputes Involving the Prime Contract and/or the Government

(a)

Any dispute arising under or related to this Agreement which relates to a matter for which Achaogen has recourse against the Government under the Achaogen Government Contract (also hereinafter sometimes referred to as the “Prime Contract”) shall be resolved as follows unless the Parties otherwise agree in writing.

(b)

Microgenics shall give Achaogen a fully supported written request for equitable adjustment or claim concerning any such dispute within [***] years after the basis of the equitable adjustment arises or claim accrues, but in no event later than [***], or Microgenics shall be barred from any remedy for such claim.

(c)

Achaogen shall forward such request for equitable adjustment or claim to the Contracting Officer on Microgenics’s behalf for final decision, subject to the limitations and other conditions contained in this provision. Achaogen shall in good faith consult with Microgenics concerning the forwarding of such request for equitable adjustment or claim to the Contracting Officer.

(d)

Any final decision of the Contracting Officer under the Prime Contract as it relates to this Agreement, whether or not it results from a claim under Section 3.1(b) and (c) of this Agreement submitted on Microgenics’s behalf under the provision stated above, shall be binding upon Microgenics; provided however, that Achaogen shall notify Microgenics immediately of any such final decision of the Contracting Officer and if: (i) Achaogen elects not to appeal such decision pursuant to the

Page 47 of 60

“Disputes” clause of the Prime Contract; (ii) Achaogen thereafter receives, no less than [***] ([***]) days before the expiration of the period of appeal under the “Disputes” clause of the Prime Contract, a written request by Microgenics to appeal such decision, and (iii) Achaogen has the right of such appeal under the Prime Contract, then Achaogen shall file an appeal from the final decision on Microgenics’s behalf.

(e)

If Achaogen appeals such a decision, whether at its election or at Microgenics’s request, any decision upon such appeal by the Board of Contract Appeals, the United States Court of Federal Claims, or any other board or agency having jurisdiction over the appeal shall be binding upon Microgenics insofar as it relates to a claim under this Section 3.1 of this Agreement, provided however, that if Microgenics timely (i.e., no less than [***] ([***]) days before the expiration of the relevant period of appeal) requests Achaogen to bring a further appeal to obtain judicial review of such final decision by a court of competent jurisdiction, Achaogen shall do so, subject to the terms below. A final judgment in any such further appeal, if binding on Achaogen under the Prime Contract, shall in turn be binding on Microgenics insofar as it relates to a claim under this Section 3.1 of this Agreement.

(f)

In any appeal brought by Achaogen on behalf of Microgenics, or at Microgenics’s request under the above provisions, [***] shall bear all costs and expenses incurred by Microgenics in prosecuting such appeal, including but not limited to, any legal fees or costs incurred. In any appeal taken or brought by Achaogen, whether at its election or at Microgenics request, Microgenics shall cooperate fully with Achaogen in its prosecution thereof in every reasonable manner and Microgenics shall be afforded reasonable opportunity to participate in the prosecution thereof to the extent Microgenics’s interest may be affected. To the extent requested by Achaogen, Microgenics shall prosecute for Achaogen any appeal taken or brought at Microgenics request and, in such event, Achaogen shall assist Microgenics in every reasonable manner.

(g)

If Achaogen is required to certify any claim of Microgenics, Achaogen shall not forward such claim unless it is reasonably satisfied the claim is in good faith, and Achaogen can certify such claim to the Contracting Officer to the extent and manner required by the Contract Disputes Act, as applicable. Microgenics agrees to provide Achaogen with such information as Achaogen reasonably may deem necessary to make this determination, including but not limited to, its own certification in the form prescribed by the Contract Disputes Act or its implementing regulations. Such certification shall be executed by a person duly authorized to bind Microgenics. Microgenics agrees that, with respect to any claim or dispute that arises under or relates to the Prime Contract which, if it were Achaogen’s claim, can properly be submitted for a decision of the Contracting Officer under the “Disputes” clause, its right of claim or appeal is limited to the procedures set forth in this provision.

(h)

Microgenics’s failure to comply with the terms of this provision shall entitle Achaogen to terminate any such appeal on Microgenics’s behalf. The rights and obligations described herein shall survive completion of and final payment under this Disputes section.

3.2

Other Disputes Any dispute arising under or related to this Agreement which relates to a matter for which Achaogen has recourse against the Government under the Prime Contract shall be resolved in accordance with Subsection 3.1. In the event of any dispute between the

Page 48 of 60

Parties arising out of or in connection with this Agreement that does not relate to a matter for which Sponsor has recourse against the Government under the Prime Contract, such dispute shall be resolved pursuant to Section 13.8 of the Agreement.

3.3

Choice of Law: This Agreement is subject to and governed by the laws of the State of Delaware, U.S.A. without regard to conflict of law principles, as applicable except that any provision in this Agreement that is (i) incorporated in full text or by reference from the Federal Acquisition Regulation (FAR) or (ii) incorporated in full text or by reference from any agency regulation that implements or supplements the FAR or (iii) substantially based on any such FAR provision or agency regulation, shall be construed and interpreted according to the federal common law of government contracts as enunciated and applied by federal judicial bodies, boards of contract appeals, and quasi-judicial agencies of the federal government.

Page 49 of 60

Appendix A
Government Provisions for Commercial Item Subcontracts
Under Contract Number HHSO100201000046C (BARDA Prime Contract)

The following provisions, as they may be amended by the United States Government over time, are incorporated by reference with the same force and effect as if set forth in full text and shall be deemed to apply solely to such portions of work as are funded using Government funds. For the purposes of this Agreement, the term “contract” shall mean this Agreement; the terms “Contractor” and “Company” shall mean Microgenics; the term “prime contractor” shall mean Achaogen; and the terms “Government” and “Contracting Officer” may mean Achaogen or the United States Government as expressly indicated on this document. The dollar amount listed parenthetically in the titles of some referenced clauses in this Appendix A is the applicability threshold for the clause. If the total cumulative amount invoiced by Microgenics for all Government Sponsored Projects performed under the BARDA Prime Contract is expected to exceed this amount, the clause applies.

Federal Acquisition Regulation


Clause	Date	Title
FAR 52.202-1	Jul-04	Definitions (Over $100,000)
FAR 52.203-3	Apr-84	Gratuities (Over $100,000)
FAR 52.203-5	Apr-84	Covenant Against Contingent Fees (Over $100,000). Substitute “Achaogen ” for “Government” or “United States” in paragraph (a) of this clause, provided however that Achaogen may annul the contract or deduct amounts only to the extent of a Government annulment or deduction due to conduct of Microgenics.
FAR 52.203-6	Sep-06	Restrictions on Subcontractor Sales to the Government (Over $100,000)
FAR 52.203-7	Jul-95	Anti-Kickback Procedures (Over $100,000)
FAR 52.203-8	Jan-97	Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity (Over $100,000). Substitute “Achaogen ” for “Government” or “United States” throughout this clause, provided however that Achaogen may rescind the contract and recover funds only to the extent of a Government rescission or recovery due to conduct of Microgenics.
FAR 52.203-10	Jan-97	Price or Fee Adjustment for Illegal or Improper Activity (Over $100,000) Substitute “Achaogen ” for “Government” or “United States” throughout this clause and “Achaogen” for “Contracting Officer” throughout this clause, provided however that Achaogen may make a reduction only to the extent that the Government makes a reduction due to conduct of Microgenics.
FAR 52.203-12	Sep-07	Limitation on Payments to Influence Certain Federal Transactions (Over $100,000)
FAR 52.203-13	Apr-10	Contractor Code of Business Ethics and Conduct (applies if Agreement is over $5,000,000 and has a performance period greater than 120 days). Disclosures made under this clause shall be made directly to the government entities listed in the clause.
FAR 52.203-14	Dec-07	Display of Hotline Poster(s). (d) Subcontracts. The Contractor shall include the substance of this clause, including this paragraph (d), in all subcontracts that exceed $5,000,000, except when the subcontract—(1) Is for the acquisition of a commercial item; or (2) Is performed entirely outside the United States.

Page 50 of 60


Clause	Date	Title
FAR 52.209-6	Sep-06	Protecting the Government’s Interests When Subcontracting With Contractors Debarred, Suspended, or Proposed for Debarment (Over $30,000)
FAR 52.215-2	Mar 09	Audit and Records- Negotiation (Over $100,000) (Only Government receives access and audit rights under this clause)
FAR 52.215-21	Oct-97	Requirements for Cost or Pricing Data or Information Other Than Cost or Pricing Data—Modifications. Substitute “Achaogen” for “Contracting Officer” throughout this clause, provided however, that Achaogen may seek from Microgenics only such information as the Government has requested, and Microgenics shall deliver any such information directly and only to the Government. FAR 52.215-21 (as modified above) shall apply only with respect to modifications funded by the Government; FAR 52.215-21 shall not apply to modifications that are not funded by the Government.
FAR 52.219-8	May-04	Utilization of Small Business Concerns (Over $100,000)
FAR 52.222-3	Jun-03	Convict Labor
FAR 52.222-21	Feb-99	Prohibition of Segregated Facilities
FAR 52.222-26	Mar-07	Equal Opportunity (Over $10,000)
FAR 52.222-35	Sept-06	Equal Opportunity for Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans (Over $100,000)
FAR 52.222-36	Jun-98	Affirmative Action for Workers with Disabilities (Over $10,000)
FAR 52.222-37	Sep-06	Employment Reports on Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans (Over $100,000)
FAR 52.222-39	Dec-04	Notification of Employee Rights Concerning Payment of Union Dues or Fees. Applicable if value of this Agreement equals or exceeds $100,000.
FAR 52.222-50	Feb-09	Combating Trafficking in Persons
FAR 52.222-54	Jan-09	Employment Eligibility Verification. Applicable to services and construction subcontracts that: (1) exceed $3,000; and (2) include work performed in the United States. This clause does not apply to subcontracts for commercial services that are (a) part of the purchase of a Commercially Available Off the Shelf (COTS) item (or an item that would be a COTS item, but for minor modifications) (b) performed by the COTS provider, and (c) are normally provided for that COTS item.
FAR 52.223-6	May-01	Drug-Free Workplace
FAR 52.224-1	Apr-84	Privacy Act Notification (If subcontract requires design, development, or operation of a system of records)
FAR 52.224-2	Apr-84	Privacy Act (If subcontract requires design, development, or operation of a system of records)
FAR 52.225-1	Feb-09	Buy American Act- Supplies
FAR 52.225-13	Jun-08	Restrictions on Certain Foreign Purchases
FAR 52.227-1	Dec-07	Authorization and Consent, Alternate I (Apr 1984) (Over $100,000)
FAR 52.227-2	Dec-07	Notice and Assistance Regarding Patent and Copyright Infringement (Over $100,000). Substitute “Achaogen” for “Contracting Officer” throughout this clause. Insert “or Achaogen” after “Government” throughout this clause.

Page 51 of 60


Clause	Date	Title
FAR 52.227-11	Dec-07	Patent Rights –Ownership by the Contractor (Only Government receives license; Achaogen receives no license.) (Note: In accordance with FAR 27.303(b)(2), paragraph (e) is modified to include the requirements in FAR 27.303(b)(2)(i) through (iv). The frequency of reporting in (i) is annual. Microgenics shall provide to Achaogen a copy of any notice or election that Microgenics submits to the Contracting Officer pursuant to subparagraph (c)(1), (c)(2) and (e)(3).
FAR 52.227-16	Jun-87	Additional Data Requirements. Substitute “Achaogen” for “Contracting Officer” throughout this clause, provided however, that Achaogen may order from Microgenics only such data that the Government has ordered and provided further that the following data are hereby specifically identified for purposes of FAR 52.227-16(b), and are not subject to disclosure obligations under FAR 52.227-16, and shall not be disclosed: (i) Immunoassay Technologies (as defined in Section 1.16); (ii) Microgenics Know-How (as defined in Section 1.18) related to Immunoassay Technologies; and (iii) any and all limited rights data (i.e., data that embody trade secrets or are commercial or financial and confidential or privileged, to the extent such data pertain to items, components, or processes developed at private expense, including minor modifications) not already included in (i) or (ii).
FAR 52.242-15	Aug-89	Stop Work Order (April 1984) (Achaogen may issue stop work order only to the extent the Government issues a stop work order) Substitute “Achaogen” for “Contracting Officer” throughout this clause.
FAR 52.244-5	Dec-96	Competition in Subcontracting
FAR 52.244-6	Jun-10	Subcontracts for Commercial Items
FAR 52.245-1	Aug-10	Government Property Applicable where government property involved in performance of subcontract; "Contracting Officer" means “Achaogen” except in the definition of Property Administrator and in paragraph h(1)(iii) and where it is unchanged, and in paragraphs (c) and (h)(4) where it includes Achaogen. "Government" is unchanged in the phrases "Government property" and "Government furnished property" and where elsewhere used except in paragraph (d)(1) where it means Achaogen and except in paragraphs (d)(2) and (g) where the term includes Achaogen.

the Department of Health and Human Services
Supplemental Regulation provisions


Clause	Date	Title
HHSAR 352.203-70	Jan-06	Anti-lobbying
HHSAR 352.223-70	Jan-06	Safety and Health
HHSAR 352.224-70	Jan-06	Privacy Act (if subcontract requires design, development, or operation of a system of records)
HHSAR 325.242-73	Jan-06	Withholding of Contract Payments
HHSAR 352.270-4	Jan-06	Protection of Human Subjects
HHSAR 352.270-5	Jan-06	Care of Live Vertebrate Animals
HHSAR 352.270-6	Jan-06	Restriction on Use of Human Subjects

Page 52 of 60


HHSAR 352.227-70	Jan-06	Publications and Publicity

Page 53 of 60

BARDA Required Provisions


Prime Contract Provision	Clause
H.2: Human Materials	The acquisition and supply of all human specimen material (including fetal material) used under this contract shall be obtained by Company in full compliance with applicable State and Local laws and the provisions of the Uniform Anatomical Gift Act in the United States, and no undue inducements, monetary or otherwise, will be offered to any person to influence their donation of human material. Company shall provide Achaogen with written documentation that all human materials obtained as a result of research involving human subjects conducted under this contract, by collaborating sites, or by subcontractors identified under this Agreement were obtained with prior approval by the Office for Human Research Protections of an Assurance to comply with the requirements of 45 CFR 46 to protect human research subjects. Provision by Company to Achaogen of a properly completed “Protection of Human Subjects Assurance Identification/IRB Certification/Declaration of Exemption,” Form OMB No. 0990-0263 (formerly optional form 310), certifying IRB review and approval of the protocol from which the human materials were obtained constitutes the written documentation required.
H.3: Research Involving Human Fetal Tissue	All research involving human fetal tissue shall be conducted in accordance with the Public Health Service Act, 42 U.S.C. 289g-1 and 289g-2. Implementing regulations and guidance for conducting research on human fetal tissue may be found at 45 C.F.R. 46, Subpart B, and http://grants1.nih.gov/grants/guide/notice-files/not93-235.html and any subsequent revisions to this NIH Guide to Grants and Contracts (“Guide”) Notice. Company shall make available, for audit by Achaogen, the secretary, HHS, the physician statements and informed consents required by 42 U.S.C. 289g-1(b) and (c), or ensure HHS access to those records, if maintained by an entity other than the Contractor.
H.4: Needle Exchange	Company shall not use contract funds to carry out any program of distributing sterile needles or syringes for the hypodermic injection of any illegal drug.
H.5: Press Releases	Company shall clearly state, when issuing statements, press releases, requests for proposals, bid solicitations and other documents describing projects or programs funded in whole or in part with Federal money: (1) the percentage of the total costs of the program or project which will be financed with Federal money; (2) the dollar amount of Federal funds for the project or program; and (3) the percentage and dollar amount of the total costs of the project or program that will be financed by nongovernmental sources.
H.7: Animal Welfare	All research involving live, vertebrate animals shall be conducted in accordance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals. This policy may be accessed at: http://grants1.nih.gov/grants/olaw/references/phspol.htm.
H.8: Protection of Personnel who Work with Nonhuman Primates	All Company personnel who work with nonhuman primates or enter rooms or areas containing nonhuman primates shall comply with the procedures set forth in NIH Policy Manual 3044-2, entitled, “Protection of NIH Personnel Who Work with Nonhuman Primates,” located at the following URL: http://www1.od.nih.gov/oma/manualchapters/intramural/3044-2/

Page 54 of 60


Prime Contract Provision	Clause
H.9: Publications and Publicity	No information related to data obtained under this contract shall be released or publicized without the prior written consent of Achaogen and the Contracting Officer Technical Representative. In addition to the requirements of HHSAR 352.227-70, Publications and Publicity incorporated by reference in section I of this contract shall acknowledge the support of the Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgment substantially as follows: “This project has been funded in whole or in part with Federal funds from the Biomedical Advanced Research and Development Authority, office of the Assistant Secretary for Preparedness and response, Office of the Secretary, Department of Health and Human Services, Under Contract No. HHSO100201000046C.”
H.10: Reporting Matters Involving Fraud, Waste and Abuse	Anyone who becomes aware of the existence or apparent existence of fraud, waste and abuse in BARDA funded programs is encouraged to report such matters to the HHS Inspector General’s Office in writing or on the Inspector General’s Hotline. The toll free number is 1-800-HHS-TIPS (1-800-447-8477). All telephone calls will be handled confidentially. The e-mail address is Htips@os.dhhs.gov and the mailing address is: Office of Inspector General Department of Health and Human Services TIPS HOTLINE P.O. Box 23489 Washington, D.C. 20026.
H.11 Prohibition on Contractor Involvement with Terrorist Activities	Company acknowledges that U.S. Executive Orders and Laws, including but not limited to E.O. 13224 and P.L. 107-56, prohibit transactions with, and the provision of resources and support to, individuals and organizations associated with terrorism. It is the legal responsibility of Company to ensure compliance with these Executive Orders and Laws. This clause must be included in all subcontracts issued under this contract.
H.15: Privacy Act Applicability	Notification is hereby given that Company and its employees are subject to criminal penalties for violation of the Privacy Act to the same extent as employees of the Government.
H.16: Laboratory license requirement	Company shall comply with all applicable requirements of Section 353 of the Public Health Service Act (Clinical Laboratory Improvement Act as Amended). This requirement shall also be included in any subcontract for services under this contract. The parties anticipate that no part of the performance of this Agreement will be subject to the Clinical Laboratory Improvement Act As Amended.
H.17: Dissemination of Information	Except for any application to the FDA for approval of a diagnostic, any publication in connection with such FDA filing or approval, and any filing in connection with obtaining patent protection, no information related to data obtained under this contract shall be released or publicized without the prior written consent of the Contracting officer, to be obtained through Achaogen.
H.18: Identification and Disposition of Data	Company will be required to provide certain data generated under this contract to the Department of Health and Human Services (DHHS). DHHS reserves the right to review any other data determined by DHHS to be directly related to and/or generated under this contract. Company shall keep copies of all data required by the Food and Drug Administration (FDA) relevant to this contract for the time period specified by the FDA.

Page 55 of 60

Prime Contract Provision

Clause

H.19: Information on Compliance With Animal Care Requirements

Registration with the U.S. Dept. of Agriculture (USDA) is required to use regulated species of animals for biomedical purposes. USDA is responsible for the enforcement of the Animal Welfare Act (7 U.S.C. 2131 et. seq), http://www.nal.usda.gov/awic/legislat/awa.htm

The Public Health Service (PHS) Policy is administered by the Office of Laboratory Animal Welfare (OLAW) http://grants2.nih.gov/grants/olaw/olaw.htm. An essential requirement of the PHS Policy, http://grants2.nih.gov/grants/olaw/references/phspol.htm is that every institution using live vertebrate animals must obtain an approved assurance from OLAW before they can receive funding from any component of the U.S. Public Health Service.

The PHS Policy requires that Assured institutions base their programs of animal care and use on the Guide for the Care and Use of Laboratory Animals http://www.nap.edu/readingroom/books/labrats/ and that they comply with the regulations (9 C.F.R., subchapter A) http://www.nal.usda.gov/awic/legislat/usdaleg1.htm issued by the U.S. Department of Agriculture (USDA) under the Animal Welfare Act. The Guide may differ from USDA regulations in some respects. Compliance with USDA regulations is an absolute requirement of this Policy.

The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) http://www.aaalac.org is a professional organization that inspects and evaluates programs of animal care institutions at their request. Those that meet the high standards are given accredited status. As of the 2002 revision of the PHS policy, the only accrediting body recognized by PHS is the AAALAC. While AAALAC Accreditation is not required to conduct biomedical research, it is highly desirable. AAALAC uses the Guide as their primary evaluation tool. They also use the Guide for the Care and Use of Agricultural Animals in Agricultural Research and Teaching. It is published by the American Science Societies. http://www.fass.org.

Page 56 of 60


Prime Contract Provision	Clause
H.20: Requirements for Adequate Assurance of Protection of Vertebrate Animal Subjects	The PHYS Policy on Humane Care and Use of Laboratory Animals requires that applicant organizations proposing to use vertebrate animals file a written Animal Welfare Assurance with the Office for Laboratory Animal Welfare (OLAW), establishing appropriate policies and procedures to ensure the humane care and use of live vertebrate animals involved in research activities supported by the PHS. The PHS Policy stipulates that an applicant organization, whether domestic or foreign, bears responsibility for the humane care and use of animals in PHS-supported research activities. Also the PHS policy defines “animal” as “any live, vertebrate animal used, or intended for use, in research, research training, experimentation, biological testing or for related purposes.” This policy implements and supplements the U.S. Government Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research, and Training, and requires that institutions use the Guide for the Care and Use of Laboratory Animals as a basis for developing and implementing an institutional animal care use program. This Policy does not affect applicable State or local laws or regulations that impose more stringent standards for the care and use of laboratory animals. All institutions are required to comply, as applicable, with the Animal Welfare Act, as amended and other Federal statutes and regulations relating to animals. These documents are available from the Office of Laboratory Animal Welfare, National Institutes of Health, Bethesda, MD 20892, (301) 496-7163. http://grants.nih.gov/grants/olaw/olaw.htm. No PHYS supported work or research involving vertebrate animals will be conducted by an organization, unless that organization is operating in accordance with an approved Animal Welfare Assurance and provides verification that the Institutional Animal Care and Use Committee (IACUC) has reviewed and approved the proposed activity in accordance with the PHS policy. Applications may be referred by the PHS back to the institution for further review in the case of an apparent or potential violations of the PHS policy. No award to an individual will be made unless that individual is affiliated with an assured organization that accepts responsibility for compliance with the PHS Policy. Foreign applicant organizations applying for PHS awards for activities involving vertebrate animals are required to comply with PHS Policy or provide evidence that acceptable standards for the humane care and use of animals will be met. Foreign applicant organizations are not required to submit IACUC approval, but should provide information that is satisfactory to the Government to provide assurances for the humane care of such animals.
H.21: Approval of Required Assurance by OLAW	Under governing regulations, federal funds which are administered by DHHS, Office of Biomedical Advanced Research and Development Authority (BARDA) shall not be expended by the contractor for research involving live vertebrate animals, nor shall live vertebrate animals be involved in research activities by Company under this award unless a satisfactory assurance of compliance with 7 U.S.C. 2316 and 9 CFR Sections 2.25-2.28 is submitted within 30 days of the date of this award and approved by the Office of Laboratory Animal Welfare (OLAW). Each performance site (if any) must also assure compliance, with the following restriction: Only activities which do not directly involve live vertebrate animals (i.e., are clearly severable and independent from those activities) may be conducted by the contractor or individual performance sites pending OLAW approval of their respective assurance of compliance.

Page 57 of 60


Prime Contract Provision	Clause
H.22: Registration with the Select Agent Program for Work involving the possession, use, and/or transfer of select biological agents or toxins	Company shall not conduct work involving select agents or toxins under this contract until it and any associated subcontractor(s) comply with the following: For prime or subcontract awards to domestic institutions that possess, use, and/or transfer Select Agents under this contract, the institution must comply with the provisions of 42 C.F.R. part 73, 7 C.F.R. part 331, and/or 9 C.F.R. part 121 ( http://www.aphis.usda.gov/programs/ag_selectagent/FinalRule3-18-05.pdf ) as required, before using NIH funds for work involving a Select Agent or Toxin. No government funds can be used for research involving a Select Agent or Toxin at a domestic institution without a valid registration certificate. For prime or subcontract awards to foreign institutions that possess, use, and/or transfer a Select Agent or Toxin, before using NIH funds for any work directly involving a Select Agent or Toxin, the foreign institution must provide information satisfactory to the government that safety, security, and training standards equivalent to those described in 42 C.F.R. part 73, 7 C.F.R. part 331, and/or 9 C.F.R. part 121 are in place and will be administered on behalf of all Select Agent or Toxin work supported by these funds. The process for making this determination includes inspection of the foreign laboratory facility by a government representative. During this inspection, the foreign institution must provide the following information: concise summaries of safety, security, and training plans; names of individuals at the foreign institution who will have access to the Select Agents and procedures for ensuring that only approved and appropriate individuals, in accordance with institution procedures, will have access to the Select Agents under the contract; and copies of or links to any applicable laws, regulations, policies, and procedures applicable to that institution for the safe and secure possession, use, and/or transfer of select agents. No funds can be used for work involving a Select Agent or Toxin at a foreign institution without written approval from Achaogen. Listings of HHS select agents and toxins, and overlap select agents or toxins as well as information about the registration process for domestic institutions, are available on the Select Agent Program Web site at http:// www.cdc.gov/od/sap/ and http://www.cdc.gov/od/sap/docs/salist.pdf. Listings of USDA select agents and toxins as well as information about the registration process for domestic institutions are available on the APHIS/USDA website at: http://www.aphis.usda.gov/programs/ag_selectagent/ index.html and: http://www.aphis.usda.gov/programs/ag_selectagent/ag_bioterr_forms.html For foreign institutions, see the NIAID Select Agent Award information: http://www.niaid.nih.gov/ncn/clinical/default_biodefense.htm.
H.23: EPA Energy Star Requirements	All microcomputers, including personal computers, monitors, and printers purchased with government funds in the performance of a contract shall be equipped with or meet the energy efficient low-power standby feature as defined by the EPA Energy Star program unless the equipment always satisfies Energy Star efficiency levels.

Page 58 of 60


Prime Contract Provision	Clause
H.24: Acknowledgement of Federal Funding	(a)Section 507 of P.L. 104-208 mandates that contractors funded with Federal dollars, in whole or in part, acknowledge Federal funding when issuing statements, press releases, requests for proposals, bid solicitations and other documents. Contractors are required to state (1) the percentage and dollar amounts of the total program or project costs financed with federal money, and (2) the percentage and dollar amount of the total costs financed by nongovernmental sources. This requirement is in addition to the continuing requirement to provide an acknowledgement of support and disclaimer on any publication reporting the results of a contract funded activity. (b)Publication and Publicity. The contractor shall acknowledge the support of the Department of Health and Human Service, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgment substantially as follows: “This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract no. HHSO100201000046C. (c)Press Releases. Pursuant to Section 508 of Public Law 105-78, the contractor shall clearly state, when issuing statements, press releases, requests for proposals, bid solicitations and other documents describing projects or programs funded in whole or in part with federal money that: (1) the percentage of the total costs of the program or project which will be financed with federal money; (2) the dollar amount of Federal funds for the project or program; and (3) the percentage and dollar amount of the total costs of the project or program that will be financed by nongovernmental sources.
H.25: Manufacturing Standards	The Current Good Manufacturing Practice Regulations (“cGMP”) (21 C.F.R. Parts 210-211) and regulations pertaining to biological products (21 C.F.R. Part 600) will be the standard to be applied for manufacturing, processing, packing, storage, and delivery of this product. If at any time during the life of the contract, Company fails to comply with cGMP in the manufacturing, processing and packaging of this product and such failure results in a material adverse effect on the safety, purity or potency of this product (a material failure), the Contractor shall have thirty (30) calendar days from the time such material failure is identified to cure such material failure. If the Contractor fails to take such an action within the thirty (30) calendar day period, then the contract may be terminated for default.
H.26: Export Control Notification	Company is responsible for ensuring compliance with all export control laws and regulations that may be applicable to the export of and foreign access to their proposed technologies.

Page 59 of 60

Prime Contract Provision

Clause

H.27: Institutional responsibility Regarding Conflicting Interests of Investigators

Company shall comply with the requirements of 45 CFR Part 94, Responsible Prospective Contractors, which promotes objectivity in research by establishing standards to ensure that investigators (defined as the principle investigator and any other person who is responsible for design, conduct, or reporting of research funded under BARDA contracts) will not be biased by any conflicting financial interest. For the purposes of this part relating to financial interest, “investigator” includes the investigator’s spouse and dependent children.

Company shall at a minimum:

(a)Maintain a written, enforceable policy on conflict of interest and inform each investigator of the policy, the investigator’s reporting responsibilities, and the applicable regulations. The contractor must take reasonable steps to ensure that investigators working as collaborators or subcontractors comply with the regulations.

(b)Designate and official to review financial disclosure statements from each investigator participating in BARDA-funded research. Based on established guidelines consistent with the regulations, the designated official must determine whether a conflict of interest exists, and if so, determine what actions should be taken to manage, reduce, or eliminate such a conflict.

(c)Require updating of financial disclosure statements during the period of award.

(d)Maintain records taken under this provision for three years after final payment.

(e)Establish adequate enforcement mechanisms.

If a conflict of interest is identified, the Institution shall report to Achaogen the existence of the conflicting interest found. This report shall be made and the conflicting interest managed, reduced, or eliminated, at least on a temporary basis, within thirty (30) days of that identification.

Order Of Precedence

In the event of a conflict between the terms of this Appendix and any term of the Agreement or an Exhibit or other appendix issued there under, the terms of this Appendix shall govern.

Page 60 of 60

EX-31.1 7 akao-ex311_796.htm EX-31.1 akao-ex311_796.htm

Exhibit 31.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO

SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)

I, Kenneth J. Hillan, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Achaogen, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 8, 2017

/s/ Kenneth J. Hillan

Kenneth J. Hillan

Chief Executive Officer

(principal executive officer)

EX-31.2 8 akao-ex312_709.htm EX-31.2 akao-ex312_709.htm

Exhibit 31.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO

SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)

I, Tobin C. Schilke, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Achaogen, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 8, 2017

/s/ Tobin C. Schilke

Tobin C. Schilke

Chief Financial Officer

(principal financial and accounting officer)

EX-32.1 9 akao-ex321_797.htm EX-32.1 akao-ex321_797.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Achaogen, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended March 31, 2017, as filed with the Securities and Exchange Commission (the “Report”), Kenneth J. Hillan, Chief Executive Officer of the Company, and Tobin C. Schilke, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

•

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

•

The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2017

/s/ Kenneth J. Hillan

Kenneth J. Hillan

Chief Executive Officer

(principal executive officer)

/s/ Tobin C. Schilke

Tobin C. Schilke

Chief Financial Officer

(principal financial and accounting officer)

GRAPHIC 10 g2017050820074132828.jpg GRAPHIC begin 644 g2017050820074132828.jpg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end GRAPHIC 11 g2017050820074727611.jpg GRAPHIC begin 644 g2017050820074727611.jpg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g2017050820074719210.jpg GRAPHIC begin 644 g2017050820074719210.jpg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end GRAPHIC 13 g2017050820074732712.jpg GRAPHIC begin 644 g2017050820074732712.jpg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end GRAPHIC 14 g2017050820074745713.jpg GRAPHIC begin 644 g2017050820074745713.jpg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end GRAPHIC 15 g2017050820081152514.jpg GRAPHIC begin 644 g2017050820081152514.jpg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end GRAPHIC 16 g2017050820081368717.jpg GRAPHIC begin 644 g2017050820081368717.jpg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end EX-101.INS 17 akao-20170331.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares akao:Segment pure akao:milestone utr:sqft 0001301501 2017-01-01 2017-03-31 0001301501 2017-05-03 0001301501 2017-03-31 0001301501 2016-12-31 0001301501 2016-01-01 2016-03-31 0001301501 2015-12-31 0001301501 2016-03-31 0001301501 akao:BlackScholesMember 2017-01-01 2017-03-31 0001301501 akao:MonteCarloSimulationMember 2017-01-01 2017-03-31 0001301501 akao:RedeemableCommonStockMember us-gaap:PrivatePlacementMember us-gaap:SubsequentEventMember 2017-05-02 2017-05-03 0001301501 us-gaap:PrivatePlacementMember us-gaap:SubsequentEventMember 2017-05-03 0001301501 us-gaap:PrivatePlacementMember us-gaap:SubsequentEventMember 2017-05-02 2017-05-03 0001301501 us-gaap:SubsequentEventMember us-gaap:MaximumMember 2017-05-02 2017-05-03 0001301501 us-gaap:SubsequentEventMember 2017-05-02 2017-05-03 0001301501 us-gaap:SubsequentEventMember 2017-05-03 0001301501 akao:UnderwrittenPublicOfferingMember 2016-12-18 2016-12-19 0001301501 akao:UnderwrittenPublicOfferingMember 2016-12-19 0001301501 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2016-06-02 2016-06-03 0001301501 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2016-06-03 0001301501 us-gaap:PrivatePlacementMember 2016-06-02 2016-06-03 0001301501 us-gaap:PrivatePlacementMember 2016-06-03 0001301501 us-gaap:PrivatePlacementMember us-gaap:MaximumMember 2016-06-02 2016-06-03 0001301501 2015-04-07 0001301501 akao:ATMEquityOfferingProgramMember 2015-04-07 0001301501 akao:ATMEquityOfferingProgramMember 2017-01-01 2017-03-31 0001301501 akao:ATMEquityOfferingProgramMember us-gaap:WeightedAverageMember 2017-03-31 0001301501 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0001301501 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0001301501 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-03-31 0001301501 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-03-31 0001301501 us-gaap:WarrantMember 2017-01-01 2017-03-31 0001301501 us-gaap:WarrantMember 2016-01-01 2016-03-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2017-03-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member akao:RestrictedCashMember 2017-03-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2017-03-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2017-03-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2017-03-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2017-03-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2017-03-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2017-03-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember 2017-03-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2017-03-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember akao:RestrictedCashMember 2017-03-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2017-03-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember 2017-03-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2016-12-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member akao:RestrictedCashMember 2016-12-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2016-12-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2016-12-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2016-12-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2016-12-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember 2016-12-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2016-12-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember akao:RestrictedCashMember 2016-12-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2016-12-31 0001301501 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001301501 2016-01-01 2016-12-31 0001301501 us-gaap:CorporateDebtSecuritiesMember 2017-03-31 0001301501 us-gaap:SecuredDebtMember 2015-08-04 2015-08-05 0001301501 us-gaap:SecuredDebtMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2016-12-31 0001301501 us-gaap:DerivativeMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-01-01 2017-03-31 0001301501 us-gaap:DerivativeMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-03-31 0001301501 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2017-03-31 0001301501 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2016-06-02 2016-06-03 0001301501 2017-02-01 2017-02-28 0001301501 2017-02-28 0001301501 2016-06-03 0001301501 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2016-12-31 0001301501 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2017-01-01 2017-03-31 0001301501 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2017-03-31 0001301501 us-gaap:DerivativeMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2016-12-31 0001301501 us-gaap:OfficeEquipmentMember 2017-03-31 0001301501 us-gaap:OfficeEquipmentMember 2016-12-31 0001301501 us-gaap:EquipmentMember 2017-03-31 0001301501 us-gaap:EquipmentMember 2016-12-31 0001301501 us-gaap:LeaseholdImprovementsMember 2017-03-31 0001301501 us-gaap:LeaseholdImprovementsMember 2016-12-31 0001301501 us-gaap:ConstructionInProgressMember 2017-03-31 0001301501 us-gaap:ConstructionInProgressMember 2016-12-31 0001301501 akao:ThermoFisherScientificIncMember 2016-04-01 2016-04-30 0001301501 akao:ThermoFisherScientificIncMember 2017-03-31 0001301501 akao:ThermoFisherScientificIncMember 2017-01-01 2017-03-31 0001301501 akao:ThermoFisherScientificIncMember 2016-01-01 2016-03-31 0001301501 akao:CrystalBiosciencesIncMember 2016-05-01 2016-05-31 0001301501 akao:SeriesAConvertiblePreferredStockMember akao:IsisPharmaceuticalsLicenseAgreementMember akao:UpfrontLicenseFeesMember 2006-01-31 0001301501 akao:IsisPharmaceuticalsLicenseAgreementMember akao:UpfrontLicenseFeesMember 2006-01-01 2006-01-31 0001301501 akao:IsisPharmaceuticalsLicenseAgreementMember 2006-01-01 2006-01-31 0001301501 akao:IsisPharmaceuticalsLicenseAgreementMember 2006-01-31 0001301501 akao:IsisPharmaceuticalsLicenseAgreementMember 2017-01-01 2017-03-31 0001301501 akao:IsisPharmaceuticalsLicenseAgreementMember 2017-03-31 0001301501 akao:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2010-08-01 2010-08-31 0001301501 akao:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2012-09-01 2012-09-30 0001301501 akao:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2013-04-01 2013-04-30 0001301501 akao:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2016-05-01 2016-05-26 0001301501 akao:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2017-01-01 2017-03-31 0001301501 akao:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2016-01-01 2016-03-31 0001301501 akao:NationalInstituteOfAllergyAndInfectiousDiseasesMember 2015-07-01 2015-07-31 0001301501 akao:NationalInstituteOfAllergyAndInfectiousDiseasesMember 2016-04-01 2016-04-30 0001301501 akao:NationalInstituteOfAllergyAndInfectiousDiseasesMember 2016-01-01 2016-01-31 0001301501 akao:NationalInstituteOfAllergyAndInfectiousDiseasesMember 2014-07-01 2014-07-31 0001301501 akao:NationalInstituteOfAllergyAndInfectiousDiseasesMember 2017-01-01 2017-03-31 0001301501 akao:NationalInstituteOfAllergyAndInfectiousDiseasesMember 2016-01-01 2016-03-31 0001301501 us-gaap:SecuredDebtMember us-gaap:MaximumMember 2015-08-05 0001301501 us-gaap:SecuredDebtMember 2016-06-19 2016-06-20 0001301501 us-gaap:SecuredDebtMember 2015-08-05 0001301501 us-gaap:SecuredDebtMember 2017-01-01 2017-03-31 0001301501 us-gaap:SecuredDebtMember 2016-01-01 2016-03-31 0001301501 akao:ATMEquityOfferingProgramMember 2017-03-31 0001301501 us-gaap:PrivatePlacementMember us-gaap:ChiefOperatingOfficerMember 2016-06-02 2016-06-03 0001301501 us-gaap:PrivatePlacementMember us-gaap:ChiefOperatingOfficerMember 2016-06-03 0001301501 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-01-01 2016-12-31 0001301501 akao:StockIncentivePlanTwoThousandFourteenMember 2017-01-01 2017-01-02 0001301501 akao:StockIncentivePlanTwoThousandFourteenMember 2017-03-31 0001301501 akao:StockIncentivePlanTwoThousandFourteenMember 2017-01-01 2017-03-31 0001301501 akao:TwoThousandFourteenEmploymentCommencementIncentivePlanMember 2017-03-31 0001301501 akao:TwoThousandFourteenEmploymentCommencementIncentivePlanMember 2017-02-21 2017-02-22 0001301501 us-gaap:EmployeeStockMember 2017-01-01 2017-01-02 0001301501 us-gaap:EmployeeStockMember 2017-01-01 2017-03-31 0001301501 us-gaap:EmployeeStockMember 2017-03-31 0001301501 akao:StockIncentivePlanTwoThousandThreeMember 2017-01-01 2017-03-31 0001301501 akao:StockIncentivePlanTwoThousandThreeMember 2017-03-31 0001301501 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-03-31 0001301501 us-gaap:ResearchAndDevelopmentExpenseMember akao:StockOptionsGrantedToEmployeesAndNonEmployeeDirectorsMember 2017-01-01 2017-03-31 0001301501 us-gaap:ResearchAndDevelopmentExpenseMember akao:StockOptionsGrantedToEmployeesAndNonEmployeeDirectorsMember 2016-01-01 2016-03-31 0001301501 us-gaap:GeneralAndAdministrativeExpenseMember akao:StockOptionsGrantedToEmployeesAndNonEmployeeDirectorsMember 2017-01-01 2017-03-31 0001301501 us-gaap:GeneralAndAdministrativeExpenseMember akao:StockOptionsGrantedToEmployeesAndNonEmployeeDirectorsMember 2016-01-01 2016-03-31 0001301501 akao:StockOptionsGrantedToEmployeesAndNonEmployeeDirectorsMember 2017-01-01 2017-03-31 0001301501 akao:StockOptionsGrantedToEmployeesAndNonEmployeeDirectorsMember 2016-01-01 2016-03-31 0001301501 akao:StockOptionsAndRestrictedStockUnitsMember akao:FormerChiefMedicalOfficerMember 2017-01-01 2017-03-31 0001301501 us-gaap:EmployeeStockOptionMember 2017-03-31 0001301501 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0001301501 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0001301501 akao:NonEmployeesMember 2017-01-01 2017-03-31 0001301501 akao:NonEmployeesMember 2016-01-01 2016-03-31 0001301501 akao:BlackScholesMember akao:NonEmployeesMember 2017-01-01 2017-03-31 0001301501 us-gaap:RestrictedStockUnitsRSUMember akao:EmployeesMember 2017-01-01 2017-03-31 0001301501 us-gaap:RestrictedStockUnitsRSUMember akao:EmployeesMember 2017-03-31 0001301501 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0001301501 us-gaap:RestrictedStockUnitsRSUMember 2017-03-31 0001301501 us-gaap:EmployeeStockOptionMember akao:EmployeesThatContainPerformanceConditionsMember 2017-01-01 2017-03-31 0001301501 us-gaap:EmployeeStockOptionMember akao:EmployeesThatContainPerformanceConditionsMember 2016-01-01 2016-03-31 0001301501 us-gaap:RestrictedStockUnitsRSUMember akao:EmployeesThatContainPerformanceConditionsMember 2017-01-01 2017-03-31 0001301501 us-gaap:RestrictedStockUnitsRSUMember akao:EmployeesThatContainPerformanceConditionsMember 2016-01-01 2016-03-31 0001301501 akao:MonteCarloSimulationMember us-gaap:MinimumMember 2017-01-01 2017-03-31 0001301501 akao:MonteCarloSimulationMember us-gaap:MinimumMember 2016-01-01 2016-03-31 0001301501 akao:MonteCarloSimulationMember us-gaap:MaximumMember 2017-01-01 2017-03-31 0001301501 akao:MonteCarloSimulationMember us-gaap:MaximumMember 2016-01-01 2016-03-31 0001301501 akao:MonteCarloSimulationMember 2016-01-01 2016-03-31 0001301501 akao:HovioneLimitedMember 2017-01-01 2017-03-31 0001301501 akao:HovioneLimitedMember 2017-03-01 2017-03-31 0001301501 us-gaap:MinimumMember akao:HovioneLimitedMember 2017-03-01 2017-03-31 0001301501 us-gaap:MaximumMember akao:HovioneLimitedMember 2017-03-01 2017-03-31 0001301501 akao:HovioneLimitedMember 2015-07-01 2015-07-31 0001301501 akao:HovioneLimitedMember 2017-03-31 0001301501 akao:HovioneLimitedMember 2016-12-31 0001301501 akao:HovioneLimitedMember 2016-01-01 2016-03-31 0001301501 akao:RawMaterialAgreementMember 2016-01-01 2016-12-31 0001301501 akao:RawMaterialAgreementMember 2017-03-31 0001301501 2016-08-31 0001301501 2016-08-01 2016-08-31 0001301501 us-gaap:SubsequentEventMember akao:RedeemableCommonStockMember 2017-05-02 2017-05-03 0001301501 us-gaap:SubsequentEventMember akao:RedeemableCommonStockMember 2017-05-03 10-Q false 2017-03-31 2017 Q1 AKAO Achaogen Inc 0001301501 --12-31 Accelerated Filer 35853669 37639000 118964000 94405000 26912000 5866000 12151000 9037000 2189000 127000 127000 147074000 160343000 8449000 3261000 250000 250000 33000 71000 155806000 163925000 11585000 5739000 6490000 9698000 7292000 4167000 45000 104000 25412000 19708000 18192000 21110000 27289000 13874000 622000 602000 5654000 1896000 77169000 57190000 36000 35000 0 0 359139000 353927000 -280479000 -247220000 -59000 -7000 78637000 106735000 155806000 163925000 0.001 0.001 290000000 290000000 35846301 35638052 35846301 35638052 0.001 0.001 10000000 10000000 0 0 0 0 7463000 5849000 18597000 13893000 6751000 3777000 25348000 17670000 -17885000 -11821000 706000 438000 -14956000 -12000 288000 74000 -33259000 -12197000 -0.93 -0.66 35725876 18398288 -52000 55000 -33311000 -12142000 113000 121000 42000 -160000 2911000 827000 14956000 12000 207000 135000 -6285000 27000 6810000 1390000 2316000 3544000 -95000 -51000 -13418000 -8866000 1185000 269000 86759000 19256000 8280000 -68688000 8011000 42000 535000 288000 781000 -81325000 -855000 119341000 20414000 38016000 19559000 499000 303000 1521000 3794000 <div> 1. Organization and Basis of Presentation and Consolidation Achaogen, Inc. (together with its consolidated subsidiary, the “Company”) is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterial treatments against multi-drug resistant gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of bacterial infections due to multi-drug resistant Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (“CRE”). The Company’s Phase 3 study of plazomicin in the treatment of patients with complicated urinary tract infections (“cUTI”) and acute pyelonephritis (“AP”), entitled EPIC (Evaluating Plazomicin In cUTI), is expected to serve as a single pivotal study supporting a new drug application (“NDA”) for plazomicin in the United States. In addition, the Company’s Phase 3 study of plazomicin, the CARE (Combating Antibiotic Resistant Enterobacteriaceae) trial, which is a resistant pathogen-specific trial designed to evaluate the efficacy and safety of plazomicin in patients with infections due to CRE. The Company was incorporated in Delaware in 2002 and commenced operations in 2004. Since commencing operations in 2004, the Company has devoted substantially all its resources to identifying and developing its product candidates, including conducting preclinical studies and clinical trials and providing general and administrative support for these operations. Reclassifications The change in derivative liability for the three-month period ended March 31, 2016 has been reclassified to be included in the change in warrant and derivative liabilities to conform to the current year’s presentation. Such reclassifications did not impact the Company’s net loss or financial position. Basis of Presentation and Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and following the requirements of the Securities and Exchange Commission (the “SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company’s financial information. The results of operations for the three-month period ended March 31, 2017 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December 31, 2016 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. Intercompany accounts and transactions have been eliminated upon consolidation. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K. In May 2017, the Company entered into an agreement with the Bill & Melinda Gates Foundation (the “Gates Foundation”) to discover drug candidates against gram-negative pathogens intended to prevent neonatal sepsis (the “Grant Agreement”). Pursuant to the Grant Agreement, the Gates Foundation awarded the Company up to approximately $10.5 million in grant funding over a three-year research term, of which approximately $3.2 million will be advanced to the Company within 15 days after signing (the “Advance Funds”). Concurrently with the Grant Agreement, the Company entered into a Common Stock Purchase Agreement with the Gates Foundation, pursuant to which the Company agreed to sell 407,331 shares of its redeemable common stock to the Gates Foundation in a private placement at a purchase price per share equal to $24.55, for gross proceeds to the Company of $10.0 million (“Gates Investment”). In connection with the Grant Agreement and the Gates Investment, the Company entered into a strategic relationship with the Gates Foundation (the “Letter Agreement”). Under the terms of the Letter Agreement, the Gates Investment and Advanced Funds may only be used to conduct mutually agreed upon work, including the scale up of the Company’s platform technology to launch a product intended to prevent neonatal sepsis (the “NSP”). Pursuant to the Letter Agreement, the Company agreed to make the NSP available and accessible in certain developing countries and to grant the Gates Foundation a non-exclusive license to commercialize selected drug candidates in specified developing countries, which may only be exercised in the event of certain defaults as described in the Letter Agreement (the “Global Access”). The Global Access will continue in effect until the earlier of 25 years from the closing of the Gates Investment or 7 years following the termination of all funding provided by the Gates Foundation; provided, that the Global Access will continue for any products or services developed with funding provided by the Gates Foundation which continue to be developed or available in certain developing countries. On December 19, 2016, the Company completed an underwritten public offering of common stock made under a prospectus supplement and related prospectus pursuant to a Registration Statement on Form S-3 (File No. 333-203282) filed on April 7, 2015 (the “Shelf Registration Statement”). This offering resulted in the sale of 7,475,000 shares, at a price to the public of $13.50 per share, including the full exercise of the underwriters’ option to purchase an additional 975,000 shares of common stock.  The Company received net proceeds from the offering of $94.6 million, after deducting the underwriting discounts and commissions and estimated offering expenses. On June 3, 2016, the Company sold 7,999,996 shares of its common stock and warrants to purchase 1,999,999 shares of its common stock pursuant to Securities Purchase Agreement (the "Purchase Agreement") for aggregate gross proceeds of $25.4 million and aggregate net proceeds of $25.1 million, after deducting the issuance costs, in connection with a private placement financing transaction (the "Private Placement"). The warrants have an exercise price of $3.66 per share and are exercisable up to five years from the date of issuance. On April 7, 2015, the Company filed the Shelf Registration Statement, declared effective by the SEC on April 21, 2015, covering the offering of up to $150.0 million of common stock, preferred stock, debt securities, warrants, purchase contracts and/or units. The Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $30.0 million of shares of our common stock from time to time in an "at-the-market" ("ATM") equity offering pursuant to a sales agreement with Cowen and Company, LLC. As of March 31, 2017, the Company had sold 1,105,549 shares pursuant to its ATM equity offering program at a weighted-average price of $4.82 per share for aggregate offering proceeds of $5.3 million and aggregate net proceeds of $5.1 million, after deducting the sales commissions and offering expenses. The Company has incurred losses and negative cash flows from operations every year since its inception.  As of March 31, 2017, the Company had unrestricted cash, cash equivalents and short-term investments of approximately $132.0 million and an accumulated deficit of approximately $280.5 million. Management expects that, based on its current operating plans, the Company’s existing cash, cash equivalents and short-term investments as of March 31, 2017 will be sufficient to fund its current planned operations for at least the next twelve months from the issuance of these financial statements. Management plans to raise additional funds through equity or debt financing arrangements, government contracts, and/or third party collaboration funding in the future to fund its operations, including the commercial launch of plazomicin. However, there can be no assurance that such funding sources will be available at terms acceptable to the Company or at all. If the Company is unable to raise additional funding to meet its working capital needs, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.  The financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.</div> <div> 2. Summary of Significant Accounting Policies Use of Estimates The accompanying financial statements have been prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, assumptions and estimates that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures of contingent liabilities. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of liabilities, common stock and stock-based awards and income taxes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates. Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, contracts receivable, prepaid and other current assets, accounts payable, accrued liabilities, and other current liabilities approximate fair value due to their short-term maturities. Short-term investments consist of available-for-sale securities and are carried at fair value. Based upon the borrowing rates (which is a Level 2 input) currently available to the Company for loans with similar terms, the Company believes the carrying amount of the loan payable approximates its fair value. The warrant and derivative liabilities are recorded at estimated fair value with changes in estimated fair value recorded in the Company's statements of operations. Cash and Cash Equivalents Cash equivalents include only securities having a maturity of three months or less at the time of purchase. As of March 31, 2017 and December 31, 2016, cash and cash equivalents consisted of bank deposits, cash, commercial paper, cash repurchase agreement investments and investments in money market funds. Short-term Investments Short-term investments consist of debt securities with maturities greater than three months, but less than one year from the date of acquisition, and are classified as available for sale. Short-term investments are carried at fair value. Unrealized gains and losses on available-for-sale securities are excluded from earnings and reported as a component of net unrealized gain (loss) on available-for-sale securities in the Company's consolidated statements of comprehensive loss. The amortized cost of debt securities reflects amortization of purchase premiums and accretion of purchase discounts to date, which are included in interest income. The Company reviews all of its marketable securities on a regular basis to evaluate whether any security has experienced an other-than-temporary decline in fair value. Restricted Cash At March 31, 2017 and December 31, 2016, the Company had restricted cash of $377,000. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,639</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,964</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash, current</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash, non-current</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,341</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The restricted cash, which consists of money market accounts with one of the Company’s financial institutions, serves as collateral for the letters of credit provided as security deposits under the Company’s facility leases. As of March 31, 2017 and December 31, 2016, $127,000 of restricted cash is classified as current assets and relates to the current facility lease that expires on April 14, 2017. Warrant Liability On June 3, 2016, the Company issued warrants to purchase 1,999,999 shares of its common stock in connection with the Private Placement. Each warrant has an exercise price of $3.66 per share and is exercisable for five years from the date of issuance. The Company accounts for these warrants as a liability instrument measured at estimated fair value. The initial fair value of the warrants was determined using a calibration model that involved using the Black-Scholes Pricing Model ("Black-Scholes"), which requires inputs such as the risk-free interest rate, expected share price volatility, underlying price per share of the Company's common stock and remaining term of the warrants. The warrants are subject to remeasurement at each balance sheet date, using Black-Scholes, with any changes in the fair value of the outstanding warrants recognized in the condensed consolidated statements of operations. Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The Company has one operating segment. Customer Concentration For the three-month periods ended March 31, 2017 and 2016, the Company’s revenue was generated solely from funding pursuant to U.S. government contracts, and accordingly all contracts receivable relate to funding from U.S. government contracts. Concentration of Credit Risk Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash, cash equivalents and short-term investments. Cash and cash equivalents are deposited in checking and money market accounts at one financial institution with balances that generally exceed federally insured limits. Management believes that the financial institution is financially sound, and, accordingly, minimal credit risk exists with respect to this financial institution. The Company’s investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of default by the institutions holding its cash and cash equivalents or issuing the debt securities. As of March 31, 2017 and December 31, 2016, the Company had not experienced any credit losses in such accounts or investments. Revenue Recognition The Company recognizes revenue when: (i) evidence of an arrangement exists, (ii) fees are fixed or determinable, (iii) services have been delivered, and (iv) collectability is reasonably assured. The Company currently generates revenue entirely from government contracts. Government contracts are agreements that provide the Company with payments for certain types of expenditures in return for research and development activities over a contractually-defined period. Revenue from government contracts is recognized in the period during which the related costs are incurred and the related services are rendered, provided that the applicable conditions under the government contracts have been met.  Costs of contract revenue are recorded as a component of operating expenses in the Company's consolidated statement of operations. Funds received from third parties under contract arrangements are recorded as revenue if the Company is deemed to be the principal participant in the contract arrangements because the activities under the contracts are part of the Company’s development programs. If the Company is not the principal participant, the funds from contracts are recorded as a reduction to research and development expense. Contract funds received are not refundable and are recognized when the related qualified research and development costs are incurred and when there is reasonable assurance that the funds will be received. Funds billed and received in advance are recorded as deferred revenue. Research and Development Costs Research and development costs are expensed as incurred. Research and development expenses include certain payroll and personnel expenses; laboratory supplies; consulting costs; external contract research and development expenses; and allocated overhead, including rent, equipment depreciation and utilities, and relate to both Company-sponsored programs as well as costs incurred pursuant to collaboration agreements and government contracts. The Company estimates preclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and other current assets and recognized as an expense as the goods are delivered or the related services are performed. Recent Accounting Pronouncements In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740) - Balance Sheet Classification of Deferred Taxes. This guidance simplifies the presentation of deferred income taxes in a classified balance sheet to require that deferred tax liabilities and assets be classified as noncurrent and is effective for annual reporting periods, including interim reporting periods, beginning after December 15, 2016. The Company adopted this ASU effective January 1, 2017. The adoption had no impact on the Company’s consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases, which, for operating leases, requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. This ASU will be effective for the Company in fiscal year 2019. Early adoption is permitted. The Company is currently assessing the potential effects of this ASU on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815) - Contingent Put and Call Options in Debt Instruments.  This ASU clarifies the requirements for assessing whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts.  An entity performing the assessment under the amendments in this Update is required to assess the embedded call (put) options solely in accordance with the four-step decision sequence.  This guidance should be applied on a modified retrospective basis to existing debt instruments as of the beginning of the fiscal year in which the amendments are effective. This ASU is effective beginning January 1, 2017 and the Company assessed that the effects of this ASU had no impact on its consolidated financial statements. In March 2016, the FASB issued ASU No 2016-09, Compensation - Stock Compensation (Topic 718) - Improvements to Employee Share-Based Payment Accounting. This ASU simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. This ASU will be effective for fiscal years beginning after December 15, 2016, including interim periods. The Company adopted this ASU effective January 1, 2017 and elected to account for forfeitures on an estimated basis. The adoption had no impact on the Company’s consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The Company has not yet finalized its preliminary assessment and conclusions on how the adoption of this ASU will affect its current policies related to revenue recognition. The Company expects to adopt the new revenue standard on January 1, 2018, and through the remainder of 2017, will continue to assess the potential impact of adopting this new standard on any current, new or significantly modified customer contracts. In subsequent quarters, the Company will finalize its selection of transition methods and complete its evaluation of additional disclosures that may be required upon adoption of the new standard. Net Loss Per Share Basic net loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period.  Diluted net loss per common share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common share equivalents outstanding during the period. For purposes of this calculation, preferred stock, stock options, restricted stock units and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. For the three-month periods ended March 31, 2017 and 2016, all potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported. Below are listed the potentially dilutive securities outstanding as of March 31, 2017 and 2016:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,470,187</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,793,404</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,658</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">495,274</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,231,659</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,024</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Warrants outstanding as of March 31, 2017 have a weighted-average exercise price of $3.78.</div> <div> 3. Fair Value Measurements Financial assets and liabilities are recorded at fair value. The carrying amount of certain financial instruments, including cash and cash equivalents, contracts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Where quoted prices are available in an active market, securities are classified as Level 1 of the valuation hierarchy. The Company’s Level 2 valuations of marketable securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy. Level 3 liabilities that are measured at estimated fair value on a recurring basis consist of a derivative liability in connection with loan payable and a warrant liability in connection with the Private Placement. As of March 31, 2017 and December 31, 2016, financial assets and liabilities measured and recognized at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above were as follows (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,779</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,779</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 1:</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,860</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,860</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,237</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,237</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 2:</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,031</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,007</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury bills</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,033</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,998</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,400</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,400</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,464</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,405</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,480</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,421</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reported as:</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,639</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,405</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, Level 3</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant Liability</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,289</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative Liability</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">622</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,911</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,728</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,728</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 1:</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,236</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,236</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,613</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,613</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 2:</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,969</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,962</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,950</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,950</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,919</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,912</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,260</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,253</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reported as:</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,964</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,912</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, Level 3</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,874</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">602</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,476</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> All available-for-sale securities held as of March 31, 2017 had maturities less than one year from the date of acquisition. There were no sales of available-for-sale securities in any of the periods presented. The carrying value of debt securities that were in unrealized loss positions totaled $63.9 million as of March 31, 2017. The Company has determined that (i) it does not have the intent to sell any of these investments, and (ii) it is not more likely than not that it will be required to sell any of these investments before recovery of the entire amortized cost basis. The Company anticipates that it will recover the entire amortized cost basis of such debt securities and has determined that no other-than-temporary impairments associated with credit losses were required to be recognized during the three-month period ended March 31, 2017. Pursuant to the loan and security agreement with Solar Capital Ltd. (see Note 7), the Company entered into a Success Fee Agreement under which the Company agreed to pay $1.0 million in cash (the "Success Fee") if the Company obtains approval to market plazomicin from the Food and Drug Administration (the "FDA"). If such approval is obtained, the Success Fee shall be due the later of (i) August 5, 2019 or (ii) the date such FDA approval is obtained. The fair value of the Success Fee, approximately $602,000 at December 31, 2016, is recorded as a derivative liability and included in other long-term liabilities on the accompanying condensed consolidated balance sheet. The estimated fair value of the derivative liability as of March 31, 2017 increased by $20,000 to $622,000 from December 31, 2016, as a result of the time value of money, which is presented as change in warrant and derivative liabilities in the Company's condensed consolidated statements of operations for the three-month period ended March 31, 2017. The fair value of the derivative liability was determined using a discounted cash flow analysis, and is classified as a Level 3 measurement within the fair value hierarchy since the Company’s valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the derivative instrument include: i) the Company’s estimates of both the probability and timing of a potential $1.0 million payment to Solar Capital Ltd. upon FDA approval to market plazomicin, and ii) a discount rate of 13% which was derived from the Company's estimated cost of debt. The estimated fair value of the derivative liability is most sensitive to the probability of FDA approval. Should the probability of FDA approval change by 5%, the fair value of the derivative liability as of March 31, 2017 would change by approximately $37,000. For the three-month period ended March 31, 2017, there was no change to the key assumptions used in the calculation of the estimated fair value. Any changes in the estimated fair values are presented as changes in warrant and derivative liabilities in the Company's condensed consolidated statements of operations. Pursuant to the Private Placement (see Note 2), the Company issued warrants to purchase 1,999,999 shares of common stock at an exercise price of $3.66. The Company classified these warrants as a liability measured at fair value using Black-Scholes. Under certain entity conditions, the holder of a warrant may require the Company to settle the warrant in cash at its estimated fair value using Black-Scholes. On the closing date of the Private Placement, June 3, 2016, the $2.6 million initial estimated fair value of the warrants was recorded as a warrant liability on the accompanying condensed consolidated balance sheet. At March 31, 2017 and December 31, 2016, the estimated fair values of the warrants were approximately $27.3 million and $13.9 million, respectively. The change in the estimated fair value is primarily due to the increase in the Company's stock price and is included in changes in warrant and derivative liabilities in the Company's condensed consolidated statements of operations. In February 2017, certain holders of these warrants exercised warrants to purchase 78,585 shares of common stock. The Company received $0.3 million in proceeds from these warrant exercises. The Company is required to record the exercised warrants at its estimated fair value at the time of exercise, with any change included in changes in warrant and derivative liabilities in the Company’s condensed consolidated statements of operations. The Company estimated the fair value of these exercised warrants at their respective exercise dates to be $1.5 million, an increase of $1.4 million from its initial valuation, at June 3, 2016, of $0.1 million, primarily due to an increase in the Company’s stock price.   The fair value of the warrant liability is classified as a Level 3 measurement within the fair value hierarchy since the Company’s valuation utilized significant unobservable inputs, including the risk-free interest rate, expected share price volatility, underlying price per share of the Company's common stock and remaining term of the warrants. At March 31, 2017 and December 31, 2016, the estimated fair values of the warrants were determined using Black-Scholes with the following assumptions: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.9%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The expected volatility is based on the Company's expected volatility. The expected term is based on the remaining life of the warrants. The risk-free interest rate is obtained from the yields on actively traded U.S. Treasury securities for a period equal to the expected term of the warrants. The dividend yield is zero because the Company has never paid cash dividends and has no present intention to pay cash dividends. Should the share price change by 5%, the fair value of the warrant liability as of March 31, 2017 would change by approximately $1.5 million. Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as changes in warrant and derivative liabilities in the Company's condensed consolidated statements of operations and were as follows for the three-month period ended March 31, 2017 (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.9%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Fair Value <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Warrant Liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Fair Value <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Derivative Liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance of Level 3 Liabilities at December 31, 2016</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,874</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">602</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in estimated fair value of warrant liability</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,936</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to additional paid in capital upon exercise of warrants</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,521</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in estimated fair value of derivative liability</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.9%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance of Level 3 Liabilities at March 31, 2017</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,289</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">622</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> 4. Balance Sheet Components Prepaids and other current assets Prepaids and other current assets consisted of the following (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred research and development costs</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,042</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">660</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,660</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,390</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">335</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,037</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,189</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Property and Equipment, net Property and equipment, net consisted of the following (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,071</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">644</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,989</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,038</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,072</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,072</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction-in-progress</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,751</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,896</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,883</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,650</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,434</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,389</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,449</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,261</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Depreciation and amortization expense for the three-month periods ended March 31, 2017 and 2016 was $113,000 and $121,000, respectively. Accrued Liabilities Accrued liabilities consisted of the following (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical and development expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,394</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,681</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related bonus expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,788</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,941</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,308</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,076</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,490</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,698</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> 5. License and Collaboration Agreements Thermo Fisher Scientific, Inc. In April 2016, the Company entered into an agreement with its collaboration partner, Microgenics Corporation (“Thermo Fisher”), a wholly owned subsidiary of Thermo Fisher Scientific, Inc., to develop and commercialize an assay to support plazomicin. If approved, the Company and Thermo Fisher plan to have a commercial assay for plazomicin available at launch to enable health care professionals to make decisions on safe and efficacious doses of plazomicin. In accordance with the terms of the agreement, the Company is required to make milestone payments with respect to research, development, regulatory and commercialization milestones (if any). All such milestone payments may total, in aggregate, up to but no more than $6,453,000. In further consideration of this agreement, in the event of a successful commercialization of the assay, the Company is required to pay a minimum threshold annual revenue to Thermo Fisher. As of March 31, 2017, the Company has incurred $1,433,000 in milestone payments and the cost was fully recorded as research and development expense. The Company recorded $915,000 and zero of research and development expense during the three-month periods ending March 31, 2017 and 2016, respectively, under this agreement. In February 2017, the Company announced the achievement of a strategic milestone in its ongoing collaboration to develop an assay enabling therapeutic drug management of plazomicin. Crystal Biosciences, Inc. In May 2016, the Company entered into a collaboration and license agreement with Crystal Biosciences, Inc. (“Crystal”). Pursuant to the terms of this agreement, the Company and Crystal agreed to collaborate on the discovery of monoclonal antibodies against multiple targets. Crystal agreed to conduct the initial discovery work with its antibody platform and the Company has the right to develop and commercialize the antibodies discovered through this collaboration. The Company is required to provide signing and milestone payments with respect to research, development, regulatory and commercialization milestones (if any). All such milestone payments may total, in aggregate, up to but no more than $20,550,000. The upfront signing fee, technology access fees and research funding were recorded as research and development expense. This collaboration and license agreement also provides that the Company shall pay royalties equal to a low single-digit percentage of annual worldwide net sales of the commercialized product. Ionis Pharmaceuticals In January 2006, the Company entered into a license agreement with Ionis Pharmaceuticals, Inc. (“Ionis”). Ionis granted the Company an exclusive, worldwide license with the right to grant and authorize sublicenses related to the research and development of aminoglycoside products. As an up-front fee, the Company issued 97,402 shares of Series A convertible preferred stock at a fair value of $15.40 per share. This license fee of $1,500,000 was recorded as research and development expense in 2006. In further consideration of this license, and in accordance with the terms of the agreement, the Company is required to make milestone payments with respect to development, regulatory and commercialization milestones, and to pay a percentage of revenue received from sublicensees (if any). All such milestone and sublicense revenue payments may total, in the aggregate, up to but no more than $19,500,000 for the first product and $9,750,000 following the second product commercialized under the agreement with Ionis. The Company is also required to pay additional milestone payments of up to $20,000,000 in the aggregate upon the first achievement of specified threshold levels of annual net sales of all aminoglycoside products in a calendar year. The license agreement also provides that the Company shall pay royalties equal to a low single-digit percentage of annual worldwide net sales of all licensed products, including, if applicable, plazomicin. Through March 31, 2017, the Company had compensated Ionis $7,000,000 in connection with the first three milestones under the license for the first aminoglycoside product candidate. As of March 31, 2017, the Company had no outstanding payments due under the agreement.</div> <div> 6. Government Contracts Certain of the Company’s drug discovery and development activities are performed under contracts with U.S. government agencies. Management has determined that the Company is the principal participant in the following contract arrangements, and, accordingly, the Company records amounts earned under the arrangements as revenue. Costs incurred under revenue contracts are recorded as operating expenses in the Company's consolidated statements of operations. Biomedical Advanced Research and Development Authority In August 2010, the Company was awarded a contract with the Biomedical Advanced Research and Development Authority (“BARDA”) for the development, manufacturing, nonclinical and clinical evaluation of, and regulatory filings for, plazomicin as a countermeasure for disease caused by antibiotic-resistant pathogens and biothreats. The original contract included committed funding of $27,600,000 for the first two years of the contract and subsequent options exercisable by BARDA to provide additional funding. In September 2012, BARDA exercised an additional $15,798,000 contract option ("Option 1"), which increased the total contract committed funding to $43,398,000 through March 2014. In April 2013, the Company was awarded an additional $60,410,000 under the contract to support its Phase 3 clinical trial of plazomicin ("Option 2") to increase the total committed funding under this contract to $103,808,000. On May 26, 2016, the Company was awarded an additional $20 million ("Option 3") under the contract to support its Phase 3 EPIC trial of plazomicin. This brings the total committed funding under the contract to $123,808,000. The Company recorded contract revenue of $7,114,000 and $5,270,000 under this agreement during the three-month periods ended March 31, 2017 and 2016, respectively. National Institute of Allergy and Infectious Diseases In July 2015, the Company was awarded a contract by the National Institute of Allergy and Infectious Diseases ("NIAID") for $1.5 million committed through June 30, 2016, with total funding of up to $4.5 million available if all options are exercised under the contract.  In January 2016, an additional committed funding of $0.5 million was added to the awarded funding and the total potential funding was increased to $5.0 million.  In April 2016, NIAID modified the contract to exercise an option which increased the total contract committed funding to $4.4 million through February 2018, with total potential funding remaining at $5.0 million if the remaining option is exercised. In July 2014, the Company was awarded a one-year, $407,000 grant by NIAID to conduct discovery research on novel antibiotics targeting gram-negative bacteria. In July 2015, NIAID extended the grant term through July 31, 2016. The Company recorded contract revenue of $349,000 and $579,000 under these agreements during the three-month periods ended March 31, 2017 and 2016, respectively.</div> <div> 7. Borrowings Solar Capital Ltd. Loan Agreement On August 5, 2015, the Company entered into a loan and security agreement (the “Loan Agreement”) with Solar Capital Ltd. (the “Lender”) pursuant to which the Lender agreed to make available to the Company term loans in an aggregate principal amount of up to $25.0 million with a maturity date of August 5, 2019. An initial $15.0 million term loan was funded at closing on August 5, 2015, and a second $10.0 million term loan was funded on June 20, 2016. Borrowings under the term loans bear interest per annum at 6.99% plus the greater of 1% or the one-month LIBOR. The Company is currently required to make interest-only payments on the term loans through August 2017, and beginning on September 1, 2017 the Company is required to make monthly payments of interest plus equal monthly payments of principal over a term of 24 months. The Loan Agreement requires collateral by a security interest in all of the Company’s assets except intellectual property (which is subject to a negative pledge) and contains customary affirmative and negative covenants, and also includes standard events of default, including payment defaults. Upon the occurrence of an event of default, a default interest rate of an additional 4% may be applied to the outstanding loan balances, and the Lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. There were no financial covenants attached to the loan. The Loan Agreement included a closing fee of $250,000 which was paid at closing, and the Company is obligated to pay a fee equal to 8% of the term loans funded upon the earliest to occur of the maturity date, the acceleration of the term loans or the voluntary prepayment of the term loans. The cost of these fees is being amortized as interest expense over the term of the loan using the effective-interest method. The Company may voluntarily prepay all, but not less than all, of the outstanding term loans. The Loan Agreement contains customary representations, warranties and covenants. In addition, the Loan Agreement contains customary events of default that entitle the Lender to cause the Company’s indebtedness under the Loan Agreement to become immediately due and payable. On August 5, 2015, pursuant to the Loan Agreement, the Company entered into a Success Fee Agreement with the Lender under which the Company agreed to pay the Lender $1.0 million if the Company obtains FDA approval to market plazomicin. If such approval is obtained, the Success Fee shall be due the later of (i) August 5, 2019 or (ii) the date such FDA approval is obtained. The fair value of the Success Fee at the date of issuance of approximately $356,000 was recorded as a debt discount and is being amortized as interest expense over the term of the loan using the effective-interest method. Future principal debt payments on the currently outstanding term loan are payable as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,167</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,500</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,333</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total principal payments</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Final fee due at maturity in 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total principal and final fee payments</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized discount and debt issuance costs</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,516</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,292</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loan payable, long-term</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,192</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The obligation includes a final fee of $2,000,000, representing 8% of the term loan currently funded, which accretes over the life of the loan as interest expense.  The Company recorded interest expense related to the loan of $0.7 million and $0.4 million for the three-month periods ended March 31, 2017 and 2016, respectively.</div> <div> 8. Stockholders' Equity On April 7, 2015, the Company entered into a Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”), pursuant to which the Company may issue and sell shares of its common stock having aggregate sales proceeds of up to $30.0 million from time to time through an ATM equity program under which Cowen acts as sales agent. As of March 31, 2017, the Company had sold 1,105,549 shares of common stock under the Sales Agreement, at a weighted-average price of approximately $4.82 per share for aggregate gross proceeds of $5.3 million and net proceeds of $5.1 million after deducting the sales commissions and offering expenses. As of March 31, 2017, $24.7 million of common stock remained available to be sold under the Sales Agreement, subject to certain conditions specified therein. On June 3, 2016, the Company sold 7,999,996 shares of its common stock and warrants to purchase 1,999,999 shares of its common stock pursuant to the Purchase Agreement for aggregate gross proceeds of $25.4 million in the Private Placement. The warrants have an exercise price of $3.66 and are exercisable up to five years from the date of issuance. The Company's Chief Operating Officer, a related party, participated in the Private Placement by purchasing 141,453 shares of common stock and a warrant to purchase 35,363 shares of common stock for an aggregate purchase price of $0.5 million. Issuance costs of $0.3 million were offset against equity as a reduction from gross proceeds. At the close of the Private Placement, the estimated fair values of the common stock and warrants issued were $22.9 million and $2.6 million, respectively. At March 31, 2017, using Black-Scholes, the Company estimated the fair value of the remaining warrants outstanding to be $27.3 million and recorded a charge of $11.3 million and $13.4 million, for the increase in the liability, in the condensed consolidated statements of operations, for the year ended December 31, 2016 and three-month period ended March 31, 2017, respectively. Equity Incentive Plans 2014 Equity Incentive Award Plan In February 2014, the Company’s stockholders approved the 2014 Equity Incentive Award Plan (the "2014 Plan"), which became effective as of March 11, 2014. Under the 2014 Plan, the Company may grant incentive stock options ("ISOs"), nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units ("RSUs") and other stock-based awards for the purchase of that number of shares of common stock. Effective, January 1, 2017, the compensation committee of the board of directors approved an evergreen increase of 1,425,522 shares that may be granted in accordance with the terms of the 2014 Plan. As of March 31, 2017, 909,040 shares were available for future issuance under the 2014 Plan. Under the 2014 Plan, the terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2014 Plan. Options granted by the Company typically vest over a four year period and the exercise price may not be less than fair market value on the date of grant. Certain of the options are subject to acceleration of vesting in the event of certain change of control transactions. Options granted under the 2014 Plan expire no later than 10 years from the date of grant. 2014 Employment Commencement Incentive Plan In December 2014, the Company adopted a 2014 Employment Commencement Incentive Plan (the "Inducement Plan"). The Inducement Plan is designed to comply with the inducement exemption contained in Nasdaq’s Rule 5635(c)(4), which provides for the grant of non-qualified stock options, RSUs, restricted stock awards, performance awards, dividend equivalents, deferred stock awards, deferred stock units, stock payment and stock appreciation rights to a person not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to the individual’s entering into employment with the Company.  As of March 31, 2017, a total of 1,600,000 shares of common stock have been authorized under the Inducement Plan, including the additional 450,000 shares that became available resulting from an amendment adopted by the board of directors as of February 22, 2017.  As of March 31, 2017, 356,588 shares were available for future issuance under the Inducement Plan. 2014 Employee Stock Purchase Plan In February 2014, the Company’s stockholders approved the 2014 Employee Stock Purchase Plan (the “ESPP”), which became effective as of March 11, 2014. Effective, January 1, 2017, the compensation committee of the board of directors approved an evergreen increase of 178,190 shares that may be granted in accordance with the terms of the ESPP. As of March 31, 2017, 225,261 shares of common stock have been issued to employees participating in the ESPP, and 461,406 shares are available for issuance under the ESPP. Amended and Restated 2003 Stock Plan The Company’s Amended and Restated 2003 Stock Plan (the "2003 Plan"), provided for the granting of incentive and non-statutory stock options to employees, directors and consultants at the discretion of the board of directors. The Company granted options under its 2003 Plan until January 2014 and it was terminated as to future awards in March 2014, although it continues to govern the terms of options that remain outstanding under the 2003 Plan. Options granted under the 2003 Plan expire no later than 10 years from the date of grant. Options granted under the 2003 Plan vest over periods determined by the board of directors, generally over four years. The 2003 Plan allows for early exercise of certain options prior to vesting. Upon termination of employment, the unvested shares are subject to repurchase at the original exercise price. Stock options granted or modified after March 21, 2002, that are subsequently exercised for cash prior to vesting, are not deemed to be issued until those shares vest. As of March 31, 2017 and December 31, 2016 there were no shares subject to repurchase relating to the early exercise of options. In connection with the board of directors’ and stockholders’ approval of the 2014 Plan, all remaining shares available for future awards under the 2003 Plan were transferred to the 2014 Plan, and the 2003 Plan was terminated as to future awards. As of March 31, 2017, a total of 862,720 shares of common stock are subject to options outstanding under the 2003 plan, which shares will become available under the 2014 Plan to the extent the options are forfeited or lapse unexercised. The following table summarizes stock option activity under the stock plans, excluding the ESPP, and related information:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for grant</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subject to <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">639,374</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,540,293</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.31</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.98</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional shares authorized</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,875,522</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,067,657</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,067,657</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.23</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,585</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.79</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,178</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(83,178</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.61</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs granted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(288,064</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,275</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, March 31, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,265,628</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,470,187</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.90</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Stock-based compensation expense recognized for stock options granted to employees and non-employee directors in the Company’s condensed consolidated statements of operations was as follows (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,602</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">454</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,090</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">373</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,692</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">827</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Stock based compensation expense for the three-month period ended March 31, 2017 includes $0.7 million of expense that relate to stock options and restricted stock units held by the former Chief Medical Officer, which were modified upon his resignation in March 2017, including $0.7 million related to such modifications. As of March 31, 2017, approximately $20,534,000 of total unrecognized stock-based compensation expense related to unvested stock options is expected to be recognized over a weighted-average period of 3.37 years. The estimated grant date fair value of employee stock options with time-based vesting terms was calculated using the Black-Scholes valuation model, based on the following assumptions: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80%–81%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0%–2.1%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Stock Options Granted to Non-Employees During the three-month periods ended March 31, 2017 and 2016, the Company did not grant any stock options to non-employees. The Company recorded non-employee stock-based compensation expense of approximately $219,000 and zero for the three-month periods ended March 31, 2017 and 2016, respectively. The Company measures the estimated fair value of the award for each period until the award is fully vested. The non-employee stock-based compensation expense, during the three-month period ended March 31, 2017, was estimated using Black-Scholes with the following assumptions: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.16%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.48%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.16%;"> Expected term</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;">  </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.51 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.16%;"> Expected volatility</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.34%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.16%;"> Risk-free interest rate</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.34%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.16%;"> Expected dividend yield</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.34%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> </table></div> Restricted Stock Units Granted to Employees During the three-month period ended March 31, 2017, the Company granted RSUs to employees to receive 288,064 shares of common stock under the Company's stock plans with a weighted-average estimated grant-date fair value of $21.90 per share. RSUs generally vest annually over a 4-year service period and vesting is contingent on continued service. As of March 31, 2017, there were unrecognized compensation costs of $8,401,000 related to outstanding RSUs, which are expected to be recognized over a weighted-average period of 3.33 years. A summary of RSU activity is as follows: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSU Awards Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.76%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date Fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Market Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">605,052</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.60</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,878</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.76%;"> RSUs granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288,064</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.90</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.76%;"> RSUs released</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,183</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.11</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.76%; border-bottom:solid 0.75pt transparent;"> RSUs cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,275</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.32</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.76%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, March 31, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,658</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.49</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,201</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Stock Options and Restricted Stock Units Granted to Employees that Contain Performance Conditions During the three-month periods ended March 31, 2017 and 2016, the Company granted options to purchase an aggregate of 142,200 and 199,750 shares of common stock, respectively, and 25,800 and 47,425 RSUs, respectively, that vest upon the achievement of market-based common stock price targets. The fair value was estimated at the grant date using a Monte-Carlo simulation model (“Monte-Carlo”), which requires the use of a range of assumptions. The expected life assumption is not used in Monte-Carlo, but the output of the model indicates an expected term. The associated stock-based compensation expense is being recognized on a straight-line basis over the implicit service period (expected time to vest) derived from Monte-Carlo. The fair value of awards granted to employees was estimated using Monte-Carlo with the following assumptions: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5–2.0 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.0–6.0 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> 9. Commitments Commercial Manufacturing Agreement In March 2017, the Company entered into a commercial validation and manufacturing agreement (the “Manufacturing Agreement”) with Hovione Limited (“Hovione”).  Under the Manufacturing Agreement, Hovione has agreed to complete the validation program to validate and scale up the Company’s technology to manufacture the active pharmaceutical ingredient for plazomicin (the “Product”) and supply the Product to the Company. The Manufacturing Agreement has an initial term of seven years after the first delivery of the Product.  Subject to the successful completion of the validation program and the Company’s launch of plazomicin, the Company has agreed to purchase a minimum quantity of the Product from Hovione depending on the Company’s requirements and the period of time following approval by the FDA. For the first three years following approval of plazomicin by the FDA, the Company is required to purchase at least 80% of its required quantity from Hovione. Following the initial three years after FDA approval, the Company is required to purchase between 40% and 66% of its required quantity from Hovione, depending on the amounts required during any such fiscal year. Contingent upon FDA’s approval of plazomicin, the Company has minimum annual purchase commitments from Hovione, beginning in 2020 through 2024. In connection with the Manufacturing Agreement, the Company executed certain work plans to carry out the validation and commercial manufacturing of plazomicin (the “Work Plans”). The Work Plans obligate the Company to make an aggregate amount of approximately $6.2 million in nonrefundable advance payments, of which $1.5 million was for the reservation of facilities and resources, plus procurement of long lead raw materials, paid in full under a separate agreement executed in July 2015. Such advance payments are initially capitalized as prepaid and other current assets and will be recognized as research and development expenses as goods are delivered and/or services are performed. The Company assesses such prepaid and other current assets for impairment if events or changes in circumstances indicate that the carrying amount may not be recoverable or may not provide future economic benefits. Further, the Work Plans include certain terms that require the Company to compensate Hovione if it chooses to cancel the Work Plans (“Cancellation Clause”). As of March 31, 2017, $9.8 million is committed under the Cancellation Clause and the total aggregate amount of potential commitments, if all the services are rendered by Hovione, is approximately $28.1 million. As of March 31, 2017 and December 31, 2016, the Company has recorded approximately $4.8 million and $0.7 million, respectively as prepaid and other current assets and, during the three-month periods ended March 31, 2017 and 2016, has recognized $0.4 million and $0.1 million, respectively, as research and development expenses, related to the Work Plans. In December 2016, the Company entered into an agreement with Hovione to procure certain long lead raw materials to be used in the commercial production of plazomicin (the “Raw Material Agreement”). The Raw Material Agreement includes $1.2 million in nonrefundable advance payments. As of March, 31 2017, the Company has recorded $1.2 million of these nonrefundable advance payments as prepaid and other current assets. Facilities Lease Obligation The Company leased its former principal executive offices in South San Francisco under a non-cancelable lease agreement that expired on April 14, 2017. In August 2016, the Company entered into a non-cancelable agreement (the "Lease") to lease approximately 47,000 square feet of office, laboratory and research and development space for the Company's new principal executive offices (“Premises”) in South San Francisco. The Lease commenced in March 2017, after the substantial completion of certain improvements ("Tenant Improvements") required under the Lease, set to expire in August 2027 ("Lease Term"), and the Company moved into the Premises in April 2017. The Lease contains expansion options and an option to extend the Lease Term for an additional 5 years. Base rent for the first year of the Lease Term is approximately $2.7 million, with an increase in annual base rent of approximately 3.5% in each subsequent year of the Lease Term. The Lease also provides for rent abatement of approximately $1.8 million for the first year of the Lease Term.  The Company is entitled to a one-time improvement allowance of $5.7 million for the Tenant Improvements (the "Allowance"). The Landlord disburses the Allowance for the Tenant Improvement on behalf of the Company. As of March 31, 2017, the Company has recorded approximately $5.9 million within construction-in-progress under property, plant and equipment, net and other current liabilities in the condensed consolidated balance sheet related to costs incurred under the Allowance. At its election, the Company is also entitled to an additional improvements allowance of $0.9 million ("Additional Allowance"). In the event the Company elects to use the Additional Allowance, the base rent will be increased as calculated in the Lease. Further, the Company had a deposit of $250,000 included in long-term restricted cash as of March 31, 2017, restricted from withdrawal and held in a money market account with one of the Company’s financial institutions in the form of collateral for a letter of credit held as security for the Lease. Future minimum lease payments under the operating leases as of March 31, 2017 are as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amounts</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">663</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,353</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,890</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,991</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,098</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,036</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,031</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The Company recognizes rent expense on a straight-line basis over the non-cancelable lease period. Rent expense was $211,000 and $146,000 for the three-month periods ended March 31, 2017 and 2016, respectively.</div> <div> 10. Subsequent Events In May 2017, the Company entered into an agreement with the Bill & Melinda Gates Foundation (the “Gates Foundation”) to discover drug candidates against gram-negative pathogens intended to prevent neonatal sepsis (the “Grant Agreement”). Pursuant to the Grant Agreement, the Gates Foundation awarded the Company up to approximately $10.5 million in grant funding over a three-year research term, of which approximately $3.2 million will be advanced to the Company within 15 days after signing (the “Advance Funds”). The Advance Funds are replenished by the Gates Foundation each calendar year, or sooner, following the Company’s submission of a progress report, including expenses incurred for the research activities. Under certain conditions, as described in the Grant Agreement, the Gates Foundation may terminate the Grant Agreement and the Company is obligated to return to the Gates Foundation any unused portion of the Advance Funds.   Concurrently with the Grant Agreement, the Company entered into a Common Stock Purchase Agreement with the Gates Foundation, pursuant to which the Company agreed to sell 407,331 shares of its redeemable common stock (the “Shares”) to the Gates Foundation in a private placement at a purchase price per share equal to $24.55, for gross proceeds to the Company of $10.0 million (“Gates Investment”). In connection with the Grant Agreement and the Gates Investment, the Company entered into a strategic relationship with the Gates Foundation (the “Letter Agreement”). Under the terms of the Letter Agreement, the Advanced Funds and the Gates Investment may only be used to conduct mutually agreed upon work, including the scale up of the Company’s platform technology to launch a product intended to prevent neonatal sepsis (the “NSP”). If the Company defaults in its obligation to conduct certain mutually-agreed upon work or use the proceeds from the Gates Investment as described in the Letter Agreement, or otherwise triggers certain other events of default as described in the Letter Agreement (“Charitable Default”), subject to a cure period, the Gates Foundation will have the right to request that (a) the Company redeem, or facilitate the purchase by a third party of, the Shares then held by the Gates Foundation at a price per share equal to the greater of (i) the fair market value of the common stock (if the Shares are freely tradable, the closing price of the Company’s common stock on the trading day prior to the redemption or purchase, as applicable), or (ii) an amount equal to $24.55 plus a compounded annual return of 5% from the date of issuance of the Shares, or (b) if the Shares then held by the Gates Foundation are not freely tradeable, the Company register the resale of the Shares held by the Gates Foundation on an effective registration statement, subject to certain conditions and qualifications. Pursuant to the Letter Agreement, the Company agreed to make the NSP available and accessible in certain developing countries and to grant the Gates Foundation a non-exclusive license to commercialize selected drug candidates in specified developing countries, which may only be exercised in the event of a Charitable Default (the “Global Access”). The Global Access will continue in effect until the earlier of 25 years from the closing of the Gates Investment or 7 years following the termination of all funding provided by the Gates Foundation; provided, that the Global Access will continue for any products or services developed with funding provided by the Gates Foundation which continue to be developed or available in certain developing countries.</div> <div> Reclassifications The change in derivative liability for the three-month period ended March 31, 2016 has been reclassified to be included in the change in warrant and derivative liabilities to conform to the current year’s presentation. Such reclassifications did not impact the Company’s net loss or financial position.</div> <div> Basis of Presentation and Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and following the requirements of the Securities and Exchange Commission (the “SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company’s financial information. The results of operations for the three-month period ended March 31, 2017 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December 31, 2016 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. Intercompany accounts and transactions have been eliminated upon consolidation. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K. In May 2017, the Company entered into an agreement with the Bill & Melinda Gates Foundation (the “Gates Foundation”) to discover drug candidates against gram-negative pathogens intended to prevent neonatal sepsis (the “Grant Agreement”). Pursuant to the Grant Agreement, the Gates Foundation awarded the Company up to approximately $10.5 million in grant funding over a three-year research term, of which approximately $3.2 million will be advanced to the Company within 15 days after signing (the “Advance Funds”). Concurrently with the Grant Agreement, the Company entered into a Common Stock Purchase Agreement with the Gates Foundation, pursuant to which the Company agreed to sell 407,331 shares of its redeemable common stock to the Gates Foundation in a private placement at a purchase price per share equal to $24.55, for gross proceeds to the Company of $10.0 million (“Gates Investment”). In connection with the Grant Agreement and the Gates Investment, the Company entered into a strategic relationship with the Gates Foundation (the “Letter Agreement”). Under the terms of the Letter Agreement, the Gates Investment and Advanced Funds may only be used to conduct mutually agreed upon work, including the scale up of the Company’s platform technology to launch a product intended to prevent neonatal sepsis (the “NSP”). Pursuant to the Letter Agreement, the Company agreed to make the NSP available and accessible in certain developing countries and to grant the Gates Foundation a non-exclusive license to commercialize selected drug candidates in specified developing countries, which may only be exercised in the event of certain defaults as described in the Letter Agreement (the “Global Access”). The Global Access will continue in effect until the earlier of 25 years from the closing of the Gates Investment or 7 years following the termination of all funding provided by the Gates Foundation; provided, that the Global Access will continue for any products or services developed with funding provided by the Gates Foundation which continue to be developed or available in certain developing countries. On December 19, 2016, the Company completed an underwritten public offering of common stock made under a prospectus supplement and related prospectus pursuant to a Registration Statement on Form S-3 (File No. 333-203282) filed on April 7, 2015 (the “Shelf Registration Statement”). This offering resulted in the sale of 7,475,000 shares, at a price to the public of $13.50 per share, including the full exercise of the underwriters’ option to purchase an additional 975,000 shares of common stock.  The Company received net proceeds from the offering of $94.6 million, after deducting the underwriting discounts and commissions and estimated offering expenses. On June 3, 2016, the Company sold 7,999,996 shares of its common stock and warrants to purchase 1,999,999 shares of its common stock pursuant to Securities Purchase Agreement (the "Purchase Agreement") for aggregate gross proceeds of $25.4 million and aggregate net proceeds of $25.1 million, after deducting the issuance costs, in connection with a private placement financing transaction (the "Private Placement"). The warrants have an exercise price of $3.66 per share and are exercisable up to five years from the date of issuance. On April 7, 2015, the Company filed the Shelf Registration Statement, declared effective by the SEC on April 21, 2015, covering the offering of up to $150.0 million of common stock, preferred stock, debt securities, warrants, purchase contracts and/or units. The Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $30.0 million of shares of our common stock from time to time in an "at-the-market" ("ATM") equity offering pursuant to a sales agreement with Cowen and Company, LLC. As of March 31, 2017, the Company had sold 1,105,549 shares pursuant to its ATM equity offering program at a weighted-average price of $4.82 per share for aggregate offering proceeds of $5.3 million and aggregate net proceeds of $5.1 million, after deducting the sales commissions and offering expenses. The Company has incurred losses and negative cash flows from operations every year since its inception.  As of March 31, 2017, the Company had unrestricted cash, cash equivalents and short-term investments of approximately $132.0 million and an accumulated deficit of approximately $280.5 million. Management expects that, based on its current operating plans, the Company’s existing cash, cash equivalents and short-term investments as of March 31, 2017 will be sufficient to fund its current planned operations for at least the next twelve months from the issuance of these financial statements. Management plans to raise additional funds through equity or debt financing arrangements, government contracts, and/or third party collaboration funding in the future to fund its operations, including the commercial launch of plazomicin. However, there can be no assurance that such funding sources will be available at terms acceptable to the Company or at all. If the Company is unable to raise additional funding to meet its working capital needs, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.  The financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.</div> <div> Use of Estimates The accompanying financial statements have been prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, assumptions and estimates that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures of contingent liabilities. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of liabilities, common stock and stock-based awards and income taxes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</div> <div> Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, contracts receivable, prepaid and other current assets, accounts payable, accrued liabilities, and other current liabilities approximate fair value due to their short-term maturities. Short-term investments consist of available-for-sale securities and are carried at fair value. Based upon the borrowing rates (which is a Level 2 input) currently available to the Company for loans with similar terms, the Company believes the carrying amount of the loan payable approximates its fair value. The warrant and derivative liabilities are recorded at estimated fair value with changes in estimated fair value recorded in the Company's statements of operations.</div> <div> Cash and Cash Equivalents Cash equivalents include only securities having a maturity of three months or less at the time of purchase. As of March 31, 2017 and December 31, 2016, cash and cash equivalents consisted of bank deposits, cash, commercial paper, cash repurchase agreement investments and investments in money market funds.</div> <div> Short-term Investments Short-term investments consist of debt securities with maturities greater than three months, but less than one year from the date of acquisition, and are classified as available for sale. Short-term investments are carried at fair value. Unrealized gains and losses on available-for-sale securities are excluded from earnings and reported as a component of net unrealized gain (loss) on available-for-sale securities in the Company's consolidated statements of comprehensive loss. The amortized cost of debt securities reflects amortization of purchase premiums and accretion of purchase discounts to date, which are included in interest income. The Company reviews all of its marketable securities on a regular basis to evaluate whether any security has experienced an other-than-temporary decline in fair value.</div> <div> Restricted Cash At March 31, 2017 and December 31, 2016, the Company had restricted cash of $377,000. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,639</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,964</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash, current</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash, non-current</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,341</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The restricted cash, which consists of money market accounts with one of the Company’s financial institutions, serves as collateral for the letters of credit provided as security deposits under the Company’s facility leases. As of March 31, 2017 and December 31, 2016, $127,000 of restricted cash is classified as current assets and relates to the current facility lease that expires on April 14, 2017.</div> <div> Warrant Liability On June 3, 2016, the Company issued warrants to purchase 1,999,999 shares of its common stock in connection with the Private Placement. Each warrant has an exercise price of $3.66 per share and is exercisable for five years from the date of issuance. The Company accounts for these warrants as a liability instrument measured at estimated fair value. The initial fair value of the warrants was determined using a calibration model that involved using the Black-Scholes Pricing Model ("Black-Scholes"), which requires inputs such as the risk-free interest rate, expected share price volatility, underlying price per share of the Company's common stock and remaining term of the warrants. The warrants are subject to remeasurement at each balance sheet date, using Black-Scholes, with any changes in the fair value of the outstanding warrants recognized in the condensed consolidated statements of operations.</div> <div> Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The Company has one operating segment.</div> <div> Customer Concentration For the three-month periods ended March 31, 2017 and 2016, the Company’s revenue was generated solely from funding pursuant to U.S. government contracts, and accordingly all contracts receivable relate to funding from U.S. government contracts.</div> <div> Concentration of Credit Risk Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash, cash equivalents and short-term investments. Cash and cash equivalents are deposited in checking and money market accounts at one financial institution with balances that generally exceed federally insured limits. Management believes that the financial institution is financially sound, and, accordingly, minimal credit risk exists with respect to this financial institution. The Company’s investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of default by the institutions holding its cash and cash equivalents or issuing the debt securities. As of March 31, 2017 and December 31, 2016, the Company had not experienced any credit losses in such accounts or investments.</div> <div> Revenue Recognition The Company recognizes revenue when: (i) evidence of an arrangement exists, (ii) fees are fixed or determinable, (iii) services have been delivered, and (iv) collectability is reasonably assured. The Company currently generates revenue entirely from government contracts. Government contracts are agreements that provide the Company with payments for certain types of expenditures in return for research and development activities over a contractually-defined period. Revenue from government contracts is recognized in the period during which the related costs are incurred and the related services are rendered, provided that the applicable conditions under the government contracts have been met.  Costs of contract revenue are recorded as a component of operating expenses in the Company's consolidated statement of operations. Funds received from third parties under contract arrangements are recorded as revenue if the Company is deemed to be the principal participant in the contract arrangements because the activities under the contracts are part of the Company’s development programs. If the Company is not the principal participant, the funds from contracts are recorded as a reduction to research and development expense. Contract funds received are not refundable and are recognized when the related qualified research and development costs are incurred and when there is reasonable assurance that the funds will be received. Funds billed and received in advance are recorded as deferred revenue.</div> <div> Research and Development Costs Research and development costs are expensed as incurred. Research and development expenses include certain payroll and personnel expenses; laboratory supplies; consulting costs; external contract research and development expenses; and allocated overhead, including rent, equipment depreciation and utilities, and relate to both Company-sponsored programs as well as costs incurred pursuant to collaboration agreements and government contracts. The Company estimates preclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and other current assets and recognized as an expense as the goods are delivered or the related services are performed.</div> <div> Recent Accounting Pronouncements In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740) - Balance Sheet Classification of Deferred Taxes. This guidance simplifies the presentation of deferred income taxes in a classified balance sheet to require that deferred tax liabilities and assets be classified as noncurrent and is effective for annual reporting periods, including interim reporting periods, beginning after December 15, 2016. The Company adopted this ASU effective January 1, 2017. The adoption had no impact on the Company’s consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases, which, for operating leases, requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. This ASU will be effective for the Company in fiscal year 2019. Early adoption is permitted. The Company is currently assessing the potential effects of this ASU on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815) - Contingent Put and Call Options in Debt Instruments.  This ASU clarifies the requirements for assessing whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts.  An entity performing the assessment under the amendments in this Update is required to assess the embedded call (put) options solely in accordance with the four-step decision sequence.  This guidance should be applied on a modified retrospective basis to existing debt instruments as of the beginning of the fiscal year in which the amendments are effective. This ASU is effective beginning January 1, 2017 and the Company assessed that the effects of this ASU had no impact on its consolidated financial statements. In March 2016, the FASB issued ASU No 2016-09, Compensation - Stock Compensation (Topic 718) - Improvements to Employee Share-Based Payment Accounting. This ASU simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. This ASU will be effective for fiscal years beginning after December 15, 2016, including interim periods. The Company adopted this ASU effective January 1, 2017 and elected to account for forfeitures on an estimated basis. The adoption had no impact on the Company’s consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The Company has not yet finalized its preliminary assessment and conclusions on how the adoption of this ASU will affect its current policies related to revenue recognition. The Company expects to adopt the new revenue standard on January 1, 2018, and through the remainder of 2017, will continue to assess the potential impact of adopting this new standard on any current, new or significantly modified customer contracts. In subsequent quarters, the Company will finalize its selection of transition methods and complete its evaluation of additional disclosures that may be required upon adoption of the new standard.</div> <div> Net Loss Per Share Basic net loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period.  Diluted net loss per common share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common share equivalents outstanding during the period. For purposes of this calculation, preferred stock, stock options, restricted stock units and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. For the three-month periods ended March 31, 2017 and 2016, all potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported. Below are listed the potentially dilutive securities outstanding as of March 31, 2017 and 2016:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,470,187</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,793,404</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,658</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">495,274</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,231,659</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,024</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Warrants outstanding as of March 31, 2017 have a weighted-average exercise price of $3.78.</div> <div> The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,639</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,964</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash, current</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash, non-current</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,341</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> Below are listed the potentially dilutive securities outstanding as of March 31, 2017 and 2016:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,470,187</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,793,404</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,658</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">495,274</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,231,659</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,024</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> As of March 31, 2017 and December 31, 2016, financial assets and liabilities measured and recognized at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above were as follows (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,779</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,779</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 1:</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,860</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,860</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,237</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,237</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 2:</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,031</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,007</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury bills</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,033</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,998</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,400</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,400</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,464</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,405</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,480</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,421</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reported as:</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,639</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,405</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, Level 3</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant Liability</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,289</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative Liability</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">622</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,911</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,728</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,728</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 1:</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,236</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,236</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,613</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,613</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 2:</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,969</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,962</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,950</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,950</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,919</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,912</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,260</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,253</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reported as:</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,964</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,912</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, Level 3</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,874</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">602</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,476</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> the estimated fair values of the warrants were determined using Black-Scholes with the following assumptions: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.9%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as changes in warrant and derivative liabilities in the Company's condensed consolidated statements of operations and were as follows for the three-month period ended March 31, 2017 (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.9%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Fair Value <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Warrant Liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Fair Value <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Derivative Liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance of Level 3 Liabilities at December 31, 2016</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,874</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">602</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in estimated fair value of warrant liability</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,936</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to additional paid in capital upon exercise of warrants</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,521</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in estimated fair value of derivative liability</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.9%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance of Level 3 Liabilities at March 31, 2017</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,289</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">622</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> Prepaids and other current assets consisted of the following (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred research and development costs</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,042</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">660</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,660</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,390</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">335</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,037</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,189</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> Property and equipment, net consisted of the following (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,071</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">644</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,989</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,038</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,072</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,072</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction-in-progress</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,751</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,896</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,883</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,650</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,434</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,389</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,449</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,261</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> Accrued liabilities consisted of the following (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical and development expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,394</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,681</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related bonus expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,788</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,941</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,308</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,076</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,490</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,698</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> Future principal debt payments on the currently outstanding term loan are payable as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,167</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,500</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,333</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total principal payments</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Final fee due at maturity in 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total principal and final fee payments</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized discount and debt issuance costs</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,516</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,292</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loan payable, long-term</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,192</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> The following table summarizes stock option activity under the stock plans, excluding the ESPP, and related information:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for grant</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subject to <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">639,374</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,540,293</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.31</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.98</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional shares authorized</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,875,522</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,067,657</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,067,657</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.23</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,585</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.79</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,178</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(83,178</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.61</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs granted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(288,064</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,275</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, March 31, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,265,628</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,470,187</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.90</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> Stock-based compensation expense recognized for stock options granted to employees and non-employee directors in the Company’s condensed consolidated statements of operations was as follows (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,602</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">454</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,090</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">373</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,692</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">827</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> The estimated grant date fair value of employee stock options with time-based vesting terms was calculated using the Black-Scholes valuation model, based on the following assumptions: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80%–81%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0%–2.1%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> The non-employee stock-based compensation expense, during the three-month period ended March 31, 2017, was estimated using Black-Scholes with the following assumptions: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.16%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.48%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.16%;"> Expected term</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;">  </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.51 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.16%;"> Expected volatility</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.34%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.16%;"> Risk-free interest rate</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.34%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.16%;"> Expected dividend yield</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.34%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> </table></div>  </div> <div> A summary of RSU activity is as follows: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSU Awards Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.76%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date Fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Market Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">605,052</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.60</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,878</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.76%;"> RSUs granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288,064</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.90</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.76%;"> RSUs released</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,183</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.11</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.76%; border-bottom:solid 0.75pt transparent;"> RSUs cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,275</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.32</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.76%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, March 31, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,658</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.49</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,201</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> The fair value of awards granted to employees was estimated using Monte-Carlo with the following assumptions: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5–2.0 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.0–6.0 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.66%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> Future minimum lease payments under the operating leases as of March 31, 2017 are as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amounts</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">663</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,353</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,890</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,991</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,098</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,036</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,031</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> 407331 24.55 10000000 10500000 P3Y 3200000 The Global Access will continue in effect until the earlier of 25 years from the closing of the Gates Investment or 7 years following the termination of all funding provided by the Gates Foundation; provided, that the Global Access will continue for any products or services developed with funding provided by the Gates Foundation which continue to be developed or available in certain developing countries. 7475000 13.50 975000 94600000 7999996 1999999 25400000 25100000 3.66 P5Y 150000000 30000000 1105549 4.82 5300000 5100000 132000000 377000 377000 2017-04-14 P5Y 1 4470187 2793404 800658 495274 1231659 30024 3.78 4779000 377000 14860000 15237000 31031000 35033000 46400000 112464000 24000 35000 59000 4779000 377000 14860000 15237000 31007000 34998000 46400000 112405000 37639000 94405000 377000 27289000 622000 27911000 132480000 59000 132421000 3728000 377000 115236000 115613000 12969000 13950000 26919000 7000 7000 3728000 377000 115236000 115613000 12962000 13950000 26912000 118964000 26912000 377000 13874000 602000 14476000 146260000 7000 146253000 0 0 63900000 1000000 602000 20000 622000 1000000 0.13 0.05 37000 2600000 78585 300000 1500000 100000 1400000 0.80 0.80 P4Y2M12D P4Y2M12D 0.018 0.018 0.00 0.00 1500000 13874000 14936000 1521000 27289000 602000 622000 6042000 660000 2660000 1390000 335000 139000 1071000 644000 3989000 4038000 1072000 1072000 6751000 1896000 12883000 7650000 4434000 4389000 2394000 3681000 2788000 4941000 1308000 1076000 6453000 1433000 915000 0 20550000 97402 15.40 1500000 19500000 9750000 20000000 7000000 3 0 27600000 P2Y 15798000 43398000 60410000 103808000 20000000 123808000 7114000 5270000 1500000 4400000 4500000 5000000 5000000 500000 407000 P1Y 349000000 579000000 25000000 2019-08-05 15000000 10000000 0.0699 0.01 P24M 0.04 250000 0.08 356000 4167000 12500000 8333000 25000000 2000000 27000000 -1516000 2000000 700000 400000 24700000 141453 35363 300000 500000 22900000 27300000 11300000 13400000 1425522 909040 P4Y P10Y 1600000 450000 356588 178190 225261 461406 P10Y P4Y 862720 639374 1875522 1067657 0 83178 288064 23275 1265628 3540293 0 1067657 54585 83178 0 0 4470187 6.31 23.23 9.79 6.61 10.31 P7Y11M23D P7Y10M24D 1602000 454000 1090000 373000 2692000 827000 700000 700000 20534000 P3Y4M13D P6Y P6Y 0.73 0.80 0.81 0.014 0.020 0.021 0.00 0.00 0 0 219000 0 P6M4D 0.77 0.009 0.00 288064 21.90 P4Y 8401000 P3Y3M29D 605052 69183 800658 5.60 21.90 5.11 6.32 11.49 7878000 20201000 142200 199750 25800 47425 P6M P3Y P2Y P6Y 0.70 0.70 0.024 0.018 0.00 0.00 P7Y 0.80 P3Y 2020 2024 0.40 0.66 6200000 1500000 4800000 700000 400000 100000 1200 1200 47000 P5Y 2700000 0.035 1800000 5700000 5900000 5900000 900000 663000 2353000 2890000 2991000 3098000 20036000 32031000 211000 146000 0.05 407331 24.55 10000000 3200000 EX-101.SCH 18 akao-20170331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Organization and Basis of Presentation and Consolidation link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Balance Sheet Components link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - License and Collaboration Agreements link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Government Contracts link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Borrowings link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Commitments link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Balance Sheet Components (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Borrowings (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Commitments (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Organization and Basis of Presentation and Consolidation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Outstanding Excluded from the Computations of Diluted Weighted-Average Shares Outstanding (Details) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured and Recognized at Fair Value (Details) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Fair Value Measurements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Fair Value Measurements - Assumptions Used (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Fair Value Measurements - Change in Fair Value of Recurring Measurements (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Balance Sheet Components - Schedule of Prepaids and Other Current Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Balance Sheet Components - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - License and Collaboration Agreements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Government Contracts - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Borrowings - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Borrowings - Future Minimum Debt Obligation Payments (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Borrowings - Future Minimum Debt Obligation Payments (Details)2 link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Stockholders' Equity - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Equity Incentive Plans - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Equity Incentive Plans - Schedule of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Equity Incentive Plans - Schedule of Estimated Grant Date Fair Value of Employee Stock Options Using Black-Scholes Valuation Model (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Equity Incentive Plans - Schedule of Estimated Stock-Based Compensation Expense (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Equity Incentive Plans - Schedule of Estimated Fair Value of Awards Granted to Non-Employees using Monte-Carlo Assumptions (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Commitments - Commercial Manufacturing Agreement (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Commitments - Facilities Lease Obligation (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Commitments - Schedule of Future Minimum Lease Payments (Details) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Subsequent Events - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 19 akao-20170331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 20 akao-20170331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 21 akao-20170331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Warrant liability fair value disclosure. Long-term debt, maturities, payment of final fee. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Warrant liability noncurrent. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term investments Short Term Investments Contracts receivable Accounts Receivable Billed For Long Term Contracts Or Programs Prepaids and other current assets Prepaid Expense And Other Assets Current Restricted cash Restricted Cash And Cash Equivalents At Carrying Value Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Restricted cash Restricted Cash And Cash Equivalents Noncurrent Deposit and other assets Other Assets Noncurrent Total assets Assets Liabilities and stockholders’ equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued liabilities Accrued Liabilities Current Loan payable, current portion Loans Payable Current Other current liabilities Other Liabilities Current Total current liabilities Liabilities Current Loan payable, long-term Long Term Loans Payable Warrant liability Warrant Liability Noncurrent Derivative liability Derivative Liabilities Noncurrent Deferred Rent Deferred Rent Credit Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments And Contingencies Common stock, $0.001 par value, 290,000,000 shares authorized at March 31, 2017 and December 31, 2016; 35,846,301 and 35,638,052 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively Common Stock Value Preferred stock, $0.001 par value, 10,000,000 shares authorized and zero shares issued and outstanding at March 31, 2017 and December 31, 2016 Preferred Stock Value Additional paid-in-capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Common stock, par value (dollars per share) Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Preferred stock, par value (dollars per share) Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Income Statement [Abstract] Contract revenue Revenues Operating expenses Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Interest expense Interest Expense Change in warrant and derivative liabilities Liabilities Fair Value Adjustment Other income, net Other Nonoperating Income Expense Net Loss Net Income Loss Basic and diluted net loss per common share Income Loss From Continuing Operations Per Basic And Diluted Share Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share Weighted Average Number Of Share Outstanding Basic And Diluted Statement Of Income And Comprehensive Income [Abstract] Net Loss Other comprehensive (loss) income: Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Net unrealized gain (loss) on available-for-sale securities Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent Total comprehensive loss Comprehensive Income Net Of Tax Payments of issuance costs, related to underwritten public offering. Cash, cash equivalents and restricted cash period increase decrease. Cash, cash equivalents and restricted cash at carrying value. Adjustments to Additional Paid in Capital, Warrant Liability Reclassification Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation Depletion And Amortization Amortization of premium (discount) on short-term investments Accretion Amortization Of Discounts And Premiums Investments Stock-based compensation expense Allocated Share Based Compensation Expense Change in warrant and derivative liabilities Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease Non-cash interest expense relating to notes payable Interest Expense Debt Change in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Contracts receivable Increase Decrease In Contract Receivables Net Prepaids and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable and accrued liabilities Increase Decrease In Accounts Payable And Accrued Liabilities Other liabilities Increase Decrease In Other Operating Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash flows from investing activities: Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Purchase of property and equipment Payments To Acquire Property Plant And Equipment Purchase of short-term investments Payments To Acquire Short Term Investments Maturities of short-term investments Proceeds From Sale Maturity And Collection Of Shortterm Investments Net cash used in investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Cash flows from financing activities: Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Payments of issuance costs, related to underwritten public offering Payments Of Issuance Costs Related To Underwritten Public Offering Proceeds from the issuance of common stock in connection with equity incentive plans Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options Proceeds from exercise of stock warrants Proceeds From Warrant Exercises Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Net increase (decrease) in cash, cash equivalents, and restricted cash Cash Cash Equivalents And Restricted Cash Period Increase Decrease Cash, cash equivalents, and restricted cash at beginning of period Cash Cash Equivalents And Restricted Cash At Carrying Value Cash, cash equivalents, and restricted cash at end of period Supplemental disclosures of cash flow information Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid Supplemental disclosures of noncash investing and financing information Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Reclassification of warrant liability to additional paid-in capital Adjustments To Additional Paid In Capital Warrant Liability Reclassification Purchases of property plant and equipment included in deferred rent Capital Expenditures Incurred But Not Yet Paid Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization and Basis of Presentation and Consolidation Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Payables And Accruals [Abstract] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Contractors [Abstract] Government Contracts Long Term Contracts Or Programs Disclosure [Text Block] Debt Disclosure [Abstract] Borrowings Debt Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stockholders' Equity Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments Commitments And Contingencies Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Reclassifications Prior Period Reclassification Adjustment Description Basis of Presentation and Consolidation Consolidation Policy [Text Block] Use of Estimates Use Of Estimates Fair Value of Financial Instruments Fair Value Of Financial Instruments Policy Cash and Cash Equivalents Cash And Cash Equivalents Policy [Text Block] Short-term Investments Marketable Securities Policy Restricted Cash Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy Warrant liability. Warrant Liability Warrant Liability Policy [Text Block] Segment Reporting Segment Reporting Policy Policy [Text Block] Customer Concentration Major Customers Policy Policy [Text Block] Concentration of Credit Risk Concentration Risk Credit Risk Revenue Recognition Revenue Recognition Policy [Text Block] Research and Development Costs Research And Development Expense Policy Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Net Loss Per Share Earnings Per Share Policy [Text Block] Schedule of of cash, cash equivalents and restricted cash. Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash Schedule Of Of Cash Cash Equivalents And Restricted Cash Table [Text Block] Schedule of Potentially Dilutive Securities Outstanding Excluded from the Computations of Diluted Weighted-Average Shares Outstanding Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Financial Assets and Liabilities Measured and Recognized at Fair Value Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Schedule of Assumptions Used Schedule Of Assumptions Used Table [Text Block] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Input Reconciliation Table [Text Block] Schedule of Prepaids and Other Current Assets Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block] Schedule of Property and Equipment Property Plant And Equipment [Text Block] Schedule of Accrued Liabilities Schedule Of Accrued Liabilities Table [Text Block] Schedule of Future Minimum Debt Obligation Payments Schedule Of Maturities Of Long Term Debt Table [Text Block] Statement [Table] Statement [Table] Valuation Technique Valuation Technique [Axis] Valuation Technique Valuation Technique [Domain] Black-Scholes. Black Scholes Black Scholes [Member] Monte Carlo Simulation [Member] Monte Carlo Simulation Monte Carlo Simulation [Member] Statement [Line Items] Statement [Line Items] Summary of Stock Option Activity Schedule Of Share Based Compensation Activity Table [Text Block] Schedule of Stock-based Compensation Expense for Stock Options Granted to Employees and Non-employees Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block] Schedule of Estimated Grant Date Fair Value of Employee Stock Options Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Schedule of Share-based Compensation, Restricted Stock Units Award Activity Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block] Schedule of Future Minimum Lease Payments Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block] Research and development awarded grant funding amount. Research and development grant term. Advance amount received for research and development. Effective agreement terms. Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table] Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Private Placement Private Placement [Member] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Redeemable common stock. Redeemable Common Stock Redeemable Common Stock [Member] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Range Range [Axis] Range Range [Member] Maximum Maximum [Member] Underwritten public offering. Underwritten Public Offering Underwritten Public Offering [Member] Common Stock Common Stock [Member] ATM Equity Offering Program. ATM equity offering program A T M Equity Offering Program [Member] Weighted Average Weighted Average [Member] Subsidiary, Sale of Stock [Line Items] Subsidiary Sale Of Stock [Line Items] Shares issued Stock Issued During Period Shares New Issues Share price (dollars per share) Share Price Proceeds from issuance or sale of equity Proceeds From Issuance Or Sale Of Equity Research and development awarded grant funding amount Research And Development Awarded Grant Funding Amount Research term Research And Development Grant Term Advance amount received for research and development Advance Amount Received For Research And Development Effective agreement terms Effective Agreement Terms Additional shares of common stock. Additional shares of common stock Additional Shares Of Common Stock Proceeds from offering net of underwriting discounts and commissions and estimated offering expenses Proceeds From Issuance Of Common Stock Net Proceeds from issuance or sale of equity. Class of Warrant or Right, Contractual Term Number of shares authorized to be purchased Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Aggregate net proceeds from issuance of common stock Net Proceeds From Issuance Or Sale Of Equity Warrants to purchase common stock, exercise price Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Weighted average contractual term Class Of Warrantor Right Contractual Term Proceed from issuance of common stock, gross of issuance costs. Proceeds from issuance of common stock, net of commissions and other costs. Equity instruments, value authorized. Value authorized of equity instruments to be issued Equity Instruments Value Authorized Proceeds from issuance of common stock, gross of issuance costs Proceed From Issuance Of Common Stock Gross Of Issuance Costs Proceeds from sale of stock, net of commissions and other transaction costs Proceeds From Issuance Of Common Stock Net Of Commissions And Other Costs Cash, cash equivalents and short-term investments Cash Cash Equivalents And Short Term Investments Accumulated deficit Summary of significant accounting policies line items. Summary of significant accounting policies table. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Restricted cash Restricted Cash And Cash Equivalents Restricted cash, current Restricted cash, non-current Total cash, cash equivalents, and restricted cash Facility lease expiration date Lease Expiration Date1 Number of operating segments Number Of Operating Segments Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Options to purchase common stock Employee Stock Option [Member] Restricted stock units Restricted Stock Units R S U [Member] Warrants to purchase common stock Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Potentially dilutive securities outstanding (shares) Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Fair Value, Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value Measurements Recurring [Member] Fair Value, Hierarchy Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 Fair Value Inputs Level1 [Member] Level 2 Fair Value Inputs Level2 [Member] Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Cash Cash [Member] Restricted Cash [Member] Restricted cash Restricted Cash [Member] Money market funds Money Market Funds [Member] Corporate debt securities Corporate Debt Securities [Member] Commercial paper Commercial Paper [Member] Cash and cash equivalents Cash And Cash Equivalents [Member] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] U.S. Treasury bills U S Treasury Bill Securities [Member] Short-term investments Short Term Investments [Member] Level 3 Fair Value Inputs Level3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Amortized Cost Available For Sale Securities Amortized Cost Unrealized Gains Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax Unrealized Losses Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Fair Value Available For Sale Securities Warrant Liability Warrant Liability Fair Value Disclosure Derivative Liability Derivative Liabilities Total Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Long-term Debt, Type Longterm Debt Type [Axis] Long-term Debt, Type Longterm Debt Type [Domain] Secured Debt Secured Debt [Member] Financial Instrument Financial Instrument [Axis] Financial Instruments Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] Derivative Derivative [Member] Liability Class Fair Value By Liability Class [Axis] Fair Value by Liability Class Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain] Fair value, derivative liabilities Derivative Financial Instruments Liabilities [Member] Sale of available-for-sale securities Proceeds From Sale Of Available For Sale Securities Unrealized loss position Available For Sale Securities Continuous Unrealized Loss Position Fair Value Debt instrument, success fee. Debt instrument, fair value of success fee. Success fee Debt Instrument Success Fee Fair value of success fee Debt Instrument Fair Value Of Success Fee Change in estimated fair value Derivative liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Potential Payment Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change in Percent Effecting Fair Value of Derivative Liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Effect in Fair Value of Derivative Liability Due to Change in Percent of Approval Probability Potential payment to solar capital Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Value Potential Payment Discount rate, percent Fair Value Inputs Discount Rate Change in percent effecting fair value of derivative liability Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Percent Effecting Fair Value Of Derivative Liability Effect in fair value of derivative liability due to change in percent of FDA approval probability Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Effect In Fair Value Of Derivative Liability Due To Change In Percent Of Approval Probability Warrants to purchase common stock Issuance of derivative in connection with issuance of loan payable Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues Class of warrant or right number of warrants exercised. Estimated fair value of warrants exercised. Exercise of Warrants Class Of Warrant Or Right Number Of Warrants Exercised Estimated fair value of warrants exercised Estimated Fair Value Of Warrants Exercised Increase in estimated fair value of warrants exercised Fair Value Adjustment Of Warrants Expected volatility Fair Value Assumptions Expected Volatility Rate Expected term Fair Value Assumptions Expected Term Risk-free interest rate Fair Value Assumptions Risk Free Interest Rate Dividend yield Fair Value Assumptions Expected Dividend Rate Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Estimated Fair Value, Beginning Balance Reclassification of warrant liability to additional paid in capital upon exercise of warrants Estimated Fair Value, Ending Balance Reclassification of warrant liability to additional paid in capital upon exercise of warrants Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Deferred research and development costs. Prepaid Expense And Other Assets Current [Abstract] Deferred research and development costs Deferred Research And Development Costs Current Prepaid expenses Prepaid Expense Current Other current assets Other Assets Current Prepaids and other current assets Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment, Type Property Plant And Equipment By Type [Axis] Property, Plant and Equipment, Type Property Plant And Equipment Type [Domain] Office equipment Office Equipment [Member] Laboratory equipment Equipment [Member] Leasehold improvements Leasehold Improvements [Member] Construction-in-progress Construction In Progress [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Property, Plant and Equipment, Gross Property Plant And Equipment Gross Less: accumulated depreciation and amortization Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property and equipment, net Accrued Clinical And Development Expenses Accrued clinical and development expenses Accrued Clinical And Development Expenses Payroll and related bonus expenses Employee Related Liabilities Current Other Other Accrued Liabilities Current Accrued liabilities Milestone Payments For First Commercial Product Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Deferred Revenue Arrangement Type Deferred Revenue Arrangement Type [Axis] Deferred Revenue Deferred Revenue Arrangement Type [Domain] Thermo Fisher Scientific, Inc. Thermo Fisher Scientific, Inc Thermo Fisher Scientific Inc [Member] Crystal Biosciences, Inc [Member] Crystal Biosciences, Inc Crystal Biosciences Inc [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Series A Convertible Preferred Stock [Member] Series A Convertible Preferred Stock Series A Convertible Preferred Stock [Member] Isis Pharmaceuticals License Agreement [Member] Ionis Pharmaceuticals License Agreement Isis Pharmaceuticals License Agreement [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others By Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others Type [Domain] Upfront License Fees [Member] Up-front License Fee Upfront License Fees [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Milestone payments for first commercialization product Milestone Payments For First Commercial Product Deferred revenue Deferred Revenue Research and development expense Milestone Payments For Second Commercial Product Aggregate Additional Milestone Payments Shares issued Shares Issued Shares issued price per share (dollars per share) Shares Issued Price Per Share Milestone payments for second commercialization product Milestone Payments For Second Commercial Product Aggregate additional milestone payments Aggregate Additional Milestone Payments Cumulative Milestone Compensation Number of Payments in Relation to License Agreement License payment amount Cumulative milestones compensation Cumulative Milestone Compensation Number of milestones paid in relation to license agreement Number Of Payments In Relation To License Agreement Payments due License Payment Amount Research and development grant and other revenues. Research and development grant, term of agreement for additional funding. Research and development grant, additional contract funding. Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Project Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project [Axis] Project Project [Member] Biomedical Advanced Research And Development Authority [Member] Biomedical Advanced Research and Development Authority Biomedical Advanced Research And Development Authority [Member] National Institute of Allergy and Infectious Diseases [Member] National Institute of Allergy and Infectious Diseases National Institute Of Allergy And Infectious Diseases [Member] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research And Development Arrangement Contract To Perform For Others [Line Items] Research and development contract Research And Development Grant And Other Revenues Term of agreement, in years Research And Development Grant Term Of Agreement For Additional Funding Increase in research and development contract Research And Development Grant Additional Contract Funding Contracts revenue Contracts Revenue Aggregate Research And Development Grant And Other Revenues Aggregate research and development grant and other revenues Aggregate Research And Development Grant And Other Revenues Debt instrument, debt agreement terms, repayment term. Debt instrument, covenant, increase in interest rate in event of default. Debt instrument, final fee. Debt Instrument [Table] Debt Instrument [Table] Debt Instrument [Line Items] Debt Instrument [Line Items] Face amount Debt Instrument Face Amount Debt, maturity date Debt Instrument Maturity Date Proceeds from issuance of loan payable Proceeds From Issuance Of Long Term Debt Interest rate per annum (percent) Debt Instrument Interest Rate Stated Percentage Variable interest rate (percent) Debt Instrument Basis Spread On Variable Rate1 Repayment of debt term (months) Debt Instrument Debt Agreement Terms Repayment Term Increase in interest rate in event of default (percent) Debt Instrument Covenant Increase In Interest Rate In Event Of Default Closing fee Debt Instrument Unused Borrowing Capacity Fee Final fee (percent) Debt Instrument Final Fee 2017 Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year 2018 Long Term Debt Maturities Repayments Of Principal In Year Two 2019 Long Term Debt Maturities Repayments Of Principal In Year Three Total principal payments Final fee due at maturity in 2019 Long Term Debt Maturities Payment Of Final Fee Total principal and final fee payments Debt Instrument Carrying Amount Unamortized discount and debt issuance costs Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net Less current portion Loan payable, long-term Interest expense Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Chief Operating Officer Chief Operating Officer [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Class Of Stock [Line Items] Common Stock, Value Remaining Available to be Sold Value of common stock remaining available to be sold Common Stock Value Remaining Available To Be Sold Payments of stock issuance costs Payments Of Stock Issuance Costs Increase decrease in estimated fair value of remaining warrants outstanding. Estimated fair values of the common stock and warrants issued Stock Issued During Period Value New Issues Remaining warrants outstanding Warrants And Rights Outstanding Change in estimated fair value of remaining warrants outstanding Increase Decrease In Estimated Fair Value Of Remaining Warrants Outstanding Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Stock Incentive Plan Two Thousand Fourteen [Member] 2014 Equity Incentive Award Plan Stock Incentive Plan Two Thousand Fourteen [Member] Two Thousand Fourteen Employment Commencement Incentive Plan [Member] 2014 Employment Commencement Incentive Plan Two Thousand Fourteen Employment Commencement Incentive Plan [Member] Employee Stock Employee Stock [Member] Stock Incentive Plan Two Thousand Three [Member] Stock Incentive Plan 2003 Stock Incentive Plan Two Thousand Three [Member] Award Type Award Type [Axis] Equity Award Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Stock options and restricted stock. Stock Options and Restricted Stock Units Stock Options And Restricted Stock Units [Member] Title of Individual Title Of Individual [Axis] Relationship to Entity Title Of Individual With Relationship To Entity [Domain] Former Chief Medical Officer. Former Chief Medical Officer Former Chief Medical Officer [Member] Non-Employees [Member] Non-Employee Non Employees [Member] Employees. Employees Employees [Member] Employees That Contain Performance Conditions. Employees That Contain Performance Conditions Employees That Contain Performance Conditions [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Additional shares authorized Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized Outstanding shares available for future issuance (shares) Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Option expiration period Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Number of shares authorized (shares) Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Common stock issued (shares) Stock Issued During Period Shares Employee Stock Purchase Plans Shares subject to options outstanding (shares) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised In Period Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Option Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Shares Available For Grant [Abstract] Restricted Stock Units Shares Available for grant Share Based Compensation Arrangement By Share Based Payment Award Options Shares Available For Grant Roll Forward Beginning balance (shares) Additional shares authorized (shares) Options granted (shares) Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period Options exercised (shares) Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised In Period Options cancelled (shares) Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Option Forfeited Shares granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Shares cancelled Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Ending balance (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Additional Options Authorized Shares Subject to Options Outstanding Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward Beginning balance (shares) Additional shares authorized (shares) Share Based Compensation Arrangement By Share Based Payment Award Options Number Of Additional Options Authorized Options granted (shares) Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Options exercised (shares) Stock Issued During Period Shares Stock Options Exercised Options cancelled (shares) Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Ending balance (shares) Weighted- Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward Beginning balance (shares) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Options granted (shares) Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Options exercised (shares) Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Options cancelled (shares) Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Ending balance (shares) Weighted- Average Remaining Contractual Term (years) Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Stock options granted to employees and non-employee directors . Stock Options Granted To Employees And Non Employee Directors Stock Options Granted To Employees And Non Employee Directors [Member] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and development Research And Development Expense [Member] General and administrative General And Administrative Expense [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Stock-based compensation expense Allocated share based compensation expense related to stock option and restricted stock unit modifications. Stock-based compensation expense related to stock option and restricted units modification Allocated Share Based Compensation Expense Related To Stock Option And Restricted Stock Unit Modifications Unrecognized stock-based compensation Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Weighted-average period of cost expected to be recognized Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Schedule Of Deferred Compensation Arrangement With Individual Excluding Share Based Payments And Postretirement Benefits By Title Of Individual And By Type Of Deferred Compensation [Table] Schedule Of Deferred Compensation Arrangement With Individual Excluding Share Based Payments And Postretirement Benefits By Title Of Individual And By Type Of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] Deferred Compensation Arrangement With Individual Excluding Share Based Payments And Postretirement Benefits [Line Items] Expected term Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Expected volatility, minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum Expected volatility, maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum Risk-free interest rate Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate Risk-free interest rate, minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum Risk-free interest rate, maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum Expected dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Shares granted Weighted-average grant date fair market value, shares granted (dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Unrecognized compensation costs Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options Number of Shares Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Roll Forward Beginning balance (shares) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Shares released Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Shares cancelled Ending balance (shares) Weighted-Average Grant Date Fair Market Value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Roll Forward Beginning balance (dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Shares released (dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Shares canceled (dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value Ending balance (dollars per share) Aggregate Intrinsic Value (in thousands) Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value [Abstract] RSU Awards Outstanding, aggregate intrinsic value Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding Minimum Minimum [Member] Loss Contingencies [Table] Loss Contingencies [Table] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Hovione limited. Hovione Limited Hovione Limited [Member] Raw material agreement. Raw Material Agreement Raw Material Agreement [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Commercial manufacturing agreement initial term Longterm Purchase Commitment Period Percentage of long term purchase commitment minimum required quantity. Number of years for purchase commitment percentage. Percentage of long term purchase commitment. Annual purchase commitments beginning year. Annual purchase commitments ending year. Percentage of long term purchase commitment minimum required quantity Percentage Of Long Term Purchase Commitment Minimum Required Quantity Number of years for minimum supply percentage after approval Number Of Years For Purchase Commitment Percentage Minimum annual purchase commitments beginning year Annual Purchase Commitments Beginning Year Annual purchase commitments ending Year Annual Purchase Commitments Ending Year Percentage of long term purchase commitment Percentage Of Long Term Purchase Commitment Advance payments Long Term Purchase Commitment Amount Prepaid and other current assets Lessor Leasing Arrangements, Operating Leases, Rental Increase, Percent Operating Lease, Lease Abatement, Next Twelve Months Schedule Of Operating Leased Assets [Table] Schedule Of Operating Leased Assets [Table] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Square feet of office, laboratory and research and development space (sq feet) Area Of Real Estate Property Expansion option (in years) Lessor Leasing Arrangements Operating Leases Renewal Term First year base rent Operating Leases Rent Expense Minimum Rentals Lessor Leasing Arrangements, Operating Leases, Rental Increase, Percent Lessor Leasing Arrangements Operating Leases Rental Increase Percent One time, first year rent abatement Operating Lease Lease Abatement Next Twelve Months Operating Lease, Allowance for Tenant Improvements Operating Lease, Additional Allowance for Tenant Improvements Tenant improvements liabilities. One time improvement allowance Operating Lease Allowance For Tenant Improvements Tenant Improvements Liabilities Tenant Improvements Liabilities Additional allowance Operating Lease Additional Allowance For Tenant Improvements Year Ending December 31, Operating Leases Future Minimum Payments Due [Abstract] 2017 Operating Leases Future Minimum Payments Due Current 2018 Operating Leases Future Minimum Payments Due In Two Years 2019 Operating Leases Future Minimum Payments Due In Three Years 2020 Operating Leases Future Minimum Payments Due In Four Years 2021 Operating Leases Future Minimum Payments Due In Five Years Thereafter Operating Leases Future Minimum Payments Due Thereafter Total minimum lease payments Operating Leases Future Minimum Payments Due Rent expense Operating Leases Rent Expense Net Percentage of purchase price compounded annual interest. Subsequent Event [Table] Subsequent Event [Table] Subsequent Event [Line Items] Subsequent Event [Line Items] Percentage of purchase price compounded annual interest Percentage Of Purchase Price Compound Annual Interest Received an advance payment for research and development. Amount received on advance payment of research agreement Received Advance Payment For Research And Development EX-101.PRE 22 akao-20170331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 23 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1

Document and Entity Information - shares
3 Months Ended

Mar. 31, 2017

May 03, 2017

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Mar. 31, 2017

Document Fiscal Year Focus 2017

Document Fiscal Period Focus Q1

Trading Symbol AKAO

Entity Registrant Name Achaogen Inc

Entity Central Index Key 0001301501

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 35,853,669

XML 24 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 37,639,000	$ 118,964,000
Short-term investments	94,405,000	26,912,000
Contracts receivable	5,866,000	12,151,000
Prepaids and other current assets	9,037,000	2,189,000
Restricted cash	127,000	127,000
Total current assets	147,074,000	160,343,000
Property and equipment, net	8,449,000	3,261,000
Restricted cash	250,000	250,000
Deposit and other assets	33,000	71,000
Total assets	155,806,000	163,925,000
Current liabilities:
Accounts payable	11,585,000	5,739,000
Accrued liabilities	6,490,000	9,698,000
Loan payable, current portion	7,292,000	4,167,000
Other current liabilities	45,000	104,000
Total current liabilities	25,412,000	19,708,000
Loan payable, long-term	18,192,000	21,110,000
Warrant liability	27,289,000	13,874,000
Derivative liability	622,000	602,000
Deferred Rent	5,654,000	1,896,000
Total liabilities	77,169,000	57,190,000
Commitments and contingencies
Common stock, $0.001 par value, 290,000,000 shares authorized at March 31, 2017 and December 31, 2016; 35,846,301 and 35,638,052 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively	36,000	35,000
Preferred stock, $0.001 par value, 10,000,000 shares authorized and zero shares issued and outstanding at March 31, 2017 and December 31, 2016	0	0
Additional paid-in-capital	359,139,000	353,927,000
Accumulated deficit	(280,479,000)	(247,220,000)
Accumulated other comprehensive loss	(59,000)	(7,000)
Total stockholders’ equity	78,637,000	106,735,000
Total liabilities and stockholders’ equity	$ 155,806,000	$ 163,925,000

XML 25 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Common stock, par value (dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	290,000,000	290,000,000
Common stock, shares issued	35,846,301	35,638,052
Common stock, shares outstanding	35,846,301	35,638,052
Preferred stock, par value (dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

XML 26 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Contract revenue	$ 7,463	$ 5,849
Operating expenses
Research and development	18,597	13,893
General and administrative	6,751	3,777
Total operating expenses	25,348	17,670
Loss from operations	(17,885)	(11,821)
Interest expense	(706)	(438)
Change in warrant and derivative liabilities	(14,956)	(12)
Other income, net	288	74
Net Loss	$ (33,259)	$ (12,197)
Basic and diluted net loss per common share	$ (0.93)	$ (0.66)
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share	35,725,876	18,398,288

XML 27 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net Loss	$ (33,259)	$ (12,197)
Other comprehensive (loss) income:
Net unrealized gain (loss) on available-for-sale securities	(52)	55
Total comprehensive loss	$ (33,311)	$ (12,142)

XML 28 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net loss	$ (33,259)	$ (12,197)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	113	121
Amortization of premium (discount) on short-term investments	(42)	160
Stock-based compensation expense	2,911	827
Change in warrant and derivative liabilities	14,956	12
Non-cash interest expense relating to notes payable	207	135
Change in operating assets and liabilities:
Contracts receivable	6,285	(27)
Prepaids and other assets	(6,810)	(1,390)
Accounts payable and accrued liabilities	2,316	3,544
Other liabilities	(95)	(51)
Net cash used in operating activities	(13,418)	(8,866)
Cash flows from investing activities:
Purchase of property and equipment	(1,185)	(269)
Purchase of short-term investments	(86,759)
Maturities of short-term investments	19,256	8,280
Net cash used in investing activities	(68,688)	8,011
Cash flows from financing activities:
Payments of issuance costs, related to underwritten public offering	(42)
Proceeds from the issuance of common stock in connection with equity incentive plans	535
Proceeds from exercise of stock warrants	288
Net cash provided by financing activities	781
Net increase (decrease) in cash, cash equivalents, and restricted cash	(81,325)	(855)
Cash, cash equivalents, and restricted cash at beginning of period	119,341	20,414
Cash, cash equivalents, and restricted cash at end of period	38,016	19,559
Supplemental disclosures of cash flow information
Interest paid	499	$ 303
Supplemental disclosures of noncash investing and financing information
Reclassification of warrant liability to additional paid-in capital	1,521
Purchases of property plant and equipment included in deferred rent	$ 3,794

XML 29 R7.htm IDEA: XBRL DOCUMENT

Organization and Basis of Presentation and Consolidation	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Basis of Presentation and Consolidation	1. Organization and Basis of Presentation and Consolidation Achaogen, Inc. (together with its consolidated subsidiary, the “Company”) is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterial treatments against multi-drug resistant gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of bacterial infections due to multi-drug resistant Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (“CRE”). The Company’s Phase 3 study of plazomicin in the treatment of patients with complicated urinary tract infections (“cUTI”) and acute pyelonephritis (“AP”), entitled EPIC (Evaluating Plazomicin In cUTI), is expected to serve as a single pivotal study supporting a new drug application (“NDA”) for plazomicin in the United States. In addition, the Company’s Phase 3 study of plazomicin, the CARE (Combating Antibiotic Resistant Enterobacteriaceae) trial, which is a resistant pathogen-specific trial designed to evaluate the efficacy and safety of plazomicin in patients with infections due to CRE. The Company was incorporated in Delaware in 2002 and commenced operations in 2004. Since commencing operations in 2004, the Company has devoted substantially all its resources to identifying and developing its product candidates, including conducting preclinical studies and clinical trials and providing general and administrative support for these operations. Reclassifications The change in derivative liability for the three-month period ended March 31, 2016 has been reclassified to be included in the change in warrant and derivative liabilities to conform to the current year’s presentation. Such reclassifications did not impact the Company’s net loss or financial position. Basis of Presentation and Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and following the requirements of the Securities and Exchange Commission (the “SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company’s financial information. The results of operations for the three-month period ended March 31, 2017 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December 31, 2016 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. Intercompany accounts and transactions have been eliminated upon consolidation. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K. In May 2017, the Company entered into an agreement with the Bill & Melinda Gates Foundation (the “Gates Foundation”) to discover drug candidates against gram-negative pathogens intended to prevent neonatal sepsis (the “Grant Agreement”). Pursuant to the Grant Agreement, the Gates Foundation awarded the Company up to approximately $10.5 million in grant funding over a three-year research term, of which approximately $3.2 million will be advanced to the Company within 15 days after signing (the “Advance Funds”). Concurrently with the Grant Agreement, the Company entered into a Common Stock Purchase Agreement with the Gates Foundation, pursuant to which the Company agreed to sell 407,331 shares of its redeemable common stock to the Gates Foundation in a private placement at a purchase price per share equal to $24.55, for gross proceeds to the Company of $10.0 million (“Gates Investment”). In connection with the Grant Agreement and the Gates Investment, the Company entered into a strategic relationship with the Gates Foundation (the “Letter Agreement”). Under the terms of the Letter Agreement, the Gates Investment and Advanced Funds may only be used to conduct mutually agreed upon work, including the scale up of the Company’s platform technology to launch a product intended to prevent neonatal sepsis (the “NSP”). Pursuant to the Letter Agreement, the Company agreed to make the NSP available and accessible in certain developing countries and to grant the Gates Foundation a non-exclusive license to commercialize selected drug candidates in specified developing countries, which may only be exercised in the event of certain defaults as described in the Letter Agreement (the “Global Access”). The Global Access will continue in effect until the earlier of 25 years from the closing of the Gates Investment or 7 years following the termination of all funding provided by the Gates Foundation; provided, that the Global Access will continue for any products or services developed with funding provided by the Gates Foundation which continue to be developed or available in certain developing countries. On December 19, 2016, the Company completed an underwritten public offering of common stock made under a prospectus supplement and related prospectus pursuant to a Registration Statement on Form S-3 (File No. 333-203282) filed on April 7, 2015 (the “Shelf Registration Statement”). This offering resulted in the sale of 7,475,000 shares, at a price to the public of $13.50 per share, including the full exercise of the underwriters’ option to purchase an additional 975,000 shares of common stock. The Company received net proceeds from the offering of $94.6 million, after deducting the underwriting discounts and commissions and estimated offering expenses. On June 3, 2016, the Company sold 7,999,996 shares of its common stock and warrants to purchase 1,999,999 shares of its common stock pursuant to Securities Purchase Agreement (the "Purchase Agreement") for aggregate gross proceeds of $25.4 million and aggregate net proceeds of $25.1 million, after deducting the issuance costs, in connection with a private placement financing transaction (the "Private Placement"). The warrants have an exercise price of $3.66 per share and are exercisable up to five years from the date of issuance. On April 7, 2015, the Company filed the Shelf Registration Statement, declared effective by the SEC on April 21, 2015, covering the offering of up to $150.0 million of common stock, preferred stock, debt securities, warrants, purchase contracts and/or units. The Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $30.0 million of shares of our common stock from time to time in an "at-the-market" ("ATM") equity offering pursuant to a sales agreement with Cowen and Company, LLC. As of March 31, 2017, the Company had sold 1,105,549 shares pursuant to its ATM equity offering program at a weighted-average price of $4.82 per share for aggregate offering proceeds of $5.3 million and aggregate net proceeds of $5.1 million, after deducting the sales commissions and offering expenses. The Company has incurred losses and negative cash flows from operations every year since its inception. As of March 31, 2017, the Company had unrestricted cash, cash equivalents and short-term investments of approximately $132.0 million and an accumulated deficit of approximately $280.5 million. Management expects that, based on its current operating plans, the Company’s existing cash, cash equivalents and short-term investments as of March 31, 2017 will be sufficient to fund its current planned operations for at least the next twelve months from the issuance of these financial statements. Management plans to raise additional funds through equity or debt financing arrangements, government contracts, and/or third party collaboration funding in the future to fund its operations, including the commercial launch of plazomicin. However, there can be no assurance that such funding sources will be available at terms acceptable to the Company or at all. If the Company is unable to raise additional funding to meet its working capital needs, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.

XML 30 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Use of Estimates

Fair Value of Financial Instruments

Cash and Cash Equivalents

Short-term Investments

The Company reviews all of its marketable securities on a regular basis to evaluate whether any security has experienced an other-than-temporary decline in fair value.

Restricted Cash

	March 31, 2017		December 31, 2016
Cash and cash equivalents	$	37,639	$	118,964
Restricted cash, current		127		127
Restricted cash, non-current		250		250
Total cash, cash equivalents, and restricted cash	$	38,016	$	119,341

Warrant Liability

Segment Reporting

Customer Concentration

Concentration of Credit Risk

Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash, cash equivalents and short-term investments. Cash and cash equivalents are deposited in checking and money market accounts at one financial institution with balances that generally exceed federally insured limits. Management believes that the financial institution is financially sound, and, accordingly, minimal credit risk exists with respect to this financial institution. The Company’s investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of default by the institutions holding its cash and cash equivalents or issuing the debt securities. As of March 31, 2017 and December 31, 2016, the Company had not experienced any credit losses in such accounts or investments.

Revenue Recognition

Research and Development Costs

Recent Accounting Pronouncements

Net Loss Per Share

	March 31,
	2017		2016
Options to purchase common stock		4,470,187		2,793,404
Restricted stock units		800,658		495,274
Warrants to purchase common stock		1,231,659		30,024

Warrants outstanding as of March 31, 2017 have a weighted-average exercise price of $3.78.

XML 31 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

3. Fair Value Measurements

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

	March 31, 2017
	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Assets
Cash	$	4,779	$	—	$	—		$	4,779
Level 1:
Restricted cash		377		—		—			377
Money market funds		14,860		—		—			14,860
Subtotal		15,237		—		—			15,237
Level 2:
Corporate debt securities		31,031		—		(24	)		31,007
U.S. Treasury bills		35,033		—		(35	)		34,998
Commercial paper		46,400		—		—			46,400
Subtotal		112,464		—		(59	)		112,405
Total	$	132,480	$	—	$	(59	)	$	132,421
Reported as:
Cash and cash equivalents								$	37,639
Short-term investments								$	94,405
Restricted cash								$	377

Liabilities, Level 3
Warrant Liability								$	27,289
Derivative Liability								$	622
Total								$	27,911

	December 31, 2016
	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Assets
Cash	$	3,728	$	—	$	—		$	3,728
Level 1:
Restricted cash		377		—		—			377
Money market funds		115,236		—		—			115,236
Subtotal		115,613		—		—			115,613
Level 2:
Corporate debt securities		12,969		—		(7	)		12,962
Commercial paper		13,950		—		—			13,950
Subtotal		26,919		—		(7	)		26,912
Total	$	146,260	$	—	$	(7	)	$	146,253
Reported as:
Cash and cash equivalents								$	118,964
Short-term investments								$	26,912
Restricted cash								$	377

Liabilities, Level 3
Warrant liability								$	13,874
Derivative liability								$	602
Total								$	14,476

	March 31, 2017		December 31, 2016
Expected volatility		80%		80%
Expected term	4.2 years		4.2 years
Risk-free interest rate		1.8%		1.8%
Dividend yield		—%		—%

	Estimated Fair Value of Warrant Liability			Estimated Fair Value of Derivative Liability
Balance of Level 3 Liabilities at December 31, 2016	$	13,874		$	602
Change in estimated fair value of warrant liability		14,936		—
Reclassification of warrant liability to additional paid in capital upon exercise of warrants		(1,521	)	—
Change in estimated fair value of derivative liability	—				20
Balance of Level 3 Liabilities at March 31, 2017	$	27,289		$	622

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 32 R10.htm IDEA: XBRL DOCUMENT

Balance Sheet Components

3 Months Ended

Mar. 31, 2017

Payables And Accruals [Abstract]

Balance Sheet Components

4. Balance Sheet Components

Prepaids and other current assets

Prepaids and other current assets consisted of the following (in thousands):

	March 31, 2017		December 31, 2016
Deferred research and development costs	$	6,042	$	660
Prepaid expenses		2,660		1,390
Other current assets		335		139
	$	9,037	$	2,189

Property and Equipment, net

Property and equipment, net consisted of the following (in thousands):

	March 31, 2017			December 31, 2016
Office equipment	$	1,071		$	644
Laboratory equipment		3,989			4,038
Leasehold improvements		1,072			1,072
Construction-in-progress		6,751			1,896
		12,883			7,650
Less: accumulated depreciation and amortization		(4,434	)		(4,389	)
Property and equipment, net	$	8,449		$	3,261

Depreciation and amortization expense for the three-month periods ended March 31, 2017 and 2016 was $113,000 and $121,000, respectively.

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	March 31, 2017		December 31, 2016
Accrued clinical and development expenses	$	2,394	$	3,681
Payroll and related bonus expenses		2,788		4,941
Other		1,308		1,076
	$	6,490	$	9,698

XML 33 R11.htm IDEA: XBRL DOCUMENT

License and Collaboration Agreements	3 Months Ended
License and Collaboration Agreements	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
License and Collaboration Agreements	5. License and Collaboration Agreements Thermo Fisher Scientific, Inc. In April 2016, the Company entered into an agreement with its collaboration partner, Microgenics Corporation (“Thermo Fisher”), a wholly owned subsidiary of Thermo Fisher Scientific, Inc., to develop and commercialize an assay to support plazomicin. If approved, the Company and Thermo Fisher plan to have a commercial assay for plazomicin available at launch to enable health care professionals to make decisions on safe and efficacious doses of plazomicin. In accordance with the terms of the agreement, the Company is required to make milestone payments with respect to research, development, regulatory and commercialization milestones (if any). All such milestone payments may total, in aggregate, up to but no more than $6,453,000. In further consideration of this agreement, in the event of a successful commercialization of the assay, the Company is required to pay a minimum threshold annual revenue to Thermo Fisher. As of March 31, 2017, the Company has incurred $1,433,000 in milestone payments and the cost was fully recorded as research and development expense. The Company recorded $915,000 and zero of research and development expense during the three-month periods ending March 31, 2017 and 2016, respectively, under this agreement. In February 2017, the Company announced the achievement of a strategic milestone in its ongoing collaboration to develop an assay enabling therapeutic drug management of plazomicin. Crystal Biosciences, Inc. In May 2016, the Company entered into a collaboration and license agreement with Crystal Biosciences, Inc. (“Crystal”). Pursuant to the terms of this agreement, the Company and Crystal agreed to collaborate on the discovery of monoclonal antibodies against multiple targets. Crystal agreed to conduct the initial discovery work with its antibody platform and the Company has the right to develop and commercialize the antibodies discovered through this collaboration. The Company is required to provide signing and milestone payments with respect to research, development, regulatory and commercialization milestones (if any). All such milestone payments may total, in aggregate, up to but no more than $20,550,000. The upfront signing fee, technology access fees and research funding were recorded as research and development expense. This collaboration and license agreement also provides that the Company shall pay royalties equal to a low single-digit percentage of annual worldwide net sales of the commercialized product. Ionis Pharmaceuticals In January 2006, the Company entered into a license agreement with Ionis Pharmaceuticals, Inc. (“Ionis”). Ionis granted the Company an exclusive, worldwide license with the right to grant and authorize sublicenses related to the research and development of aminoglycoside products. As an up-front fee, the Company issued 97,402 shares of Series A convertible preferred stock at a fair value of $15.40 per share. This license fee of $1,500,000 was recorded as research and development expense in 2006. In further consideration of this license, and in accordance with the terms of the agreement, the Company is required to make milestone payments with respect to development, regulatory and commercialization milestones, and to pay a percentage of revenue received from sublicensees (if any). All such milestone and sublicense revenue payments may total, in the aggregate, up to but no more than $19,500,000 for the first product and $9,750,000 following the second product commercialized under the agreement with Ionis. The Company is also required to pay additional milestone payments of up to $20,000,000 in the aggregate upon the first achievement of specified threshold levels of annual net sales of all aminoglycoside products in a calendar year. The license agreement also provides that the Company shall pay royalties equal to a low single-digit percentage of annual worldwide net sales of all licensed products, including, if applicable, plazomicin. Through March 31, 2017, the Company had compensated Ionis $7,000,000 in connection with the first three milestones under the license for the first aminoglycoside product candidate. As of March 31, 2017, the Company had no outstanding payments due under the agreement.

XML 34 R12.htm IDEA: XBRL DOCUMENT

Government Contracts	3 Months Ended
Government Contracts	Mar. 31, 2017
Contractors [Abstract]
Government Contracts	6. Government Contracts Certain of the Company’s drug discovery and development activities are performed under contracts with U.S. government agencies. Management has determined that the Company is the principal participant in the following contract arrangements, and, accordingly, the Company records amounts earned under the arrangements as revenue. Costs incurred under revenue contracts are recorded as operating expenses in the Company's consolidated statements of operations. Biomedical Advanced Research and Development Authority In August 2010, the Company was awarded a contract with the Biomedical Advanced Research and Development Authority (“BARDA”) for the development, manufacturing, nonclinical and clinical evaluation of, and regulatory filings for, plazomicin as a countermeasure for disease caused by antibiotic-resistant pathogens and biothreats. The original contract included committed funding of $27,600,000 for the first two years of the contract and subsequent options exercisable by BARDA to provide additional funding. In September 2012, BARDA exercised an additional $15,798,000 contract option ("Option 1"), which increased the total contract committed funding to $43,398,000 through March 2014. In April 2013, the Company was awarded an additional $60,410,000 under the contract to support its Phase 3 clinical trial of plazomicin ("Option 2") to increase the total committed funding under this contract to $103,808,000. On May 26, 2016, the Company was awarded an additional $20 million ("Option 3") under the contract to support its Phase 3 EPIC trial of plazomicin. This brings the total committed funding under the contract to $123,808,000. The Company recorded contract revenue of $7,114,000 and $5,270,000 under this agreement during the three-month periods ended March 31, 2017 and 2016, respectively. National Institute of Allergy and Infectious Diseases In July 2015, the Company was awarded a contract by the National Institute of Allergy and Infectious Diseases ("NIAID") for $1.5 million committed through June 30, 2016, with total funding of up to $4.5 million available if all options are exercised under the contract. In January 2016, an additional committed funding of $0.5 million was added to the awarded funding and the total potential funding was increased to $5.0 million. In April 2016, NIAID modified the contract to exercise an option which increased the total contract committed funding to $4.4 million through February 2018, with total potential funding remaining at $5.0 million if the remaining option is exercised. In July 2014, the Company was awarded a one-year, $407,000 grant by NIAID to conduct discovery research on novel antibiotics targeting gram-negative bacteria. In July 2015, NIAID extended the grant term through July 31, 2016. The Company recorded contract revenue of $349,000 and $579,000 under these agreements during the three-month periods ended March 31, 2017 and 2016, respectively.

XML 35 R13.htm IDEA: XBRL DOCUMENT

Borrowings

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Borrowings

7. Borrowings

Solar Capital Ltd. Loan Agreement

On August 5, 2015, the Company entered into a loan and security agreement (the “Loan Agreement”) with Solar Capital Ltd. (the “Lender”) pursuant to which the Lender agreed to make available to the Company term loans in an aggregate principal amount of up to $25.0 million with a maturity date of August 5, 2019. An initial $15.0 million term loan was funded at closing on August 5, 2015, and a second $10.0 million term loan was funded on June 20, 2016. Borrowings under the term loans bear interest per annum at 6.99% plus the greater of 1% or the one-month LIBOR. The Company is currently required to make interest-only payments on the term loans through August 2017, and beginning on September 1, 2017 the Company is required to make monthly payments of interest plus equal monthly payments of principal over a term of 24 months. The Loan Agreement requires collateral by a security interest in all of the Company’s assets except intellectual property (which is subject to a negative pledge) and contains customary affirmative and negative covenants, and also includes standard events of default, including payment defaults. Upon the occurrence of an event of default, a default interest rate of an additional 4% may be applied to the outstanding loan balances, and the Lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. There were no financial covenants attached to the loan. The Loan Agreement included a closing fee of $250,000 which was paid at closing, and the Company is obligated to pay a fee equal to 8% of the term loans funded upon the earliest to occur of the maturity date, the acceleration of the term loans or the voluntary prepayment of the term loans. The cost of these fees is being amortized as interest expense over the term of the loan using the effective-interest method. The Company may voluntarily prepay all, but not less than all, of the outstanding term loans. The Loan Agreement contains customary representations, warranties and covenants. In addition, the Loan Agreement contains customary events of default that entitle the Lender to cause the Company’s indebtedness under the Loan Agreement to become immediately due and payable.

Future principal debt payments on the currently outstanding term loan are payable as follows (in thousands):

	March 31, 2017
2017	$	4,167
2018		12,500
2019		8,333
Total principal payments		25,000
Final fee due at maturity in 2019		2,000
Total principal and final fee payments		27,000
Unamortized discount and debt issuance costs		(1,516	)
Less current portion		(7,292	)
Loan payable, long-term	$	18,192

XML 36 R14.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Mar. 31, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stockholders' Equity

8. Stockholders' Equity

Equity Incentive Plans

2014 Equity Incentive Award Plan

2014 Employment Commencement Incentive Plan

2014 Employee Stock Purchase Plan

Amended and Restated 2003 Stock Plan

The following table summarizes stock option activity under the stock plans, excluding the ESPP, and related information:

	Shares Available for grant			Shares Subject to Options Outstanding			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (years)
Balance, December 31, 2016		639,374			3,540,293		$	6.31		7.98
Additional shares authorized		1,875,522			—
Options granted		(1,067,657	)		1,067,657		$	23.23
Options exercised		—			(54,585	)	$	9.79
Options cancelled		83,178			(83,178	)	$	6.61
RSUs granted		(288,064	)		—
RSUs cancelled		23,275			—
Balance, March 31, 2017		1,265,628			4,470,187		$	10.31		7.90

	Three Months Ended March 31,
	2017		2016
Research and development	$	1,602	$	454
General and administrative		1,090		373
Total	$	2,692	$	827

The estimated grant date fair value of employee stock options with time-based vesting terms was calculated using the Black-Scholes valuation model, based on the following assumptions:

	Three Months Ended March 31,
	2017		2016
Expected term	6.0 years		6.0 years
Expected volatility	80%–81%			73%
Risk-free interest rate	2.0%–2.1%			1.4%
Expected dividend yield		—%		—%

Stock Options Granted to Non-Employees

	Three Months Ended March 31,
	2017
Expected term	0.51 years
Expected volatility		77%
Risk-free interest rate		0.9%
Expected dividend yield		—%

Restricted Stock Units Granted to Employees

A summary of RSU activity is as follows:

	RSU Awards Outstanding
	Number of Shares			Weighted-Average Grant Date Fair Market Value		Aggregate Intrinsic Value (in thousands)
Balance, December 31, 2016		605,052		$	5.60	$	7,878
RSUs granted		288,064		$	21.90
RSUs released		(69,183	)	$	5.11
RSUs cancelled		(23,275	)	$	6.32
Balance, March 31, 2017		800,658		$	11.49	$	20,201

Stock Options and Restricted Stock Units Granted to Employees that Contain Performance Conditions

	Three Months Ended March 31,
	2017		2016
Expected term	0.5–2.0 years		3.0–6.0 years
Expected volatility	70%			70%
Risk-free interest rate		2.4%		1.8%
Expected dividend yield		—%		—%

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 37 R15.htm IDEA: XBRL DOCUMENT

Commitments

3 Months Ended

Mar. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Commitments

9. Commitments

Commercial Manufacturing Agreement

In connection with the Manufacturing Agreement, the Company executed certain work plans to carry out the validation and commercial manufacturing of plazomicin (the “Work Plans”). The Work Plans obligate the Company to make an aggregate amount of approximately $6.2 million in nonrefundable advance payments, of which $1.5 million was for the reservation of facilities and resources, plus procurement of long lead raw materials, paid in full under a separate agreement executed in July 2015. Such advance payments are initially capitalized as prepaid and other current assets and will be recognized as research and development expenses as goods are delivered and/or services are performed. The Company assesses such prepaid and other current assets for impairment if events or changes in circumstances indicate that the carrying amount may not be recoverable or may not provide future economic benefits. Further, the Work Plans include certain terms that require the Company to compensate Hovione if it chooses to cancel the Work Plans (“Cancellation Clause”). As of March 31, 2017, $9.8 million is committed under the Cancellation Clause and the total aggregate amount of potential commitments, if all the services are rendered by Hovione, is approximately $28.1 million. As of March 31, 2017 and December 31, 2016, the Company has recorded approximately $4.8 million and $0.7 million, respectively as prepaid and other current assets and, during the three-month periods ended March 31, 2017 and 2016, has recognized $0.4 million and $0.1 million, respectively, as research and development expenses, related to the Work Plans.

Facilities Lease Obligation

Future minimum lease payments under the operating leases as of March 31, 2017 are as follows (in thousands):

Year Ending December 31,	Amounts
2017	$	663
2018		2,353
2019		2,890
2020		2,991
2021		3,098
Thereafter		20,036
Total minimum lease payments	$	32,031

XML 38 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events In May 2017, the Company entered into an agreement with the Bill & Melinda Gates Foundation (the “Gates Foundation”) to discover drug candidates against gram-negative pathogens intended to prevent neonatal sepsis (the “Grant Agreement”). Pursuant to the Grant Agreement, the Gates Foundation awarded the Company up to approximately $10.5 million in grant funding over a three-year research term, of which approximately $3.2 million will be advanced to the Company within 15 days after signing (the “Advance Funds”). The Advance Funds are replenished by the Gates Foundation each calendar year, or sooner, following the Company’s submission of a progress report, including expenses incurred for the research activities. Under certain conditions, as described in the Grant Agreement, the Gates Foundation may terminate the Grant Agreement and the Company is obligated to return to the Gates Foundation any unused portion of the Advance Funds. Concurrently with the Grant Agreement, the Company entered into a Common Stock Purchase Agreement with the Gates Foundation, pursuant to which the Company agreed to sell 407,331 shares of its redeemable common stock (the “Shares”) to the Gates Foundation in a private placement at a purchase price per share equal to $24.55, for gross proceeds to the Company of $10.0 million (“Gates Investment”). In connection with the Grant Agreement and the Gates Investment, the Company entered into a strategic relationship with the Gates Foundation (the “Letter Agreement”). Under the terms of the Letter Agreement, the Advanced Funds and the Gates Investment may only be used to conduct mutually agreed upon work, including the scale up of the Company’s platform technology to launch a product intended to prevent neonatal sepsis (the “NSP”). If the Company defaults in its obligation to conduct certain mutually-agreed upon work or use the proceeds from the Gates Investment as described in the Letter Agreement, or otherwise triggers certain other events of default as described in the Letter Agreement (“Charitable Default”), subject to a cure period, the Gates Foundation will have the right to request that (a) the Company redeem, or facilitate the purchase by a third party of, the Shares then held by the Gates Foundation at a price per share equal to the greater of (i) the fair market value of the common stock (if the Shares are freely tradable, the closing price of the Company’s common stock on the trading day prior to the redemption or purchase, as applicable), or (ii) an amount equal to $24.55 plus a compounded annual return of 5% from the date of issuance of the Shares, or (b) if the Shares then held by the Gates Foundation are not freely tradeable, the Company register the resale of the Shares held by the Gates Foundation on an effective registration statement, subject to certain conditions and qualifications. Pursuant to the Letter Agreement, the Company agreed to make the NSP available and accessible in certain developing countries and to grant the Gates Foundation a non-exclusive license to commercialize selected drug candidates in specified developing countries, which may only be exercised in the event of a Charitable Default (the “Global Access”). The Global Access will continue in effect until the earlier of 25 years from the closing of the Gates Investment or 7 years following the termination of all funding provided by the Gates Foundation; provided, that the Global Access will continue for any products or services developed with funding provided by the Gates Foundation which continue to be developed or available in certain developing countries.

XML 39 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Reclassifications

Basis of Presentation and Consolidation

In connection with the Grant Agreement and the Gates Investment, the Company entered into a strategic relationship with the Gates Foundation (the “Letter Agreement”). Under the terms of the Letter Agreement, the Gates Investment and Advanced Funds may only be used to conduct mutually agreed upon work, including the scale up of the Company’s platform technology to launch a product intended to prevent neonatal sepsis (the “NSP”). Pursuant to the Letter Agreement, the Company agreed to make the NSP available and accessible in certain developing countries and to grant the Gates Foundation a non-exclusive license to commercialize selected drug candidates in specified developing countries, which may only be exercised in the event of certain defaults as described in the Letter Agreement (the “Global Access”). The Global Access will continue in effect until the earlier of 25 years from the closing of the Gates Investment or 7 years following the termination of all funding provided by the Gates Foundation; provided, that the Global Access will continue for any products or services developed with funding provided by the Gates Foundation which continue to be developed or available in certain developing countries.

Use of Estimates

Fair Value of Financial Instruments

Cash and Cash Equivalents

Short-term Investments

The Company reviews all of its marketable securities on a regular basis to evaluate whether any security has experienced an other-than-temporary decline in fair value.

Restricted Cash

	March 31, 2017		December 31, 2016
Cash and cash equivalents	$	37,639	$	118,964
Restricted cash, current		127		127
Restricted cash, non-current		250		250
Total cash, cash equivalents, and restricted cash	$	38,016	$	119,341

Warrant Liability

Segment Reporting

Customer Concentration

Concentration of Credit Risk

Revenue Recognition

Research and Development Costs

Recent Accounting Pronouncements

Net Loss Per Share

	March 31,
	2017		2016
Options to purchase common stock		4,470,187		2,793,404
Restricted stock units		800,658		495,274
Warrants to purchase common stock		1,231,659		30,024

Warrants outstanding as of March 31, 2017 have a weighted-average exercise price of $3.78.

XML 40 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):

	March 31, 2017		December 31, 2016
Cash and cash equivalents	$	37,639	$	118,964
Restricted cash, current		127		127
Restricted cash, non-current		250		250
Total cash, cash equivalents, and restricted cash	$	38,016	$	119,341

Schedule of Potentially Dilutive Securities Outstanding Excluded from the Computations of Diluted Weighted-Average Shares Outstanding

Below are listed the potentially dilutive securities outstanding as of March 31, 2017 and 2016:

	March 31,
	2017		2016
Options to purchase common stock		4,470,187		2,793,404
Restricted stock units		800,658		495,274
Warrants to purchase common stock		1,231,659		30,024

XML 41 R19.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Financial Assets and Liabilities Measured and Recognized at Fair Value

	March 31, 2017
	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Assets
Cash	$	4,779	$	—	$	—		$	4,779
Level 1:
Restricted cash		377		—		—			377
Money market funds		14,860		—		—			14,860
Subtotal		15,237		—		—			15,237
Level 2:
Corporate debt securities		31,031		—		(24	)		31,007
U.S. Treasury bills		35,033		—		(35	)		34,998
Commercial paper		46,400		—		—			46,400
Subtotal		112,464		—		(59	)		112,405
Total	$	132,480	$	—	$	(59	)	$	132,421
Reported as:
Cash and cash equivalents								$	37,639
Short-term investments								$	94,405
Restricted cash								$	377

Liabilities, Level 3
Warrant Liability								$	27,289
Derivative Liability								$	622
Total								$	27,911

	December 31, 2016
	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Assets
Cash	$	3,728	$	—	$	—		$	3,728
Level 1:
Restricted cash		377		—		—			377
Money market funds		115,236		—		—			115,236
Subtotal		115,613		—		—			115,613
Level 2:
Corporate debt securities		12,969		—		(7	)		12,962
Commercial paper		13,950		—		—			13,950
Subtotal		26,919		—		(7	)		26,912
Total	$	146,260	$	—	$	(7	)	$	146,253
Reported as:
Cash and cash equivalents								$	118,964
Short-term investments								$	26,912
Restricted cash								$	377

Liabilities, Level 3
Warrant liability								$	13,874
Derivative liability								$	602
Total								$	14,476

Schedule of Assumptions Used

the estimated fair values of the warrants were determined using Black-Scholes with the following assumptions:

	March 31, 2017		December 31, 2016
Expected volatility		80%		80%
Expected term	4.2 years		4.2 years
Risk-free interest rate		1.8%		1.8%
Dividend yield		—%		—%

Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation

	Estimated Fair Value of Warrant Liability			Estimated Fair Value of Derivative Liability
Balance of Level 3 Liabilities at December 31, 2016	$	13,874		$	602
Change in estimated fair value of warrant liability		14,936		—
Reclassification of warrant liability to additional paid in capital upon exercise of warrants		(1,521	)	—
Change in estimated fair value of derivative liability	—				20
Balance of Level 3 Liabilities at March 31, 2017	$	27,289		$	622

XML 42 R20.htm IDEA: XBRL DOCUMENT

Balance Sheet Components (Tables)

3 Months Ended

Mar. 31, 2017

Payables And Accruals [Abstract]

Schedule of Prepaids and Other Current Assets

Prepaids and other current assets consisted of the following (in thousands):

	March 31, 2017		December 31, 2016
Deferred research and development costs	$	6,042	$	660
Prepaid expenses		2,660		1,390
Other current assets		335		139
	$	9,037	$	2,189

Schedule of Property and Equipment

Property and equipment, net consisted of the following (in thousands):

	March 31, 2017			December 31, 2016
Office equipment	$	1,071		$	644
Laboratory equipment		3,989			4,038
Leasehold improvements		1,072			1,072
Construction-in-progress		6,751			1,896
		12,883			7,650
Less: accumulated depreciation and amortization		(4,434	)		(4,389	)
Property and equipment, net	$	8,449		$	3,261

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	March 31, 2017		December 31, 2016
Accrued clinical and development expenses	$	2,394	$	3,681
Payroll and related bonus expenses		2,788		4,941
Other		1,308		1,076
	$	6,490	$	9,698

XML 43 R21.htm IDEA: XBRL DOCUMENT

Borrowings (Tables)

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Schedule of Future Minimum Debt Obligation Payments

Future principal debt payments on the currently outstanding term loan are payable as follows (in thousands):

	March 31, 2017
2017	$	4,167
2018		12,500
2019		8,333
Total principal payments		25,000
Final fee due at maturity in 2019		2,000
Total principal and final fee payments		27,000
Unamortized discount and debt issuance costs		(1,516	)
Less current portion		(7,292	)
Loan payable, long-term	$	18,192

XML 44 R22.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2017

Summary of Stock Option Activity

The following table summarizes stock option activity under the stock plans, excluding the ESPP, and related information:

	Shares Available for grant			Shares Subject to Options Outstanding			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (years)
Balance, December 31, 2016		639,374			3,540,293		$	6.31		7.98
Additional shares authorized		1,875,522			—
Options granted		(1,067,657	)		1,067,657		$	23.23
Options exercised		—			(54,585	)	$	9.79
Options cancelled		83,178			(83,178	)	$	6.61
RSUs granted		(288,064	)		—
RSUs cancelled		23,275			—
Balance, March 31, 2017		1,265,628			4,470,187		$	10.31		7.90

Schedule of Stock-based Compensation Expense for Stock Options Granted to Employees and Non-employees

	Three Months Ended March 31,
	2017		2016
Research and development	$	1,602	$	454
General and administrative		1,090		373
Total	$	2,692	$	827

Schedule of Estimated Grant Date Fair Value of Employee Stock Options

The estimated grant date fair value of employee stock options with time-based vesting terms was calculated using the Black-Scholes valuation model, based on the following assumptions:

	Three Months Ended March 31,
	2017		2016
Expected term	6.0 years		6.0 years
Expected volatility	80%–81%			73%
Risk-free interest rate	2.0%–2.1%			1.4%
Expected dividend yield		—%		—%

Schedule of Share-based Compensation, Restricted Stock Units Award Activity

A summary of RSU activity is as follows:

	RSU Awards Outstanding
	Number of Shares			Weighted-Average Grant Date Fair Market Value		Aggregate Intrinsic Value (in thousands)
Balance, December 31, 2016		605,052		$	5.60	$	7,878
RSUs granted		288,064		$	21.90
RSUs released		(69,183	)	$	5.11
RSUs cancelled		(23,275	)	$	6.32
Balance, March 31, 2017		800,658		$	11.49	$	20,201

Black Scholes

Schedule of Estimated Grant Date Fair Value of Employee Stock Options

The non-employee stock-based compensation expense, during the three-month period ended March 31, 2017, was estimated using Black-Scholes with the following assumptions:

	Three Months Ended March 31,
	2017
Expected term	0.51 years
Expected volatility		77%
Risk-free interest rate		0.9%
Expected dividend yield		—%

Monte Carlo Simulation

Schedule of Estimated Grant Date Fair Value of Employee Stock Options

The fair value of awards granted to employees was estimated using Monte-Carlo with the following assumptions:

	Three Months Ended March 31,
	2017		2016
Expected term	0.5–2.0 years		3.0–6.0 years
Expected volatility	70%			70%
Risk-free interest rate		2.4%		1.8%
Expected dividend yield		—%		—%

XML 45 R23.htm IDEA: XBRL DOCUMENT

Commitments (Tables)

3 Months Ended

Mar. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Schedule of Future Minimum Lease Payments

Future minimum lease payments under the operating leases as of March 31, 2017 are as follows (in thousands):

Year Ending December 31,	Amounts
2017	$	663
2018		2,353
2019		2,890
2020		2,991
2021		3,098
Thereafter		20,036
Total minimum lease payments	$	32,031

XML 46 R24.htm IDEA: XBRL DOCUMENT

Organization and Basis of Presentation and Consolidation - Additional Information (Details) - USD ($)				3 Months Ended
	May 03, 2017	Dec. 19, 2016	Jun. 03, 2016	Mar. 31, 2017	Dec. 31, 2016	Apr. 07, 2015
Subsidiary, Sale of Stock [Line Items]
Effective agreement terms				The Global Access will continue in effect until the earlier of 25 years from the closing of the Gates Investment or 7 years following the termination of all funding provided by the Gates Foundation; provided, that the Global Access will continue for any products or services developed with funding provided by the Gates Foundation which continue to be developed or available in certain developing countries.
Warrants to purchase common stock, exercise price				$ 3.78
Value authorized of equity instruments to be issued						$ 150,000,000
Cash, cash equivalents and short-term investments				$ 132,000,000
Accumulated deficit				$ 280,479,000	$ 247,220,000
Subsequent Event
Subsidiary, Sale of Stock [Line Items]
Research term	3 years
Advance amount received for research and development	$ 3,200,000
Subsequent Event \| Maximum
Subsidiary, Sale of Stock [Line Items]
Research and development awarded grant funding amount	$ 10,500,000
Redeemable Common Stock \| Subsequent Event
Subsidiary, Sale of Stock [Line Items]
Shares issued	407,331
Share price (dollars per share)	$ 24.55
Proceeds from issuance or sale of equity	$ 10,000,000
ATM equity offering program
Subsidiary, Sale of Stock [Line Items]
Shares issued				1,105,549
Value authorized of equity instruments to be issued						$ 30,000,000
Proceeds from issuance of common stock, gross of issuance costs				$ 5,300,000
Proceeds from sale of stock, net of commissions and other transaction costs				$ 5,100,000
ATM equity offering program \| Weighted Average
Subsidiary, Sale of Stock [Line Items]
Share price (dollars per share)				$ 4.82
Private Placement
Subsidiary, Sale of Stock [Line Items]
Proceeds from issuance or sale of equity			$ 25,400,000
Aggregate net proceeds from issuance of common stock			$ 25,100,000
Warrants to purchase common stock, exercise price			$ 3.66
Weighted average contractual term			5 years
Private Placement \| Maximum
Subsidiary, Sale of Stock [Line Items]
Weighted average contractual term			5 years
Private Placement \| Subsequent Event
Subsidiary, Sale of Stock [Line Items]
Share price (dollars per share)	$ 24.55
Proceeds from issuance or sale of equity	$ 10,000,000
Private Placement \| Redeemable Common Stock \| Subsequent Event
Subsidiary, Sale of Stock [Line Items]
Shares issued	407,331
Private Placement \| Common Stock
Subsidiary, Sale of Stock [Line Items]
Shares issued			7,999,996
Number of shares authorized to be purchased			1,999,999
Underwritten Public Offering
Subsidiary, Sale of Stock [Line Items]
Shares issued		7,475,000
Share price (dollars per share)		$ 13.50
Additional shares of common stock		975,000
Proceeds from offering net of underwriting discounts and commissions and estimated offering expenses		$ 94,600,000

XML 47 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Details) $ / shares in Units, $ in Thousands		3 Months Ended
	Jun. 03, 2016 $ / shares shares	Mar. 31, 2017 USD ($) Segment $ / shares	Dec. 31, 2016 USD ($)
Summary of Significant Accounting Policies [Line Items]
Restricted cash \| $		$ 377	$ 377
Restricted cash, current \| $		$ 127	$ 127
Facility lease expiration date		Apr. 14, 2017
Warrants to purchase common stock, exercise price \| $ / shares		$ 3.78
Number of operating segments \| Segment		1
Private Placement
Summary of Significant Accounting Policies [Line Items]
Warrants to purchase common stock, exercise price \| $ / shares	$ 3.66
Weighted average contractual term	5 years
Common Stock \| Private Placement
Summary of Significant Accounting Policies [Line Items]
Number of shares authorized to be purchased \| shares	1,999,999

XML 48 R26.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Cash and cash equivalents	$ 37,639,000	$ 118,964,000
Restricted cash, current	127,000	127,000
Restricted cash, non-current	250,000	250,000
Total cash, cash equivalents, and restricted cash	$ 38,016,000	$ 119,341,000	$ 19,559,000	$ 20,414,000

XML 49 R27.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Outstanding Excluded from the Computations of Diluted Weighted-Average Shares Outstanding (Details) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding (shares)	4,470,187	2,793,404
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding (shares)	800,658	495,274
Warrants to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding (shares)	1,231,659	30,024

XML 50 R28.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Financial Assets and Liabilities Measured and Recognized at Fair Value (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	$ 132,480	$ 146,260
Unrealized Losses	(59)	(7)
Fair Value	132,421	146,253
Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	94,405	26,912
Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	4,779	3,728
Fair Value	4,779	3,728
Restricted cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	377	377
Cash and cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	37,639	118,964
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	15,237	115,613
Fair Value	15,237	115,613
Level 1 \| Restricted cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	377	377
Fair Value	377	377
Level 1 \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	14,860	115,236
Fair Value	14,860	115,236
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	112,464	26,919
Unrealized Losses	(59)	(7)
Fair Value	112,405	26,912
Level 2 \| U.S. Treasury bills
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	35,033
Unrealized Losses	(35)
Fair Value	34,998
Level 2 \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	31,031	12,969
Unrealized Losses	(24)	(7)
Fair Value	31,007	12,962
Level 2 \| Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	46,400	13,950
Fair Value	46,400	13,950
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liability	27,289	13,874
Derivative Liability	622	602
Total	$ 27,911	$ 14,476

XML 51 R29.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Additional Information (Details) - USD ($)			1 Months Ended	3 Months Ended		12 Months Ended
	Jun. 03, 2016	Aug. 05, 2015	Feb. 28, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Sale of available-for-sale securities				$ 0		$ 0
Change in estimated fair value				14,956,000	$ 12,000
Potential payment to solar capital				$ 1,000,000
Discount rate, percent				13.00%
Change in percent effecting fair value of derivative liability				5.00%
Effect in fair value of derivative liability due to change in percent of FDA approval probability				$ 1,500,000
Warrants to purchase common stock, exercise price				$ 3.78
Exercise of Warrants			78,585
Proceeds from exercise of stock warrants			$ 300,000	$ 288,000
Estimated fair value of warrants exercised	$ 100,000		1,500,000
Increase in estimated fair value of warrants exercised			$ 1,400,000
Dividend yield				0.00%		0.00%
Private Placement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants to purchase common stock, exercise price	$ 3.66
Common Stock \| Private Placement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants to purchase common stock	1,999,999
Level 3 \| Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability				$ 622,000		$ 602,000
Warrant Liability				27,289,000		13,874,000
Fair value, derivative liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Effect in fair value of derivative liability due to change in percent of FDA approval probability				37,000
Derivative \| Level 3 \| Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in estimated fair value				20,000
Derivative liability				622,000
Warrants to purchase common stock \| Level 3 \| Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in estimated fair value				14,936,000
Issuance of derivative in connection with issuance of loan payable	$ 2,600,000			1,521,000
Secured Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Success fee		$ 1,000,000
Fair value of success fee		$ 356,000
Secured Debt \| Fair value, derivative liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of success fee						$ 602,000
Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized loss position				$ 63,900,000

XML 52 R30.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Assumptions Used (Details)	3 Months Ended	12 Months Ended
Fair Value Measurements - Assumptions Used (Details)	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Expected volatility	80.00%	80.00%
Expected term	4 years 2 months 12 days	4 years 2 months 12 days
Risk-free interest rate	1.80%	1.80%
Dividend yield	0.00%	0.00%

XML 53 R31.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Change in Fair Value of Recurring Measurements (Details) - USD ($)		3 Months Ended
	Jun. 03, 2016	Mar. 31, 2017	Mar. 31, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Change in estimated fair value		$ 14,956,000	$ 12,000
Fair Value, Measurements, Recurring \| Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Estimated Fair Value, Beginning Balance		14,476,000
Estimated Fair Value, Ending Balance		27,911,000
Warrants to purchase common stock \| Fair Value, Measurements, Recurring \| Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Estimated Fair Value, Beginning Balance		13,874,000
Change in estimated fair value		14,936,000
Reclassification of warrant liability to additional paid in capital upon exercise of warrants	$ (2,600,000)	(1,521,000)
Estimated Fair Value, Ending Balance		27,289,000
Derivative \| Fair Value, Measurements, Recurring \| Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Estimated Fair Value, Beginning Balance		602,000
Change in estimated fair value		20,000
Estimated Fair Value, Ending Balance		$ 622,000

XML 54 R32.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Schedule of Prepaids and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Prepaid Expense And Other Assets Current [Abstract]
Deferred research and development costs	$ 6,042	$ 660
Prepaid expenses	2,660	1,390
Other current assets	335	139
Prepaids and other current assets	$ 9,037	$ 2,189

XML 55 R33.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 12,883	$ 7,650
Less: accumulated depreciation and amortization	(4,434)	(4,389)
Property and equipment, net	8,449	3,261
Office equipment
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	1,071	644
Laboratory equipment
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	3,989	4,038
Leasehold improvements
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	1,072	1,072
Construction-in-progress
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	6,751	$ 1,896
Property and equipment, net	$ 5,900

XML 56 R34.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Depreciation and amortization	$ 113	$ 121

XML 57 R35.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Accrued clinical and development expenses	$ 2,394	$ 3,681
Payroll and related bonus expenses	2,788	4,941
Other	1,308	1,076
Accrued liabilities	$ 6,490	$ 9,698

XML 58 R36.htm IDEA: XBRL DOCUMENT

License and Collaboration Agreements - Additional Information (Details)	1 Months Ended			3 Months Ended
	May 31, 2016 USD ($)	Apr. 30, 2016 USD ($)	Jan. 31, 2006 USD ($) $ / shares shares	Mar. 31, 2017 USD ($) milestone	Mar. 31, 2016 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense				$ 18,597,000	$ 13,893,000
Thermo Fisher Scientific, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments for first commercialization product		$ 6,453,000
Deferred revenue				1,433,000
Research and development expense				915,000	$ 0
Crystal Biosciences, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments for first commercialization product	$ 20,550,000
Ionis Pharmaceuticals License Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments for first commercialization product			$ 19,500,000
Milestone payments for second commercialization product			9,750,000
Aggregate additional milestone payments			20,000,000
Cumulative milestones compensation				$ 7,000,000
Number of milestones paid in relation to license agreement \| milestone				3
Payments due				$ 0
Ionis Pharmaceuticals License Agreement \| Up-front License Fee
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense			$ 1,500,000
Ionis Pharmaceuticals License Agreement \| Series A Convertible Preferred Stock \| Up-front License Fee
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Shares issued \| shares			97,402
Shares issued price per share (dollars per share) \| $ / shares			$ 15.40

XML 59 R37.htm IDEA: XBRL DOCUMENT

Government Contracts - Additional Information (Details) - USD ($)	1 Months Ended								3 Months Ended
	May 26, 2016	Apr. 30, 2016	Jan. 31, 2016	Jul. 31, 2015	Jul. 31, 2014	Apr. 30, 2013	Sep. 30, 2012	Aug. 31, 2010	Mar. 31, 2017	Mar. 31, 2016
Biomedical Advanced Research and Development Authority
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development contract	$ 123,808,000					$ 103,808,000	$ 43,398,000	$ 27,600,000
Term of agreement, in years								2 years
Increase in research and development contract	$ 20,000,000					$ 60,410,000	$ 15,798,000
Contracts revenue									$ 7,114,000	$ 5,270,000
National Institute of Allergy and Infectious Diseases
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development contract		$ 4,400,000		$ 1,500,000	$ 407,000
Term of agreement, in years					1 year
Increase in research and development contract			$ 500,000
Contracts revenue									$ 349,000,000	$ 579,000,000
Aggregate research and development grant and other revenues		$ 5,000,000	$ 5,000,000	$ 4,500,000

XML 60 R38.htm IDEA: XBRL DOCUMENT

Borrowings - Additional Information (Details) - USD ($)			3 Months Ended
Borrowings - Additional Information (Details) - USD ($)	Jun. 20, 2016	Aug. 05, 2015	Mar. 31, 2017	Mar. 31, 2016
Debt Instrument [Line Items]
Face amount			$ 25,000,000
Final fee due at maturity in 2019			2,000,000
Interest expense			706,000	$ 438,000
Secured Debt
Debt Instrument [Line Items]
Debt, maturity date		Aug. 05, 2019
Proceeds from issuance of loan payable	$ 10,000,000	$ 15,000,000
Interest rate per annum (percent)		6.99%
Variable interest rate (percent)		1.00%
Repayment of debt term (months)		24 months
Increase in interest rate in event of default (percent)		4.00%
Closing fee		$ 250,000
Final fee (percent)		8.00%
Success fee		$ 1,000,000
Fair value of success fee		356,000
Final fee due at maturity in 2019		2,000,000
Interest expense			$ 700,000	$ 400,000
Secured Debt \| Maximum
Debt Instrument [Line Items]
Face amount		$ 25,000,000

XML 61 R39.htm IDEA: XBRL DOCUMENT

Borrowings - Future Minimum Debt Obligation Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
2017	$ 4,167
2018	12,500
2019	8,333
Total principal payments	25,000
Final fee due at maturity in 2019	2,000
Total principal and final fee payments	27,000
Unamortized discount and debt issuance costs	(1,516)
Less current portion	(7,292)	$ (4,167)
Loan payable, long-term	$ 18,192	$ 21,110

XML 62 R40.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Details) - USD ($)		3 Months Ended	12 Months Ended
	Jun. 03, 2016	Mar. 31, 2017	Dec. 31, 2016	Apr. 07, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value authorized of equity instruments to be issued				$ 150,000,000
Warrants to purchase common stock, exercise price		$ 3.78
Warrants to purchase common stock \| Level 3 \| Fair Value, Measurements, Recurring
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of derivative in connection with issuance of loan payable	$ 2,600,000	$ 1,521,000
Remaining warrants outstanding		27,300,000
Change in estimated fair value of remaining warrants outstanding		$ 13,400,000	$ 11,300,000
Private Placement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance or sale of equity	$ 25,400,000
Warrants to purchase common stock, exercise price	$ 3.66
Weighted average contractual term	5 years
Private Placement \| Chief Operating Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued	141,453
Number of shares authorized to be purchased	35,363
Proceeds from issuance or sale of equity	$ 500,000
Payments of stock issuance costs	$ 300,000
Maximum \| Private Placement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average contractual term	5 years
ATM equity offering program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value authorized of equity instruments to be issued				$ 30,000,000
Shares issued		1,105,549
Proceeds from issuance of common stock, gross of issuance costs		$ 5,300,000
Proceeds from sale of stock, net of commissions and other transaction costs		5,100,000
Value of common stock remaining available to be sold		$ 24,700,000
ATM equity offering program \| Weighted Average
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (dollars per share)		$ 4.82
Common Stock \| Private Placement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued	7,999,996
Number of shares authorized to be purchased	1,999,999
Estimated fair values of the common stock and warrants issued	$ 22,900,000

XML 63 R41.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans - Additional Information (Details) - USD ($)			3 Months Ended
	Feb. 22, 2017	Jan. 02, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Additional shares authorized			1,875,522
Outstanding shares available for future issuance (shares)			1,265,628		639,374
Shares subject to options outstanding (shares)			4,470,187		3,540,293
Stock-based compensation expense			$ 2,911,000	$ 827,000
Options granted (shares)			1,067,657
Stock Options and Restricted Stock Units \| Former Chief Medical Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense			$ 700,000
Stock-based compensation expense related to stock option and restricted units modification			700,000
Options to purchase common stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation			$ 20,534,000
Weighted-average period of cost expected to be recognized			3 years 4 months 13 days
Non-Employee
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense			$ 219,000	$ 0
Options granted (shares)			0	0
Restricted stock units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted (shares)			0
Shares granted			288,064
Weighted-average grant date fair market value, shares granted (dollars per share)			$ 21.90
Restricted stock units \| Employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period			4 years
Weighted-average period of cost expected to be recognized			3 years 3 months 29 days
Shares granted			288,064
Weighted-average grant date fair market value, shares granted (dollars per share)			$ 21.90
Unrecognized compensation costs			$ 8,401,000
Employee Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Additional shares authorized		178,190
Outstanding shares available for future issuance (shares)			461,406
Common stock issued (shares)			225,261
2014 Equity Incentive Award Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Additional shares authorized		1,425,522
Outstanding shares available for future issuance (shares)			909,040
Vesting period			4 years
Option expiration period			10 years
2014 Employment Commencement Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Additional shares authorized	450,000
Outstanding shares available for future issuance (shares)			356,588
Number of shares authorized (shares)			1,600,000
Stock Incentive Plan 2003
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period			4 years
Option expiration period			10 years
Shares subject to options outstanding (shares)			862,720
Employees That Contain Performance Conditions \| Options to purchase common stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted (shares)			142,200	199,750
Employees That Contain Performance Conditions \| Restricted stock units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted			25,800	47,425

XML 64 R42.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans - Summary of Stock Option Activity (Detail) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Shares Available for grant
Beginning balance (shares)	639,374
Additional shares authorized (shares)	1,875,522
Options granted (shares)	(1,067,657)
Options exercised (shares)	0
Options cancelled (shares)	83,178
Ending balance (shares)	1,265,628	639,374
Shares Subject to Options Outstanding
Beginning balance (shares)	3,540,293
Additional shares authorized (shares)	0
Options granted (shares)	1,067,657
Options exercised (shares)	(54,585)
Options cancelled (shares)	(83,178)
Ending balance (shares)	4,470,187	3,540,293
Weighted- Average Exercise Price
Beginning balance (shares)	$ 6.31
Options granted (shares)	23.23
Options exercised (shares)	9.79
Options cancelled (shares)	6.61
Ending balance (shares)	$ 10.31	$ 6.31
Weighted- Average Remaining Contractual Term (years)	7 years 10 months 24 days	7 years 11 months 23 days
Restricted Stock Units
Shares Available for grant
Shares granted	(288,064)
Shares cancelled	23,275
Shares Subject to Options Outstanding
Options granted (shares)	0
Options cancelled (shares)	0

XML 65 R43.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans - Schedule of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 2,911	$ 827
Stock Options Granted To Employees And Non Employee Directors
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	2,692	827
Stock Options Granted To Employees And Non Employee Directors \| Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	1,602	454
Stock Options Granted To Employees And Non Employee Directors \| General and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 1,090	$ 373

XML 66 R44.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans - Schedule of Estimated Grant Date Fair Value of Employee Stock Options Using Black-Scholes Valuation Model (Detail) - Options to purchase common stock	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Expected term	6 years	6 years
Expected volatility		73.00%
Expected volatility, minimum	80.00%
Expected volatility, maximum	81.00%
Risk-free interest rate		1.40%
Risk-free interest rate, minimum	2.00%
Risk-free interest rate, maximum	2.10%
Expected dividend yield	0.00%	0.00%

XML 67 R45.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans - Schedule of Estimated Stock-Based Compensation Expense (Details) - Black Scholes - Non-Employee	3 Months Ended
	Mar. 31, 2017
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Expected term	6 months 4 days
Expected volatility	77.00%
Risk-free interest rate	0.90%
Expected dividend yield	0.00%

XML 68 R46.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans - Summary of Restricted Stock Activity (Details) - Restricted Stock Units - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Number of Shares
Beginning balance (shares)	605,052
Shares granted	288,064
Shares released	(69,183)
Shares cancelled	(23,275)
Ending balance (shares)	800,658
Weighted-Average Grant Date Fair Market Value
Beginning balance (dollars per share)	$ 5.60
Weighted-average grant date fair market value, shares granted (dollars per share)	21.90
Shares released (dollars per share)	5.11
Shares canceled (dollars per share)	6.32
Ending balance (dollars per share)	$ 11.49
Aggregate Intrinsic Value (in thousands)
RSU Awards Outstanding, aggregate intrinsic value	$ 20,201	$ 7,878

XML 69 R47.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans - Schedule of Estimated Fair Value of Awards Granted to Non-Employees using Monte-Carlo Assumptions (Details) - Monte Carlo Simulation	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Expected volatility	70.00%	70.00%
Risk-free interest rate	2.40%	1.80%
Expected dividend yield	0.00%	0.00%
Minimum
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Expected term	6 months	3 years
Maximum
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Expected term	2 years	6 years

XML 70 R48.htm IDEA: XBRL DOCUMENT

Commitments - Commercial Manufacturing Agreement (Details) - USD ($)	1 Months Ended		3 Months Ended		12 Months Ended
	Mar. 31, 2017	Jul. 31, 2015	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Loss Contingencies [Line Items]
Prepaid and other current assets	$ 9,037,000		$ 9,037,000		$ 2,189,000
Research and development			$ 18,597,000	$ 13,893,000
Hovione Limited
Loss Contingencies [Line Items]
Commercial manufacturing agreement initial term			7 years
Percentage of long term purchase commitment minimum required quantity	80.00%
Number of years for minimum supply percentage after approval	3 years
Minimum annual purchase commitments beginning year	2020
Annual purchase commitments ending Year	2024
Advance payments		$ 1,500,000	$ 6,200,000
Prepaid and other current assets	$ 4,800,000		4,800,000		700,000
Research and development			400,000	$ 100,000
Hovione Limited \| Minimum
Loss Contingencies [Line Items]
Percentage of long term purchase commitment	40.00%
Hovione Limited \| Maximum
Loss Contingencies [Line Items]
Percentage of long term purchase commitment	66.00%
Raw Material Agreement
Loss Contingencies [Line Items]
Advance payments					$ 1,200
Prepaid and other current assets	$ 1,200		$ 1,200

XML 71 R49.htm IDEA: XBRL DOCUMENT

Commitments - Facilities Lease Obligation (Details)	1 Months Ended	3 Months Ended
Commitments - Facilities Lease Obligation (Details)	Aug. 31, 2016 USD ($) ft²	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)
Operating Leased Assets [Line Items]
Square feet of office, laboratory and research and development space (sq feet) \| ft²	47,000
Expansion option (in years)	5 years
First year base rent	$ 2,700,000
Lessor Leasing Arrangements, Operating Leases, Rental Increase, Percent	3.50%
One time, first year rent abatement	$ 1,800,000
One time improvement allowance	5,700,000
Property and equipment, net		$ 8,449,000		$ 3,261,000
Tenant Improvements Liabilities	5,900,000
Additional allowance	$ 900,000
Restricted cash, non-current		250,000		$ 250,000
Rent expense		211,000	$ 146,000
Construction-in-progress
Operating Leased Assets [Line Items]
Property and equipment, net		$ 5,900,000

XML 72 R50.htm IDEA: XBRL DOCUMENT

Commitments - Schedule of Future Minimum Lease Payments (Details) $ in Thousands	Mar. 31, 2017 USD ($)
Year Ending December 31,
2017	$ 663
2018	2,353
2019	2,890
2020	2,991
2021	3,098
Thereafter	20,036
Total minimum lease payments	$ 32,031

XML 73 R51.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Details) - USD ($)		3 Months Ended
	May 03, 2017	Mar. 31, 2017
Subsequent Event [Line Items]
Effective agreement terms		The Global Access will continue in effect until the earlier of 25 years from the closing of the Gates Investment or 7 years following the termination of all funding provided by the Gates Foundation; provided, that the Global Access will continue for any products or services developed with funding provided by the Gates Foundation which continue to be developed or available in certain developing countries.
Subsequent Event
Subsequent Event [Line Items]
Percentage of purchase price compounded annual interest	5.00%
Research term	3 years
Amount received on advance payment of research agreement	$ 3,200,000
Subsequent Event \| Maximum
Subsequent Event [Line Items]
Research and development awarded grant funding amount	$ 10,500,000
Subsequent Event \| Redeemable Common Stock
Subsequent Event [Line Items]
Shares issued	407,331
Share price (dollars per share)	$ 24.55
Proceeds from issuance or sale of equity	$ 10,000,000

EXCEL 74 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ɳ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end XML 75 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 76 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 163 272 1 false 59 0 false 7 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.achaogen.com/20170331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.achaogen.com/20170331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.achaogen.com/20170331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.achaogen.com/20170331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.achaogen.com/20170331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.achaogen.com/20170331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - Organization and Basis of Presentation and Consolidation Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAndConsolidation Organization and Basis of Presentation and Consolidation Notes 7 false false R8.htm 100070 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 100080 - Disclosure - Fair Value Measurements Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 100090 - Disclosure - Balance Sheet Components Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureBalanceSheetComponents Balance Sheet Components Notes 10 false false R11.htm 100100 - Disclosure - License and Collaboration Agreements Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureLicenseAndCollaborationAgreements License and Collaboration Agreements Notes 11 false false R12.htm 100110 - Disclosure - Government Contracts Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureGovernmentContracts Government Contracts Notes 12 false false R13.htm 100120 - Disclosure - Borrowings Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureBorrowings Borrowings Notes 13 false false R14.htm 100130 - Disclosure - Stockholders' Equity Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 100140 - Disclosure - Commitments Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureCommitments Commitments Notes 15 false false R16.htm 100150 - Disclosure - Subsequent Events Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 16 false false R17.htm 100160 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.achaogen.com/20170331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 17 false false R18.htm 100170 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.achaogen.com/20170331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 18 false false R19.htm 100180 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.achaogen.com/20170331/taxonomy/role/DisclosureFairValueMeasurements 19 false false R20.htm 100190 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureBalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.achaogen.com/20170331/taxonomy/role/DisclosureBalanceSheetComponents 20 false false R21.htm 100200 - Disclosure - Borrowings (Tables) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureBorrowingsTables Borrowings (Tables) Tables http://www.achaogen.com/20170331/taxonomy/role/DisclosureBorrowings 21 false false R22.htm 100210 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.achaogen.com/20170331/taxonomy/role/DisclosureStockholdersEquity 22 false false R23.htm 100220 - Disclosure - Commitments (Tables) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureCommitmentsTables Commitments (Tables) Tables http://www.achaogen.com/20170331/taxonomy/role/DisclosureCommitments 23 false false R24.htm 100230 - Disclosure - Organization and Basis of Presentation and Consolidation - Additional Information (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAndConsolidationAdditionalInformationDetails Organization and Basis of Presentation and Consolidation - Additional Information (Details) Details 24 false false R25.htm 100240 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 25 false false R26.htm 100250 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) Details 26 false false R27.htm 100260 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Outstanding Excluded from the Computations of Diluted Weighted-Average Shares Outstanding (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeightedAverageSharesOutstandingDetails Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Outstanding Excluded from the Computations of Diluted Weighted-Average Shares Outstanding (Details) Details 27 false false R28.htm 100270 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured and Recognized at Fair Value (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAndRecognizedAtFairValueDetails Fair Value Measurements - Financial Assets and Liabilities Measured and Recognized at Fair Value (Details) Details 28 false false R29.htm 100280 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 29 false false R30.htm 100290 - Disclosure - Fair Value Measurements - Assumptions Used (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedDetails Fair Value Measurements - Assumptions Used (Details) Details 30 false false R31.htm 100300 - Disclosure - Fair Value Measurements - Change in Fair Value of Recurring Measurements (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureFairValueMeasurementsChangeInFairValueOfRecurringMeasurementsDetails Fair Value Measurements - Change in Fair Value of Recurring Measurements (Details) Details 31 false false R32.htm 100310 - Disclosure - Balance Sheet Components - Schedule of Prepaids and Other Current Assets (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidsAndOtherCurrentAssetsDetails Balance Sheet Components - Schedule of Prepaids and Other Current Assets (Details) Details 32 false false R33.htm 100320 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails Balance Sheet Components - Schedule of Property and Equipment (Details) Details 33 false false R34.htm 100330 - Disclosure - Balance Sheet Components - Additional Information (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails Balance Sheet Components - Additional Information (Details) Details 34 false false R35.htm 100340 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails Balance Sheet Components - Schedule of Accrued Liabilities (Details) Details 35 false false R36.htm 100350 - Disclosure - License and Collaboration Agreements - Additional Information (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails License and Collaboration Agreements - Additional Information (Details) Details 36 false false R37.htm 100360 - Disclosure - Government Contracts - Additional Information (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureGovernmentContractsAdditionalInformationDetails Government Contracts - Additional Information (Details) Details 37 false false R38.htm 100370 - Disclosure - Borrowings - Additional Information (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails Borrowings - Additional Information (Details) Details 38 false false R39.htm 100380 - Disclosure - Borrowings - Future Minimum Debt Obligation Payments (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureBorrowingsFutureMinimumDebtObligationPaymentsDetails Borrowings - Future Minimum Debt Obligation Payments (Details) Details 39 false false R40.htm 100400 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 40 false false R41.htm 100410 - Disclosure - Equity Incentive Plans - Additional Information (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails Equity Incentive Plans - Additional Information (Details) Details 41 false false R42.htm 100420 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity (Detail) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail Equity Incentive Plans - Summary of Stock Option Activity (Detail) Details 42 false false R43.htm 100430 - Disclosure - Equity Incentive Plans - Schedule of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees (Detail) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfStockBasedCompensationExpenseForStockOptionsGrantedToEmployeesAndNonEmployeesDetail Equity Incentive Plans - Schedule of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees (Detail) Details 43 false false R44.htm 100440 - Disclosure - Equity Incentive Plans - Schedule of Estimated Grant Date Fair Value of Employee Stock Options Using Black-Scholes Valuation Model (Detail) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfEstimatedGrantDateFairValueOfEmployeeStockOptionsUsingBlackScholesValuationModelDetail Equity Incentive Plans - Schedule of Estimated Grant Date Fair Value of Employee Stock Options Using Black-Scholes Valuation Model (Detail) Details 44 false false R45.htm 100450 - Disclosure - Equity Incentive Plans - Schedule of Estimated Stock-Based Compensation Expense (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfEstimatedStockBasedCompensationExpenseDetails Equity Incentive Plans - Schedule of Estimated Stock-Based Compensation Expense (Details) Details 45 false false R46.htm 100460 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Activity (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockActivityDetails Equity Incentive Plans - Summary of Restricted Stock Activity (Details) Details 46 false false R47.htm 100470 - Disclosure - Equity Incentive Plans - Schedule of Estimated Fair Value of Awards Granted to Non-Employees using Monte-Carlo Assumptions (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfEstimatedFairValueOfAwardsGrantedToNonEmployeesUsingMonteCarloAssumptionsDetails Equity Incentive Plans - Schedule of Estimated Fair Value of Awards Granted to Non-Employees using Monte-Carlo Assumptions (Details) Details 47 false false R48.htm 100480 - Disclosure - Commitments - Commercial Manufacturing Agreement (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureCommitmentsCommercialManufacturingAgreementDetails Commitments - Commercial Manufacturing Agreement (Details) Details 48 false false R49.htm 100490 - Disclosure - Commitments - Facilities Lease Obligation (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureCommitmentsFacilitiesLeaseObligationDetails Commitments - Facilities Lease Obligation (Details) Details 49 false false R50.htm 100500 - Disclosure - Commitments - Schedule of Future Minimum Lease Payments (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumLeasePaymentsDetails Commitments - Schedule of Future Minimum Lease Payments (Details) Details 50 false false R51.htm 100510 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://www.achaogen.com/20170331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 51 false false All Reports Book All Reports akao-20170331.xml akao-20170331.xsd akao-20170331_cal.xml akao-20170331_def.xml akao-20170331_lab.xml akao-20170331_pre.xml true true ZIP 80 0001564590-17-009402-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-17-009402-xbrl.zip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

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	May 03, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Trading Symbol	AKAO
Entity Registrant Name	Achaogen Inc
Entity Central Index Key	0001301501
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		35,853,669